<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Targeted therapy for metastatic renal cell carcinoma - Hofmann, F - 2020 | Cochrane Library</title> <meta content="Targeted therapy for metastatic renal cell carcinoma - Hofmann, F - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012796.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Targeted therapy for metastatic renal cell carcinoma - Hofmann, F - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012796.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012796.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Targeted therapy for metastatic renal cell carcinoma" name="citation_title"/> <meta content="Fabian Hofmann" name="citation_author"/> <meta content="Sunderby Sjukhus, Umeå University" name="citation_author_institution"/> <meta content="fhofmann@trigonum.se" name="citation_author_email"/> <meta content="Eu Chang Hwang" name="citation_author"/> <meta content="Chonnam National University Medical School, Chonnam National University Hwasun Hospital" name="citation_author_institution"/> <meta content="Thomas BL Lam" name="citation_author"/> <meta content="University of Aberdeen" name="citation_author_institution"/> <meta content="Axel Bex" name="citation_author"/> <meta content="Royal Free London NHS Foundation Trust" name="citation_author_institution"/> <meta content="Yuhong Yuan" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Lorenzo SO Marconi" name="citation_author"/> <meta content="Centro Hospitalar e Universitario de Coimbra" name="citation_author_institution"/> <meta content="Börje Ljungberg" name="citation_author"/> <meta content="Umeå University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD012796.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/10/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012796.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012796.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012796.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antibodies, Monoclonal, Humanized [adverse effects, therapeutic use]; Antineoplastic Agents [adverse effects, *therapeutic use]; Antineoplastic Agents, Immunological [therapeutic use]; Axitinib [adverse effects, therapeutic use]; Bevacizumab [adverse effects, therapeutic use]; Bias; Carcinoma, Renal Cell [*drug therapy, mortality]; Everolimus [adverse effects, therapeutic use]; Indazoles; Ipilimumab [adverse effects, therapeutic use]; Kidney Neoplasms [*drug therapy, mortality, pathology]; Phenylurea Compounds [adverse effects, therapeutic use]; Progression-Free Survival; Protein Kinase Inhibitors [adverse effects, *therapeutic use]; Pyrimidines [adverse effects, therapeutic use]; Quality of Life; Quinolines [adverse effects, therapeutic use]; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor [antagonists &amp; inhibitors]; Sirolimus [adverse effects, analogs &amp; derivatives, therapeutic use]; Sorafenib [adverse effects, therapeutic use]; Sulfonamides [adverse effects, therapeutic use]; Sunitinib [adverse effects, therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012796.pub2&amp;doi=10.1002/14651858.CD012796.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012796.pub2&amp;doi=10.1002/14651858.CD012796.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012796.pub2&amp;doi=10.1002/14651858.CD012796.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012796.pub2&amp;doi=10.1002/14651858.CD012796.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012796.pub2&amp;doi=10.1002/14651858.CD012796.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012796.pub2&amp;doi=10.1002/14651858.CD012796.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012796.pub2&amp;doi=10.1002/14651858.CD012796.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012796.pub2&amp;doi=10.1002/14651858.CD012796.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012796.pub2&amp;doi=10.1002/14651858.CD012796.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012796.pub2&amp;doi=10.1002/14651858.CD012796.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012796.pub2&amp;doi=10.1002/14651858.CD012796.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012796.pub2&amp;doi=10.1002/14651858.CD012796.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012796.pub2&amp;doi=10.1002/14651858.CD012796.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012796.pub2&amp;doi=10.1002/14651858.CD012796.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012796.pub2&amp;doi=10.1002/14651858.CD012796.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012796.pub2&amp;doi=10.1002/14651858.CD012796.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012796.pub2&amp;doi=10.1002/14651858.CD012796.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012796.pub2&amp;doi=10.1002/14651858.CD012796.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012796.pub2&amp;doi=10.1002/14651858.CD012796.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012796.pub2&amp;doi=10.1002/14651858.CD012796.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012796.pub2&amp;doi=10.1002/14651858.CD012796.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012796.pub2&amp;doi=10.1002/14651858.CD012796.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012796.pub2&amp;doi=10.1002/14651858.CD012796.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="f00EizoA";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012796\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012796\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012796\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012796\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ko","th","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012796.pub2",title:"Targeted therapy for metastatic renal cell carcinoma",firstPublishedDate:"Oct 14, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Urology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=f00EizoA&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012796.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012796.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012796.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012796.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012796.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012796.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012796.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012796.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012796.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012796.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5990 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012796.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-sec-0275"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-sec-0050"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-sec-0269"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/appendices#CD012796-sec-0280"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/supinfo/CD012796StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/supinfo/CD012796StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Targeted therapy for metastatic renal cell carcinoma</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/information#CD012796-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Fabian Hofmann</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/information#CD012796-cr-0005">Eu Chang Hwang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/information#CD012796-cr-0006">Thomas BL Lam</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/information#CD012796-cr-0007">Axel Bex</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/information#CD012796-cr-0008">Yuhong Yuan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/information#CD012796-cr-0009">Lorenzo SO Marconi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012796.pub2/information#CD012796-cr-0010">Börje Ljungberg</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/information/en#CD012796-sec-0288">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 October 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012796.pub2">https://doi.org/10.1002/14651858.CD012796.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012796-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012796-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012796-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012796-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012796-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012796-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012796-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD012796-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012796-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012796-abs-0001" lang="en"> <section id="CD012796-sec-0001"> <h3 class="title" id="CD012796-sec-0001">Background</h3> <p>Several comparative randomised controlled trials (RCTs) have been performed including combinations of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors since the publication of a Cochrane Review on targeted therapy for metastatic renal cell carcinoma (mRCC) in 2008. This review represents an update of that original review. </p> </section> <section id="CD012796-sec-0002"> <h3 class="title" id="CD012796-sec-0002">Objectives</h3> <p>To assess the effects of targeted therapies for clear cell mRCC in patients naïve to systemic therapy. </p> </section> <section id="CD012796-sec-0003"> <h3 class="title" id="CD012796-sec-0003">Search methods</h3> <p>We performed a comprehensive search with no restrictions on language or publication status. The date of the latest search was 18 June 2020. </p> </section> <section id="CD012796-sec-0004"> <h3 class="title" id="CD012796-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials, recruiting patients with clear cell mRCC naïve to previous systemic treatment. The index intervention was any TKI‐based targeted therapy. </p> </section> <section id="CD012796-sec-0005"> <h3 class="title" id="CD012796-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed the included studies and extracted data for the primary outcomes: progression‐free survival (PFS), overall survival (OS) and serious adverse events (SAEs); and the secondary outcomes: health‐related quality of life (QoL), response rate and minor adverse events (AEs). We performed statistical analyses using a random‐effects model and rated the certainty of evidence according to the GRADE approach. </p> </section> <section id="CD012796-sec-0006"> <h3 class="title" id="CD012796-sec-0006">Main results</h3> <p>We included 18 RCTs reporting on 11,590 participants randomised across 18 comparisons. This abstract focuses on the primary outcomes of select comparisons. </p> <p><b>1. Pazopanib versus sunitinib</b> </p> <p>Pazopanib may result in little to no difference in PFS as compared to sunitinib (hazard ratio (HR) 1.05, 95% confidence interval (CI) 0.90 to 1.23; 1 study, 1110 participants; low‐certainty evidence). Based on the control event risk of 420 per 1000 in this trial at 12 months, this corresponds to 18 fewer participants experiencing PFS (95% CI 76 fewer to 38 more) per 1000 participants. Pazopanib may result in little to no difference in OS compared to sunitinib (HR 0.92, 95% CI 0.80 to 1.06; 1 study, 1110 participants; low‐certainty evidence). Based on the control event risk of 550 per 1000 in this trial at 12 months, this corresponds to 27 more OSs (95% CI 19 fewer to 70 more) per 1000 participants. Pazopanib may result in little to no difference in SAEs as compared to sunitinib (risk ratio (RR) 1.01, 95% CI 0.94 to 1.09; 1 study, 1102 participants; low‐certainty evidence). Based on the control event risk of 734 per 1000 in this trial, this corresponds to 7 more participants experiencing SAEs (95% CI 44 fewer to 66 more) per 1000 participants. </p> <p><b>2. Sunitinib versus avelumab and axitinib</b> </p> <p>Sunitinib probably reduces PFS as compared to avelumab plus axitinib (HR 1.45, 95% CI 1.17 to 1.80; 1 study, 886 participants; moderate‐certainty evidence). Based on the control event risk of 550 per 1000 in this trial at 12 months, this corresponds to 130 fewer participants experiencing PFS (95% CI 209 fewer to 53 fewer) per 1000 participants. Sunitinib may result in little to no difference in OS (HR 1.28, 95% CI 0.92 to 1.79; 1 study, 886 participants; low‐certainty evidence). Based on the control event risk of 890 per 1000 in this trial at 12 months, this would result in 29 fewer OSs (95% CI 78 fewer to 8 more) per 1000 participants. Sunitinib may result in little to no difference in SAEs (RR 1.01, 95% CI 0.93 to 1.10; 1 study, 873 participants; low‐certainty evidence). Based on the control event risk of 705 per 1000 in this trial, this corresponds to 7 more SAEs (95% CI 49 fewer to 71 more) per 1000 participants.  </p> <p><b>3. Sunitinib versus pembrolizumab and axitinib</b> </p> <p>Sunitinib probably reduces PFS as compared to pembrolizumab plus axitinib (HR 1.45, 95% CI 1.19 to 1.76; 1 study, 861 participants; moderate‐certainty evidence). Based on the control event risk of 590 per 1000 in this trial at 12 months, this corresponds to 125 fewer participants experiencing PFS (95% CI 195 fewer to 56 fewer) per 1000 participants. Sunitinib probably reduces OS (HR 1.90, 95% CI 1.36 to 2.65; 1 study, 861 participants; moderate‐certainty evidence). Based on the control event risk of 880 per 1000 in this trial at 12 months, this would result in 96 fewer OSs (95% CI 167 fewer to 40 fewer) per 1000 participants. Sunitinib may reduce SAEs as compared to pembrolizumab plus axitinib (RR 0.90, 95% CI 0.81 to 1.02; 1 study, 854 participants; low‐certainty evidence) although the CI includes the possibility of no effect. Based on the control event risk of 604 per 1000 in this trial, this corresponds to 60 fewer SAEs (95% CI 115 fewer to 12 more) per 1000 participants.  </p> <p><b>4. Sunitinib versus nivolumab and ipilimumab</b> </p> <p>Sunitinib may reduce PFS as compared to nivolumab plus ipilimumab (HR 1.30, 95% CI 1.11 to 1.52; 1 study, 847 participants; low‐certainty evidence). Based on the control event risk of 280 per 1000 in this trial at 30 months' follow‐up, this corresponds to 89 fewer PFSs (95% CI 136 fewer to 37 fewer) per 1000 participants. Sunitinib reduces OS (HR 1.52, 95% CI 1.23 to 1.89; 1 study, 847 participants; high‐certainty evidence). Based on the control event risk 600 per 1000 in this trial at 30 months, this would result in 140 fewer OSs (95% CI 219 fewer to 67 fewer) per 1000 participants. Sunitinib probably increases SAEs (RR 1.37, 95% CI 1.22 to 1.53; 1 study, 1082 participants; moderate‐certainty evidence). Based on the control event risk of 457 per 1000 in this trial, this corresponds to 169 more SAEs (95% CI 101 more to 242 more) per 1000 participants. </p> </section> <section id="CD012796-sec-0007"> <h3 class="title" id="CD012796-sec-0007">Authors' conclusions</h3> <p>Based on the low to high certainty of evidence, several combinations of immune checkpoint inhibitors appear to be superior to single‐agent targeted therapy in terms of PFS and OS, and with a favourable AE profile. Some single‐agent targeted therapies demonstrated a similar or improved oncological outcome compared to others; minor differences were observed for AE within this group. The certainty of evidence was variable ranging from high to very low and all comparisons were based on single trials. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012796-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012796-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012796-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012796-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012796-abs-0017">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012796-abs-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012796-abs-0012">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012796-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012796-abs-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD012796-abs-0010">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012796-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012796-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012796-abs-0002" lang="en"> <h3>Targeted drug treatment for kidney cancer which has spread</h3> <p><b>Review question</b> </p> <p>How effective is targeted drug treatment for patients with kidney cancer which has spread compared with other targeted drug treatments? </p> <p><b>Background</b> </p> <p>Kidney cancer which has spread was treated over the last decade with a group of drugs called targeted therapy which act specifically on molecular pathways. However, the last few years have seen the emergence of a promising, newer group of drugs called immune checkpoint inhibitors which exploit the immune system (hence called immunotherapy). Some of these drugs are currently used in combinations. This review assesses how effective targeted therapies are in comparison with different targeted therapies, immune checkpoint inhibitors or different combinations of these drugs. </p> <p><b>Study characteristics</b> </p> <p>We included only studies in which chance determined whether people got a targeted drug or other targeted drug, and which were reported in medical literature up to 18 June 2020. Most of the studies examined the effects on kidney cancer growth (called progression), survival (life expectancy) and serious unwanted effects. </p> <p><b>Key results</b> </p> <p>We found 18 studies that answered our review question. Participants included in these trials had metastatic (cancer that has spread to other parts of the body) or advanced cancer that could not be removed by surgery. We reported up‐to‐date comparisons that are most important to doctors and participants. </p> <p><b>1. Pazopanib versus sunitinib (targeted therapy versus targeted therapy)</b> </p> <p>Pazopanib may make little to no difference in progression, survival, and serious unwanted effects compared to sunitinib. </p> <p><b>2. Sunitinib versus avelumab and axitinib (targeted agent versus immunotherapy + targeted agent)</b> </p> <p>Sunitinib probably results in more progression but may make little to no difference on death and serious unwanted effects compared to avelumab and axitinib. </p> <p><b>3. Sunitinib versus pembrolizumab and axitinib (targeted agent versus immunotherapy + targeted agent)</b> </p> <p>Sunitinib probably results in more progression and death but may slightly reduce serious unwanted effects compared to pembrolizumab and axitinib. </p> <p><b>4. Sunitinib versus nivolumab and ipilimumab (targeted therapy versus combinations of immunotherapy)</b> </p> <p>Sunitinib may result in more progression and serious unwanted effects compared to nivolumab and ipilimumab. Sunitinib results in more deaths compared to combinations. </p> <p><b>Certainty of the evidence</b> </p> <p>The certainty of the evidence for most outcomes was low to high, meaning that there is some uncertainty regarding the findings. Nevertheless, there is sufficient data for us to make definitive conclusions regarding how these drugs should be used in the management of patients with kidney cancer which has spread. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012796-sec-0275" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012796-sec-0275"></div> <h3 class="title" id="CD012796-sec-0276">Implications for practice</h3> <section id="CD012796-sec-0276"> <p>Single‐agent vascular endothelial growth factor receptor‐tyrosine kinase inhibitors (VEGFR TKI), having being the first‐line treatment option in the management of metastatic RCC for years, appear to have been superseded by combinations of immune checkpoint inhibitors. However targeted therapy drugs have proved to be an effective treatment for those who cannot receive or tolerate immune checkpoint inhibition. </p> <p>At present two immune checkpoint inhibitor‐based combinations with proven OS benefit are available as new standard of care for first‐line treatment of clear‐cell mRCC (<a href="./references#CD012796-bbs2-0081" title="LjungbergB , AlbigesL , BensalahK , BexA , GilesRH , HoraM , et al. EAU Guidelines on Renal Cell Carcinoma. Edn. presented at the EAU Annual Congress Amsterdam. EAU Guidelines Office, 2020. 978-94-92671-07-3.">EAU Guidelines 2020</a>; <a href="./references#CD012796-bbs2-0083" title="EscudierB , PortaC , SchmidingerM , Rioux-LeclerqN , BexA , KhooV , et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology2019;30(5):706-20. [PMID: 30788497]">ESMO Clinical Practice Guidelines 2019</a>). In terms of comparative effectiveness within this new group of drugs, interpretation of data is limited by the short follow‐up of studies. ORR and PFS appear higher for the pembrolizumab plus axitinib combination than for ipilimumab plus nivolumab. With regard to complete response rates, it is possible they may improve for pembrolizumab plus axitinib, but decisive conclusions cannot be drawn at this stage. </p> </section> <h3 class="title" id="CD012796-sec-0277">Implications for research</h3> <section id="CD012796-sec-0277"> <p>Results of this review underpin the trend towards a wider field of application for targeted immunotherapy agents alone or in combination with classic targeted therapy in the first‐line setting. However, some of these drugs are already successfully used in further lines for treating metastatic renal cell carcinoma patients. Further research is needed to answer the question of how to sequence therapies. This is of special importance now that combinations of immune checkpoint inhibitors (pembrolizumab) and VEGFR‐TKI (axitinib) are being used in treatment‐naive patients. While it would be intuitive to use a VEGFR‐TKI upon progression with dual immune checkpoint inhibitor combination such as ipilimumab and nivolumab this is less clear for combinations with VEGFR‐TKI in the first‐line treatment setting. In addition, some trials are investigating triple combinations such as ipilimumab plus nivolumab plus cabozantinib (<a href="./references#CD012796-bbs2-0072" title="ChoueiriTK , AlbigesL , PowlesT , ScheffoldC , WangF , MotzerRJ , et al. A phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor-risk. Journal of Clinical Oncology2020;38(6_suppl):TPS767. [DOI: 10.1200/JCO.2020.38.6_suppl.TPS767]NCT03937219. Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (COSMIC-313). https://clinicaltrials.gov/ct2/show/NCT03937219 (first received June 2020). ">Choueiri 2019</a>), based on the emerging evidence that immune checkpoint inhibitor combination therapies are more effective than the same drugs in sequence. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012796-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012796-sec-0008"></div> <div class="table" id="CD012796-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Sorafenib compared to sunitinib (targeted agent versus targeted agent)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (any cell type)<br/><b>Setting:</b> Germany and the Netherlands/muticentre/likely outpatient<br/><b>Intervention:</b> Sorafenib<br/><b>Comparison:</b> Sunitinib </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Sunitinib</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Sorafenib</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> <p>(absolute effect size estimates based on survival rate at 10 months)<br/>follow‐up: mean 10.3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>365<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.19<br/>(0.92 to 1.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>340 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 fewer per 1000<br/>(148 fewer to 31 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 24 months)<br/>follow‐up: mean 10.3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>365<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.99<br/>(0.74 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>550 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 more per 1000<br/>(98 fewer to 92 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v3.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>353<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.99<br/>(0.85 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>670 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 fewer per 1000<br/>(101 fewer to 94 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><sup>5</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for study limitations; high risk of performance and detection bias and unclear risk of other bias </p> <p><sup>2</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (included harm and no harm) </p> <p><sup>3</sup> Downgraded by 1 level for study limitations; unclear risk of other bias </p> <p><sup>4</sup> Downgraded by 2 levels for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference: wide confidence interval (included both benefit and harm) </p> <p><sup>5</sup> Health‐related quality of life: no available data </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012796-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Pazopanib compared to sunitinib (targeted agent versus targeted agent)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (clear cell type)<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Pazopanib<br/><b>Comparison:</b> Sunitinib </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Sunitinib</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Pazopanib</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> <p>(absolute effect size estimates based on survival rate at 12 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1110<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.05<br/>(0.90 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>420 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 fewer per 1000<br/>(76 fewer to 38 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 24 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1110<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.92<br/>(0.80 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>550 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 more per 1000<br/>(19 fewer to 70 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v3.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1102<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(0.94 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>734 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 more per 1000<br/>(44 fewer to 66 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> (mean change value)<br/>assessed with: FACIT‐F (higher scores indicating less fatigue)<br/>Scale from: 0 to 52 </p> <p>follow‐up: after 4 cycle</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>467<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>5 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life (mean change value) was ‐6.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.6 higher<br/>(1.76 higher to 5.44 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>FACIT‐F:</b> Functional Assessment of Chronic Illness Therapy–Fatigue scale; <b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for study limitations; high risk of performance and detection bias and unclear risk of other bias </p> <p><sup>2</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (included harm and no harm) </p> <p><sup>3</sup> Downgraded by 1 level for study limitations; unclear risk of other bias </p> <p><sup>4</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (included no benefit and benefit) </p> <p><sup>5</sup> Downgraded by 1 level for study limitations; high risk of performance, detection and attrition bias and unclear risk of other bias </p> <p><sup>6</sup> Downgraded by 1 level for imprecision; confidence interval crossed the assumed threshold of a clinically important difference (3 points, included benefit and little benefit) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012796-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Tivozanib compared to sorafenib (targeted agent versus targeted agent)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (clear cell type)<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Tivozanib<br/><b>Comparison:</b> Sorafenib </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Sorafenib</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Tivozanib</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> <p>(absolute effect size estimates based on survival rate at 12 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>517<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.79<br/>(0.64 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>360 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86 more per 1000<br/>(4 more to 160 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 24 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>517<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.25<br/>(0.95 to 1.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>620 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 fewer per 1000<br/>(163 fewer to 15 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v3.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>516<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.85<br/>(0.74 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>689 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103 fewer per 1000<br/>(179 fewer to 21 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><br/>assessed with: EQ‐5D Health State Index<br/>Scale from: ‐0.59 (worst health state) to 1 (best health state)<br/>follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>506<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life was ‐0.06</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.01 higher<br/>(0.05 lower to 0.07 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>EQ‐5D:</b> EuroQol‐5D; <b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for imprecision; confidence interval crossed the assumed threshold of a clinically important difference (included benefit and little benefit) </p> <p><sup>2</sup> Downgraded by 1 level for study limitations; high risk of performance, detection and other bias </p> <p><sup>3</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (included harm and no harm) </p> <p><sup>4</sup> Downgraded by 1 level for study limitations; high risk of other bias </p> <p><sup>5</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (0.06 points, included benefit and no benefit) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012796-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Sorafenib compared to pazopanib (targeted agent versus targeted agent)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (any cell type)<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Sorafenib<br/><b>Comparison:</b> Pazopanib </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Pazopanib</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Sorafenib</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> <p>(absolute effect size estimates based on survival rate at 12 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>377<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.92<br/>(1.74 to 2.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>380 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>224 fewer per 1000<br/>(250 fewer to 194 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 24 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>377<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.22<br/>(0.91 to 1.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>520 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 fewer per 1000<br/>(178 fewer to 32 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v4.03 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>366<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.92<br/>(0.78 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>639 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 fewer per 1000<br/>(141 fewer to 58 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><br/>(mean change value)<br/>assessed with: FACIT‐F (higher scores indicating less fatigue)<br/>Scale from: 0 to 52 </p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>267<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>5 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life was ‐9.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.1 higher<br/>(1.82 lower to 8.02 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>FACIT‐F:</b> Functional Assessment of Chronic Illness Therapy–Fatigue scale; <b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for study limitations; unclear risk of selection, detection, and reporting bias and high risk of performance bias </p> <p><sup>2</sup> Downgraded by 1 level for study limitations; unclear risk of selection, and reporting bias </p> <p><sup>3</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (included harm and no harm) </p> <p><sup>4</sup> Downgraded by 2 levels for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference: wide confidence interval (included both benefit and harm) </p> <p><sup>5</sup> Downgraded by 1 level for study limitations; unclear risk of selection, detection, and reporting bias and high risk of performance and attrition bias </p> <p><sup>6</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (3 points, included benefit and no benefit) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012796-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Sunitinib compared to everolimus (targeted agent versus targeted agent)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (any cell type)<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Sunitinib<br/><b>Comparison:</b> Everolimus </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Everolimus</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Sunitinib</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> <p>(absolute effect size estimates based on survival rate at 12 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>471<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.71<br/>(0.59 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125 more per 1000<br/>(51 more to 191 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 24 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>471<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.90<br/>(0.72 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>470 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 more per 1000<br/>(37 fewer to 111 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v3.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>469<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.34<br/>(1.14 to 1.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>471 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160 more per 1000<br/>(66 more to 278 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><br/>assessed with: EORTC QLQ‐C30 (Global health status scale: high score represent better functioning)<br/>Scale from: 0 to 100<br/>follow‐up: 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>288<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life was 65.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 5 lower<br/>(10.4 lower to 0.4 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>EORTC QLQ‐C30:</b> European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; <b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for study limitations; high risk of performance, detection and other bias </p> <p><sup>2</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (included benefit and no benefit) </p> <p><sup>3</sup> Downgraded by 1 level for study limitations; high risk of other bias </p> <p><sup>4</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (10 points, included harm and no harm) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012796-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Sunitinib compared to avelumab + axitinib (targeted agent versus immunotherapy + targeted agent)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (clear cell type)<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Sunitinib<br/><b>Comparison:</b> Avelumab + Axitinib </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Avelumab + Axitinib</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Sunitinib</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b><br/>(absolute effect size estimates based on survival rate at 12 months) </p> <p>follow‐up: median 10.8 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>886<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.45<br/>(1.17 to 1.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>550 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130 fewer per 1000<br/>(209 fewer to 53 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 12 months)<br/>follow‐up: median 12.0 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>886<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.28<br/>(0.92 to 1.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>890 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 fewer per 1000<br/>(78 fewer to 8 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v4.03 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>873<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(0.93 to 1.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>705 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 more per 1000<br/>(49 fewer to 71 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><sup>4</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for study limitations: high risk of performance bias and unclear risk of reporting bias </p> <p><sup>2</sup> Downgraded by 1 level for imprecision: confidence interval crossed the assumed threshold of a clinically important difference (included no benefit and harm) </p> <p><sup>3</sup> Downgraded by 1 level for study limitations: unclear risk of reporting bias </p> <p><sup>4</sup> Health‐related quality of life: no available data </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012796-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Sunitinib compared to pembrolizumab + axitinib (targeted agent versus immunotherapy + targeted agent)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (clear cell type)<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Sunitinib<br/><b>Comparison:</b> Pembrolizumab + Axitinib </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Pembrolizumab + Axitinib</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Sunitinib</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b><br/>(absolute effect size estimates based on survival rate at 12 months) </p> <p>follow‐up: median 12.8 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>861<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.45<br/>(1.19 to 1.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>590 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125 fewer per 1000<br/>(195 fewer to 56 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 12 months)<br/>follow‐up: median 12.8 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>861<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.90<br/>(1.36 to 2.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>880 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 fewer per 1000<br/>(167 fewer to 40 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v4.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>854<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/>(0.81 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>604 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 fewer per 1000<br/>(115 fewer to 12 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><sup>4</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for study limitations; high risk of performance bias </p> <p><sup>2</sup> Downgraded by 1 level for imprecision; confidence interval crossed the assumed threshold of a clinically important difference (included harm and little harm) </p> <p><sup>3</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (included benefit and no benefit) </p> <p><sup>4</sup> Health‐related quality of life: no available data </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012796-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Sunitinib compared to atezolizumab + bevacizumab (targeted agent versus immunotherapy + targeted agent)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (clear cell type)<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Sunitinib<br/><b>Comparison:</b> Atezolizumab + Bevacizumab </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Atezolizumab + Bevacizumab</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Sunitinib</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b><br/>(absolute effect size estimates based on survival rate at 12 months) </p> <p>follow‐up: range 15 months to 20.7 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1117<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.18<br/>(1.02 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>480 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 fewer per 1000<br/>(111 fewer to 7 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b><br/>(absolute effect size estimates based on survival rate at 24 months) </p> <p>follow‐up: range 20.7 months to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1117<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.99<br/>(0.73 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>630 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 more per 1000<br/>(89 fewer to 84 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v4.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1098<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2 4 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.22<br/>(1.00 to 1.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>446 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 more per 1000<br/>(0 fewer to 218 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><br/>assessed with: MDASI (high score indicates worse QoL)<br/>Scale from: 0 to 10<br/>follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>691<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life ranged from 0.56 to 1.57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1 higher<br/>(0.68 higher to 1.32 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>HR:</b> Hazard ratio; <b>MDASI:</b> MD Anderson Symptom Inventory; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for imprecision; confidence interval crossed the assumed threshold of a clinically important difference (included harm and little harm) </p> <p><sup>2</sup> Downgraded by 1 level for study limitations; high and unclear risk of 1 or more domains. </p> <p><sup>3</sup> Downgraded by 2 levels for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference: wide confidence interval (included both benefit and harm) </p> <p><sup>4</sup> Downgraded by 1 level for inconsistency; moderate to substantial heterogeneity: unexplained differences between study results </p> <p><sup>5</sup> Downgraded by 1 level for imprecision; confidence interval reached the line of no difference and crossed the assumed threshold of a clinically important difference (included harm and no harm) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012796-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Sunitinib compared to IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted agent)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (clear cell type)<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Sunitinib<br/><b>Comparison:</b> IMA901 + Sunitinib </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with IMA901 + Sunitinib</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Sunitinib</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> <p>(absolute effect size estimates based on survival rate at 12 months)<br/>follow‐up: median 33.27 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>339<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.95<br/>(0.70 to 1.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>590 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 more per 1000<br/>(86 fewer to 101 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 12 months)<br/>follow‐up: median 33.27 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>339<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.75<br/>(0.54 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 more per 1000<br/>(7 fewer to 86 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse</b> events (Grade 3 or 4)<br/>assessed with: CTCAE v4.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>334<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.74<br/>(0.59 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>550 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143 fewer per 1000<br/>(225 fewer to 27 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><sup>6</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 2 levels for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference: wide confidence interval (included both benefit and harm) </p> <p><sup>2</sup> Downgraded by 1 level for study limitations; high risk of performance and other bias </p> <p><sup>3</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (included benefit and no benefit) </p> <p><sup>4</sup> Downgraded by 1 level for study limitations: high risk of other bias </p> <p><sup>5</sup> Downgraded by 1 level for imprecision; confidence interval crossed the assumed threshold of a clinically important difference (included benefit and little benefit) </p> <p><sup>6</sup> Health‐related quality of life: no available data </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012796-tbl-0010"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Sunitinib compared to interferon‐α (IFN‐α) (targeted agent versus classic immunotherapy)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (clear cell type)<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Sunitinib<br/><b>Comparison:</b> Interferon‐α (IFN‐α) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Interferon‐α (IFN‐α)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Sunitinib</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> <p>(absolute effect size estimates based on survival rate at 6 months)<br/>follow‐up: median 31 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>750<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.54<br/>(0.45 to 0.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210 more per 1000<br/>(156 more to 262 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 24 months)<br/>follow‐up: median 31 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>750<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.82<br/>(0.67 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>480 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 more per 1000<br/>(0 fewer to 132 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed as: CTCAE v3.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>735<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.75<br/>(1.43 to 2.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>258 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194 more per 1000<br/>(111 more to 300 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><br/>assessed with: EQ‐5D Health State Index<br/>Scale from: ‐0.59 (worst health state) to 1 (best health state) </p> <p>follow‐up: after 2 cycle</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>544<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life was 0.74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.01 lower<br/>(0.05 lower to 0.03 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval;<b>EQ‐5D:</b> EuroQol‐5D; <b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for study limitations; unclear risk of selection bias and high risk of performance and other bias </p> <p><sup>2</sup> Downgraded by 1 level for study limitations; unclear risk of selection bias and high risk of other bias </p> <p><sup>3</sup> Downgraded by 1 level for imprecision; confidence interval reached the line of no difference and crossed the assumed threshold of a clinically important difference (included benefit and no benefit) </p> <p><sup>4</sup> Downgraded by 1 level for study limitations; unclear risk of selection and attrition bias and high risk of performance and other bias </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012796-tbl-0011"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Temsirolimus compared to IFN‐α (targeted agent versus classic immunotherapy)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (any cell type [80% clear cell])<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Temsirolimus<br/><b>Comparison:</b> IFN‐α </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with IFN‐α</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Temsirolimus</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> (absolute effect size estimates based on survival rate at 12 months) </p> <p>follow‐up: up to 80 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>416<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.74<br/>(0.60 to 0.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82 more per 1000<br/>(23 more to 151 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival survival (</b>absolute effect size estimates based on survival rate at 12 months ) </p> <p>follow‐up: up to 80 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>416<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.78<br/>(0.63 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 more per 1000<br/>(11 more to 168 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE version: not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>408<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/>(0.76 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>780 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109 fewer per 1000<br/>(187 fewer to 23 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> <br/>assessed with: EQ‐5D Health State Index<br/>Scale from: ‐0.59 (worst health state) to 1 (best health state) </p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>401<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life was 0.66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.03 higher<br/>(0.01 lower to 0.07 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>EQ‐5D:</b> EuroQol‐5D; <b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for imprecision; confidence interval crossed the assumed threshold of a clinically important difference (included benefit and no benefit) </p> <p><sup>2</sup> Downgraded by 1 level for study limitations; high risk of performance and detection bias </p> <p><sup>3</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (included benefit and no benefit) </p> <p><sup>4</sup> Downgraded by 1 level for study limitations; high risk of performance, detection and attrition bias </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012796-tbl-0012"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 12.</span> <span class="table-title">Sunitinib compared to atezolizumab (targeted therapy versus immunotherapy)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (clear cell type)<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Sunitinib<br/><b>Comparison:</b> Atezolizumab </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Atezolizumab</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Sunitinib</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> <p>(absolute effect size estimates based on survival rate at 12 months)<br/>follow‐up: median 20.7 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>204<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.84<br/>(0.58 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>420 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 more per 1000<br/>(73 fewer to 185 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 24 months)<br/>follow‐up: median 20.7 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>204<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.94<br/>(0.58 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>630 per 1000 <sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 more per 1000<br/>(139 fewer to 135 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v4.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>203<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.73<br/>(1.32 to 2.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>398 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>291 more per 1000<br/>(127 more to 506 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><br/>assessed with: MDASI (high score indicates worse QoL)<br/>Scale from: 0 to 10<br/>follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>157<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>4 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life was 1.04</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.46 higher<br/>(0.8 higher to 2.12 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>HR:</b> Hazard ratio; <b>MDASI:</b> MD Anderson Symptom Inventory; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 2 levels for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference: wide confidence interval (included both benefit and harm) </p> <p><sup>2</sup> Downgraded by 1 level for study limitations; high risk of selection, performance and detection bias and unclear risk of other bias </p> <p><sup>3</sup> Downgraded by 1 level for study limitations; high risk of selection and unclear risk of other bias </p> <p><sup>4</sup> Downgraded by 1 level for imprecision; confidence interval crossed the assumed threshold of a clinically important difference (1 point, included harm and little harm) </p> <p><sup>5</sup> Downgraded by 1 level for study limitations; high risk of selection, performance and detection bias and unclear risk of other bias </p> <p><sup>6</sup> Baseline risk for overall survival in the atezolizumab group was assumed to be 63% (moderate risk) at 24 months as reported in <a href="./references#CD012796-bbs2-0017" title="AtkinsMB , RiniBI , MotzerRJ , PowlesT , McDermottDF , SuarezC , et al. Patient-reported outcomes from the phase 3 randomized IMmotion151 trial: atezolizumab + bevacizumab vs sunitinib in treatment-naive metastatic renal cell carcinoma. Clinical Cancer Research2020;26(11):2506-2514. EscudierB , MotzerRJ , RiniBI , PowlesT , McDermottDF , SuarezC , et al. Patient-reported outcomes (PROs) in IMmotion151: atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2018;36(15_suppl):4511. [DOI: 10.1200/JCO.2018.36.15_suppl.4511]MotzerRJ , PowlesT , AtkinsMB , EscudierB , McDermottDF , SuarezC , et al. IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2018;36(6 suppl):578. [DOI: 10.1200/JCO.2018.36.6_suppl.578]NCT02420821. A study of atezolizumab in combination with bevacizumab versus sunitinib in participants with untreated advanced renal cell carcinoma (RCC) (IMmotion151) [A phase III, open-label, randomized study of atezolizumab (Anti-PD-L1 Antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT02420821 (first received 20 April 2015). [NCT02420821]RiniBI , PowlesT , AtkinsMB , EscudierB , McDermottDF , SuarezC , et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet2019;393(10189):2404-15. [PMID: 31079938]">Rini 2019b</a> </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012796-tbl-0013"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 13.</span> <span class="table-title">Bevacizumab + IFN compared to IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (clear cell type)<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Bevacizumab + IFN<br/><b>Comparison:</b> IFN (+ placebo) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with IFN (+ placebo)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Bevacizumab + IFN</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> <p>(absolute effect size estimates based on survival rate at 12 months)</p> <p>follow‐up: intervention: 13.3 months</p> <p>comparator: 12.8 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1381<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.68<br/>(0.60 to 0.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135 more per 1000<br/>(90 more to 181 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 24 months)</p> <p>follow‐up: intervention: 23 months</p> <p>comparator: 21 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1381<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.88<br/>(0.79 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 more per 1000<br/>(3 more to 78 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v3.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1356<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.31<br/>(1.20 to 1.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>536 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166 more per 1000<br/>(107 more to 225 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><sup>3</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for study limitations; high and unclear risk of 1 or more domains </p> <p><sup>2</sup> Downgraded by 1 level for imprecision; confidence interval crossed the assumed threshold of a clinically important difference (included benefit and little benefit) </p> <p><sup>3</sup> Health‐related quality of life: no available data </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012796-tbl-0014"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 14.</span> <span class="table-title">Temsirolimus + IFN‐α compared to IFN‐α (targeted agent + classic immunotherapy versus classic immunotherapy)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (any cell type [80% clear cell])<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Temsirolimus + IFN‐α<br/><b>Comparison:</b> IFN‐α </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with IFN‐α</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Temsirolimus + IFN‐α</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> (absolute effect size estimates based on survival rate at 12 months) follow‐up: up to 80 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>417<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.76<br/>(0.62 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74 more per 1000<br/>(17 more to 140 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 12 months) follow‐up: up to 80 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>417<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.93<br/>(0.75 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 more per 1000<br/>(50 fewer to 105 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE version: not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>408<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.12<br/>(1.02 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>780 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94 more per 1000<br/>(16 more to 172 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> <br/>assessed with: EQ‐5D Health State Index<br/>Scale from: ‐0.59 (worst health state) to 1 (best health state) </p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>394<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>5 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life was 0.66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.03 higher<br/>(0.01 lower to 0.07 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>EQ‐5D:</b> EuroQol‐5D; <b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for imprecision; confidence interval crossed the assumed threshold of a clinically important difference (included benefit and no benefit) </p> <p><sup>2</sup> Downgraded by 1 level for study limitations; high risk of performance and detection bias </p> <p><sup>3</sup> Downgraded by 2 levels for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference: wide confidence interval (included both benefit and harm) </p> <p><sup>4</sup> Downgraded by 1 level for imprecision; confidence interval crossed the assumed threshold of a clinically important difference (included harm and no harm) </p> <p><sup>5</sup> Downgraded by 1 level for study limitations; high risk of performance, detection and attrition bias </p> <p><sup>6</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (included benefit and no benefit) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012796-tbl-0015"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 15.</span> <span class="table-title">Temsirolimus + bevacizumab compared to bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (any cell type [80% clear cell])<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Temsirolimus + Bevacizumab<br/><b>Comparison:</b> Bevacizumab + IFN‐α </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Bevacizumab + IFN‐α</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Temsirolimus + Bevacizumab</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> <p>(absolute effect size estimates based on survival rate at 12 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>791<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.10<br/>(0.90 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>420 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 fewer per 1000<br/>(107 fewer to 38 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 24 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>791<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.08<br/>(0.90 to 1.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>550 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 fewer per 1000<br/>(90 fewer to 34 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v3.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>784<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05<br/>(0.98 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>760 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 more per 1000<br/>(15 fewer to 99 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><sup>3</sup> </p> <p>assessed with: FKSI–15</p> <p>Scale from: 0 to 60</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>no available data</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>FKSI:</b> Functional Assessment of Cancer Therapy–Kidney Symptom Index; <b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (included harm and no harm) </p> <p><sup>2</sup> Downgraded by 1 level for study limitations; high risk of performance bias (we are not concerned with unclear risk of other bias) </p> <p><sup>3</sup> Health‐related quality of life: no available data </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012796-tbl-0016"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 16.</span> <span class="table-title">Everolimus + bevacizumab compared to IFN α‐2a + bevacizumab (targeted agent + targeted agent versus targeted agent + classic immunotherapy)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (any cell type)<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Everolimus + Bevacizumab<br/><b>Comparison:</b> IFN α‐2a + Bevacizumab </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with IFN α‐2a + Bevacizumab</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Everolimus + Bevacizumab</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> <p>(absolute effect size estimates based on survival rate at 18 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>365<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.91<br/>(0.69 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 more per 1000<br/>(61 fewer to 134 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 24 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>365<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.01<br/>(0.75 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>533 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 fewer per 1000<br/>(108 fewer to 91 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v3.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>361<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.06<br/>(0.95 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>762 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 more per 1000<br/>(38 fewer to 137 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><sup>5</sup><br/>assessed with: EORTC QLQ‐C30 (Global health status scale: high score represent better functioning)<br/>Scale from: 0 to 100 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>no available data</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>EORTC QLQ‐C30:</b> European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; <b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for study limitations; unclear risk of selection, performance and other bias and high risk of detection bias </p> <p><sup>2</sup> Downgraded by 2 levels for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference: wide confidence interval (included both benefit and harm) </p> <p><sup>3</sup> Downgraded by 1 level for study limitations; unclear risk of selection and other bias </p> <p><sup>4</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (included harm and no harm) </p> <p><sup>5</sup> Health‐related quality of life: no available data </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012796-tbl-0017"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 17.</span> <span class="table-title">Sunitinib compared to nivolumab + ipilimumab (targeted agent versus combinations of immunotherapy)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Sunitinib<br/><b>Comparison:</b> Nivolumab + Ipilimumab </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Nivolumab + Ipilimumab</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Sunitinib</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> <p>(absolute effect size estimates based on survival rate at 30 months)<br/>follow‐up: median 32.4 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>847<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.30<br/>(1.11 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>280 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89 fewer per 1000<br/>(136 fewer to 37 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 30 months)<br/>follow‐up: median 32.4 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>847<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.52<br/>(1.23 to 1.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140 fewer per 1000<br/>(219 fewer to 67 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v4.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1082<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.37<br/>(1.22 to 1.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>457 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169 more per 1000<br/>(101 more to 242 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><br/>assessed with: FKSI‐19 (higher scores indicating fewer symptoms) </p> <p>Scale from: 0 to 76<br/>follow‐up: 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>460<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life was 2.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 4.1 lower<br/>(5.75 lower to 2.45 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>FKSI:</b> Functional Assessment of Cancer Therapy–Kidney Symptom Index<b>HR:</b> Hazard ratio; <b>IMDC:</b> International Metastatic Renal Cell Carcinoma Database Consortium; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for imprecision; confidence interval crossed the assumed threshold of a clinically important difference (included harm and no harm) </p> <p><sup>2</sup> Downgraded by 1 level for study limitations; high risk of performance and detection bias </p> <p><sup>3</sup> Downgraded by 1 level for study limitations; high risk of performance and detection bias and unclear risk of attrition bias </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012796-tbl-0018"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 18.</span> <span class="table-title">Pazopanib compared to placebo (targeted agent versus placebo)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type)<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Pazopanib<br/><b>Comparison:</b> Placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Placebo</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Pazopanib</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> <p>(absolute effect size estimates based on survival rate at 12 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>435<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.46<br/>(0.34 to 0.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>274 more per 1000<br/>(165 more to 378 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 24 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>435<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.91<br/>(0.72 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>480 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 more per 1000<br/>(53 fewer to 110 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v3.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>435<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.00<br/>(1.40 to 2.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 more per 1000<br/>(80 more to 370 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><br/>assessed with: EORTC QLQ‐C30 (Global health status scale: high score represent better functioning but negative change from baseline represents a worsening condition)<br/>Scale from: 0 to 100<br/>follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life was ‐0.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.1 lower<br/>(7.76 lower to 1.56 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>EORTC QLQ‐C30:</b> European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; <b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 2 levels for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (included both benefit and harm) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012796-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012796-sec-0009"></div> <section id="CD012796-sec-0010"> <h3 class="title" id="CD012796-sec-0010">Description of the condition</h3> <p>Renal cell carcinoma (RCC) incidence represents about 2.2% of all invasive cancers and has a projected 2018 population age‐standardised mortality rate of 1.8 per 100,000 worldwide (<a href="./references#CD012796-bbs2-0086" title="BrayF , FerlayJ , SoerjomataramI , SiegelRL , TorreLA , JemalA . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians2018;68(6):394-424. [PMID: 30207593]">GLOBOCAN 2018</a>; <a href="./references#CD012796-bbs2-0097" title="HowladerN , NooneAM , KrapchoM , MillerD , BishopK , KosaryCL , et al (eds). SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD. seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017.">Howlader 2017</a>). Two‐thirds of cases occur in men. These figures include both renal cell carcinoma and the less common urothelial carcinoma of the renal pelvis: the latter is biologically related to bladder cancer and we do not consider it here. Renal cell carcinoma is divided into different pathologic subtypes, of which the clear cell subtype represents about 75% (<a href="./references#CD012796-bbs2-0114" title="SrigleyJR , DelahuntB , EbleJN , EgevadL , EpsteinJI , GrignonD , et al. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. American Journal of Surgical Pathology2013;37(10):1469-89. [PMID: 24025519]">Srigley 2013</a>). The more uncommon subtypes are collectively referred to by clinicians as non‐clear renal cell carcinomas: they respond differently to treatment as compared to clear cell renal cell carcinoma (<a href="./references#CD012796-bbs2-0084" title="Fernández-PelloS , HofmannF , TahbazR , MarconiL , LamTB , AlbigesL , et al. A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma. European Urology2017;71(3):426-43. [PMID: 27939075]">Fernández‐Pello 2017</a>). Death from renal cell carcinoma is usually from metastases, either detected during staging of newly‐diagnosed patients (Stage IV) or detected during follow‐up after nephrectomy. A minority of patients are diagnosed with locally advanced disease which is too advanced for surgical resection but without metastatic findings. The term 'advanced renal cell carcinoma' has been used by authors to include both metastatic and locally advanced disease that have aspects that require separate consideration. </p> <p>There has been great interest in finding more effective treatments for metastatic renal cell carcinoma. The search for specific targets for therapy goes back at least to Paul Ehrlich's 'magic bullet' over a century ago (<a href="./references#CD012796-bbs2-0117" title="StrebhardtK , UllrichA . Paul Ehrlich's magic bullet concept: 100 years of progress. Nature Reviews Cancer2008;8(6):473-80. [PMID: 18469827]">Strebhardt 2008</a>). This concept has gained renewed interest owing to the identification of multiple molecular targets and the potential for associated therapies that are target‐specific and therefore might have greater efficacy with less toxicity (<a href="./references#CD012796-bbs2-0111" title="SawyersC . Targeted cancer therapy. Nature2004;432(7015):294-7. [PMID: 15549090]">Sawyers 2004</a>). Clinical proof of concept came with the remarkable success of single‐agent imatinib for chronic myeloid leukaemia (<a href="./references#CD012796-bbs2-0080" title="DeiningerM , BuchdungerE , DrukerBJ . The development of imatinib as a therapeutic agent for chronic myeloid leukeamia. Blood2005;105(7):2640-53. [PMID: 15618470]">Deininger 2005</a>). Here we review the subsequent development of targeted therapy for metastatic renal cell carcinoma. </p> </section> <section id="CD012796-sec-0011"> <h3 class="title" id="CD012796-sec-0011">Description of the intervention</h3> <p>Prior to the development of targeted agents, renal cell carcinoma was one of the most drug‐resistant malignancies. Hormonal and cytotoxic chemotherapy agents have not been demonstrated to improve overall survival (OS) for this condition, and remissions with those agents occur at a frequency similar to that seen with no therapy or with placebo (<a href="./references#CD012796-bbs2-0085" title="GleaveME , ElhilaliM , FradetY , DavisI , VennerP , SaadF , et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. New England Journal of Medicine1998;338(18):1265-71. [PMID: 9562580]">Gleave 1998</a>; <a href="./references#CD012796-bbs2-0105" title="OliverRTD , NethersellABW , BottomlyJM . Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. British Journal of Urology1989;63(2):128-31. [PMID: 2702395]">Oliver 1989</a>). Until the past decades, immunotherapy was the main focus of the search for an effective drug therapy for renal cell carcinoma and was the main initial comparator for targeted therapy; it was the subject of a companion Cochrane Review (<a href="./references#CD012796-bbs2-0077" title="CoppinC , PorzsoltF , AutenriethM , KumpfJ , ColdmanA , WiltT . Immunotherapy for advanced renal cell cancer. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD001425. [DOI: 10.1002/14651858.CD001425.pub2]">Coppin 2004</a>). In summary, classic immunotherapy, for example interferon‐alpha or interleukin‐2, has been associated with very modest survival benefit at best. When targeted agents were first being evaluated, the immunotherapy agent interferon‐alpha was considered the standard comparator for first‐line therapy of metastatic renal cell carcinoma (<a href="./references#CD012796-bbs2-0103" title="MickischGH . Rational selection of a control arm for randomised trials in metastatic renal cell carcinoma. European Urology2003;43(6):670-9. [PMID: 12767369]">Mickisch 2003</a>; <a href="./references#CD012796-bbs2-0104" title="MotzerRJ , BacikJ , MurphyBA , RussoP , MazumdarM . Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. Journal of Clinical Oncology2002;20(1):289-96. [PMID: 11773181]">Motzer 2002</a>); placebo‐controlled trials have been appropriate in the second‐line setting. One should be aware that the distribution of prognostic risk strata in clinical trials is changing to a more favourable profile, such that direct comparisons of interventions through head‐to‐head clinical trials remain essential (<a href="./references#CD012796-bbs2-0106" title="PatilS , IshillN , DelucaJ , MotzerRJ . Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients. Cancer2010;116(2):347-54. [PMID: 19921736]">Patil 2010</a>). </p> <p>Molecular pathways with multiple targets that are of particular interest in renal cell carcinoma currently fall into two major groups: angiogenesis (<a href="./references#CD012796-bbs2-0109" title="RiniBI , SmallEJ . Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. Journal of Clinical Oncology2005;23(5):1028-43. [PMID: 15534359]">Rini 2005</a>), and intracellular signal transduction pathways (<a href="./references#CD012796-bbs2-0075" title="AdjeiAA , HidalgoM . Intracellular signal transduction pathway proteins as targets for cancer therapy. Journal of Clinical Oncology2005;23(23):5386-403. [PMID: 15983388]">Adjei 2005</a>). The presence of a target may or may not translate into benefit from a targeted agent (<a href="./references#CD012796-bbs2-0076" title="BergslandEK . When does the presence of the target predict response to the targeted agent?Journal of Clinical Oncology2006;24(2):213-6. [PMID: 16365177]">Bergsland 2006</a>). Some agents have activity against multiple targets. Classic immunotherapies such as interferon‐alpha may have anti‐angiogenic activity but are considered a separate class of agent (<a href="./references#CD012796-bbs2-0077" title="CoppinC , PorzsoltF , AutenriethM , KumpfJ , ColdmanA , WiltT . Immunotherapy for advanced renal cell cancer. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD001425. [DOI: 10.1002/14651858.CD001425.pub2]">Coppin 2004</a>). Suitably large randomised controlled trials have a high financial and resource cost, so that selection of agents for phase III testing requires strategic decision‐making (<a href="./references#CD012796-bbs2-0110" title='Roberts TG Jr, Lynch TJ Jr, ChabnerBA . The phase III trial in the era of targeted therapy: unravelling the "go or no go" decision. Journal of Clinical Oncology2003;21(19):3683-95. [PMID: 14512401]'>Roberts 2003</a>). </p> <p>A new class of drugs has been introduced into the treatment paradigm of clear cell RCC (<a href="./references#CD012796-bbs2-0047" title="MotzerRJ , EscudierB , McDermottDF , GeorgeS , HammersHJ , SrinivasS , et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine2015;373(19):1803-13. [PMID: 26406148]">Motzer 2015a</a>). Immune checkpoint inhibitors are a new type of targeted immunotherapy and have been very successfully tested in other immunogenic tumours such as melanoma. </p> <p>Since neither multi‐kinase inhibitors nor immune checkpoint inhibitors are necessarily cytotoxic, it is possible that tumour shrinkage may not be a reliable indicator of drug activity (<a href="./references#CD012796-bbs2-0115" title="StadlerWM . New targets, therapies, and toxicities: lessons to be learned. Journal of Clinical Oncology2006;24(1):4-5. [PMID: 16314613]">Stadler 2006</a>); for example, objective stabilisation of previously progressive disease might result in extension of OS. This is especially the case for immune checkpoint inhibition which in second‐line RCC treatment leads to prolonged OS without benefit in progression‐free survival (PFS). </p> <p>Drug therapy for metastatic renal cell carcinoma has yet to demonstrate curative potential. Improvement in OS is the preferred and definitive outcome of interest to patients, and is a realistic outcome if there is only one effective intervention for an incurable cancer, as was the situation for metastatic renal cell carcinoma at the beginning of the targeted era (i.e. from 2000 onwards). However, when participants with progressive cancer in one arm of a randomised trial are permitted cross‐over to the other arm, as is commonly done for ethical reasons or to enhance recruitment, then any survival benefit (or detriment) of the investigational agent might be obscured; the same problem might happen if sequential active therapies are applied. For these reasons and as in other cancer sites, the duration of freedom from cancer progression may be accepted by regulatory bodies as adequate evidence of benefit for drug approval purposes (<a href="./references#CD012796-bbs2-0098" title="JohnsonJR , Ning Y-M, FarrellA , JusticeR , KeeganP , PazdurR . Accelerated approval of oncology products: the Food and Drug Adminstration experience. Journal of the National Cancer Institute2011;103(8):636-44. [PMID: 21422403]">Johnson 2011</a>). Surrogate endpoints such as PFS should preferably be accompanied by patient‐reported outcomes. </p> </section> <section id="CD012796-sec-0012"> <h3 class="title" id="CD012796-sec-0012">How the intervention might work</h3> <p>Molecular analysis of renal cell carcinoma has shown that this cancer is not a homogeneous condition (<a href="./references#CD012796-bbs2-0090" title="HackerKE , RathmellWK . Emerging molecular classification in renal cell carcinoma: implications for drug development. Targeted Oncology2010;5(2):75-84. [PMID: 20645016]">Hacker 2010</a>; <a href="./references#CD012796-bbs2-0102" title="LinehanWM , GrubbRL , ColemanJA , ZbarB , WaltherMM . The genetic basis of cancer of kidney cancer: implications for gene-specific clinical management. BJU International2005;95 Suppl 2:2-7. [PMID: 15720328]">Linehan 2005</a>). A high proportion of sporadic clear cell renal cell carcinomas have biallelic abnormalities of the Von Hippel‒Lindau (VHL) tumour‐suppressor gene (<a href="./references#CD012796-bbs2-0122" title="YoungAC , CravenRA , CohenD , TaylorC , BoothC , HarndenP , et al. Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clinical Cancer Research2009;15(24):7582-92. [PMID: 19996202]">Young 2009</a>), whereas other subtypes do not. Absence of the active VHL gene produces results in unregulated activation of the hypoxia‐inducible system and accumulation of growth factors such as vascular endothelial growth factor (VEGF). In subtypes such as papillary and chromophobe RCC, other pathways such as MET proto‐oncogene (MET) and tuberous sclerosis (TSC) alterations have been identified through investigation of hereditary and sporadic forms. Therefore the mainstays of first‐line therapy until now are multi‐kinase inhibitors targeting predominantly the VEGF‐receptor kinases but other targets are included to various degrees, such as MET, AXL receptor tyrosine kinase (AXL), platelet‐derived growth factor receptor (PDGFR) and epidermal growth factor receptor (EGFR). Immune checkpoint inhibitors targeting the programmed death‐ligand (PD‐L1) or its receptor (PD‐1) have been tested successfully in second‐ and third‐line treatments after failure of one or two lines of VEGFR‐targeting therapies (<a href="./references#CD012796-bbs2-0047" title="MotzerRJ , EscudierB , McDermottDF , GeorgeS , HammersHJ , SrinivasS , et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine2015;373(19):1803-13. [PMID: 26406148]">Motzer 2015a</a>). These drugs counteract the tumour‐driven inhibition of T‐cell receptor‐mediated activation of IL‐2 production and T‐cell proliferation which leads to a successful anti‐tumour T‐cell‐mediated immune activity. Currently, these drugs are tested in first‐line trials in combination with either multi‐kinase inhibitors or other monoclonal antibodies targeting circulating VEGF or anti‐CTLA4 against the current first‐line monotherapy with VEGFR‐targeted therapies. With more treatment options being approved and investigated, it will be necessary to distinguish the impact of therapy on different molecularly‐defined tumour types as well as on tumours which have been treated with previous lines of therapy to better select patients for a given drug based on their predicted outcome. Although available, the necessary technology is not yet used in clinical routine. The molecular complexities of both the disease (renal cell carcinoma) and the treatment (targeted therapy) are resulting in a rapidly‐evolving and exciting phase in the history of the treatment of metastatic disease. According to <a href="./references#CD012796-bbs2-0119" title="UzzoRG , CairnsP , Al-SaleemT , HudesG , HaasN , GreenbergRE , et al. The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician. Urologic Clinics of North America2003;30(3):423-36. [PMID: 12953746]">Uzzo 2003</a>, "an understanding of the basic biology of renal cell carcinoma is more advanced than that of any other solid malignancy." Further molecular subclassification within clear cell renal cell carcinoma may well become feasible (<a href="./references#CD012796-bbs2-0099" title="Kaelin WG Jr. Kidney cancer: now available in a new flavor. Cancer Cell2008;14(6):423-4. [PMID: 19061830]">Kaelin 2008</a>). </p> </section> <section id="CD012796-sec-0013"> <h3 class="title" id="CD012796-sec-0013">Why it is important to do this review</h3> <p>The topic of this review is systemic therapy of treatment‐naïve metastatic renal cell carcinoma, an important type of malignancy for which the therapy has changed greatly over the past decade and continues to be a strong focus of development of new agents and comparative studies. This review is needed to provide an objective and up‐to‐date resource for researchers, clinicians and consumers. </p> <p>This is an update of a Cochrane Review first published in 2008 and previously updated in 2011 (<a href="./references#CD012796-bbs2-0124" title="CoppinC , LeL , WiltTJ , KollmannsbergerC . Targeted therapy for advanced renal cell carcinoma. Cochrane Database of Systematic Reviews2008, Issue 2. Art. No: CD006017. [DOI: 10.1002/14651858.CD006017.pub2]">Coppin 2008</a>; <a href="./references#CD012796-bbs2-0125" title="CoppinC , KollmannsbergerC , LeL , PorzsoltF , WiltTJ . Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU International2011;108(10):1556-63. [PMID: 21952069]">Coppin 2011</a>). Since the last date of full literature search, a number of additional studies have been published and there is an evolving shift to using previously validated targeted agents as the comparator rather than placebo, quasi‐placebo such as hormone therapy, or immunotherapy such as interferon‐alpha. There is also increasing emphasis on second‐line therapy now that targeted agents are established for first‐line therapy of metastatic renal cell carcinoma. In addition, new agents such as immune checkpoint inhibitors are increasingly being compared against first‐line standard therapies (<a href="./references#CD012796-bbs2-0100" title="KuuskT , AlbigesL , EscudierB , GrivasN , HaanenJ , PowlesT , et al. Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer. Angiogenesis2017;20(2):205-15. [PMID: 28401381]">Kuusk 2017</a>). </p> <p>This updated review reflects a restriction of scope in order to focus on metastatic renal cell carcinoma within the broader category of 'advanced disease' that additionally included locally‐advanced cancers without metastases. The main reason for this change of scope is because the management of locally‐advanced disease may include both systemic and surgical interventions, and therefore the complex interaction between the two modalities as well as additional outcomes such as resectability and local control rates. Other reasons include lack of criteria for inoperability that include both cancer and patient factors, and the possibility that drug response to the primary tumour might be different from the response of its metastases. </p> <p>This review originates from a collaboration between the previous Cochrane Review authorship and the Renal Cell Carcinoma Guideline Panel of the European Association of Urology (EAU panel). Preliminary discussions with the EAU panel demonstrated a high level of overlap between the protocols of the two groups. This review is designed to minimise residual differences. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012796-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012796-sec-0014"></div> <p>To assess the effects of targeted therapies for clear cell mRCC in patients naïve to systemic therapy. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012796-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012796-sec-0015"></div> <section id="CD012796-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012796-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials, including randomised discontinuation trials in which treatment was stopped early because of obvious benefits or harms (<a href="./references#CD012796-bbs2-0115" title="StadlerWM . New targets, therapies, and toxicities: lessons to be learned. Journal of Clinical Oncology2006;24(1):4-5. [PMID: 16314613]">Stadler 2006</a>). Quasi‐randomised trials such as alternate allocation were eligible for consideration. We excluded randomised phase I trials as well as cluster‐randomised trials or trials of factorial design. Additionally, we imposed a stricter inclusion criterion of more than 100 patients per arm for study inclusion. This was a decision driven by pragmatic and methodological considerations, to avoid including small, methodologically‐flawed and underpowered studies with low internal and external validity and high clinical and methodological heterogeneity, whose findings are highly unlikely to inform, guide or influence clinical practice. </p> </section> <section id="CD012796-sec-0018"> <h4 class="title">Types of participants</h4> <p>Participants were eligible if: older than 18 years of age; they had mRCC histologically or pathologically verified at presentation or relapse; they had an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 or equivalent. No prior systemic treatment was allowed. </p> <p>Exclusion criteria were: the presence of symptomatic brain metastases; a life expectancy of less than 12 weeks; a serious acute or chronic illness or recent history of cardiac event. </p> <p>Studies which allow solid tumours other than renal cell carcinoma were eligible only if participants with renal cell carcinoma were stratified and reported separately from other tumour types. </p> <p>Diagnosis must be reported using the standard criteria (e.g. TNM Classification of Malignant Tumors) valid at the time that the trial began. </p> <p>A predominant clear cell renal cell carcinoma histology was required.</p> <p>We excluded studies for analysis of oncological outcomes that are designed for or include more than 20% of participants without metastases (i.e. locally‐advanced disease or unfit for nephrectomy). We included evaluation of adverse events if reported, however. </p> </section> <section id="CD012796-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Agents with known or presumed molecular targets were part of the therapeutic regimen of at least one study arm. Non‐specific agents considered previously were no longer eligible, as they are of historic interest only; these include ABT‐510, AE‐941, and carboxyaminoimidazole. We excluded classic immunotherapy agents, including recombinant cytokines and their predecessors, from the definition of targeted therapy, but they were allowed as part of combined regimens in any study arm (i.e. either as index interventions or as comparators). </p> <p>Our approach to targeting immunotherapies (including PD1 or PD‐L1 checkpoint inhibitors) deserves special mention. As the main focus of the review was on VEGF‐targeted therapies on the basis of the earlier version of our review, and the fact that VEGF‐targeted therapies have been established as the mainstay of treatment for mRCC at the inception of this review, we considered targeting immunotherapies as a comparator intervention. In addition, targeted immunotherapies for mRCC are being considered as an index intervention in a separate Cochrane Review (<a href="./references#CD012796-bbs2-0118" title="UnverzagtS , MoldenhauerI , NothackerM , RoßmeißlD , HadjinicolaouAV , PeinemannF , et al. Immunotherapy for metastatic renal cell carcinoma. Cochrane Database of Systematic Reviews2017, Issue 5. Art. No: CD011673. [DOI: 10.1002/14651858.CD011673.pub2]">Unverzagt 2017</a>). </p> <p>See <a href="#CD012796-tbl-0019">Table 1</a> for a list of targeted agents to be sought, although additional targeted agents were identified during the search process. Studies in which maintenance therapy by a targeted agent was the randomised variable were eligible. Studies of dose or schedule of a targeted agent were eligible. There were no restrictions on drug route, dose, or schedule. </p> <div class="table" id="CD012796-tbl-0019"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Individual targeted agents to be searched</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Axitinib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bevacizumab</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dovitinib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erlotinib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Everolimus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lapatinib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pazopanib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sorafenib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Temsirolimus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tivozanib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other agents identified during search</p> </td> </tr> </tbody> </table> </div> <p>We investigated the following comparisons of target agents listed in <a href="#CD012796-tbl-0019">Table 1</a> versus control/comparator. </p> <section id="CD012796-sec-0020"> <h5 class="title">Intervention</h5> <p> <ol id="CD012796-list-0001"> <li> <p>Targeted agent</p> </li> </ol> </p> </section> <section id="CD012796-sec-0021"> <h5 class="title">Comparator</h5> <p> <ol id="CD012796-list-0002"> <li> <p>Targeted agent other than the ones used in intervention</p> </li> <li> <p>Targeted agent in combination with immunotherapy</p> </li> <li> <p>Immunotherapy</p> </li> <li> <p>Combinations of immunotherapy</p> </li> <li> <p>Placebo</p> </li> </ol> </p> <p>We considered whether the control arm has been validated by a prior randomised study.</p> </section> <section id="CD012796-sec-0022"> <h5 class="title">Minimum duration of intervention</h5> <p>Minimum duration of intervention was four weeks.</p> </section> <section id="CD012796-sec-0023"> <h5 class="title">Minimum duration of follow‐up</h5> <p>Minimum duration of follow‐up was 12 weeks. We evaluated extended follow‐up periods after the trial termination only for adverse events. </p> </section> <section id="CD012796-sec-0024"> <h5 class="title">Specific exclusion criteria</h5> <p>Studies observing neoadjuvant or adjuvant treatment or both with targeted agents were not eligible for analysis. </p> </section> </section> <section id="CD012796-sec-0025"> <h4 class="title">Types of outcome measures</h4> <p>Studies had to assess at least one efficacy outcome by allocation arm. We examined 'quality of life' outcomes where available, with reference to minimally important clinical differences where known for the assessment tools used. We evaluated adverse events in all studies. Our selection of outcomes for GRADE assessment was based on discussions amongst an expert panel (EAU panel) and authors of the previous review, and reflects outcomes of importance to stakeholders including patients, clinicians and healthcare providers. </p> <section id="CD012796-sec-0026"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD012796-list-0003"> <li> <p>Progression‐free survival (PFS)</p> </li> <li> <p>Overall survival (OS)</p> </li> <li> <p>Serious adverse events (SAEs; Grade 3 or 4)</p> </li> </ol> </p> </section> <section id="CD012796-sec-0027"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD012796-list-0004"> <li> <p>Health‐related quality of life (QoL)</p> </li> <li> <p>Response rate</p> </li> <li> <p>Minor adverse events (minor AEs; Grade 1 or 2)</p> </li> </ol> </p> <section id="CD012796-sec-0028"> <h6 class="title">Method and timing of outcome measurement</h6> <p> <ol id="CD012796-list-0005"> <li> <p>PFS: time from date of randomisation to date of clinical or radiological progression</p> </li> <li> <p>OS: length of time from date of randomisation that participants are still alive</p> </li> <li> <p>SAEs: all adverse events measured at any time that needed surgical, endoscopic, radiological or anesthesiological intervention, as well as any life‐threatening complications after participants received at least one treatment in intervention or comparator groups, classified by Common Terminology Criteria for Adverse Events (<a href="./references#CD012796-bbs2-0078" title="National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf (accessed 18 May 2019).">CTCAE</a>) </p> </li> <li> <p>QoL: evaluated by a validated instrument such as Supplementary Quality of Life Questionnaire (SQLQ), Functional Assessment of Cancer Therapy (FACT), Functional Assessment of Cancer Therapy–Kidney Symptom Index (FKSI) or European Quality of Life‐5 Dimensions (EQ‐5D). If available, we focused on data of pre‐ to post‐treatment evaluation </p> </li> <li> <p>Response rate: measured by Response Evaluation Criteria in Solid Tumors (RECIST) or modified RECIST criteria (<a href="./references#CD012796-bbs2-0082" title="EisenhauerEA , TherasseP , BogaertsJ , SchwartzLH , SargentD , FordR , et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer2009;45(2):228-47. [PMID: 19097774]">Eisenhauer 2009</a>) </p> </li> <li> <p>Minor AEs: all adverse events measured at any time that could be managed by observation or pharmacological treatment after participants received at least one treatment in intervention or comparator groups, classified by Common Terminology Criteria for Adverse Events (<a href="./references#CD012796-bbs2-0078" title="National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf (accessed 18 May 2019).">CTCAE</a>) </p> </li> </ol> </p> <p>We considered a 5% absolute risk difference as clinically important for primary outcomes (PFS, OS and SAEs); we considered a 10% absolute risk difference as clinically important for the secondary outcomes of response rate and minor AEs. We used published threshold for QoL instruments.  </p> <p>If time‐to‐event data were not available, we tried to assess the number of events per total for dichotomised outcomes at certain time points (e.g. at one, two, three, four, five years, or at the longest reported follow‐up). </p> </section> <section id="CD012796-sec-0029"> <h6 class="title">Main outcomes for 'Summary of findings' table</h6> <p> <ol id="CD012796-list-0006"> <li> <p>Progression‐free survival</p> </li> <li> <p>Overall survival</p> </li> <li> <p>Serious adverse events</p> </li> <li> <p>Quality of life</p> </li> </ol> </p> </section> </section> </section> </section> <section id="CD012796-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <p>Overall time frame: we conducted a search from 1 January 2000 (we found no earlier studies in the previous version of this review) to an agreed cut‐off date that was at least one month before the date of search, to allow for indexing. We initially compared duplicate searches from separate time segments for consistency. For example the current authors have completed a search to 18 June 2020 using the algorithm in <a href="./appendices#CD012796-sec-0281">Appendix 1</a>, and the Canadian authors have searched to 30 June 2010 as described previously (<a href="./references#CD012796-bbs2-0124" title="CoppinC , LeL , WiltTJ , KollmannsbergerC . Targeted therapy for advanced renal cell carcinoma. Cochrane Database of Systematic Reviews2008, Issue 2. Art. No: CD006017. [DOI: 10.1002/14651858.CD006017.pub2]">Coppin 2008</a>, electronically updated to 30 June 2011 for <a href="./references#CD012796-bbs2-0125" title="CoppinC , KollmannsbergerC , LeL , PorzsoltF , WiltTJ . Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU International2011;108(10):1556-63. [PMID: 21952069]">Coppin 2011</a>). </p> <p>There were no restrictions by language or publication status.</p> <section id="CD012796-sec-0031"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and LILACS databases, as well as trial registers <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> and the World Health Organization (WHO) International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch</a>). </p> </section> <section id="CD012796-sec-0032"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD012796-list-0007"> <li> <p>We handsearched abstracts in the proceedings of the annual meetings of the American Urological Association, the European Cancer Conference (ECCO), the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO), all from 2000 to current year; and the annual ASCO genitourinary meeting (2008 to current year) </p> </li> <li> <p>We handsearched the bibliographies of included primary studies and of recent systematic reviews of targeted therapies for metastatic or advanced renal cell carcinoma </p> </li> <li> <p>We consulted clinical experts (EAU panel) to identify additional potentially important or seminal studies which may have been missed by the electronic searches </p> </li> <li> <p>We tried to identify other potentially eligible trials or ancillary publications by searching the reference lists of included trials, systematic reviews, meta‐analyses and health technology assessment reports. We also contacted authors of included trials to identify any additional information on the retrieved trials, and to determine if further trials exist that we may have missed. We also searched databases from regulatory agencies (European Medicines Agency (EMA) and US Food and Drugs Administration (FDA)) (<a href="./references#CD012796-bbs2-0091" title="HartB , LundhA , BeroL . Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. BMJ2012;344:d7202. [PMID: 22214754]">Hart 2012</a>; <a href="./references#CD012796-bbs2-0112" title="SchrollJ , BeroL . Regulatory agencies hold the key to improving Cochrane Reviews of drugs. Cochrane Database of Systematic Reviews2015, Issue 4. [DOI: 10.1002/14651858.ED000098]">Schroll 2015</a>). </p> </li> </ol> </p> </section> </section> <section id="CD012796-sec-0033"> <h3 class="title" id="CD012796-sec-0033">Data collection and analysis</h3> <section id="CD012796-sec-0034"> <h4 class="title">Selection of studies</h4> <section id="CD012796-sec-0035"> <h5 class="title">Inclusion and exclusion of studies</h5> <p>Two review authors (FH; and LM or TL or AB or BL) independently conducted searches, assessed full‐text records, and independently mapped records to potentially eligible studies for inclusion/exclusion. We resolved disagreements by discussion. </p> <p>We referred to trials by their eight‐digit NCT number where known. We classified studies as included studies, excluded studies, studies awaiting classification, or ongoing studies, in accordance with the criteria for each provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012796-bbs2-0095" title="HigginsJPT , ChurchillR , ChandlerJ , Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017a</a>). We documented the search process in a study flow diagram. </p> <p>We document reasons for exclusion of identified studies not suitable for this review in the <a href="#CD012796-sec-0059">Excluded studies</a> table. We included studies that did not report on our primary or secondary outcomes, and considered them for qualitative analysis. </p> </section> </section> <section id="CD012796-sec-0036"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (FH; and LM or TL or AB) independently extracted data using an agreed template which we had piloted, and resolved any disagreements by consensus, with recourse to a third review author (TL or AB) if needed. We constructed a master database of consensus‐agreed data, which was available to all review authors. </p> <p>Data extraction fields for each study included:</p> <p> <ol id="CD012796-list-0008"> <li> <p>basic study design features (e.g. parallel‐group randomised trial);</p> </li> <li> <p>dates when the study was conducted;</p> </li> <li> <p>study setting;</p> </li> <li> <p>participant eligibility criteria and actual accrual by arm for age, race, gender, performance status, prior nephrectomy, prior systemic therapy, histologic subtype, and prognostic risk method and distribution; </p> </li> <li> <p>stratification parameters, if any;</p> </li> <li> <p>detailed interventions, including criteria for discontinuing therapy and cross‐over to the investigational arm; </p> </li> <li> <p>the sample size for each included study and for each intervention/comparator group;</p> </li> <li> <p>details (such as dose, route, frequency, duration, as applicable) of each intervention/comparator relevant to this review; </p> </li> <li> <p>treatment delivery evaluation such as time point of administration and masking of treatment in interventional/comparator groups; </p> </li> <li> <p>frequency and protocol status (e.g. planned versus later protocol modification) of cross‐over to the investigational arm; </p> </li> <li> <p>details of the outcome definition for outcomes relevant to this review that were assessed in each study, method of outcome measurement for each outcome, timing of outcome measurement for each outcome, subgroups relevant to this review that were assessed for each outcome; </p> </li> <li> <p>reported statistics for each time‐dependent outcome, i.e. hazard ratio and two‐sided log rank P value; </p> </li> <li> <p>all adverse events reported by allocation;</p> </li> <li> <p>study funding sources;</p> </li> <li> <p>details of declarations of interest among the trialists.</p> </li> </ol> </p> <p>We attempted to contact study investigators to obtain missing data for primary outcomes for eligible studies. </p> <p>We report identified studies in the <a href="./references#CD012796-sec-0295" title="">Characteristics of included studies</a> table. If an eligible trial was ongoing and did not report any results, we collected information in the <a href="./references#CD012796-sec-0297" title="">Characteristics of ongoing studies</a> table. </p> <section id="CD012796-sec-0037"> <h5 class="title">Dealing with duplicate and companion publications</h5> <p>In the event of duplicate publications, companion documents or multiple reports of a primary trial, we maximised the information yield by collating all available data and used the most complete data set aggregated across all known publications. We listed duplicate publications, companion documents, multiple reports of a primary trial and trial documents of included trials (such as trial registry information) as secondary references under the study ID of the included trial. We also listed duplicate publications, companion documents, multiple reports of a trial and trial documents of excluded trials (such as trial registry information) as secondary references under the study ID of the excluded trial. </p> </section> <section id="CD012796-sec-0038"> <h5 class="title">Data from clinical trial registers</h5> <p>In cases where data of included trials were available as study results in clinical trial registers such as <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> or similar resources, we made full use of this information and extracted data. If there was also a full publication of the trial, we collated and critically appraised all available data. If an included trial was marked as a completed study in a clinical trial register but no additional information (study results, publication or both) was available, we added this trial to the table Characteristics of studies awaiting classification. </p> </section> </section> <section id="CD012796-sec-0039"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (FH; and TL or ECH) independently used the latest version of the Cochrane tool for assessing risk of bias to construct a 'Risk of bias' table for each study, resolving disagreements by discussion (<a href="./references#CD012796-bbs2-0096" title="HigginsJPT , AltmanDG , Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017b</a>). If needed, a third review author (either AB or BL) was involved to enable us to reach consensus. We rated the following domains at low, high, or unclear risk of bias. </p> <p> <ol id="CD012796-list-0009"> <li> <p>Random sequence generation</p> </li> <li> <p>Allocation concealment</p> </li> <li> <p>Blinding of participants and personnel</p> </li> <li> <p>Blinding of outcome assessment</p> </li> <li> <p>Incomplete outcome data</p> </li> <li> <p>Selective reporting</p> </li> <li> <p>Other potential sources of bias</p> </li> </ol> </p> <p>We assessed the 'Risk of bias' domains 'Blinding of participants and personnel', 'Blinding of outcome assessment', and 'Incomplete outcome data' on an outcome‐specific basis, grouping subjective outcomes and objective outcomes for the blinding domains, and grouping outcomes according to similar completeness of data for the outcome‐specific assessment of 'Incomplete outcome data'. We regarded all outcomes except for 'Overall survival of the total population' as susceptible to performance bias and detection bias. We summarised the risk of bias across domains for each outcome in each included study. We assessed the risk of attrition bias in three combined outcome groups that we defined by oncological, adverse event and quality‐of‐life outcomes. We present our judgements in a 'Risk of bias' summary and 'Risk of bias' graph. </p> </section> <section id="CD012796-sec-0040"> <h4 class="title">Measures of treatment effect</h4> <p>When at least two included trials were available for a comparison and a given outcome, we tried to express dichotomous data as a risk ratio (RR) or odds ratio (OR) with 95% confidence intervals (CIs). For continuous outcomes measured on the same scale we estimated the intervention effect using the mean difference (MD) with 95% CIs. For continuous outcomes measuring the same underlying concept but using different measurement scales, we calculated the standardised mean difference (SMD). We expressed time‐to‐event data as a hazard ratio (HR) with 95% CIs. </p> </section> <section id="CD012796-sec-0041"> <h4 class="title">Unit of analysis issues</h4> <p>If more than one comparison from the same trial was eligible for inclusion in the same meta‐analysis, we either combined groups to create a single pairwise comparison or appropriately reduced the sample size so that the same participants do not contribute to multiple comparisons (splitting the 'shared' group into two or more groups). While the latter approach offered some solution to adjusting the precision of the comparison, it did not account for correlation arising from the same set of participants being in multiple comparisons (<a href="./references#CD012796-bbs2-0095" title="HigginsJPT , ChurchillR , ChandlerJ , Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017a</a>). </p> </section> <section id="CD012796-sec-0042"> <h4 class="title">Dealing with missing data</h4> <p>We planned to perform intention‐to‐treat analyses where data were available; however, we did not impute missing data. We included studies that combine outcomes from metastatic and locally‐advanced disease in tabulations if the locally‐advanced subgroup is documented as less than 20% of the total participants randomised; we considered other studies separately. </p> <p>Whenever possible, we obtained missing data from the authors of the included trials. We carefully evaluated important numerical data such as screened, randomly‐assigned participants as well as intention‐to‐treat, and 'as treated' and 'per protocol' populations. We investigated attrition rates (e.g. dropouts, losses to follow‐up, withdrawals), and we critically appraised issues concerning missing data and use of imputation methods (e.g. last observation carried forward). </p> </section> <section id="CD012796-sec-0043"> <h4 class="title">Assessment of heterogeneity</h4> <p>In the event of substantial clinical or methodological heterogeneity, we did not report trial results as the pooled effect estimate in a meta‐analysis. We identified heterogeneity (inconsistency) by visually inspecting the forest plots and by using a standard Chi² test with a significance level of α = 0.1. In view of the low power of this test, we also considered the I² statistic, which quantifies inconsistency across trials, to assess the impact of heterogeneity on the meta‐analysis (<a href="./references#CD012796-bbs2-0092" title="HigginsJPT , ThompsonSG . Quantifying heterogeneity in a meta-analysis. Statistics in Medicine2002;21(11):1539-58. [PMID: 12111919]">Higgins 2002</a>; <a href="./references#CD012796-bbs2-0093" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [PMID: 12958120]">Higgins 2003</a>). We interpret the I² statistic as follows. </p> <p> <ol id="CD012796-list-0010"> <li> <p>0% to 40%: may not be important</p> </li> <li> <p>30% to 60%: represents moderate heterogeneity</p> </li> <li> <p>50% to 90%: represents substantial heterogeneity</p> </li> <li> <p>75% to 100%: represents considerable heterogeneity</p> </li> </ol> </p> <p>We attempted to determine possible reasons for heterogeneity by examining individual study and subgroup characteristics. </p> </section> <section id="CD012796-sec-0044"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not find 10 or more trials that investigate a particular outcome, and did not use funnel plots to assess small‐trial effects. Several explanations may account for funnel plot asymmetry, including true heterogeneity of effect with respect to trial size, poor methodological design (and hence bias of small trials) and publication bias, so we were cautious in our interpretation of results (<a href="./references#CD012796-bbs2-0116" title="SterneJA , SuttonAJ , IoannidisJP , TerrinN , JonesDR , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ2011;343:d4002. [PMID: 21784880]">Sterne 2011</a>). </p> </section> <section id="CD012796-sec-0045"> <h4 class="title">Data synthesis</h4> <p>We conducted (or displayed) a meta‐analysis only if we judged participants, interventions, comparisons and outcomes to be sufficiently similar to ensure an answer that is clinically meaningful. Unless good evidence showed homogeneous effects across trials, we primarily summarised low risk of bias data using a random‐effects model (<a href="./references#CD012796-bbs2-0121" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ2008;336(7644):601-5. [PMID: 18316340]">Wood 2008</a>). We interpreted random‐effects meta‐analyses with due consideration for the whole distribution of effects, ideally by presenting a prediction interval (<a href="./references#CD012796-bbs2-0094" title="HigginsJP , ThompsonSG , SpiegelhalterDJ . A re-evaluation of random-effects meta-analysis. Journal of the Royal Statistical Society. Series A, (Statistics in Society)2009;172(1):137-59. [PMID: 19381330]">Higgins 2009</a>). This specifies a predicted range for the true treatment effect in an individual trial (<a href="./references#CD012796-bbs2-0108" title="RileyRD , HigginsJP , DeeksJJ . Interpretation of random effects meta-analyses. BMJ2011;342:d549. [PMID: 21310794]">Riley 2011</a>). For rare events such as event rates below 1% we planned to use the Peto odds ratio, provided that there was no substantial imbalance between intervention and comparator group sizes, and that intervention effects were not exceptionally large. We also performed statistical analyses using Review Manager 5 software provided by Cochrane (<a href="./references#CD012796-bbs2-0107" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>), according to the statistical guidelines presented in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012796-bbs2-0095" title="HigginsJPT , ChurchillR , ChandlerJ , Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017a</a>). </p> <section id="CD012796-sec-0046"> <h5 class="title">Statistical analysis</h5> <p>We anticipated analysis of four types of outcomes: categorical outcomes, such as tumour remission; single time‐dependent outcomes, such as OS; quality‐of‐life surveys; and toxicity tables. Of these, methods for analysis of dichotomous outcomes were fully covered by standard Cochrane procedures (<a href="./references#CD012796-bbs2-0079" title="DeeksJJ , HigginsJPT , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Deeks 2017</a>). We considered multidimensional quality‐of‐life and toxicity outcomes individually. Time‐dependent outcomes were potentially problematic. Where only a single study was available for a comparison, we accepted any standard statistical analysis, such as the log‐rank test used by the author, but we preferred the hazard ratio and log‐rank testing. For meta‐analysis of multiple studies of the same type, we used extraction of a dichotomous endpoint such as survival at one year from randomisation (see also <a href="#CD012796-sec-0040">Measures of treatment effect</a> above). </p> </section> </section> <section id="CD012796-sec-0047"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform a subgroup analysis for the following.</p> <p> <ol id="CD012796-list-0011"> <li> <p>Nephrectomy done or not done prior to treatment</p> </li> <li> <p>ECOG performance status (0, 1 or 2)</p> </li> </ol> </p> </section> <section id="CD012796-sec-0048"> <h4 class="title">Sensitivity analysis</h4> <p>We planned a sensitivity analysis for studies that were at a high risk of bias for sequence generation, allocation concealment and blinding versus studies at low risk of bias. We planned to conduct a separate meta‐analysis for validation of results of studies at low risk of bias only. </p> </section> <section id="CD012796-sec-0049"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We present results for the outcomes as described in the <a href="#CD012796-sec-0025">Types of outcome measures</a> section. We present the overall certainty of the evidence for each outcome according to the GRADE approach, which takes into account five criteria not only related to internal validity (risk of bias, inconsistency, imprecision, publication bias), but also to external validity, such as directness of results (<a href="./references#CD012796-bbs2-0088" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6. [PMID: 18436948]">Guyatt 2008</a>). For each comparison, two review authors (ECH, FH) independently rated the quality of evidence for each outcome as 'high', 'moderate', 'low', or 'very low', using GRADEpro Guideline Development Tool (GDT) software (<a href="./references#CD012796-bbs2-0087" title="GRADEpro GDT. Version accessed 10 March 2019. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT 2015</a>). We resolved any disagreements by discussion or, if needed, by recourse to a third review author (TL, AB). For each comparison, we present a summary of the evidence for the main outcomes in a 'Summary of findings' table, which provides key information about the best estimate of the magnitude of the effect in relative terms and absolute differences for each relevant comparison of alternative management strategies; numbers of participants and studies addressing each important outcome; and the rating of the overall confidence in effect estimates for each outcome (<a href="./references#CD012796-bbs2-0089" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94. [PMID: 21195583]">Guyatt 2011</a>; <a href="./references#CD012796-bbs2-0113" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , AklE , et al, on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Schünemann 2017</a>). We justified all decisions to downgrade the quality of trials using footnotes, and we made comments to aid the reader's understanding of the Cochrane Review where necessary. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012796-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012796-sec-0050"></div> <section id="CD012796-sec-0051"> <h3 class="title">Description of studies</h3> <p>Our literature search identified 7738 records eligible for screening. We excluded 7668 records that did not meet our predefined inclusion criteria from further evaluation. Of these, we marked four as ongoing and included them in the <a href="./references#CD012796-sec-0297" title="">Characteristics of ongoing studies</a> section. </p> <section id="CD012796-sec-0052"> <h4 class="title">Results of the search</h4> <p>We found 70 titles and abstracts to be eligible for full‐text evaluation. Of these, we selected 18 trials for qualitative synthesis and included four of them in a quantitative analysis. We excluded 52 articles; our reasons are presented in <a href="#CD012796-fig-0001">Figure 1</a> and under <a href="./references#CD012796-sec-0296" title="">Characteristics of excluded studies</a>. </p> <div class="figure" id="CD012796-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012796-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012796-sec-0053"> <h4 class="title">Included studies</h4> <p>Additional information on included studies is available in the following tables: <a href="./references#CD012796-sec-0295" title="">Characteristics of included studies</a>; Participants disposition (<a href="#CD012796-tbl-0020">Table 2</a>); and Baseline characteristics (<a href="#CD012796-tbl-0021">Table 3</a>). </p> <div class="table" id="CD012796-tbl-0020"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Participants disposition</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention(s)/ Comparator(s)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Randomised (N)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Received treatment (N)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Discontinued treatment (N)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Efficacy analysis (N)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Safety analysis (N)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Eichelberg 2015</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Soreafenib/ Sunitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>177</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib/ Sorafenib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>176</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Escudier 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bevacizumab + IFN‐a2a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>325</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>337</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IFN‐a2a + Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>304</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Escudier 2017 <sup>1</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>535</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nivolumab + Ipilimumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>547</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Hudes 2007</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Temsirolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>208</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Temsirolimus + Interferon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>208</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interferon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>McDermott 2017</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atezolizumab + Bevacizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atezolizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Motzer 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IFN‐a2a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>360</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Motzer 2013a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pazopanib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>557</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>554</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>557</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>554</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>548</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Motzer 2013b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tivozanib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>259</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sorafenib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>257</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Motzer 2014</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib/ Everolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>231</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Everolimus/ Sunitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>238</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Motzer 2019</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>439</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Avelumab + Axitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>434</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Ravaud 2015</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Everolimus + Bevacizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>180</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interferon + Bevacizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>181</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Retz 2019</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sorafenib/ Pazopanib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pazopanib/ Sorafenib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Rini 2008</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bevacizumab + IFN‐a2b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>366</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IFN‐a2b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>349</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Rini 2014</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Temsirolimus + Bevacizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>393</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Temsirolimus + Interferon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>391</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Rini 2016</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>132</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IMA901 + Sunitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>202</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Rini 2019a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>425</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pembrolizumab + Axitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>429</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Rini 2019b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>446</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>446</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atezolizumab + Bevacizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>451</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Sternberg 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pazopanib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>290</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11590</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11590</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11437</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Included overall population; but in the data and analyses section and summary of findings table, we used IMDC intermediate and poor risk patients for efficacy analysis. </p> </div> </div> <div class="table" id="CD012796-tbl-0021"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Baseline characteristics</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Phase of study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Accrual</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Blinding</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>RCC subtype</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Prior therapy</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparator</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Eichelberg 2015</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Feb 2009 to Dec 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>any, 87% clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Soreafenib/Sunitinib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib/Sorafenib</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Escudier 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Jun 2004 to Oct 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>double‐blind study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bevacizumab + IFN‐a2a</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IFN‐a2a + Placebo</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Escudier 2017</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Oct 2014 to Feb 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nivolumab + Ipilimumab</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Hudes 2007</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Jul 2003 to Apr 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>any, 80% clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Temsirolimus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Temsirolimus + Interferon</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inferferon</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>McDermott 2017</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Jan 2014 to Mar 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atezolizumab + Bevacizumab</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atezolizumab</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Motzer 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Aug 2004 to Oct 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>radiologic assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IFN‐a2a</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Motzer 2013a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Aug 2008 to Sep 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pazopanib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Motzer 2013b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Feb 2010 to Aug 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tivozanib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sorafenib</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Motzer 2014</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Sep 2009 to Jun 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>any, 85% clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib/ Everolimus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Everolimus/ Sunitinib</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Motzer 2019</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Mar 2016 to Dec 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Avelumab + Axitinib</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Ravaud 2015</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>any 96% clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Everolimus + Bevacizumab</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interferon + Bevacizumab</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Retz 2019</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Jun 2012 to Nov 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>any, 87% clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sorafenib/ Pazopanib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pazopanib/ Sorafenib</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Rini 2008</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Oct 2003 to Jul 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bevacizumab + IFN‐a2b</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IFN‐a2b</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Rini 2014</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Apr 2008 to Oct 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>any, 80% clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Temsirolimus + Bevacizumab</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bevacizumab + Inferferon</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Rini 2016</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Dec 2010 to Dec 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IMA901 + Sunitinib</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Rini 2019a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Oct 2016 to Jan 2018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pembrolizumab + Axitinib</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Rini 2019b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>May 2015 to Oct 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atezolizumab + Bevacizumab</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Sternberg 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Apr 2006 to Apr 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>double‐blind study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>54% naive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pazopanib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>‐ denotes not reported</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>IFN: interferon; RCC: renal cell carcinoma</p> </div> </div> <section id="CD012796-sec-0054"> <h5 class="title">Source of data</h5> <p>In total we included 18 trials in this review, all of which we identified by electronic database search. All trials were available as peer‐reviewed publications and published in English. We contacted corresponding authors of nine trials to obtain additional information on results (<a href="./references#CD012796-bbs2-0003" title="CellaD , GrunwaldV , EscudierB , HammersHJ , GeorgeS , NathanP , et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncology2019;20(2):297-310. [PMID: 30658932]EscudierB , TannirN , McDermottDF , FronteraOA , MelicharB , PlimackER , et al. CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups. Annals of Oncology2017;28(suppl 5):621-2. [DOI: 10.1093/annonc/mdx440.029]MotzerRJ , RiniBI , McDermottDF , Aren FronteraO , HammersHJ , CarducciMA , et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncology2019;S1470-2045(19):30413-9. [PMID: 31427204]MotzerRJ , TannirN , McDermottDF , FronteraOA , MelicharB , ChoueiriTK , et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. New England Journal of Medicine2018;378(14):1277-90. [PMID: 29562145]NCT02231749. Nivolumab combined with ipilimumab versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma (CheckMate 214) [A phase 3, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, advanced or metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT02231749 (first received 4 September 2014). [NCT02231749]TannirNM , HammersHJ , AminA , Grimm M-O, RiniBI , MekanS , et al. Characterization of the benefit-risk profile of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced renal cell carcinoma (aRCC; CheckMate 214). Journal of Clinical Oncology2018;28(6 suppl):686. [DOI: 10.1200/JCO.2018.36.6_suppl.686]VyasC , MotzerRJ , TannirNM , McDermottDF , FronteraOA , MelicharB , et al. Nivolumab + ipilimumab (N+I) vs sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (aRCC): results from checkmate 214, including overall survival by subgroups. Journal of Oncology Pharmacy Practice2018;24(5_suppl):17-8. ">Escudier 2017</a>; <a href="./references#CD012796-bbs2-0004" title="AlemaoE , RajagopalanS , YangS , et al. Quality adjusted survival in randomized, controlled trials: application of inverse probability weighting in renal cell cancer. In: Genitourinary Cancers Symposium, ASCO, abstr 399. 2010. ArmstrongAJ , GeorgeDJ , HalabiS . Serum lactate dehydrogenase as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2010;28(15 suppl):4361. [DOI: 10.1200/jco.2010.28.15_suppl.4631]DutcherJP , SzczylikC , TannirN , BenedettoP , RuffP , HsuA , et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon-alpha. Journal of Clinical Oncology2007;25(18 suppl):5033. [DOI: 10.1200/jco.2007.25.18_suppl.5033]DutcherJP , deSouzaP , FiglinR , et al. Effect of temsirolimus versus interferon- on survival of patients with advanced renal cell carcinoma of different histologies. In: Genitourinary Cancers Symposium, ASCO, abstr 384. 2008. DutcherJP , deSouzaP , McDermottD , FiglinRA , BerkenblitA , ThieleA , et al. Effect of temsirolimus versus interferon- on outcome of patients with advanced renal cell carcinoma of different histologies. Medical Oncology2009;26(2):202–9. [PMID: 19229667]HudesG , CarducciM , TomczakP , DutcherJ , FiglinR , KapoorA , et al. A phase 3, randomized, 3-arm study of temsirolimus or interferon alpha or the combination in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma. Journal of Clinical Oncology2006;24(18 suppl):LBA4. [DOI: 10.1200/jco.2006.24.18_suppl.lba4]HudesG , CarducciM , TomczakP , DutcherJ , FiglinR , KapoorA , et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine2007;356(22):2271–81. [PMID: 17538086]LoganT , McDermottD , DutcherJ , et al. Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features. In: Genitourinary Cancers Symposium, ASCO, abstr 281. 2009. NCT00065468. Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma (ARCC). clinicaltrials.gov/ct2/show/results/NCT00065468 (first received July 25 2003). [NCT00065468]PabloM , HudesG , DutcherJ , WhiteC , KrygowskiM , CincottaM , et al. Radiographic findings of drug-induced pneumonitis and clinical correlation inpatients with advanced renal cell carcinoma treated with temsirolimus. European Journal of Cancer Supplements2009;7(2):426-7. [DOI: 10.1016/S1359-6349(09)71446-6]ParasuramanS , HudesG , LevyD , StrahsA , MooreL , De MariniseR , et al. Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon- (IFN) or the combination of IFN+TEMSR. Journal of Clinical Oncology2007;25(18 suppl):5049. [DOI: 10.1200/jco.2007.25.18_suppl.5049]YangS , HudesG , deSouzaP , AlemaoE , StrahsA , PurvisJ . Evaluation of quality of life in patients with advanced renal cell carcinoma treated with temsirolimus vs interferon-alfa: results from a phase III randomized trial. European Journal of Cancer Supplements2009;7(2):433. [DOI: 10.1016/S1359-6349(09)71467-3]ZbrozekAS , HudesG , LevyD , StrahsA , BerkenblitA , DeMarinisR , et al. Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma. Pharmacoeconomics2010;28(7):577–84. [PMID: 20550223]">Hudes 2007</a>; <a href="./references#CD012796-bbs2-0006" title="CastellanoD , delMuroXG , Pérez-GraciaJL , González-LarribaJL , AbrioMV , RuizMA , et al. Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population. Annals of Oncology2009;20(11):1803-12. [PMID: 19549706]CellaD , CappelleriJC , BushmakinA , CharbonneauC , LiJZ , KimST , et al. Quality of life predicts progression-free survival in patients with renal cell carcinoma treated with sunitinib versus interferon alfa. Journal of Oncology Practice2009;5(2):66-70. [PMID: 20856722]CellaD , LiJZ , CappelariJC , BushmakinA , CharbonneauC , KimST , et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. Journal of Clinical Oncology2008;26(22):3763-9. [PMID: 18669464]CellaD , LiJZ , CappelleriJC , BushmakinA , CharbonneauC , KimST , ChenI , et al. Quality of life (QOL) predicts for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib compared to interferon-alpha (IFN-α). Journal of Clinical Oncology2007;25(18 suppl):6594. [DOI: 10.1200/jco.2007.25.18_suppl.6594]CellaD , MichaelsonMD , BushmakinAG , CappelleriJC , CharbonneauC , KimST , et al. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-a in a phase III trial: final results and geographical analysis. British Journal of Cancer2010;102(4):658-64. [PMID: 20104222]FiginRA , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , NegrierS , et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2008;26(15 suppl):5024. [DOI: 10.1200/jco.2008.26.15_suppl.5024]MotzerRJ , BukowskiRM , FiglinRA , HutsonTE , MichaelsonMD , KimST , et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer2008;113(7):1552-8. [PMID: 18720362]MotzerRJ , FiglinRA , HutsonTE , TomczakP , BukowskiRM , RixeO , et al. Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors. Journal of Clinical Oncology2007;25(18 suppl):5024. [DOI: 10.1200/jco.2007.25.18_suppl.5024]MotzerRJ , FiglinRA , HutsonTE , TomczakP , BukowskiRM , RixeO , et al. Sunitinib versus interferon-alfa as first-line treatment of metastatic renal cell carcinoma: updated results and analysis of prognostic factors. In: www.asco.org/virtual meeting. 2007. MotzerRJ , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , OudardS , et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2009;27(22):3584-90. [PMID: 19487381]MotzerRJ , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , RixeO , et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2006;24(18 suppl):LBA3. [DOI: 10.1200/jco.2006.24.18_suppl.lba3]MotzerRJ , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , RixeO , et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine2007;356(2):115-24. [PMID: 17215529]MotzerRJ , MichaelsonMD , HutsonTE , TomczakP , BukowskiRM , RixeO , et al. Sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors. European Journal of Cancer Supplements2007;5(4):301. [DOI: 10.1016/S1359-6349(07)71140-0]NCT00083889. SU011248 versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma [A phase 3, randomized study of SU011248 versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00083889 (first received 4 June 2004). [NCT00083889]PatilS , FiglinRA , HutsonTE , MichaelsonD , NegrierS , KimST , et al. TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-α). Journal of Clinical Oncology2010;28(15 suppl):4594. [DOI: 10.1200/jco.2010.28.15_suppl.4594]WilkersonJ , SteinWD , KimST , HuangX , MotzerRJ , FojoAT , et al. Validation of kinetic analysis of renal cancer regression and growth following treatment with sunitinib and interferon-alfa: analysis of the pivotal randomized trial. Journal of Clinical Oncology2010;28(15 suppl):4597. [DOI: 10.1200/jco.2010.28.15_suppl.4597]">Motzer 2010</a>; <a href="./references#CD012796-bbs2-0009" title="KnoxJJ , BarriosCH , KimTM , CosgriffT , SrimuninnimitV , PittmanK , et al. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Annals of Oncology2017;28(6):1339-45. [PMID: 28327953]KnoxJJ , BarriosCH , KimTM , CosgriffT , SrimuninnimitV , PittmanKB , et al. Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC). Journal of Clinical Oncology2015;33(15 suppl):4554. [DOI: 10.1200/jco.2015.33.15_suppl.4554]MotzerRJ , BarriosCH , KimTM , FalconS , CosgriffT , HarkerWG , et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2014;32(25):2765-72. [PMID: 25049330]NCT00903175. Efficacy and safety comparison of RAD001 versus sunitinib in the first-line and second-line treatment of patients with metastatic renal cell carcinoma (RECORD-3) [An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as First-line followed by second-line RAD001 in the treatment of patients with metastatic renal cell carcinoma.]. clinicaltrials.gov/ct2/show/NCT00903175 (first received 18 May 2009). [NCT00903175]">Motzer 2014</a>; <a href="./references#CD012796-bbs2-0011" title="NCT00719264. Safety and efficacy of bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment in adult patients with kidney cancer [A randomized, open-label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a plus bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney]. clinicaltrials.gov/ct2/show/study/NCT00719264 (first received 21 July 2008). [NCT00719264]RavaudA , BarriosCH , AlekseevB , TayMH , AgarwalaSS , YalcinS , et al. RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. Annals of Oncology2015;26(7):1378-84. [PMID: 25851632]">Ravaud 2015</a>; <a href="./references#CD012796-bbs2-0012" title="NCT01613846. Phase III sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma (SWITCH-II) [Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT01613846 (first received 7 June 2012). [NCT01613846]RetzM , BedkeJ , BögemannM , GrimmMO , ZimmermannU , MüllerL , et al. SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). European Journal of Cancer2019;107:37-45. [PMID: 30529901]RetzM , BedkeJ, HerrmannE , GrimmM , ZimmermannU , MüllerL , et al. Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib sorafenib in the treatment of metastatic renal cell carcinoma(SWITCH-II). Annals of Oncology2017;28(suppl 5):295. [DOI: 10.1093/annonc/mdx371]">Retz 2019</a>; <a href="./references#CD012796-bbs2-0013" title="HalabiS , RiniBI , StadlerWM , SmallEJ . Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2010;28(15 suppl):4525. [DOI: 10.1200/jco.2010.28.15_suppl.4525]HarzstarkAL , HalabiS , StadlerWM , et al. Hypertensionis associated with clinical outcome for patients with metastatic renal cell carcinoma treated with interferon and bevacizumab on CALGB 90206. In: Genitourinary Cancers Symposium, ASCO, abstr 351. 2010. NCT00072046. Interferon alfa-2b with or without bevacizumab in treating patients with advanced renal cell carcinoma (Kidney Cancer) [A randomized phase III trial of interferon alfa-2B or interferon alfa-2B plus bevacizumab in patients with advanced renal carcinoma]. clinicaltrials.gov/ct2/show/study/NCT00072046 (first received 6 November 2003). [NCT00072046]RiniBI , HalabiS , RosenbergJ , StadlerWM , VaenaDA , AtkinsJN , et al. Bevacizumab plus interferon-alfa versus interferon-alfa monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206. Journal of Clinical Oncology2009;27(18 suppl):LBA5019. [DOI: 10.1200/jco.2009.27.18_suppl.lba5019 ]RiniBI , HalabiS , RosenbergJE , StadlerWM , VaenaDA , OuSS , et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB90206. Journal of Clinical Oncology2008;26(33):5422-8. [PMID: 18936475]RiniBI , HalabiS , RosenbergJE , et al. CALGB 90206:a phase III trial of bevacizumab plus interferon-alfa versus interferon-alfa monotherapy in metastatic renal cell carcinoma. In: Genitourinary Cancers Symposium, ASCO, abstr 350. 2008. RiniBI , HalabiS , TaylorJ , SmallEJ , SchilskyRL , Cancer and Leukemia Group B . Cancerand Leukemia Group B 90206: a randomized phase III trial of interferon-a or interferon-a plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clinical Cancer Research2004;10(8):2584-6. [PMID: 15102658]">Rini 2008</a>; <a href="./references#CD012796-bbs2-0014" title="NCT00631371. Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (INTORACT). linicaltrials.gov/ct2/show/NCT00631371 (first received 20 May 2019). [NCT00631371]RiniBI , BellmuntJ , ClancyJ , WangK , NiethammerAG , HariharanS , et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. Journal of Clinical Oncology2014;32(8):752-9. [PMID: 24297945]">Rini 2014</a>; <a href="./references#CD012796-bbs2-0018" title="CellaD , PickardAS , DuhMS , GuerinA , MishaginaN , AntràsL , et al. Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. European Journal of Cancer2012;48(3):311-23. [PMID: 21689927]HutsonTE , BukowskiRM . A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma. Clinical Genitourinary Cancer2006;4(4):296-8. [PMID: 16729915]HutsonTE , DavisID , MachielsJP , deSouzaPL , HongBF , RotteyS , et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). Journal of Clinical Oncology2007;25(18 suppl):5031. [DOI: 10.1200/jco.2007.25.18_suppl.5031]NCT00334282. Safety and efficacy of GW786034 (pazopanib) In metastatic renal cell carcinoma [A randomised, double-blind, placebo controlled, multi-center phase III study to evaluate the efficacy and safety of pazopanib (GW786034) compared to placebo in patients with locally advanced and/or metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT00334282 (first received 7 June 2006). [NCT00334282]SternbergCN , DavisID , MardiakJ , SzczylikC , LeeE , WagstaffJ , et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of Clinical Oncology2010;28(6):1061-8. [PMID: 20100962]SternbergCN , HawkinsRE , WagstaffJ , SalmanP , MardiakJ , BarriosCH , et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. European Journal of Cancer2013;49(6):1287-96. [PMID: 23321547]SternbergCN , SzczylikC , LeeE , SalmanPV , MardiakJ , DavisID , et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). Journal of Clinical Oncology2009;27(15S):5021. [DOI: 10.1200/jco.2009.27.15s.5021]">Sternberg 2010</a>). We received three replies (<a href="./references#CD012796-bbs2-0012" title="NCT01613846. Phase III sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma (SWITCH-II) [Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT01613846 (first received 7 June 2012). [NCT01613846]RetzM , BedkeJ , BögemannM , GrimmMO , ZimmermannU , MüllerL , et al. SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). European Journal of Cancer2019;107:37-45. [PMID: 30529901]RetzM , BedkeJ, HerrmannE , GrimmM , ZimmermannU , MüllerL , et al. Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib sorafenib in the treatment of metastatic renal cell carcinoma(SWITCH-II). Annals of Oncology2017;28(suppl 5):295. [DOI: 10.1093/annonc/mdx371]">Retz 2019</a>; <a href="./references#CD012796-bbs2-0014" title="NCT00631371. Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (INTORACT). linicaltrials.gov/ct2/show/NCT00631371 (first received 20 May 2019). [NCT00631371]RiniBI , BellmuntJ , ClancyJ , WangK , NiethammerAG , HariharanS , et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. Journal of Clinical Oncology2014;32(8):752-9. [PMID: 24297945]">Rini 2014</a>; <a href="./references#CD012796-bbs2-0018" title="CellaD , PickardAS , DuhMS , GuerinA , MishaginaN , AntràsL , et al. Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. European Journal of Cancer2012;48(3):311-23. [PMID: 21689927]HutsonTE , BukowskiRM . A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma. Clinical Genitourinary Cancer2006;4(4):296-8. [PMID: 16729915]HutsonTE , DavisID , MachielsJP , deSouzaPL , HongBF , RotteyS , et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). Journal of Clinical Oncology2007;25(18 suppl):5031. [DOI: 10.1200/jco.2007.25.18_suppl.5031]NCT00334282. Safety and efficacy of GW786034 (pazopanib) In metastatic renal cell carcinoma [A randomised, double-blind, placebo controlled, multi-center phase III study to evaluate the efficacy and safety of pazopanib (GW786034) compared to placebo in patients with locally advanced and/or metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT00334282 (first received 7 June 2006). [NCT00334282]SternbergCN , DavisID , MardiakJ , SzczylikC , LeeE , WagstaffJ , et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of Clinical Oncology2010;28(6):1061-8. [PMID: 20100962]SternbergCN , HawkinsRE , WagstaffJ , SalmanP , MardiakJ , BarriosCH , et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. European Journal of Cancer2013;49(6):1287-96. [PMID: 23321547]SternbergCN , SzczylikC , LeeE , SalmanPV , MardiakJ , DavisID , et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). Journal of Clinical Oncology2009;27(15S):5021. [DOI: 10.1200/jco.2009.27.15s.5021]">Sternberg 2010</a>); and could include additional data for one trial (<a href="./references#CD012796-bbs2-0012" title="NCT01613846. Phase III sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma (SWITCH-II) [Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT01613846 (first received 7 June 2012). [NCT01613846]RetzM , BedkeJ , BögemannM , GrimmMO , ZimmermannU , MüllerL , et al. SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). European Journal of Cancer2019;107:37-45. [PMID: 30529901]RetzM , BedkeJ, HerrmannE , GrimmM , ZimmermannU , MüllerL , et al. Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib sorafenib in the treatment of metastatic renal cell carcinoma(SWITCH-II). Annals of Oncology2017;28(suppl 5):295. [DOI: 10.1093/annonc/mdx371]">Retz 2019</a>). </p> </section> <section id="CD012796-sec-0055"> <h5 class="title">Study design and settings</h5> <p>Two of the 18 included randomised controlled trials were conducted with a double blind design in which participants and personnel were unaware of allocated intervention (<a href="./references#CD012796-bbs2-0002" title="BajettaE , RavaudA , BracardaS , NégrierS , SzczylikC , BellmuntJ , et al. Efficacy and safety of first-line bevacizumab (BEV) plus interferon-α2a (IFN) in patients (pts) ≥65 years with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2008;26(15 suppl):5095. [DOI: 10.1200/jco.2008.26.15_suppl.5095]BellmuntJ , MelicharB , BracardaS , NegrierSN , RavaudA , LaeufleR , et al. Bevacizumab (BEV) and interferon (IFN) therapy does not increase risk of cardiac events in metastatic renal cell carcinoma(mRCC). European Journal of Cancer Supplements2009;7(2):429. [DOI: 10.1016/S1359-6349(09)71454-5]BracardaS , BellmuntJ , NegrierSN , MelicharB , RavaudA , JethwaS , et al. What is the impact of subsequent antineoplastic therapy on overall survival (OS) following first-line bevacizumab (BEV)/interferonalpha2a (IFN) in metastatic renal cell carcinoma (mRCC)? – Experience from AVOREN. European Journal of Cancer Supplements2009;7(2):431. [DOI: 10.1016/S1359-6349(09)71459-4]BracardaS , KoralewskiP , PluzanskaA , RavaudA , SzczylikC , ChevreauC , et al. Bevacizumab/interferon-alpha2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN). European Journal of Cancer Supplements2007;5(4):281-2. [DOI: 10.1016/S1359-6349(07)71076-5]EscudierB , KoralewskiP , PluzanskaA , RavaudA , BracardaS , SzczylikC , et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma. Journal of Clinical Oncology2007;25(18 suppl):3. [DOI: 10.1200/jco.2007.25.18_suppl.3]EscudierB , PluzanskaA , KoralewskiP , RavaudA , BracardaS , SzczylikC , et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized double-blind phase III trial. Lancet2007;370(9605):2103-11. [PMID: 18156031]EscudierBB , BellmuntJ , NegrierS , BajettaE , MelicharB , BracardaS , et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. Journal of Clinical Oncology2010;28(13):2144-50. [PMID: 20368553]EscudierBJ , BellmuntJ , NegrierS , MelicharB , BracardaS , RavaudA , et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2009;27(15 suppl):5020. [DOI: 10.1200/jco.2009.27.15_suppl.5020]EscudierBJ , NegrierS , ChevreauC , et al. Analysis of prognostic risk categories in the phase III AVOREN trial of first-line bevacizumab plus interferon-α2a in patients with metastatic renal cell carcinoma: French prognostic scoring system. In: Genitourinary Cancers Symposium, ASCO, abst 417. 2010. EscudierBJ , RavaudA , NegrierS , SzczylikC , BellmuntJ , BracardaS , et al. Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis. Journal of Clinical Oncology2008;26(15 suppl):5025. [DOI: 10.1200/jco.2008.26.15_suppl.5025]KarakiewiczP , SunM , SnellerV , EscudierB . Use of a nomogram to quantify overall survival (OS) benefit in patients with metastatic renal cell carcinoma receiving bevacizumab (BEV) with interferon (IFN) versus IFN alone. Journal of Clinical Oncology2010;28(15 suppl):4592. [DOI: 10.1200/jco.2010.28.15_suppl.4592 ]KarakiewiczPI , SunM , SnellerV , et al. Use of a nomogram to quantify progression-free survival benefit in metastatic renal cell carcinoma patients receiving bevacizumab plus interferon or interferon alone. In: Genitourinary Cancers Symposium, ASCO, abstr 392. 2010. MelicharB , KoralewskiP , PluzanskaA , RavaudA , BracardaS , SzczylikC , et al. First-line bevacizumab improves progression-free survival with lower doses of interferon-α2a in the treatment of patients with metastatic renal cell carcinoma (AVOREN). European Journal of Cancer Supplements2007;5(4):304. [DOI: 10.1016/S1359-6349(07)71149-7]MelicharB , KoralewskiP , RavaudA , PluzanskaA , BracardaS , SzczylikC , et al. First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma. Annals of Oncology2008;19(8):1470-6. [PMID: 18408224]NCT00738530. A study of avastin (bevacizumab) added to interferon alfa-2a (roferon) therapy in patients with metastatic renal cell cancer with nephrectomy [A randomised, double-blind study to evaluate the efficacy and safety of avastin plus roferon compared with placebo plus roferon on overall survival and tumor assessment in nephrectomised patients with metastatic clear cell renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00738530 (first received 20 August 2008). [NCT00738530]">Escudier 2010</a>; <a href="./references#CD012796-bbs2-0018" title="CellaD , PickardAS , DuhMS , GuerinA , MishaginaN , AntràsL , et al. Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. European Journal of Cancer2012;48(3):311-23. [PMID: 21689927]HutsonTE , BukowskiRM . A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma. Clinical Genitourinary Cancer2006;4(4):296-8. [PMID: 16729915]HutsonTE , DavisID , MachielsJP , deSouzaPL , HongBF , RotteyS , et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). Journal of Clinical Oncology2007;25(18 suppl):5031. [DOI: 10.1200/jco.2007.25.18_suppl.5031]NCT00334282. Safety and efficacy of GW786034 (pazopanib) In metastatic renal cell carcinoma [A randomised, double-blind, placebo controlled, multi-center phase III study to evaluate the efficacy and safety of pazopanib (GW786034) compared to placebo in patients with locally advanced and/or metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT00334282 (first received 7 June 2006). [NCT00334282]SternbergCN , DavisID , MardiakJ , SzczylikC , LeeE , WagstaffJ , et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of Clinical Oncology2010;28(6):1061-8. [PMID: 20100962]SternbergCN , HawkinsRE , WagstaffJ , SalmanP , MardiakJ , BarriosCH , et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. European Journal of Cancer2013;49(6):1287-96. [PMID: 23321547]SternbergCN , SzczylikC , LeeE , SalmanPV , MardiakJ , DavisID , et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). Journal of Clinical Oncology2009;27(15S):5021. [DOI: 10.1200/jco.2009.27.15s.5021]">Sternberg 2010</a>). All other studies were open label without masking treatments. Three trials used a phase 2 trial design (<a href="./references#CD012796-bbs2-0005" title="AtkinsMB , McDermottDF , PowlesT , MotzerRJ , RiniBI , FongL , et al. IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). Journal of Clinical Oncology2017;35(15 suppl):4505. [DOI: 10.1200/JCO.2017.35.15_suppl.4505]McDermottDF , AtkinsMB , MotzerRJ , RiniBI , EscudierBJ , FongL , et al. A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). Journal of Clinical Oncology2017;35(6 suppl):431. [DOI: 10.1200/JCO.2017.35.6_suppl.431]McDermottDF , HuseniMA , AtkinsMB , MotzerRJ , RiniBI , EscudierB , et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine2018;24(6):749-57. [PMID: 29867230]NCT01984242. A study of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) as monotherapy or in combination with bevacizumab (avastin®) compared to sunitinib (Sutent®) in participants with untreated advanced renal cell carcinoma (IMmotion150) [A phase II, randomized study of atezolizumab (anti-PD-L1 antibody) administered as monotherapy or in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT01984242 (first received 14 November 2013). [NCT01984242]PalSK , McDermottDF , AtkinsMB , EscudierB , RiniBI , MotzerRJ , et al. Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. BJU Int2020;126:73-82. [DOI: 10.1111/bju.15058]PowlesT, McDermottDF , RiniB , MotzerRJ , AtkinsMB , FongL , et al. IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC). Annals of Oncology2017;28(suppl 5):624. [DOI: 10.1093/annonc/mdx440.033]">McDermott 2018</a>; <a href="./references#CD012796-bbs2-0009" title="KnoxJJ , BarriosCH , KimTM , CosgriffT , SrimuninnimitV , PittmanK , et al. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Annals of Oncology2017;28(6):1339-45. [PMID: 28327953]KnoxJJ , BarriosCH , KimTM , CosgriffT , SrimuninnimitV , PittmanKB , et al. Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC). Journal of Clinical Oncology2015;33(15 suppl):4554. [DOI: 10.1200/jco.2015.33.15_suppl.4554]MotzerRJ , BarriosCH , KimTM , FalconS , CosgriffT , HarkerWG , et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2014;32(25):2765-72. [PMID: 25049330]NCT00903175. Efficacy and safety comparison of RAD001 versus sunitinib in the first-line and second-line treatment of patients with metastatic renal cell carcinoma (RECORD-3) [An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as First-line followed by second-line RAD001 in the treatment of patients with metastatic renal cell carcinoma.]. clinicaltrials.gov/ct2/show/NCT00903175 (first received 18 May 2009). [NCT00903175]">Motzer 2014</a>; <a href="./references#CD012796-bbs2-0011" title="NCT00719264. Safety and efficacy of bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment in adult patients with kidney cancer [A randomized, open-label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a plus bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney]. clinicaltrials.gov/ct2/show/study/NCT00719264 (first received 21 July 2008). [NCT00719264]RavaudA , BarriosCH , AlekseevB , TayMH , AgarwalaSS , YalcinS , et al. RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. Annals of Oncology2015;26(7):1378-84. [PMID: 25851632]">Ravaud 2015</a>); all others were performed in a phase 3 setting. Eight trials allowed a cross‐over between treatment arms or to active treatment if disease progression occurred (<a href="./references#CD012796-bbs2-0001" title="EichelbergC , GoebellPJ , VervenneWL , De SantisM , Fischer von WeikersthalL , LerchenmüllerC , et al. Updated overall survival, multivariate, and Q-TWiST analyses of a randomized, sequential, open-label study (SWITCH) to evaluate the efficacy and safety of sorafenib (So)-sunitinib (Su) versus Su-So in the treatment of metastatic renal cell cancer. Annals of Oncology2014;25(suppl 4):iv290. [DOI: 10.1093/annonc/mdu337.28]EichelbergC , VervenneWL , De SantisM , Fischer von WeikersthalL , GoebellPJ , LerchenmüllerC , et al. SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer. European Urology2015;68(5):837-47. [PMID: 25952317]GoebellPJ , VervenneW , De SantisM , Fischer Von WeikersthalL , LerchenmullerCA , ZimmermannU , et al. Subgroup analyses of a randomized sequential open-label study (SWITCH) to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). Journal of Clinical Oncology2014;32(15 suppl):4567. [DOI: 10.1200/jco.2014.32.15_suppl.4567]MichelMS , VervenneW , deSantisM , Fischer von WeikersthalL , GoebellPJ , LerchenmuellerJ , et al. SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). Journal of Clinical Oncology2014;32(4 suppl):393. [DOI: 10.1200/jco.2014.32.4_suppl.393]NCT00732914. Sequential study to treat renal cell carcinoma [A phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by sunitinib versus sunitinib followed by sorafenib in the treatment of first-line advanced / metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00732914 (first received 12 August 2008). [NCT00732914]">Eichelberg 2015</a>; <a href="./references#CD012796-bbs2-0002" title="BajettaE , RavaudA , BracardaS , NégrierS , SzczylikC , BellmuntJ , et al. Efficacy and safety of first-line bevacizumab (BEV) plus interferon-α2a (IFN) in patients (pts) ≥65 years with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2008;26(15 suppl):5095. [DOI: 10.1200/jco.2008.26.15_suppl.5095]BellmuntJ , MelicharB , BracardaS , NegrierSN , RavaudA , LaeufleR , et al. Bevacizumab (BEV) and interferon (IFN) therapy does not increase risk of cardiac events in metastatic renal cell carcinoma(mRCC). European Journal of Cancer Supplements2009;7(2):429. [DOI: 10.1016/S1359-6349(09)71454-5]BracardaS , BellmuntJ , NegrierSN , MelicharB , RavaudA , JethwaS , et al. What is the impact of subsequent antineoplastic therapy on overall survival (OS) following first-line bevacizumab (BEV)/interferonalpha2a (IFN) in metastatic renal cell carcinoma (mRCC)? – Experience from AVOREN. European Journal of Cancer Supplements2009;7(2):431. [DOI: 10.1016/S1359-6349(09)71459-4]BracardaS , KoralewskiP , PluzanskaA , RavaudA , SzczylikC , ChevreauC , et al. Bevacizumab/interferon-alpha2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN). European Journal of Cancer Supplements2007;5(4):281-2. [DOI: 10.1016/S1359-6349(07)71076-5]EscudierB , KoralewskiP , PluzanskaA , RavaudA , BracardaS , SzczylikC , et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma. Journal of Clinical Oncology2007;25(18 suppl):3. [DOI: 10.1200/jco.2007.25.18_suppl.3]EscudierB , PluzanskaA , KoralewskiP , RavaudA , BracardaS , SzczylikC , et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized double-blind phase III trial. Lancet2007;370(9605):2103-11. [PMID: 18156031]EscudierBB , BellmuntJ , NegrierS , BajettaE , MelicharB , BracardaS , et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. Journal of Clinical Oncology2010;28(13):2144-50. [PMID: 20368553]EscudierBJ , BellmuntJ , NegrierS , MelicharB , BracardaS , RavaudA , et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2009;27(15 suppl):5020. [DOI: 10.1200/jco.2009.27.15_suppl.5020]EscudierBJ , NegrierS , ChevreauC , et al. Analysis of prognostic risk categories in the phase III AVOREN trial of first-line bevacizumab plus interferon-α2a in patients with metastatic renal cell carcinoma: French prognostic scoring system. In: Genitourinary Cancers Symposium, ASCO, abst 417. 2010. EscudierBJ , RavaudA , NegrierS , SzczylikC , BellmuntJ , BracardaS , et al. Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis. Journal of Clinical Oncology2008;26(15 suppl):5025. [DOI: 10.1200/jco.2008.26.15_suppl.5025]KarakiewiczP , SunM , SnellerV , EscudierB . Use of a nomogram to quantify overall survival (OS) benefit in patients with metastatic renal cell carcinoma receiving bevacizumab (BEV) with interferon (IFN) versus IFN alone. Journal of Clinical Oncology2010;28(15 suppl):4592. [DOI: 10.1200/jco.2010.28.15_suppl.4592 ]KarakiewiczPI , SunM , SnellerV , et al. Use of a nomogram to quantify progression-free survival benefit in metastatic renal cell carcinoma patients receiving bevacizumab plus interferon or interferon alone. In: Genitourinary Cancers Symposium, ASCO, abstr 392. 2010. MelicharB , KoralewskiP , PluzanskaA , RavaudA , BracardaS , SzczylikC , et al. First-line bevacizumab improves progression-free survival with lower doses of interferon-α2a in the treatment of patients with metastatic renal cell carcinoma (AVOREN). European Journal of Cancer Supplements2007;5(4):304. [DOI: 10.1016/S1359-6349(07)71149-7]MelicharB , KoralewskiP , RavaudA , PluzanskaA , BracardaS , SzczylikC , et al. First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma. Annals of Oncology2008;19(8):1470-6. [PMID: 18408224]NCT00738530. A study of avastin (bevacizumab) added to interferon alfa-2a (roferon) therapy in patients with metastatic renal cell cancer with nephrectomy [A randomised, double-blind study to evaluate the efficacy and safety of avastin plus roferon compared with placebo plus roferon on overall survival and tumor assessment in nephrectomised patients with metastatic clear cell renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00738530 (first received 20 August 2008). [NCT00738530]">Escudier 2010</a>; <a href="./references#CD012796-bbs2-0005" title="AtkinsMB , McDermottDF , PowlesT , MotzerRJ , RiniBI , FongL , et al. IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). Journal of Clinical Oncology2017;35(15 suppl):4505. [DOI: 10.1200/JCO.2017.35.15_suppl.4505]McDermottDF , AtkinsMB , MotzerRJ , RiniBI , EscudierBJ , FongL , et al. A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). Journal of Clinical Oncology2017;35(6 suppl):431. [DOI: 10.1200/JCO.2017.35.6_suppl.431]McDermottDF , HuseniMA , AtkinsMB , MotzerRJ , RiniBI , EscudierB , et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine2018;24(6):749-57. [PMID: 29867230]NCT01984242. A study of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) as monotherapy or in combination with bevacizumab (avastin®) compared to sunitinib (Sutent®) in participants with untreated advanced renal cell carcinoma (IMmotion150) [A phase II, randomized study of atezolizumab (anti-PD-L1 antibody) administered as monotherapy or in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT01984242 (first received 14 November 2013). [NCT01984242]PalSK , McDermottDF , AtkinsMB , EscudierB , RiniBI , MotzerRJ , et al. Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. BJU Int2020;126:73-82. [DOI: 10.1111/bju.15058]PowlesT, McDermottDF , RiniB , MotzerRJ , AtkinsMB , FongL , et al. IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC). Annals of Oncology2017;28(suppl 5):624. [DOI: 10.1093/annonc/mdx440.033]">McDermott 2018</a>; <a href="./references#CD012796-bbs2-0006" title="CastellanoD , delMuroXG , Pérez-GraciaJL , González-LarribaJL , AbrioMV , RuizMA , et al. Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population. Annals of Oncology2009;20(11):1803-12. [PMID: 19549706]CellaD , CappelleriJC , BushmakinA , CharbonneauC , LiJZ , KimST , et al. Quality of life predicts progression-free survival in patients with renal cell carcinoma treated with sunitinib versus interferon alfa. Journal of Oncology Practice2009;5(2):66-70. [PMID: 20856722]CellaD , LiJZ , CappelariJC , BushmakinA , CharbonneauC , KimST , et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. Journal of Clinical Oncology2008;26(22):3763-9. [PMID: 18669464]CellaD , LiJZ , CappelleriJC , BushmakinA , CharbonneauC , KimST , ChenI , et al. Quality of life (QOL) predicts for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib compared to interferon-alpha (IFN-α). Journal of Clinical Oncology2007;25(18 suppl):6594. [DOI: 10.1200/jco.2007.25.18_suppl.6594]CellaD , MichaelsonMD , BushmakinAG , CappelleriJC , CharbonneauC , KimST , et al. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-a in a phase III trial: final results and geographical analysis. British Journal of Cancer2010;102(4):658-64. [PMID: 20104222]FiginRA , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , NegrierS , et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2008;26(15 suppl):5024. [DOI: 10.1200/jco.2008.26.15_suppl.5024]MotzerRJ , BukowskiRM , FiglinRA , HutsonTE , MichaelsonMD , KimST , et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer2008;113(7):1552-8. [PMID: 18720362]MotzerRJ , FiglinRA , HutsonTE , TomczakP , BukowskiRM , RixeO , et al. Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors. Journal of Clinical Oncology2007;25(18 suppl):5024. [DOI: 10.1200/jco.2007.25.18_suppl.5024]MotzerRJ , FiglinRA , HutsonTE , TomczakP , BukowskiRM , RixeO , et al. Sunitinib versus interferon-alfa as first-line treatment of metastatic renal cell carcinoma: updated results and analysis of prognostic factors. In: www.asco.org/virtual meeting. 2007. MotzerRJ , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , OudardS , et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2009;27(22):3584-90. [PMID: 19487381]MotzerRJ , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , RixeO , et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2006;24(18 suppl):LBA3. [DOI: 10.1200/jco.2006.24.18_suppl.lba3]MotzerRJ , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , RixeO , et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine2007;356(2):115-24. [PMID: 17215529]MotzerRJ , MichaelsonMD , HutsonTE , TomczakP , BukowskiRM , RixeO , et al. Sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors. European Journal of Cancer Supplements2007;5(4):301. [DOI: 10.1016/S1359-6349(07)71140-0]NCT00083889. SU011248 versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma [A phase 3, randomized study of SU011248 versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00083889 (first received 4 June 2004). [NCT00083889]PatilS , FiglinRA , HutsonTE , MichaelsonD , NegrierS , KimST , et al. TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-α). Journal of Clinical Oncology2010;28(15 suppl):4594. [DOI: 10.1200/jco.2010.28.15_suppl.4594]WilkersonJ , SteinWD , KimST , HuangX , MotzerRJ , FojoAT , et al. Validation of kinetic analysis of renal cancer regression and growth following treatment with sunitinib and interferon-alfa: analysis of the pivotal randomized trial. Journal of Clinical Oncology2010;28(15 suppl):4597. [DOI: 10.1200/jco.2010.28.15_suppl.4597]">Motzer 2010</a>; <a href="./references#CD012796-bbs2-0008" title="HutsonT , NosovD , TomczakP , BondarenkoI , LipatovON , SternbergCN , et al. Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902). Journal of Clinical Oncology2015;33(15 suppl):4557. [DOI: 10.1200/jco.2015.33.15_suppl.4557]MotzerRJ , NosovD , EisenT , BondarenkoI , LesovoyV , LipatovO , et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. Journal of Clinical Oncology2013;31(30):3791-9. [PMID: 24019545]NCT01030783. A study to compare tivozanib (AV-951) to sorafenib in subjects with advanced renal cell carcinoma (TIVO-1) [A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib (AV-951) to sorafenib in subjects with advanced renal cell carcinoma (TIVO-1)]. clinicaltrials.gov/ct2/show/NCT01030783 (first received 11 December 2009). [NCT01030783]">Motzer 2013b</a>; <a href="./references#CD012796-bbs2-0009" title="KnoxJJ , BarriosCH , KimTM , CosgriffT , SrimuninnimitV , PittmanK , et al. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Annals of Oncology2017;28(6):1339-45. [PMID: 28327953]KnoxJJ , BarriosCH , KimTM , CosgriffT , SrimuninnimitV , PittmanKB , et al. Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC). Journal of Clinical Oncology2015;33(15 suppl):4554. [DOI: 10.1200/jco.2015.33.15_suppl.4554]MotzerRJ , BarriosCH , KimTM , FalconS , CosgriffT , HarkerWG , et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2014;32(25):2765-72. [PMID: 25049330]NCT00903175. Efficacy and safety comparison of RAD001 versus sunitinib in the first-line and second-line treatment of patients with metastatic renal cell carcinoma (RECORD-3) [An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as First-line followed by second-line RAD001 in the treatment of patients with metastatic renal cell carcinoma.]. clinicaltrials.gov/ct2/show/NCT00903175 (first received 18 May 2009). [NCT00903175]">Motzer 2014</a>; <a href="./references#CD012796-bbs2-0012" title="NCT01613846. Phase III sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma (SWITCH-II) [Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT01613846 (first received 7 June 2012). [NCT01613846]RetzM , BedkeJ , BögemannM , GrimmMO , ZimmermannU , MüllerL , et al. SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). European Journal of Cancer2019;107:37-45. [PMID: 30529901]RetzM , BedkeJ, HerrmannE , GrimmM , ZimmermannU , MüllerL , et al. Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib sorafenib in the treatment of metastatic renal cell carcinoma(SWITCH-II). Annals of Oncology2017;28(suppl 5):295. [DOI: 10.1093/annonc/mdx371]">Retz 2019</a>; <a href="./references#CD012796-bbs2-0018" title="CellaD , PickardAS , DuhMS , GuerinA , MishaginaN , AntràsL , et al. Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. European Journal of Cancer2012;48(3):311-23. [PMID: 21689927]HutsonTE , BukowskiRM . A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma. Clinical Genitourinary Cancer2006;4(4):296-8. [PMID: 16729915]HutsonTE , DavisID , MachielsJP , deSouzaPL , HongBF , RotteyS , et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). Journal of Clinical Oncology2007;25(18 suppl):5031. [DOI: 10.1200/jco.2007.25.18_suppl.5031]NCT00334282. Safety and efficacy of GW786034 (pazopanib) In metastatic renal cell carcinoma [A randomised, double-blind, placebo controlled, multi-center phase III study to evaluate the efficacy and safety of pazopanib (GW786034) compared to placebo in patients with locally advanced and/or metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT00334282 (first received 7 June 2006). [NCT00334282]SternbergCN , DavisID , MardiakJ , SzczylikC , LeeE , WagstaffJ , et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of Clinical Oncology2010;28(6):1061-8. [PMID: 20100962]SternbergCN , HawkinsRE , WagstaffJ , SalmanP , MardiakJ , BarriosCH , et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. European Journal of Cancer2013;49(6):1287-96. [PMID: 23321547]SternbergCN , SzczylikC , LeeE , SalmanPV , MardiakJ , DavisID , et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). Journal of Clinical Oncology2009;27(15S):5021. [DOI: 10.1200/jco.2009.27.15s.5021]">Sternberg 2010</a>). All trials were multicentre studies with an accrual period between 2003 and 2019. </p> </section> <section id="CD012796-sec-0056"> <h5 class="title">Participants</h5> <p>Combining the numbers of all studies, there were 11,590 participants included of which 11,419 received the allocated treatment. All randomised participants were included in the efficacy analysis, 98% were assessed for safety. Most trials allowed only participants with a clear cell histology or a clear cell component. Six trials allowed any histology but 85% of the participants were diagnosed with clear cell renal cell carcinoma (<a href="./references#CD012796-bbs2-0001" title="EichelbergC , GoebellPJ , VervenneWL , De SantisM , Fischer von WeikersthalL , LerchenmüllerC , et al. Updated overall survival, multivariate, and Q-TWiST analyses of a randomized, sequential, open-label study (SWITCH) to evaluate the efficacy and safety of sorafenib (So)-sunitinib (Su) versus Su-So in the treatment of metastatic renal cell cancer. Annals of Oncology2014;25(suppl 4):iv290. [DOI: 10.1093/annonc/mdu337.28]EichelbergC , VervenneWL , De SantisM , Fischer von WeikersthalL , GoebellPJ , LerchenmüllerC , et al. SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer. European Urology2015;68(5):837-47. [PMID: 25952317]GoebellPJ , VervenneW , De SantisM , Fischer Von WeikersthalL , LerchenmullerCA , ZimmermannU , et al. Subgroup analyses of a randomized sequential open-label study (SWITCH) to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). Journal of Clinical Oncology2014;32(15 suppl):4567. [DOI: 10.1200/jco.2014.32.15_suppl.4567]MichelMS , VervenneW , deSantisM , Fischer von WeikersthalL , GoebellPJ , LerchenmuellerJ , et al. SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). Journal of Clinical Oncology2014;32(4 suppl):393. [DOI: 10.1200/jco.2014.32.4_suppl.393]NCT00732914. Sequential study to treat renal cell carcinoma [A phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by sunitinib versus sunitinib followed by sorafenib in the treatment of first-line advanced / metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00732914 (first received 12 August 2008). [NCT00732914]">Eichelberg 2015</a>; <a href="./references#CD012796-bbs2-0004" title="AlemaoE , RajagopalanS , YangS , et al. Quality adjusted survival in randomized, controlled trials: application of inverse probability weighting in renal cell cancer. In: Genitourinary Cancers Symposium, ASCO, abstr 399. 2010. ArmstrongAJ , GeorgeDJ , HalabiS . Serum lactate dehydrogenase as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2010;28(15 suppl):4361. [DOI: 10.1200/jco.2010.28.15_suppl.4631]DutcherJP , SzczylikC , TannirN , BenedettoP , RuffP , HsuA , et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon-alpha. Journal of Clinical Oncology2007;25(18 suppl):5033. [DOI: 10.1200/jco.2007.25.18_suppl.5033]DutcherJP , deSouzaP , FiglinR , et al. Effect of temsirolimus versus interferon- on survival of patients with advanced renal cell carcinoma of different histologies. In: Genitourinary Cancers Symposium, ASCO, abstr 384. 2008. DutcherJP , deSouzaP , McDermottD , FiglinRA , BerkenblitA , ThieleA , et al. Effect of temsirolimus versus interferon- on outcome of patients with advanced renal cell carcinoma of different histologies. Medical Oncology2009;26(2):202–9. [PMID: 19229667]HudesG , CarducciM , TomczakP , DutcherJ , FiglinR , KapoorA , et al. A phase 3, randomized, 3-arm study of temsirolimus or interferon alpha or the combination in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma. Journal of Clinical Oncology2006;24(18 suppl):LBA4. [DOI: 10.1200/jco.2006.24.18_suppl.lba4]HudesG , CarducciM , TomczakP , DutcherJ , FiglinR , KapoorA , et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine2007;356(22):2271–81. [PMID: 17538086]LoganT , McDermottD , DutcherJ , et al. Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features. In: Genitourinary Cancers Symposium, ASCO, abstr 281. 2009. NCT00065468. Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma (ARCC). clinicaltrials.gov/ct2/show/results/NCT00065468 (first received July 25 2003). [NCT00065468]PabloM , HudesG , DutcherJ , WhiteC , KrygowskiM , CincottaM , et al. Radiographic findings of drug-induced pneumonitis and clinical correlation inpatients with advanced renal cell carcinoma treated with temsirolimus. European Journal of Cancer Supplements2009;7(2):426-7. [DOI: 10.1016/S1359-6349(09)71446-6]ParasuramanS , HudesG , LevyD , StrahsA , MooreL , De MariniseR , et al. Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon- (IFN) or the combination of IFN+TEMSR. Journal of Clinical Oncology2007;25(18 suppl):5049. [DOI: 10.1200/jco.2007.25.18_suppl.5049]YangS , HudesG , deSouzaP , AlemaoE , StrahsA , PurvisJ . Evaluation of quality of life in patients with advanced renal cell carcinoma treated with temsirolimus vs interferon-alfa: results from a phase III randomized trial. European Journal of Cancer Supplements2009;7(2):433. [DOI: 10.1016/S1359-6349(09)71467-3]ZbrozekAS , HudesG , LevyD , StrahsA , BerkenblitA , DeMarinisR , et al. Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma. Pharmacoeconomics2010;28(7):577–84. [PMID: 20550223]">Hudes 2007</a>; <a href="./references#CD012796-bbs2-0009" title="KnoxJJ , BarriosCH , KimTM , CosgriffT , SrimuninnimitV , PittmanK , et al. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Annals of Oncology2017;28(6):1339-45. [PMID: 28327953]KnoxJJ , BarriosCH , KimTM , CosgriffT , SrimuninnimitV , PittmanKB , et al. Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC). Journal of Clinical Oncology2015;33(15 suppl):4554. [DOI: 10.1200/jco.2015.33.15_suppl.4554]MotzerRJ , BarriosCH , KimTM , FalconS , CosgriffT , HarkerWG , et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2014;32(25):2765-72. [PMID: 25049330]NCT00903175. Efficacy and safety comparison of RAD001 versus sunitinib in the first-line and second-line treatment of patients with metastatic renal cell carcinoma (RECORD-3) [An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as First-line followed by second-line RAD001 in the treatment of patients with metastatic renal cell carcinoma.]. clinicaltrials.gov/ct2/show/NCT00903175 (first received 18 May 2009). [NCT00903175]">Motzer 2014</a>; <a href="./references#CD012796-bbs2-0011" title="NCT00719264. Safety and efficacy of bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment in adult patients with kidney cancer [A randomized, open-label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a plus bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney]. clinicaltrials.gov/ct2/show/study/NCT00719264 (first received 21 July 2008). [NCT00719264]RavaudA , BarriosCH , AlekseevB , TayMH , AgarwalaSS , YalcinS , et al. RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. Annals of Oncology2015;26(7):1378-84. [PMID: 25851632]">Ravaud 2015</a>; <a href="./references#CD012796-bbs2-0012" title="NCT01613846. Phase III sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma (SWITCH-II) [Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT01613846 (first received 7 June 2012). [NCT01613846]RetzM , BedkeJ , BögemannM , GrimmMO , ZimmermannU , MüllerL , et al. SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). European Journal of Cancer2019;107:37-45. [PMID: 30529901]RetzM , BedkeJ, HerrmannE , GrimmM , ZimmermannU , MüllerL , et al. Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib sorafenib in the treatment of metastatic renal cell carcinoma(SWITCH-II). Annals of Oncology2017;28(suppl 5):295. [DOI: 10.1093/annonc/mdx371]">Retz 2019</a>; <a href="./references#CD012796-bbs2-0014" title="NCT00631371. Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (INTORACT). linicaltrials.gov/ct2/show/NCT00631371 (first received 20 May 2019). [NCT00631371]RiniBI , BellmuntJ , ClancyJ , WangK , NiethammerAG , HariharanS , et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. Journal of Clinical Oncology2014;32(8):752-9. [PMID: 24297945]">Rini 2014</a>). Median age amongst the total population was 61 years; 72% were males; and 9048 were treated with a nephrectomy prior to systemic therapy. </p> </section> <section id="CD012796-sec-0057"> <h5 class="title">Interventions</h5> <p>Most trials had two arms comparing either two active treatments or an active treatment against placebo. Two trials had a design with multiple comparisons (<a href="./references#CD012796-bbs2-0004" title="AlemaoE , RajagopalanS , YangS , et al. Quality adjusted survival in randomized, controlled trials: application of inverse probability weighting in renal cell cancer. In: Genitourinary Cancers Symposium, ASCO, abstr 399. 2010. ArmstrongAJ , GeorgeDJ , HalabiS . Serum lactate dehydrogenase as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2010;28(15 suppl):4361. [DOI: 10.1200/jco.2010.28.15_suppl.4631]DutcherJP , SzczylikC , TannirN , BenedettoP , RuffP , HsuA , et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon-alpha. Journal of Clinical Oncology2007;25(18 suppl):5033. [DOI: 10.1200/jco.2007.25.18_suppl.5033]DutcherJP , deSouzaP , FiglinR , et al. Effect of temsirolimus versus interferon- on survival of patients with advanced renal cell carcinoma of different histologies. In: Genitourinary Cancers Symposium, ASCO, abstr 384. 2008. DutcherJP , deSouzaP , McDermottD , FiglinRA , BerkenblitA , ThieleA , et al. Effect of temsirolimus versus interferon- on outcome of patients with advanced renal cell carcinoma of different histologies. Medical Oncology2009;26(2):202–9. [PMID: 19229667]HudesG , CarducciM , TomczakP , DutcherJ , FiglinR , KapoorA , et al. A phase 3, randomized, 3-arm study of temsirolimus or interferon alpha or the combination in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma. Journal of Clinical Oncology2006;24(18 suppl):LBA4. [DOI: 10.1200/jco.2006.24.18_suppl.lba4]HudesG , CarducciM , TomczakP , DutcherJ , FiglinR , KapoorA , et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine2007;356(22):2271–81. [PMID: 17538086]LoganT , McDermottD , DutcherJ , et al. Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features. In: Genitourinary Cancers Symposium, ASCO, abstr 281. 2009. NCT00065468. Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma (ARCC). clinicaltrials.gov/ct2/show/results/NCT00065468 (first received July 25 2003). [NCT00065468]PabloM , HudesG , DutcherJ , WhiteC , KrygowskiM , CincottaM , et al. Radiographic findings of drug-induced pneumonitis and clinical correlation inpatients with advanced renal cell carcinoma treated with temsirolimus. European Journal of Cancer Supplements2009;7(2):426-7. [DOI: 10.1016/S1359-6349(09)71446-6]ParasuramanS , HudesG , LevyD , StrahsA , MooreL , De MariniseR , et al. Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon- (IFN) or the combination of IFN+TEMSR. Journal of Clinical Oncology2007;25(18 suppl):5049. [DOI: 10.1200/jco.2007.25.18_suppl.5049]YangS , HudesG , deSouzaP , AlemaoE , StrahsA , PurvisJ . Evaluation of quality of life in patients with advanced renal cell carcinoma treated with temsirolimus vs interferon-alfa: results from a phase III randomized trial. European Journal of Cancer Supplements2009;7(2):433. [DOI: 10.1016/S1359-6349(09)71467-3]ZbrozekAS , HudesG , LevyD , StrahsA , BerkenblitA , DeMarinisR , et al. Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma. Pharmacoeconomics2010;28(7):577–84. [PMID: 20550223]">Hudes 2007</a>; <a href="./references#CD012796-bbs2-0005" title="AtkinsMB , McDermottDF , PowlesT , MotzerRJ , RiniBI , FongL , et al. IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). Journal of Clinical Oncology2017;35(15 suppl):4505. [DOI: 10.1200/JCO.2017.35.15_suppl.4505]McDermottDF , AtkinsMB , MotzerRJ , RiniBI , EscudierBJ , FongL , et al. A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). Journal of Clinical Oncology2017;35(6 suppl):431. [DOI: 10.1200/JCO.2017.35.6_suppl.431]McDermottDF , HuseniMA , AtkinsMB , MotzerRJ , RiniBI , EscudierB , et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine2018;24(6):749-57. [PMID: 29867230]NCT01984242. A study of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) as monotherapy or in combination with bevacizumab (avastin®) compared to sunitinib (Sutent®) in participants with untreated advanced renal cell carcinoma (IMmotion150) [A phase II, randomized study of atezolizumab (anti-PD-L1 antibody) administered as monotherapy or in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT01984242 (first received 14 November 2013). [NCT01984242]PalSK , McDermottDF , AtkinsMB , EscudierB , RiniBI , MotzerRJ , et al. Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. BJU Int2020;126:73-82. [DOI: 10.1111/bju.15058]PowlesT, McDermottDF , RiniB , MotzerRJ , AtkinsMB , FongL , et al. IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC). Annals of Oncology2017;28(suppl 5):624. [DOI: 10.1093/annonc/mdx440.033]">McDermott 2018</a>). </p> <p>Five trials compared two different targeted therapies against each other; sorafenib versus sunitinib (<a href="./references#CD012796-bbs2-0001" title="EichelbergC , GoebellPJ , VervenneWL , De SantisM , Fischer von WeikersthalL , LerchenmüllerC , et al. Updated overall survival, multivariate, and Q-TWiST analyses of a randomized, sequential, open-label study (SWITCH) to evaluate the efficacy and safety of sorafenib (So)-sunitinib (Su) versus Su-So in the treatment of metastatic renal cell cancer. Annals of Oncology2014;25(suppl 4):iv290. [DOI: 10.1093/annonc/mdu337.28]EichelbergC , VervenneWL , De SantisM , Fischer von WeikersthalL , GoebellPJ , LerchenmüllerC , et al. SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer. European Urology2015;68(5):837-47. [PMID: 25952317]GoebellPJ , VervenneW , De SantisM , Fischer Von WeikersthalL , LerchenmullerCA , ZimmermannU , et al. Subgroup analyses of a randomized sequential open-label study (SWITCH) to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). Journal of Clinical Oncology2014;32(15 suppl):4567. [DOI: 10.1200/jco.2014.32.15_suppl.4567]MichelMS , VervenneW , deSantisM , Fischer von WeikersthalL , GoebellPJ , LerchenmuellerJ , et al. SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). Journal of Clinical Oncology2014;32(4 suppl):393. [DOI: 10.1200/jco.2014.32.4_suppl.393]NCT00732914. Sequential study to treat renal cell carcinoma [A phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by sunitinib versus sunitinib followed by sorafenib in the treatment of first-line advanced / metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00732914 (first received 12 August 2008). [NCT00732914]">Eichelberg 2015</a>), pazopanib versus sunitinib (<a href="./references#CD012796-bbs2-0007" title="MotzerRJ , HutsonTE , CellaD , ReevesJ , HawkinsR , GuoJ , et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. New England Journal of Medicine2013;369(8):722-1. [PMID: 23964934]MotzerRJ , HutsonTE , McCannL , DeenK , ChoueiriTK . Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. New England Journal of Medicine2014;370(18):1769-70. [PMID: 24785224]NCT00720941. Pazopanib versus sunitinib in the treatment of locally advanced and/or metastatic renal cell carcinoma (COMPARZ) [Study VEG108844, A study of pazopanib versus sunitinib in the treatment of subjects with locally advanced and/or metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00720941 (first received 23 July 2008). [NCT00720941]">Motzer 2013a</a>), tivozanib versus sorafenib (<a href="./references#CD012796-bbs2-0008" title="HutsonT , NosovD , TomczakP , BondarenkoI , LipatovON , SternbergCN , et al. Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902). Journal of Clinical Oncology2015;33(15 suppl):4557. [DOI: 10.1200/jco.2015.33.15_suppl.4557]MotzerRJ , NosovD , EisenT , BondarenkoI , LesovoyV , LipatovO , et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. Journal of Clinical Oncology2013;31(30):3791-9. [PMID: 24019545]NCT01030783. A study to compare tivozanib (AV-951) to sorafenib in subjects with advanced renal cell carcinoma (TIVO-1) [A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib (AV-951) to sorafenib in subjects with advanced renal cell carcinoma (TIVO-1)]. clinicaltrials.gov/ct2/show/NCT01030783 (first received 11 December 2009). [NCT01030783]">Motzer 2013b</a>), sorafenib versus pazopanib (<a href="./references#CD012796-bbs2-0012" title="NCT01613846. Phase III sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma (SWITCH-II) [Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT01613846 (first received 7 June 2012). [NCT01613846]RetzM , BedkeJ , BögemannM , GrimmMO , ZimmermannU , MüllerL , et al. SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). European Journal of Cancer2019;107:37-45. [PMID: 30529901]RetzM , BedkeJ, HerrmannE , GrimmM , ZimmermannU , MüllerL , et al. Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib sorafenib in the treatment of metastatic renal cell carcinoma(SWITCH-II). Annals of Oncology2017;28(suppl 5):295. [DOI: 10.1093/annonc/mdx371]">Retz 2019</a>), sunitinib versus everolimus (<a href="./references#CD012796-bbs2-0009" title="KnoxJJ , BarriosCH , KimTM , CosgriffT , SrimuninnimitV , PittmanK , et al. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Annals of Oncology2017;28(6):1339-45. [PMID: 28327953]KnoxJJ , BarriosCH , KimTM , CosgriffT , SrimuninnimitV , PittmanKB , et al. Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC). Journal of Clinical Oncology2015;33(15 suppl):4554. [DOI: 10.1200/jco.2015.33.15_suppl.4554]MotzerRJ , BarriosCH , KimTM , FalconS , CosgriffT , HarkerWG , et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2014;32(25):2765-72. [PMID: 25049330]NCT00903175. Efficacy and safety comparison of RAD001 versus sunitinib in the first-line and second-line treatment of patients with metastatic renal cell carcinoma (RECORD-3) [An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as First-line followed by second-line RAD001 in the treatment of patients with metastatic renal cell carcinoma.]. clinicaltrials.gov/ct2/show/NCT00903175 (first received 18 May 2009). [NCT00903175]">Motzer 2014</a>). </p> <p>One trial compared pazopanib against a placebo (<a href="./references#CD012796-bbs2-0018" title="CellaD , PickardAS , DuhMS , GuerinA , MishaginaN , AntràsL , et al. Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. European Journal of Cancer2012;48(3):311-23. [PMID: 21689927]HutsonTE , BukowskiRM . A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma. Clinical Genitourinary Cancer2006;4(4):296-8. [PMID: 16729915]HutsonTE , DavisID , MachielsJP , deSouzaPL , HongBF , RotteyS , et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). Journal of Clinical Oncology2007;25(18 suppl):5031. [DOI: 10.1200/jco.2007.25.18_suppl.5031]NCT00334282. Safety and efficacy of GW786034 (pazopanib) In metastatic renal cell carcinoma [A randomised, double-blind, placebo controlled, multi-center phase III study to evaluate the efficacy and safety of pazopanib (GW786034) compared to placebo in patients with locally advanced and/or metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT00334282 (first received 7 June 2006). [NCT00334282]SternbergCN , DavisID , MardiakJ , SzczylikC , LeeE , WagstaffJ , et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of Clinical Oncology2010;28(6):1061-8. [PMID: 20100962]SternbergCN , HawkinsRE , WagstaffJ , SalmanP , MardiakJ , BarriosCH , et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. European Journal of Cancer2013;49(6):1287-96. [PMID: 23321547]SternbergCN , SzczylikC , LeeE , SalmanPV , MardiakJ , DavisID , et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). Journal of Clinical Oncology2009;27(15S):5021. [DOI: 10.1200/jco.2009.27.15s.5021]">Sternberg 2010</a>). </p> <p>Four trials assessed the effectiveness of sunitinib against targeted immunotherapy in combination with targeted therapy. Avelumab and axitinib (<a href="./references#CD012796-bbs2-0010" title="MotzerRJ , PenkovK , HaanenJ , RiniB , AlbigesL , CampbellMT , et al. Avelumab plus axitinib versus sunitinib for advanced renal cell carcinoma. New England Journal of Medicine2019;380(12):1103-5. [PMID: 30779531]NCT02684006. A study of avelumab with axitinib versus sunitinib in advanced renal cell cancer (JAVELIN Renal 101) [A phase 3, multinational, randomized, open-label, parallel-arm study of avelumab (MSB0010718C) in combination with axitinib (Inlyta(registered)) versus sunitinib (Sutent(registered)) monotherapy in the first-line treatment of patients with advanced renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT02684006 (first received 17 February 2016). [NCT02684006]">Motzer 2019</a>), pembrolizumab and axitinib (<a href="./references#CD012796-bbs2-0016" title="NCT02853331. Study to evaluate the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib versus sunitinib monotherapy in participants with renal cell carcinoma (MK-3475-426/KEYNOTE-426) [A phase III randomized, open-label study to evaluate efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib versus sunitinib monotherapy as a first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (KEYNOTE-426)]. clinicaltrials.gov/ct2/show/NCT02853331 (first received 2 August 2016). [NCT02853331]PowlesT , PlimackER , StusV , GafanovRA , HawkinsRE , NosovD . Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study. Journal of Clinical Oncology2019;37(7 suppl):543-543. RiniBI , PlimackER , StusV , GafanovR , HawkinsR , NosovD , et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. New England Journal of Medicine2019;380(12):1116-27. [PMID: 30779529]">Rini 2019a</a>), and atezolizumab and bevacizumab (<a href="./references#CD012796-bbs2-0017" title="AtkinsMB , RiniBI , MotzerRJ , PowlesT , McDermottDF , SuarezC , et al. Patient-reported outcomes from the phase 3 randomized IMmotion151 trial: atezolizumab + bevacizumab vs sunitinib in treatment-naive metastatic renal cell carcinoma. Clinical Cancer Research2020;26(11):2506-2514. EscudierB , MotzerRJ , RiniBI , PowlesT , McDermottDF , SuarezC , et al. Patient-reported outcomes (PROs) in IMmotion151: atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2018;36(15_suppl):4511. [DOI: 10.1200/JCO.2018.36.15_suppl.4511]MotzerRJ , PowlesT , AtkinsMB , EscudierB , McDermottDF , SuarezC , et al. IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2018;36(6 suppl):578. [DOI: 10.1200/JCO.2018.36.6_suppl.578]NCT02420821. A study of atezolizumab in combination with bevacizumab versus sunitinib in participants with untreated advanced renal cell carcinoma (RCC) (IMmotion151) [A phase III, open-label, randomized study of atezolizumab (Anti-PD-L1 Antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT02420821 (first received 20 April 2015). [NCT02420821]RiniBI , PowlesT , AtkinsMB , EscudierB , McDermottDF , SuarezC , et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet2019;393(10189):2404-15. [PMID: 31079938]">Rini 2019b</a>; <a href="./references#CD012796-bbs2-0005" title="AtkinsMB , McDermottDF , PowlesT , MotzerRJ , RiniBI , FongL , et al. IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). Journal of Clinical Oncology2017;35(15 suppl):4505. [DOI: 10.1200/JCO.2017.35.15_suppl.4505]McDermottDF , AtkinsMB , MotzerRJ , RiniBI , EscudierBJ , FongL , et al. A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). Journal of Clinical Oncology2017;35(6 suppl):431. [DOI: 10.1200/JCO.2017.35.6_suppl.431]McDermottDF , HuseniMA , AtkinsMB , MotzerRJ , RiniBI , EscudierB , et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine2018;24(6):749-57. [PMID: 29867230]NCT01984242. A study of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) as monotherapy or in combination with bevacizumab (avastin®) compared to sunitinib (Sutent®) in participants with untreated advanced renal cell carcinoma (IMmotion150) [A phase II, randomized study of atezolizumab (anti-PD-L1 antibody) administered as monotherapy or in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT01984242 (first received 14 November 2013). [NCT01984242]PalSK , McDermottDF , AtkinsMB , EscudierB , RiniBI , MotzerRJ , et al. Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. BJU Int2020;126:73-82. [DOI: 10.1111/bju.15058]PowlesT, McDermottDF , RiniB , MotzerRJ , AtkinsMB , FongL , et al. IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC). Annals of Oncology2017;28(suppl 5):624. [DOI: 10.1093/annonc/mdx440.033]">McDermott 2018</a>) were used as comparators. <a href="./references#CD012796-bbs2-0005" title="AtkinsMB , McDermottDF , PowlesT , MotzerRJ , RiniBI , FongL , et al. IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). Journal of Clinical Oncology2017;35(15 suppl):4505. [DOI: 10.1200/JCO.2017.35.15_suppl.4505]McDermottDF , AtkinsMB , MotzerRJ , RiniBI , EscudierBJ , FongL , et al. A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). Journal of Clinical Oncology2017;35(6 suppl):431. [DOI: 10.1200/JCO.2017.35.6_suppl.431]McDermottDF , HuseniMA , AtkinsMB , MotzerRJ , RiniBI , EscudierB , et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine2018;24(6):749-57. [PMID: 29867230]NCT01984242. A study of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) as monotherapy or in combination with bevacizumab (avastin®) compared to sunitinib (Sutent®) in participants with untreated advanced renal cell carcinoma (IMmotion150) [A phase II, randomized study of atezolizumab (anti-PD-L1 antibody) administered as monotherapy or in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT01984242 (first received 14 November 2013). [NCT01984242]PalSK , McDermottDF , AtkinsMB , EscudierB , RiniBI , MotzerRJ , et al. Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. BJU Int2020;126:73-82. [DOI: 10.1111/bju.15058]PowlesT, McDermottDF , RiniB , MotzerRJ , AtkinsMB , FongL , et al. IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC). Annals of Oncology2017;28(suppl 5):624. [DOI: 10.1093/annonc/mdx440.033]">McDermott 2018</a> had a three‐arm design which even included a direct comparison of sunitinib against atezolizumab. Another trial compared sunitinib against the combination of nivolumab and ipilimumab (<a href="./references#CD012796-bbs2-0003" title="CellaD , GrunwaldV , EscudierB , HammersHJ , GeorgeS , NathanP , et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncology2019;20(2):297-310. [PMID: 30658932]EscudierB , TannirN , McDermottDF , FronteraOA , MelicharB , PlimackER , et al. CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups. Annals of Oncology2017;28(suppl 5):621-2. [DOI: 10.1093/annonc/mdx440.029]MotzerRJ , RiniBI , McDermottDF , Aren FronteraO , HammersHJ , CarducciMA , et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncology2019;S1470-2045(19):30413-9. [PMID: 31427204]MotzerRJ , TannirN , McDermottDF , FronteraOA , MelicharB , ChoueiriTK , et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. New England Journal of Medicine2018;378(14):1277-90. [PMID: 29562145]NCT02231749. Nivolumab combined with ipilimumab versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma (CheckMate 214) [A phase 3, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, advanced or metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT02231749 (first received 4 September 2014). [NCT02231749]TannirNM , HammersHJ , AminA , Grimm M-O, RiniBI , MekanS , et al. Characterization of the benefit-risk profile of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced renal cell carcinoma (aRCC; CheckMate 214). Journal of Clinical Oncology2018;28(6 suppl):686. [DOI: 10.1200/JCO.2018.36.6_suppl.686]VyasC , MotzerRJ , TannirNM , McDermottDF , FronteraOA , MelicharB , et al. Nivolumab + ipilimumab (N+I) vs sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (aRCC): results from checkmate 214, including overall survival by subgroups. Journal of Oncology Pharmacy Practice2018;24(5_suppl):17-8. ">Escudier 2017</a>). </p> <p>One trial compared sunitinib against a combination of tumour vaccine, chemotherapy and sunitinib (<a href="./references#CD012796-bbs2-0015" title="NCT01265901. IMA901 in patients receiving sunitinib for advanced/metastatic renal cell carcinoma [A randomized, controlled phase III study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT01265901 (first received 23 December 2010). [NCT01265901]RiniBI , StenzlA , ZdrojowyR , KoganM , ShkolnikM , OudardS , et al. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncology2016;17(11):1599-611. [PMID: 27720136]">Rini 2016</a>). </p> <p>Interferon alpha was compared to targeted therapy or combinations of targeted therapy in four studies: sunitinib (<a href="./references#CD012796-bbs2-0006" title="CastellanoD , delMuroXG , Pérez-GraciaJL , González-LarribaJL , AbrioMV , RuizMA , et al. Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population. Annals of Oncology2009;20(11):1803-12. [PMID: 19549706]CellaD , CappelleriJC , BushmakinA , CharbonneauC , LiJZ , KimST , et al. Quality of life predicts progression-free survival in patients with renal cell carcinoma treated with sunitinib versus interferon alfa. Journal of Oncology Practice2009;5(2):66-70. [PMID: 20856722]CellaD , LiJZ , CappelariJC , BushmakinA , CharbonneauC , KimST , et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. Journal of Clinical Oncology2008;26(22):3763-9. [PMID: 18669464]CellaD , LiJZ , CappelleriJC , BushmakinA , CharbonneauC , KimST , ChenI , et al. Quality of life (QOL) predicts for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib compared to interferon-alpha (IFN-α). Journal of Clinical Oncology2007;25(18 suppl):6594. [DOI: 10.1200/jco.2007.25.18_suppl.6594]CellaD , MichaelsonMD , BushmakinAG , CappelleriJC , CharbonneauC , KimST , et al. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-a in a phase III trial: final results and geographical analysis. British Journal of Cancer2010;102(4):658-64. [PMID: 20104222]FiginRA , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , NegrierS , et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2008;26(15 suppl):5024. [DOI: 10.1200/jco.2008.26.15_suppl.5024]MotzerRJ , BukowskiRM , FiglinRA , HutsonTE , MichaelsonMD , KimST , et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer2008;113(7):1552-8. [PMID: 18720362]MotzerRJ , FiglinRA , HutsonTE , TomczakP , BukowskiRM , RixeO , et al. Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors. Journal of Clinical Oncology2007;25(18 suppl):5024. [DOI: 10.1200/jco.2007.25.18_suppl.5024]MotzerRJ , FiglinRA , HutsonTE , TomczakP , BukowskiRM , RixeO , et al. Sunitinib versus interferon-alfa as first-line treatment of metastatic renal cell carcinoma: updated results and analysis of prognostic factors. In: www.asco.org/virtual meeting. 2007. MotzerRJ , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , OudardS , et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2009;27(22):3584-90. [PMID: 19487381]MotzerRJ , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , RixeO , et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2006;24(18 suppl):LBA3. [DOI: 10.1200/jco.2006.24.18_suppl.lba3]MotzerRJ , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , RixeO , et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine2007;356(2):115-24. [PMID: 17215529]MotzerRJ , MichaelsonMD , HutsonTE , TomczakP , BukowskiRM , RixeO , et al. Sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors. European Journal of Cancer Supplements2007;5(4):301. [DOI: 10.1016/S1359-6349(07)71140-0]NCT00083889. SU011248 versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma [A phase 3, randomized study of SU011248 versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00083889 (first received 4 June 2004). [NCT00083889]PatilS , FiglinRA , HutsonTE , MichaelsonD , NegrierS , KimST , et al. TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-α). Journal of Clinical Oncology2010;28(15 suppl):4594. [DOI: 10.1200/jco.2010.28.15_suppl.4594]WilkersonJ , SteinWD , KimST , HuangX , MotzerRJ , FojoAT , et al. Validation of kinetic analysis of renal cancer regression and growth following treatment with sunitinib and interferon-alfa: analysis of the pivotal randomized trial. Journal of Clinical Oncology2010;28(15 suppl):4597. [DOI: 10.1200/jco.2010.28.15_suppl.4597]">Motzer 2010</a>); temsirolimus (<a href="./references#CD012796-bbs2-0004" title="AlemaoE , RajagopalanS , YangS , et al. Quality adjusted survival in randomized, controlled trials: application of inverse probability weighting in renal cell cancer. In: Genitourinary Cancers Symposium, ASCO, abstr 399. 2010. ArmstrongAJ , GeorgeDJ , HalabiS . Serum lactate dehydrogenase as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2010;28(15 suppl):4361. [DOI: 10.1200/jco.2010.28.15_suppl.4631]DutcherJP , SzczylikC , TannirN , BenedettoP , RuffP , HsuA , et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon-alpha. Journal of Clinical Oncology2007;25(18 suppl):5033. [DOI: 10.1200/jco.2007.25.18_suppl.5033]DutcherJP , deSouzaP , FiglinR , et al. Effect of temsirolimus versus interferon- on survival of patients with advanced renal cell carcinoma of different histologies. In: Genitourinary Cancers Symposium, ASCO, abstr 384. 2008. DutcherJP , deSouzaP , McDermottD , FiglinRA , BerkenblitA , ThieleA , et al. Effect of temsirolimus versus interferon- on outcome of patients with advanced renal cell carcinoma of different histologies. Medical Oncology2009;26(2):202–9. [PMID: 19229667]HudesG , CarducciM , TomczakP , DutcherJ , FiglinR , KapoorA , et al. A phase 3, randomized, 3-arm study of temsirolimus or interferon alpha or the combination in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma. Journal of Clinical Oncology2006;24(18 suppl):LBA4. [DOI: 10.1200/jco.2006.24.18_suppl.lba4]HudesG , CarducciM , TomczakP , DutcherJ , FiglinR , KapoorA , et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine2007;356(22):2271–81. [PMID: 17538086]LoganT , McDermottD , DutcherJ , et al. Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features. In: Genitourinary Cancers Symposium, ASCO, abstr 281. 2009. NCT00065468. Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma (ARCC). clinicaltrials.gov/ct2/show/results/NCT00065468 (first received July 25 2003). [NCT00065468]PabloM , HudesG , DutcherJ , WhiteC , KrygowskiM , CincottaM , et al. Radiographic findings of drug-induced pneumonitis and clinical correlation inpatients with advanced renal cell carcinoma treated with temsirolimus. European Journal of Cancer Supplements2009;7(2):426-7. [DOI: 10.1016/S1359-6349(09)71446-6]ParasuramanS , HudesG , LevyD , StrahsA , MooreL , De MariniseR , et al. Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon- (IFN) or the combination of IFN+TEMSR. Journal of Clinical Oncology2007;25(18 suppl):5049. [DOI: 10.1200/jco.2007.25.18_suppl.5049]YangS , HudesG , deSouzaP , AlemaoE , StrahsA , PurvisJ . Evaluation of quality of life in patients with advanced renal cell carcinoma treated with temsirolimus vs interferon-alfa: results from a phase III randomized trial. European Journal of Cancer Supplements2009;7(2):433. [DOI: 10.1016/S1359-6349(09)71467-3]ZbrozekAS , HudesG , LevyD , StrahsA , BerkenblitA , DeMarinisR , et al. Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma. Pharmacoeconomics2010;28(7):577–84. [PMID: 20550223]">Hudes 2007</a>); temsirolimus and interferon alpha (<a href="./references#CD012796-bbs2-0004" title="AlemaoE , RajagopalanS , YangS , et al. Quality adjusted survival in randomized, controlled trials: application of inverse probability weighting in renal cell cancer. In: Genitourinary Cancers Symposium, ASCO, abstr 399. 2010. ArmstrongAJ , GeorgeDJ , HalabiS . Serum lactate dehydrogenase as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2010;28(15 suppl):4361. [DOI: 10.1200/jco.2010.28.15_suppl.4631]DutcherJP , SzczylikC , TannirN , BenedettoP , RuffP , HsuA , et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon-alpha. Journal of Clinical Oncology2007;25(18 suppl):5033. [DOI: 10.1200/jco.2007.25.18_suppl.5033]DutcherJP , deSouzaP , FiglinR , et al. Effect of temsirolimus versus interferon- on survival of patients with advanced renal cell carcinoma of different histologies. In: Genitourinary Cancers Symposium, ASCO, abstr 384. 2008. DutcherJP , deSouzaP , McDermottD , FiglinRA , BerkenblitA , ThieleA , et al. Effect of temsirolimus versus interferon- on outcome of patients with advanced renal cell carcinoma of different histologies. Medical Oncology2009;26(2):202–9. [PMID: 19229667]HudesG , CarducciM , TomczakP , DutcherJ , FiglinR , KapoorA , et al. A phase 3, randomized, 3-arm study of temsirolimus or interferon alpha or the combination in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma. Journal of Clinical Oncology2006;24(18 suppl):LBA4. [DOI: 10.1200/jco.2006.24.18_suppl.lba4]HudesG , CarducciM , TomczakP , DutcherJ , FiglinR , KapoorA , et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine2007;356(22):2271–81. [PMID: 17538086]LoganT , McDermottD , DutcherJ , et al. Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features. In: Genitourinary Cancers Symposium, ASCO, abstr 281. 2009. NCT00065468. Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma (ARCC). clinicaltrials.gov/ct2/show/results/NCT00065468 (first received July 25 2003). [NCT00065468]PabloM , HudesG , DutcherJ , WhiteC , KrygowskiM , CincottaM , et al. Radiographic findings of drug-induced pneumonitis and clinical correlation inpatients with advanced renal cell carcinoma treated with temsirolimus. European Journal of Cancer Supplements2009;7(2):426-7. [DOI: 10.1016/S1359-6349(09)71446-6]ParasuramanS , HudesG , LevyD , StrahsA , MooreL , De MariniseR , et al. Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon- (IFN) or the combination of IFN+TEMSR. Journal of Clinical Oncology2007;25(18 suppl):5049. [DOI: 10.1200/jco.2007.25.18_suppl.5049]YangS , HudesG , deSouzaP , AlemaoE , StrahsA , PurvisJ . Evaluation of quality of life in patients with advanced renal cell carcinoma treated with temsirolimus vs interferon-alfa: results from a phase III randomized trial. European Journal of Cancer Supplements2009;7(2):433. [DOI: 10.1016/S1359-6349(09)71467-3]ZbrozekAS , HudesG , LevyD , StrahsA , BerkenblitA , DeMarinisR , et al. Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma. Pharmacoeconomics2010;28(7):577–84. [PMID: 20550223]">Hudes 2007</a>); and bevacizumab and interferon alpha (<a href="./references#CD012796-bbs2-0002" title="BajettaE , RavaudA , BracardaS , NégrierS , SzczylikC , BellmuntJ , et al. Efficacy and safety of first-line bevacizumab (BEV) plus interferon-α2a (IFN) in patients (pts) ≥65 years with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2008;26(15 suppl):5095. [DOI: 10.1200/jco.2008.26.15_suppl.5095]BellmuntJ , MelicharB , BracardaS , NegrierSN , RavaudA , LaeufleR , et al. Bevacizumab (BEV) and interferon (IFN) therapy does not increase risk of cardiac events in metastatic renal cell carcinoma(mRCC). European Journal of Cancer Supplements2009;7(2):429. [DOI: 10.1016/S1359-6349(09)71454-5]BracardaS , BellmuntJ , NegrierSN , MelicharB , RavaudA , JethwaS , et al. What is the impact of subsequent antineoplastic therapy on overall survival (OS) following first-line bevacizumab (BEV)/interferonalpha2a (IFN) in metastatic renal cell carcinoma (mRCC)? – Experience from AVOREN. European Journal of Cancer Supplements2009;7(2):431. [DOI: 10.1016/S1359-6349(09)71459-4]BracardaS , KoralewskiP , PluzanskaA , RavaudA , SzczylikC , ChevreauC , et al. Bevacizumab/interferon-alpha2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN). European Journal of Cancer Supplements2007;5(4):281-2. [DOI: 10.1016/S1359-6349(07)71076-5]EscudierB , KoralewskiP , PluzanskaA , RavaudA , BracardaS , SzczylikC , et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma. Journal of Clinical Oncology2007;25(18 suppl):3. [DOI: 10.1200/jco.2007.25.18_suppl.3]EscudierB , PluzanskaA , KoralewskiP , RavaudA , BracardaS , SzczylikC , et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized double-blind phase III trial. Lancet2007;370(9605):2103-11. [PMID: 18156031]EscudierBB , BellmuntJ , NegrierS , BajettaE , MelicharB , BracardaS , et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. Journal of Clinical Oncology2010;28(13):2144-50. [PMID: 20368553]EscudierBJ , BellmuntJ , NegrierS , MelicharB , BracardaS , RavaudA , et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2009;27(15 suppl):5020. [DOI: 10.1200/jco.2009.27.15_suppl.5020]EscudierBJ , NegrierS , ChevreauC , et al. Analysis of prognostic risk categories in the phase III AVOREN trial of first-line bevacizumab plus interferon-α2a in patients with metastatic renal cell carcinoma: French prognostic scoring system. In: Genitourinary Cancers Symposium, ASCO, abst 417. 2010. EscudierBJ , RavaudA , NegrierS , SzczylikC , BellmuntJ , BracardaS , et al. Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis. Journal of Clinical Oncology2008;26(15 suppl):5025. [DOI: 10.1200/jco.2008.26.15_suppl.5025]KarakiewiczP , SunM , SnellerV , EscudierB . Use of a nomogram to quantify overall survival (OS) benefit in patients with metastatic renal cell carcinoma receiving bevacizumab (BEV) with interferon (IFN) versus IFN alone. Journal of Clinical Oncology2010;28(15 suppl):4592. [DOI: 10.1200/jco.2010.28.15_suppl.4592 ]KarakiewiczPI , SunM , SnellerV , et al. Use of a nomogram to quantify progression-free survival benefit in metastatic renal cell carcinoma patients receiving bevacizumab plus interferon or interferon alone. In: Genitourinary Cancers Symposium, ASCO, abstr 392. 2010. MelicharB , KoralewskiP , PluzanskaA , RavaudA , BracardaS , SzczylikC , et al. First-line bevacizumab improves progression-free survival with lower doses of interferon-α2a in the treatment of patients with metastatic renal cell carcinoma (AVOREN). European Journal of Cancer Supplements2007;5(4):304. [DOI: 10.1016/S1359-6349(07)71149-7]MelicharB , KoralewskiP , RavaudA , PluzanskaA , BracardaS , SzczylikC , et al. First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma. Annals of Oncology2008;19(8):1470-6. [PMID: 18408224]NCT00738530. A study of avastin (bevacizumab) added to interferon alfa-2a (roferon) therapy in patients with metastatic renal cell cancer with nephrectomy [A randomised, double-blind study to evaluate the efficacy and safety of avastin plus roferon compared with placebo plus roferon on overall survival and tumor assessment in nephrectomised patients with metastatic clear cell renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00738530 (first received 20 August 2008). [NCT00738530]">Escudier 2010</a>; <a href="./references#CD012796-bbs2-0013" title="HalabiS , RiniBI , StadlerWM , SmallEJ . Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2010;28(15 suppl):4525. [DOI: 10.1200/jco.2010.28.15_suppl.4525]HarzstarkAL , HalabiS , StadlerWM , et al. Hypertensionis associated with clinical outcome for patients with metastatic renal cell carcinoma treated with interferon and bevacizumab on CALGB 90206. In: Genitourinary Cancers Symposium, ASCO, abstr 351. 2010. NCT00072046. Interferon alfa-2b with or without bevacizumab in treating patients with advanced renal cell carcinoma (Kidney Cancer) [A randomized phase III trial of interferon alfa-2B or interferon alfa-2B plus bevacizumab in patients with advanced renal carcinoma]. clinicaltrials.gov/ct2/show/study/NCT00072046 (first received 6 November 2003). [NCT00072046]RiniBI , HalabiS , RosenbergJ , StadlerWM , VaenaDA , AtkinsJN , et al. Bevacizumab plus interferon-alfa versus interferon-alfa monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206. Journal of Clinical Oncology2009;27(18 suppl):LBA5019. [DOI: 10.1200/jco.2009.27.18_suppl.lba5019 ]RiniBI , HalabiS , RosenbergJE , StadlerWM , VaenaDA , OuSS , et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB90206. Journal of Clinical Oncology2008;26(33):5422-8. [PMID: 18936475]RiniBI , HalabiS , RosenbergJE , et al. CALGB 90206:a phase III trial of bevacizumab plus interferon-alfa versus interferon-alfa monotherapy in metastatic renal cell carcinoma. In: Genitourinary Cancers Symposium, ASCO, abstr 350. 2008. RiniBI , HalabiS , TaylorJ , SmallEJ , SchilskyRL , Cancer and Leukemia Group B . Cancerand Leukemia Group B 90206: a randomized phase III trial of interferon-a or interferon-a plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clinical Cancer Research2004;10(8):2584-6. [PMID: 15102658]">Rini 2008</a>). </p> <p>Combinations of targeted therapies were used in two trials. <a href="./references#CD012796-bbs2-0014" title="NCT00631371. Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (INTORACT). linicaltrials.gov/ct2/show/NCT00631371 (first received 20 May 2019). [NCT00631371]RiniBI , BellmuntJ , ClancyJ , WangK , NiethammerAG , HariharanS , et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. Journal of Clinical Oncology2014;32(8):752-9. [PMID: 24297945]">Rini 2014</a> compared temsirolimus and bevacizumab against bevacizumab and interferon alpha; <a href="./references#CD012796-bbs2-0011" title="NCT00719264. Safety and efficacy of bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment in adult patients with kidney cancer [A randomized, open-label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a plus bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney]. clinicaltrials.gov/ct2/show/study/NCT00719264 (first received 21 July 2008). [NCT00719264]RavaudA , BarriosCH , AlekseevB , TayMH , AgarwalaSS , YalcinS , et al. RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. Annals of Oncology2015;26(7):1378-84. [PMID: 25851632]">Ravaud 2015</a> compared everolimus and bevacizumab against interferon alpha and bevacizumab. </p> </section> <section id="CD012796-sec-0058"> <h5 class="title">Outcomes</h5> <p>All included studies reported our primary outcomes PFS, OS and SAEs as well as response rates and minor AEs which were predefined secondary outcomes. An assessment of QoL was performed in 11 trials (<a href="./references#CD012796-bbs2-0003" title="CellaD , GrunwaldV , EscudierB , HammersHJ , GeorgeS , NathanP , et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncology2019;20(2):297-310. [PMID: 30658932]EscudierB , TannirN , McDermottDF , FronteraOA , MelicharB , PlimackER , et al. CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups. Annals of Oncology2017;28(suppl 5):621-2. [DOI: 10.1093/annonc/mdx440.029]MotzerRJ , RiniBI , McDermottDF , Aren FronteraO , HammersHJ , CarducciMA , et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncology2019;S1470-2045(19):30413-9. [PMID: 31427204]MotzerRJ , TannirN , McDermottDF , FronteraOA , MelicharB , ChoueiriTK , et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. New England Journal of Medicine2018;378(14):1277-90. [PMID: 29562145]NCT02231749. Nivolumab combined with ipilimumab versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma (CheckMate 214) [A phase 3, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, advanced or metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT02231749 (first received 4 September 2014). [NCT02231749]TannirNM , HammersHJ , AminA , Grimm M-O, RiniBI , MekanS , et al. Characterization of the benefit-risk profile of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced renal cell carcinoma (aRCC; CheckMate 214). Journal of Clinical Oncology2018;28(6 suppl):686. [DOI: 10.1200/JCO.2018.36.6_suppl.686]VyasC , MotzerRJ , TannirNM , McDermottDF , FronteraOA , MelicharB , et al. Nivolumab + ipilimumab (N+I) vs sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (aRCC): results from checkmate 214, including overall survival by subgroups. Journal of Oncology Pharmacy Practice2018;24(5_suppl):17-8. ">Escudier 2017</a>; <a href="./references#CD012796-bbs2-0004" title="AlemaoE , RajagopalanS , YangS , et al. Quality adjusted survival in randomized, controlled trials: application of inverse probability weighting in renal cell cancer. In: Genitourinary Cancers Symposium, ASCO, abstr 399. 2010. ArmstrongAJ , GeorgeDJ , HalabiS . Serum lactate dehydrogenase as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2010;28(15 suppl):4361. [DOI: 10.1200/jco.2010.28.15_suppl.4631]DutcherJP , SzczylikC , TannirN , BenedettoP , RuffP , HsuA , et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon-alpha. Journal of Clinical Oncology2007;25(18 suppl):5033. [DOI: 10.1200/jco.2007.25.18_suppl.5033]DutcherJP , deSouzaP , FiglinR , et al. Effect of temsirolimus versus interferon- on survival of patients with advanced renal cell carcinoma of different histologies. In: Genitourinary Cancers Symposium, ASCO, abstr 384. 2008. DutcherJP , deSouzaP , McDermottD , FiglinRA , BerkenblitA , ThieleA , et al. Effect of temsirolimus versus interferon- on outcome of patients with advanced renal cell carcinoma of different histologies. Medical Oncology2009;26(2):202–9. [PMID: 19229667]HudesG , CarducciM , TomczakP , DutcherJ , FiglinR , KapoorA , et al. A phase 3, randomized, 3-arm study of temsirolimus or interferon alpha or the combination in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma. Journal of Clinical Oncology2006;24(18 suppl):LBA4. [DOI: 10.1200/jco.2006.24.18_suppl.lba4]HudesG , CarducciM , TomczakP , DutcherJ , FiglinR , KapoorA , et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine2007;356(22):2271–81. [PMID: 17538086]LoganT , McDermottD , DutcherJ , et al. Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features. In: Genitourinary Cancers Symposium, ASCO, abstr 281. 2009. NCT00065468. Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma (ARCC). clinicaltrials.gov/ct2/show/results/NCT00065468 (first received July 25 2003). [NCT00065468]PabloM , HudesG , DutcherJ , WhiteC , KrygowskiM , CincottaM , et al. Radiographic findings of drug-induced pneumonitis and clinical correlation inpatients with advanced renal cell carcinoma treated with temsirolimus. European Journal of Cancer Supplements2009;7(2):426-7. [DOI: 10.1016/S1359-6349(09)71446-6]ParasuramanS , HudesG , LevyD , StrahsA , MooreL , De MariniseR , et al. Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon- (IFN) or the combination of IFN+TEMSR. Journal of Clinical Oncology2007;25(18 suppl):5049. [DOI: 10.1200/jco.2007.25.18_suppl.5049]YangS , HudesG , deSouzaP , AlemaoE , StrahsA , PurvisJ . Evaluation of quality of life in patients with advanced renal cell carcinoma treated with temsirolimus vs interferon-alfa: results from a phase III randomized trial. European Journal of Cancer Supplements2009;7(2):433. [DOI: 10.1016/S1359-6349(09)71467-3]ZbrozekAS , HudesG , LevyD , StrahsA , BerkenblitA , DeMarinisR , et al. Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma. Pharmacoeconomics2010;28(7):577–84. [PMID: 20550223]">Hudes 2007</a>; <a href="./references#CD012796-bbs2-0005" title="AtkinsMB , McDermottDF , PowlesT , MotzerRJ , RiniBI , FongL , et al. IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). Journal of Clinical Oncology2017;35(15 suppl):4505. [DOI: 10.1200/JCO.2017.35.15_suppl.4505]McDermottDF , AtkinsMB , MotzerRJ , RiniBI , EscudierBJ , FongL , et al. A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). Journal of Clinical Oncology2017;35(6 suppl):431. [DOI: 10.1200/JCO.2017.35.6_suppl.431]McDermottDF , HuseniMA , AtkinsMB , MotzerRJ , RiniBI , EscudierB , et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine2018;24(6):749-57. [PMID: 29867230]NCT01984242. A study of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) as monotherapy or in combination with bevacizumab (avastin®) compared to sunitinib (Sutent®) in participants with untreated advanced renal cell carcinoma (IMmotion150) [A phase II, randomized study of atezolizumab (anti-PD-L1 antibody) administered as monotherapy or in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT01984242 (first received 14 November 2013). [NCT01984242]PalSK , McDermottDF , AtkinsMB , EscudierB , RiniBI , MotzerRJ , et al. Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. BJU Int2020;126:73-82. [DOI: 10.1111/bju.15058]PowlesT, McDermottDF , RiniB , MotzerRJ , AtkinsMB , FongL , et al. IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC). Annals of Oncology2017;28(suppl 5):624. [DOI: 10.1093/annonc/mdx440.033]">McDermott 2018</a>; <a href="./references#CD012796-bbs2-0006" title="CastellanoD , delMuroXG , Pérez-GraciaJL , González-LarribaJL , AbrioMV , RuizMA , et al. Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population. Annals of Oncology2009;20(11):1803-12. [PMID: 19549706]CellaD , CappelleriJC , BushmakinA , CharbonneauC , LiJZ , KimST , et al. Quality of life predicts progression-free survival in patients with renal cell carcinoma treated with sunitinib versus interferon alfa. Journal of Oncology Practice2009;5(2):66-70. [PMID: 20856722]CellaD , LiJZ , CappelariJC , BushmakinA , CharbonneauC , KimST , et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. Journal of Clinical Oncology2008;26(22):3763-9. [PMID: 18669464]CellaD , LiJZ , CappelleriJC , BushmakinA , CharbonneauC , KimST , ChenI , et al. Quality of life (QOL) predicts for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib compared to interferon-alpha (IFN-α). Journal of Clinical Oncology2007;25(18 suppl):6594. [DOI: 10.1200/jco.2007.25.18_suppl.6594]CellaD , MichaelsonMD , BushmakinAG , CappelleriJC , CharbonneauC , KimST , et al. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-a in a phase III trial: final results and geographical analysis. British Journal of Cancer2010;102(4):658-64. [PMID: 20104222]FiginRA , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , NegrierS , et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2008;26(15 suppl):5024. [DOI: 10.1200/jco.2008.26.15_suppl.5024]MotzerRJ , BukowskiRM , FiglinRA , HutsonTE , MichaelsonMD , KimST , et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer2008;113(7):1552-8. [PMID: 18720362]MotzerRJ , FiglinRA , HutsonTE , TomczakP , BukowskiRM , RixeO , et al. Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors. Journal of Clinical Oncology2007;25(18 suppl):5024. [DOI: 10.1200/jco.2007.25.18_suppl.5024]MotzerRJ , FiglinRA , HutsonTE , TomczakP , BukowskiRM , RixeO , et al. Sunitinib versus interferon-alfa as first-line treatment of metastatic renal cell carcinoma: updated results and analysis of prognostic factors. In: www.asco.org/virtual meeting. 2007. MotzerRJ , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , OudardS , et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2009;27(22):3584-90. [PMID: 19487381]MotzerRJ , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , RixeO , et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2006;24(18 suppl):LBA3. [DOI: 10.1200/jco.2006.24.18_suppl.lba3]MotzerRJ , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , RixeO , et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine2007;356(2):115-24. [PMID: 17215529]MotzerRJ , MichaelsonMD , HutsonTE , TomczakP , BukowskiRM , RixeO , et al. Sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors. European Journal of Cancer Supplements2007;5(4):301. [DOI: 10.1016/S1359-6349(07)71140-0]NCT00083889. SU011248 versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma [A phase 3, randomized study of SU011248 versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00083889 (first received 4 June 2004). [NCT00083889]PatilS , FiglinRA , HutsonTE , MichaelsonD , NegrierS , KimST , et al. TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-α). Journal of Clinical Oncology2010;28(15 suppl):4594. [DOI: 10.1200/jco.2010.28.15_suppl.4594]WilkersonJ , SteinWD , KimST , HuangX , MotzerRJ , FojoAT , et al. Validation of kinetic analysis of renal cancer regression and growth following treatment with sunitinib and interferon-alfa: analysis of the pivotal randomized trial. Journal of Clinical Oncology2010;28(15 suppl):4597. [DOI: 10.1200/jco.2010.28.15_suppl.4597]">Motzer 2010</a>; <a href="./references#CD012796-bbs2-0007" title="MotzerRJ , HutsonTE , CellaD , ReevesJ , HawkinsR , GuoJ , et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. New England Journal of Medicine2013;369(8):722-1. [PMID: 23964934]MotzerRJ , HutsonTE , McCannL , DeenK , ChoueiriTK . Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. New England Journal of Medicine2014;370(18):1769-70. [PMID: 24785224]NCT00720941. Pazopanib versus sunitinib in the treatment of locally advanced and/or metastatic renal cell carcinoma (COMPARZ) [Study VEG108844, A study of pazopanib versus sunitinib in the treatment of subjects with locally advanced and/or metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00720941 (first received 23 July 2008). [NCT00720941]">Motzer 2013a</a>; <a href="./references#CD012796-bbs2-0008" title="HutsonT , NosovD , TomczakP , BondarenkoI , LipatovON , SternbergCN , et al. Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902). Journal of Clinical Oncology2015;33(15 suppl):4557. [DOI: 10.1200/jco.2015.33.15_suppl.4557]MotzerRJ , NosovD , EisenT , BondarenkoI , LesovoyV , LipatovO , et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. Journal of Clinical Oncology2013;31(30):3791-9. [PMID: 24019545]NCT01030783. A study to compare tivozanib (AV-951) to sorafenib in subjects with advanced renal cell carcinoma (TIVO-1) [A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib (AV-951) to sorafenib in subjects with advanced renal cell carcinoma (TIVO-1)]. clinicaltrials.gov/ct2/show/NCT01030783 (first received 11 December 2009). [NCT01030783]">Motzer 2013b</a>; <a href="./references#CD012796-bbs2-0009" title="KnoxJJ , BarriosCH , KimTM , CosgriffT , SrimuninnimitV , PittmanK , et al. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Annals of Oncology2017;28(6):1339-45. [PMID: 28327953]KnoxJJ , BarriosCH , KimTM , CosgriffT , SrimuninnimitV , PittmanKB , et al. Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC). Journal of Clinical Oncology2015;33(15 suppl):4554. [DOI: 10.1200/jco.2015.33.15_suppl.4554]MotzerRJ , BarriosCH , KimTM , FalconS , CosgriffT , HarkerWG , et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2014;32(25):2765-72. [PMID: 25049330]NCT00903175. Efficacy and safety comparison of RAD001 versus sunitinib in the first-line and second-line treatment of patients with metastatic renal cell carcinoma (RECORD-3) [An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as First-line followed by second-line RAD001 in the treatment of patients with metastatic renal cell carcinoma.]. clinicaltrials.gov/ct2/show/NCT00903175 (first received 18 May 2009). [NCT00903175]">Motzer 2014</a>; <a href="./references#CD012796-bbs2-0012" title="NCT01613846. Phase III sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma (SWITCH-II) [Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT01613846 (first received 7 June 2012). [NCT01613846]RetzM , BedkeJ , BögemannM , GrimmMO , ZimmermannU , MüllerL , et al. SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). European Journal of Cancer2019;107:37-45. [PMID: 30529901]RetzM , BedkeJ, HerrmannE , GrimmM , ZimmermannU , MüllerL , et al. Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib sorafenib in the treatment of metastatic renal cell carcinoma(SWITCH-II). Annals of Oncology2017;28(suppl 5):295. [DOI: 10.1093/annonc/mdx371]">Retz 2019</a>; <a href="./references#CD012796-bbs2-0014" title="NCT00631371. Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (INTORACT). linicaltrials.gov/ct2/show/NCT00631371 (first received 20 May 2019). [NCT00631371]RiniBI , BellmuntJ , ClancyJ , WangK , NiethammerAG , HariharanS , et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. Journal of Clinical Oncology2014;32(8):752-9. [PMID: 24297945]">Rini 2014</a>; <a href="./references#CD012796-bbs2-0017" title="AtkinsMB , RiniBI , MotzerRJ , PowlesT , McDermottDF , SuarezC , et al. Patient-reported outcomes from the phase 3 randomized IMmotion151 trial: atezolizumab + bevacizumab vs sunitinib in treatment-naive metastatic renal cell carcinoma. Clinical Cancer Research2020;26(11):2506-2514. EscudierB , MotzerRJ , RiniBI , PowlesT , McDermottDF , SuarezC , et al. Patient-reported outcomes (PROs) in IMmotion151: atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2018;36(15_suppl):4511. [DOI: 10.1200/JCO.2018.36.15_suppl.4511]MotzerRJ , PowlesT , AtkinsMB , EscudierB , McDermottDF , SuarezC , et al. IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2018;36(6 suppl):578. [DOI: 10.1200/JCO.2018.36.6_suppl.578]NCT02420821. A study of atezolizumab in combination with bevacizumab versus sunitinib in participants with untreated advanced renal cell carcinoma (RCC) (IMmotion151) [A phase III, open-label, randomized study of atezolizumab (Anti-PD-L1 Antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT02420821 (first received 20 April 2015). [NCT02420821]RiniBI , PowlesT , AtkinsMB , EscudierB , McDermottDF , SuarezC , et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet2019;393(10189):2404-15. [PMID: 31079938]">Rini 2019b</a>; <a href="./references#CD012796-bbs2-0018" title="CellaD , PickardAS , DuhMS , GuerinA , MishaginaN , AntràsL , et al. Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. European Journal of Cancer2012;48(3):311-23. [PMID: 21689927]HutsonTE , BukowskiRM . A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma. Clinical Genitourinary Cancer2006;4(4):296-8. [PMID: 16729915]HutsonTE , DavisID , MachielsJP , deSouzaPL , HongBF , RotteyS , et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). Journal of Clinical Oncology2007;25(18 suppl):5031. [DOI: 10.1200/jco.2007.25.18_suppl.5031]NCT00334282. Safety and efficacy of GW786034 (pazopanib) In metastatic renal cell carcinoma [A randomised, double-blind, placebo controlled, multi-center phase III study to evaluate the efficacy and safety of pazopanib (GW786034) compared to placebo in patients with locally advanced and/or metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT00334282 (first received 7 June 2006). [NCT00334282]SternbergCN , DavisID , MardiakJ , SzczylikC , LeeE , WagstaffJ , et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of Clinical Oncology2010;28(6):1061-8. [PMID: 20100962]SternbergCN , HawkinsRE , WagstaffJ , SalmanP , MardiakJ , BarriosCH , et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. European Journal of Cancer2013;49(6):1287-96. [PMID: 23321547]SternbergCN , SzczylikC , LeeE , SalmanPV , MardiakJ , DavisID , et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). Journal of Clinical Oncology2009;27(15S):5021. [DOI: 10.1200/jco.2009.27.15s.5021]">Sternberg 2010</a>). </p> </section> </section> <section id="CD012796-sec-0059"> <h4 class="title">Excluded studies</h4> <p>We excluded 52 trials at the stage of full‐text screening. The main reasons for exclusion were: less than 100 participants in one treatment arm in 25 trials (<a href="./references#CD012796-bbs2-0022" title="BroomRJ , HinderV , SharplesK , ProctorJ , DuffeyS , PollardS , et al. Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: A randomized first-line phase II trial. Clinical Genitourinary Cancer2015;13(1):50-8. [PMID: 25163397]">Broom 2015</a>; <a href="./references#CD012796-bbs2-0023" title="BukowskiRM , KabbinavarF , FiglinRA , FlahertyK , SrinivasS , VaishampayanUN , et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. Journal of Clinical Oncology2007;25(29):4536–41. [PMID: 17876014]">Bukowski 2007</a>; <a href="./references#CD012796-bbs2-0025" title="ChoueiriTK , HalabiS , SanfordBL , HahnO , MichaelsonMD , WalshMK , et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The Alliance A031203 CABOSUN Trial. Journal of Clinical Oncology2017;35(6):591-7. [PMID: 28199818]">Choueiri 2017</a>; <a href="./references#CD012796-bbs2-0026" title="CirkelGA , HambergP , SleijferS , LoosveldOJL , DercksenMW , LosM , et al. Alternating treatment with pazopanib and everolimus vs continuous pazopanib to delay disease progressionin patients with metastatic clear cell renal cell cancer: The ROPETAR randomized clinical trial. JAMA Oncology2017;3(4):501-8. [PMID: 27918762]">Cirkel 2016</a>; <a href="./references#CD012796-bbs2-0029" title="EisenT , Loembé A-B, ShparykY , MacLeodN , JonesRJ , MazurkiewiczM , TempleG , et al. A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results. British Journal of Cancer2015;113(8):1140-7. [PMID: 26448178]">Eisen 2015</a>; <a href="./references#CD012796-bbs2-0031" title="EscudierB , SzczylikC , HutsonTE , DemkowT , StaehlerM , RollandF , et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2009;27:1280–9. [PMID: 19171708]">Escudier 2009</a>; <a href="./references#CD012796-bbs2-0033" title="FlahertyKT , ManolaJB , PinsM , McDermottDF , AtkinsMB , DutcherJJ , et al. BEST: A randomized phase II study of vascular endothelial growth factor, RAF Kinase, and mammalian target of rapamycin combination targeted therapy with bevacizumab, sorafenib, and temsirolimus in advanced renal cell carcinoma--A trial of the ECOG-ACRIN cancer research group (E2804). Journal of Clinical Oncology2015;33(21):2384-91. [PMID: 26077237]">Flaherty 2015</a>; <a href="./references#CD012796-bbs2-0035" title="HainsworthJD , ReevesJA , MaceJR , CraneEJ , HamidO , StilleJR , et al. A randomized, open-Label phase 2 study of the CXCR4 Inhibitor LY2510924 in combination with sunitinib versus sunitinib alone in patients with metastatic renal cell carcinoma (RCC). Targeted Oncology2016;11(5):643-53. [PMID: 27154357]">Hainsworth 2015</a>; <a href="./references#CD012796-bbs2-0039" title="JonaschE , CornP , PagliaroLC , WarnekeCL , JohnsonMM , TamboliP , et al. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma. Cancer2010;116(1):57-65. [PMID: 19862815]">Jonasch 2010</a>; <a href="./references#CD012796-bbs2-0050" title="MuldersP , HawkinsR , NathanP , deJongI , OsantoS , PorfiriE , et al. Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study. European Journal of Cancer2012;48(4):527-37. [PMID: 22285180]">Mulders 2012</a>; <a href="./references#CD012796-bbs2-0051" title="NégrierS , GravisG , PérolD , ChevreauC , DelvaR , BayJO , et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncology2011;12(7):673-80. [PMID: 21664867]">Négrier 2011</a>; <a href="./references#CD012796-bbs2-0052" title="NosovDA , EstevesB , LipatovON , LyulkoAA , AnischenkoAA , ChackoRT , et al. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma. Journal of Clinical Oncology2012;30(14):1678-85. [PMID: 22493422]">Nosov 2012</a>; <a href="./references#CD012796-bbs2-0053" title="PalS , AzadA , BhatiaS , DrabkinH , CostelloB , SarantopoulosJ , et al. A Phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma. Clinical Cancer Research2015;21(15):3420-7. [PMID: 25788492]">Pal 2015</a>; <a href="./references#CD012796-bbs2-0054" title="PiliR , ManolaJ , CarducciMA , DutcherJP , ApplemanLJ , GroteluschenDL , et al. Randomized phase II study of two different doses of AVE0005 (VEGF Trap, aflibercept) in patients (pts) with metastatic renal cell carcinoma (RCC): An ECOG-ACRIN study [E4805]. Journal of Clinical Oncology2015;33(15_suppl):4549. [DOI: 10.1200/jco.2015.33.15_suppl.4549]">Pili 2015</a>; <a href="./references#CD012796-bbs2-0055" title="PowlesT , OudardS , EscudierBJ , BrownJE , HawkinsRE , CastellanoDE , et al. A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT). Journal of Clinical Oncology2014;32(15_suppl):4525. [DOI: 10.1200/jco.2014.32.15_suppl.4525]">Powles 2014</a>; <a href="./references#CD012796-bbs2-0056" title="PowlesT , WheaterM , DinO , GeldartT , BoletiE , StockdaleA , et al. A randomised phase 2 study of AZD2014 versus everolimus in patients with VEGF-refractory metastatic clear cell renal cancer. European Urology2016;69(3):450-6. [PMID: 26364551]">Powles 2016a</a>; <a href="./references#CD012796-bbs2-0057" title="PowlesT , BrownJ , LarkinJ , JonesR , RalphC , HawkinsR , et al. A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer(COSAK). Annals of Oncology2016;27(5):880–6. [PMID: 26802156]">Powles 2016b</a>; <a href="./references#CD012796-bbs2-0058" title="ProcopioG , VerzoniE , BracardaS , RicciS , SaccoC , RidolfiL , et al. Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. British Journal of Cancer2011;104(8):1256-61. [PMID: 21448165]">Procopio 2011</a>; <a href="./references#CD012796-bbs2-0059" title="RatainMJ , EisenT , StadlerWM , FlahertyKT , KayeSB , RosnerGL , et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2006;24(16):2505-12. [PMID: 16636341]">Ratain 2006</a>; <a href="./references#CD012796-bbs2-0063" title="RiniBI , MelicharB , UedaT , GrünwaldV , FishmanMN , ArranzJA , et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncology2013;14(12):1233-42. [PMID: 24140184]">Rini 2013</a>; <a href="./references#CD012796-bbs2-0066" title="TannirNM , JonaschE , AlbigesL , AltinmakasE , NgCS , MatinSF , et al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): A randomized multicenter phase 2 trial. European Urology2016;69(5):866-74. [PMID: 26626617]">Tannir 2016</a>; <a href="./references#CD012796-bbs2-0067" title="TannirNM , RossJA , DevineCE , ChandramohanA , WangX , LimZD , et al. A randomized phase II trial of pazopanib (PAZ) versus temsirolimus (TEM) in patients (pts) with advanced clear-cell renal cell carcinoma (aCCRCC) of intermediate and poor-risk (the TemPa trial). Journal of Clinical Oncology2018;36(6_suppl):583. [DOI: 10.1200/JCO.2018.36.6_suppl.583]">Tannir 2018</a>; <a href="./references#CD012796-bbs2-0068" title="TomitaY , NaitoS , SassaN , TakahashiA , KondoT , KoieT , et al. Sunitinib versus sorafenib as first-line therapy for patients with metastatic renal cell carcinoma with favourable or intermediate MSKCC risk factors: A multicenter randomized trial, CROSS-J-RCC. Journal of Clinical Oncology2014;32(4_suppl):502. [DOI: 10.1200/jco.2014.32.4_suppl.502]">Tomita 2014</a>; <a href="./references#CD012796-bbs2-0069" title="TwardowskiP , PletsM , PlimackER , AgarwalN , TangenCM , VogelzangNJ , et al. SWOG 1107: Parallel (randomized) phase II evaluation of tivantinib (ARQ-197) and tivantinib in combination with erlotinib in patients (Pts) with papillary renal cell carcinoma (pRCC). Journal of Clinical Oncology2015;33(15_suppl):4523. [DOI: 10.1200/jco.2015.33.15_suppl.4523]">Twardowski 2015</a>; <a href="./references#CD012796-bbs2-0070" title="YangJC , HaworthL , SherryRM , HwuP , SchwartzentruberDJ , TopalianSL , et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. New England Journal of Medicine2003;349(5):427-34. [PMID: 12890841]">Yang 2003</a>); participants were not treatment naïve in 12 studies (<a href="./references#CD012796-bbs2-0024" title="ChoueiriTK , EscudierB , PowlesT , MainwaringPN , RiniBI , DonskovF , et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. New England Journal of Medicine2015;373(19):1814–23. [PMID: 26406150]">Choueiri 2015</a>; <a href="./references#CD012796-bbs2-0027" title="DorffTB , LongmateJA , PalSK , StadlerWM , FishmanMN , VaishampayanUN , et al. Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer2017;123(23):4566-73. [PMID: 28832978]">Dorff 2015</a>; <a href="./references#CD012796-bbs2-0032" title="EscudierB , EisenT , StadlerWM , SzczylikC , OudardS , SiebelsM , et al. Sorafenib in advanced clear-cell renal-cell carcinoma. New England Journal of Medicine2007;356(2):125-34. [PMID: 17215530]">Escudier 2010a</a>; <a href="./references#CD012796-bbs2-0037" title="HutsonTE , LesovoyV , Al-ShukriS , StusVP , LipatovON , BairAH , et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncology2013;14(13):1287-94. [PMID: 24206640]">Hutson 2013</a>; <a href="./references#CD012796-bbs2-0038" title="HutsonTE , EscudierB , EstebanE , BjarnasonGA , LimHY , PittmanKB , et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2014;32(8):760-7. [PMID: 24297950]">Hutson 2014</a>; <a href="./references#CD012796-bbs2-0040" title="JonaschE , HasanovE , CornPG , MossT , ShawKR , StovallS , et al. A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma. Annals of Oncology2017;28(4):804-8. [PMID: 28049139]">Jonasch 2017</a>; <a href="./references#CD012796-bbs2-0044" title="MotzerRJ , EscudierB , OudardS , HutsonTE , PortaC , BracardaS , et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet2008;372(9637):449-56. [PMID: 18653228]">Motzer 2008</a>; <a href="./references#CD012796-bbs2-0046" title="MotzerRJ , PortaC , VogelzangNJ , SternbergCN , SzczylikC , ZolnierekJ , et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma:an open-label, randomised phase 3 trial. Lancet Oncology2014;15(3):286-96. [PMID: 24556040]">Motzer 2014b</a>; <a href="./references#CD012796-bbs2-0047" title="MotzerRJ , EscudierB , McDermottDF , GeorgeS , HammersHJ , SrinivasS , et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine2015;373(19):1803-13. [PMID: 26406148]">Motzer 2015a</a>; <a href="./references#CD012796-bbs2-0048" title="MotzerRJ , RiniBI , McDermottDF , RedmanBG , KuzelT , HarrisonMR , et al. Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial. Journal of Clinical Oncology2014;32(15_suppl):5009. [DOI: 10.1200/jco.2014.32.15_suppl.5009]">Motzer 2015b</a>; <a href="./references#CD012796-bbs2-0049" title="MotzerRJ , HutsonTE , GlenH , MichaelsonMD , MolinaA , EisenT , et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncology2015;16(15):1473-82. [PMID: 26482279]">Motzer 2015c</a>; <a href="./references#CD012796-bbs2-0061" title="RiniBI , EscudierB , TomczakP , KaprinA , SzczylikC , HutsonTE , et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet2011;378(9807):1931-9. [PMID: 22056247]">Rini 2011</a>); the intervention or comparison did not include a targeted therapy in nine trials (<a href="./references#CD012796-bbs2-0030" title="EscudierB , ChoueiriTK , OudardS , SzczylikC , NégrierS , RavaudA , et al. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. Journal of Urology2007;178:1901-5. [PMID: 17868728]">Escudier 2007</a>; <a href="./references#CD012796-bbs2-0034" title="GordonMS , ManolaJ , FaircloughD , CellaD , RichardsonR , SosmanJ , et al. Low dose interferon-α2b + thalidomide in patients with previously untreated renal cell cancer. Improvement in progression-free survival but not quality of life or overall survival. A phase III study of the Eastern Cooperative Oncology Group(E2898). Journal of Clinical Oncology2004;22(14 suppl):4516. [DOI: 10.1200/jco.2004.22.90140.4516]">Gordon 2004</a>; <a href="./references#CD012796-bbs2-0036" title="HawkinsR , GoreM , ShparykY , BondarV , GladkovO , GanevT , et al. A randomized phase II/III study of naptumomab estafenatox þ IFNa versus IFNa in renal cell carcinoma: final analysis with baseline biomarker subgroup and trend analysis. Clinical Cancer Research2016;22(13):3172-81. [PMID: 26851187]">Hawkins 2016</a>; <a href="./references#CD012796-bbs2-0041" title="LeeCP , PatelPM , SelbyPJ , HancockBW , MakI , PyleL , et al. Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2006;24(6):898-903. [PMID: 16484699]">Lee 2006</a>; <a href="./references#CD012796-bbs2-0043" title="MadhusudanS , ProtheroeA , VaseyP , PatelP , SelbyP , AltmanD , et al. A randomized phase II study of interferon alpha alone or in combination with thalidomide in metastatic renal cancer. Journal of Clinical Oncology2004;22(14_suppl):4742. [DOI: 10.1200/jco.2004.22.90140.4742]">Madhusudan 2004</a>; <a href="./references#CD012796-bbs2-0060" title="RavaudA , HawkinsR , GardnerJP , von derMaaseH , ZantlN , HarperP , et al. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. Journal of Clinical Oncology2008;26(14):2285-91. [PMID: 18467719]">Ravaud 2008</a>, <a href="./references#CD012796-bbs2-0062" title="RiniB , SzczylikC , TannirNM , KoralewskiP , TomczakP , DeptalaA , et al. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer2012;118(24):6152-61. [PMID: 22692704]">Rini 2012</a>; <a href="./references#CD012796-bbs2-0064" title="SrinivasS , GuardingAE . A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma. BJU International2005;96(4):536-9. [PMID: 16104906]">Srinivas 2005</a>; <a href="./references#CD012796-bbs2-0065" title="StadlerWM , RosnerG , SmallE , HollisD , RiniB , ZaentzDS , et al. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma -CALGB 69901. Journal of Clinical Oncology2005;23(16):3726-32. [PMID: 15923569]">Stadler 2005</a>); both intervention and comparison arms used the same drug with different dosages in five trials (<a href="./references#CD012796-bbs2-0020" title="AtkinsMB , HidalgoM , StadlerW , LoganTF , DutcherJP , HudesGR , et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin inhibitor, in patients with advanced refractory renal cell carcinoma. Journal of Clinical Oncology2004;22:909-18. [PMID: 14990647]">Atkins 2004</a>; <a href="./references#CD012796-bbs2-0021" title="BracardaS , PortaC , BoniC , SantoroA , MucciariniC , PazzolaA , et al. Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY). European Urology2013;63(2):254-61. [PMID: 22964169]">Bracarda 2010</a>; <a href="./references#CD012796-bbs2-0028" title="EbbinghausS , HussainM , TannirN , GordonM , DesaiAA , KnightRA , et al. Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clinical Cancer Research2007;13(22 Pt 1):6689–95. [PMID: 18006769]">Ebbinghaus 2007</a>; <a href="./references#CD012796-bbs2-0042" title="LeeJL , KimMK , ParkI , AhnJH , LeeDH , RyooHM , et al. Randomized phase II trial of sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type Renal cell carcinoma: RESTORE trial. Annals of Oncology2015;26(11):2300-5. [PMID: 26347107]">Lee 2015</a>; <a href="./references#CD012796-bbs2-0045" title="MotzerRJ , HutsonTE , OlsenMR , HudesGR , BurkeJM , EdenfieldWJ , et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. Journal of Clinical Oncology2012;30(12):1371-7. [PMID: 22430274 ]">Motzer 2012</a>); and one trial included only non‐clear cell renal cell carcinoma participants (<a href="./references#CD012796-bbs2-0019" title="ArmstrongAJ , HalabiS , EisenT , BroderickS , StadlerWM , JonesRJ , et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncology2016;17(3):378-88. [PMID: 26794930]">Armstrong 2016</a>). </p> </section> </section> <section id="CD012796-sec-0060"> <h3 class="title">Risk of bias in included studies</h3> <p>For details, please refer to '<a href="./references#CD012796-sec-0295" title="">Characteristics of included studies</a>' section, the 'Risk of bias' table, and each 'Summary of findings table', as well as <a href="#CD012796-fig-0002">Figure 2</a> and <a href="#CD012796-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD012796-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Categories: green point (+) = low risk of bias; yellow point (?) = unclear risk of bias; red point (‐) = high risk of bias." data-id="CD012796-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Categories: green point (+) = low risk of bias; yellow point (?) = unclear risk of bias; red point (‐) = high risk of bias. </p> </div> </div> </div> <div class="figure" id="CD012796-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012796-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD012796-sec-0061"> <h4 class="title">Allocation</h4> <section id="CD012796-sec-0062"> <h5 class="title">Random sequence generation</h5> <p>We judged 15 trials to have a low risk of bias (<a href="./references#CD012796-bbs2-0001" title="EichelbergC , GoebellPJ , VervenneWL , De SantisM , Fischer von WeikersthalL , LerchenmüllerC , et al. Updated overall survival, multivariate, and Q-TWiST analyses of a randomized, sequential, open-label study (SWITCH) to evaluate the efficacy and safety of sorafenib (So)-sunitinib (Su) versus Su-So in the treatment of metastatic renal cell cancer. Annals of Oncology2014;25(suppl 4):iv290. [DOI: 10.1093/annonc/mdu337.28]EichelbergC , VervenneWL , De SantisM , Fischer von WeikersthalL , GoebellPJ , LerchenmüllerC , et al. SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer. European Urology2015;68(5):837-47. [PMID: 25952317]GoebellPJ , VervenneW , De SantisM , Fischer Von WeikersthalL , LerchenmullerCA , ZimmermannU , et al. Subgroup analyses of a randomized sequential open-label study (SWITCH) to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). Journal of Clinical Oncology2014;32(15 suppl):4567. [DOI: 10.1200/jco.2014.32.15_suppl.4567]MichelMS , VervenneW , deSantisM , Fischer von WeikersthalL , GoebellPJ , LerchenmuellerJ , et al. SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). Journal of Clinical Oncology2014;32(4 suppl):393. [DOI: 10.1200/jco.2014.32.4_suppl.393]NCT00732914. Sequential study to treat renal cell carcinoma [A phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by sunitinib versus sunitinib followed by sorafenib in the treatment of first-line advanced / metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00732914 (first received 12 August 2008). [NCT00732914]">Eichelberg 2015</a>; <a href="./references#CD012796-bbs2-0002" title="BajettaE , RavaudA , BracardaS , NégrierS , SzczylikC , BellmuntJ , et al. Efficacy and safety of first-line bevacizumab (BEV) plus interferon-α2a (IFN) in patients (pts) ≥65 years with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2008;26(15 suppl):5095. [DOI: 10.1200/jco.2008.26.15_suppl.5095]BellmuntJ , MelicharB , BracardaS , NegrierSN , RavaudA , LaeufleR , et al. Bevacizumab (BEV) and interferon (IFN) therapy does not increase risk of cardiac events in metastatic renal cell carcinoma(mRCC). European Journal of Cancer Supplements2009;7(2):429. [DOI: 10.1016/S1359-6349(09)71454-5]BracardaS , BellmuntJ , NegrierSN , MelicharB , RavaudA , JethwaS , et al. What is the impact of subsequent antineoplastic therapy on overall survival (OS) following first-line bevacizumab (BEV)/interferonalpha2a (IFN) in metastatic renal cell carcinoma (mRCC)? – Experience from AVOREN. European Journal of Cancer Supplements2009;7(2):431. [DOI: 10.1016/S1359-6349(09)71459-4]BracardaS , KoralewskiP , PluzanskaA , RavaudA , SzczylikC , ChevreauC , et al. Bevacizumab/interferon-alpha2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN). European Journal of Cancer Supplements2007;5(4):281-2. [DOI: 10.1016/S1359-6349(07)71076-5]EscudierB , KoralewskiP , PluzanskaA , RavaudA , BracardaS , SzczylikC , et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma. Journal of Clinical Oncology2007;25(18 suppl):3. [DOI: 10.1200/jco.2007.25.18_suppl.3]EscudierB , PluzanskaA , KoralewskiP , RavaudA , BracardaS , SzczylikC , et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized double-blind phase III trial. Lancet2007;370(9605):2103-11. [PMID: 18156031]EscudierBB , BellmuntJ , NegrierS , BajettaE , MelicharB , BracardaS , et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. Journal of Clinical Oncology2010;28(13):2144-50. [PMID: 20368553]EscudierBJ , BellmuntJ , NegrierS , MelicharB , BracardaS , RavaudA , et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2009;27(15 suppl):5020. [DOI: 10.1200/jco.2009.27.15_suppl.5020]EscudierBJ , NegrierS , ChevreauC , et al. Analysis of prognostic risk categories in the phase III AVOREN trial of first-line bevacizumab plus interferon-α2a in patients with metastatic renal cell carcinoma: French prognostic scoring system. In: Genitourinary Cancers Symposium, ASCO, abst 417. 2010. EscudierBJ , RavaudA , NegrierS , SzczylikC , BellmuntJ , BracardaS , et al. Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis. Journal of Clinical Oncology2008;26(15 suppl):5025. [DOI: 10.1200/jco.2008.26.15_suppl.5025]KarakiewiczP , SunM , SnellerV , EscudierB . Use of a nomogram to quantify overall survival (OS) benefit in patients with metastatic renal cell carcinoma receiving bevacizumab (BEV) with interferon (IFN) versus IFN alone. Journal of Clinical Oncology2010;28(15 suppl):4592. [DOI: 10.1200/jco.2010.28.15_suppl.4592 ]KarakiewiczPI , SunM , SnellerV , et al. Use of a nomogram to quantify progression-free survival benefit in metastatic renal cell carcinoma patients receiving bevacizumab plus interferon or interferon alone. In: Genitourinary Cancers Symposium, ASCO, abstr 392. 2010. MelicharB , KoralewskiP , PluzanskaA , RavaudA , BracardaS , SzczylikC , et al. First-line bevacizumab improves progression-free survival with lower doses of interferon-α2a in the treatment of patients with metastatic renal cell carcinoma (AVOREN). European Journal of Cancer Supplements2007;5(4):304. [DOI: 10.1016/S1359-6349(07)71149-7]MelicharB , KoralewskiP , RavaudA , PluzanskaA , BracardaS , SzczylikC , et al. First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma. Annals of Oncology2008;19(8):1470-6. [PMID: 18408224]NCT00738530. A study of avastin (bevacizumab) added to interferon alfa-2a (roferon) therapy in patients with metastatic renal cell cancer with nephrectomy [A randomised, double-blind study to evaluate the efficacy and safety of avastin plus roferon compared with placebo plus roferon on overall survival and tumor assessment in nephrectomised patients with metastatic clear cell renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00738530 (first received 20 August 2008). [NCT00738530]">Escudier 2010</a>; <a href="./references#CD012796-bbs2-0003" title="CellaD , GrunwaldV , EscudierB , HammersHJ , GeorgeS , NathanP , et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncology2019;20(2):297-310. [PMID: 30658932]EscudierB , TannirN , McDermottDF , FronteraOA , MelicharB , PlimackER , et al. CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups. Annals of Oncology2017;28(suppl 5):621-2. [DOI: 10.1093/annonc/mdx440.029]MotzerRJ , RiniBI , McDermottDF , Aren FronteraO , HammersHJ , CarducciMA , et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncology2019;S1470-2045(19):30413-9. [PMID: 31427204]MotzerRJ , TannirN , McDermottDF , FronteraOA , MelicharB , ChoueiriTK , et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. New England Journal of Medicine2018;378(14):1277-90. [PMID: 29562145]NCT02231749. Nivolumab combined with ipilimumab versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma (CheckMate 214) [A phase 3, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, advanced or metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT02231749 (first received 4 September 2014). [NCT02231749]TannirNM , HammersHJ , AminA , Grimm M-O, RiniBI , MekanS , et al. Characterization of the benefit-risk profile of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced renal cell carcinoma (aRCC; CheckMate 214). Journal of Clinical Oncology2018;28(6 suppl):686. [DOI: 10.1200/JCO.2018.36.6_suppl.686]VyasC , MotzerRJ , TannirNM , McDermottDF , FronteraOA , MelicharB , et al. Nivolumab + ipilimumab (N+I) vs sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (aRCC): results from checkmate 214, including overall survival by subgroups. Journal of Oncology Pharmacy Practice2018;24(5_suppl):17-8. ">Escudier 2017</a>; <a href="./references#CD012796-bbs2-0004" title="AlemaoE , RajagopalanS , YangS , et al. Quality adjusted survival in randomized, controlled trials: application of inverse probability weighting in renal cell cancer. In: Genitourinary Cancers Symposium, ASCO, abstr 399. 2010. ArmstrongAJ , GeorgeDJ , HalabiS . Serum lactate dehydrogenase as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2010;28(15 suppl):4361. [DOI: 10.1200/jco.2010.28.15_suppl.4631]DutcherJP , SzczylikC , TannirN , BenedettoP , RuffP , HsuA , et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon-alpha. Journal of Clinical Oncology2007;25(18 suppl):5033. [DOI: 10.1200/jco.2007.25.18_suppl.5033]DutcherJP , deSouzaP , FiglinR , et al. Effect of temsirolimus versus interferon- on survival of patients with advanced renal cell carcinoma of different histologies. In: Genitourinary Cancers Symposium, ASCO, abstr 384. 2008. DutcherJP , deSouzaP , McDermottD , FiglinRA , BerkenblitA , ThieleA , et al. Effect of temsirolimus versus interferon- on outcome of patients with advanced renal cell carcinoma of different histologies. Medical Oncology2009;26(2):202–9. [PMID: 19229667]HudesG , CarducciM , TomczakP , DutcherJ , FiglinR , KapoorA , et al. A phase 3, randomized, 3-arm study of temsirolimus or interferon alpha or the combination in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma. Journal of Clinical Oncology2006;24(18 suppl):LBA4. [DOI: 10.1200/jco.2006.24.18_suppl.lba4]HudesG , CarducciM , TomczakP , DutcherJ , FiglinR , KapoorA , et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine2007;356(22):2271–81. [PMID: 17538086]LoganT , McDermottD , DutcherJ , et al. Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features. In: Genitourinary Cancers Symposium, ASCO, abstr 281. 2009. NCT00065468. Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma (ARCC). clinicaltrials.gov/ct2/show/results/NCT00065468 (first received July 25 2003). [NCT00065468]PabloM , HudesG , DutcherJ , WhiteC , KrygowskiM , CincottaM , et al. Radiographic findings of drug-induced pneumonitis and clinical correlation inpatients with advanced renal cell carcinoma treated with temsirolimus. European Journal of Cancer Supplements2009;7(2):426-7. [DOI: 10.1016/S1359-6349(09)71446-6]ParasuramanS , HudesG , LevyD , StrahsA , MooreL , De MariniseR , et al. Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon- (IFN) or the combination of IFN+TEMSR. Journal of Clinical Oncology2007;25(18 suppl):5049. [DOI: 10.1200/jco.2007.25.18_suppl.5049]YangS , HudesG , deSouzaP , AlemaoE , StrahsA , PurvisJ . Evaluation of quality of life in patients with advanced renal cell carcinoma treated with temsirolimus vs interferon-alfa: results from a phase III randomized trial. European Journal of Cancer Supplements2009;7(2):433. [DOI: 10.1016/S1359-6349(09)71467-3]ZbrozekAS , HudesG , LevyD , StrahsA , BerkenblitA , DeMarinisR , et al. Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma. Pharmacoeconomics2010;28(7):577–84. [PMID: 20550223]">Hudes 2007</a>; <a href="./references#CD012796-bbs2-0005" title="AtkinsMB , McDermottDF , PowlesT , MotzerRJ , RiniBI , FongL , et al. IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). Journal of Clinical Oncology2017;35(15 suppl):4505. [DOI: 10.1200/JCO.2017.35.15_suppl.4505]McDermottDF , AtkinsMB , MotzerRJ , RiniBI , EscudierBJ , FongL , et al. A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). Journal of Clinical Oncology2017;35(6 suppl):431. [DOI: 10.1200/JCO.2017.35.6_suppl.431]McDermottDF , HuseniMA , AtkinsMB , MotzerRJ , RiniBI , EscudierB , et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine2018;24(6):749-57. [PMID: 29867230]NCT01984242. A study of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) as monotherapy or in combination with bevacizumab (avastin®) compared to sunitinib (Sutent®) in participants with untreated advanced renal cell carcinoma (IMmotion150) [A phase II, randomized study of atezolizumab (anti-PD-L1 antibody) administered as monotherapy or in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT01984242 (first received 14 November 2013). [NCT01984242]PalSK , McDermottDF , AtkinsMB , EscudierB , RiniBI , MotzerRJ , et al. Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. BJU Int2020;126:73-82. [DOI: 10.1111/bju.15058]PowlesT, McDermottDF , RiniB , MotzerRJ , AtkinsMB , FongL , et al. IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC). Annals of Oncology2017;28(suppl 5):624. [DOI: 10.1093/annonc/mdx440.033]">McDermott 2018</a>; <a href="./references#CD012796-bbs2-0007" title="MotzerRJ , HutsonTE , CellaD , ReevesJ , HawkinsR , GuoJ , et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. New England Journal of Medicine2013;369(8):722-1. [PMID: 23964934]MotzerRJ , HutsonTE , McCannL , DeenK , ChoueiriTK . Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. New England Journal of Medicine2014;370(18):1769-70. [PMID: 24785224]NCT00720941. Pazopanib versus sunitinib in the treatment of locally advanced and/or metastatic renal cell carcinoma (COMPARZ) [Study VEG108844, A study of pazopanib versus sunitinib in the treatment of subjects with locally advanced and/or metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00720941 (first received 23 July 2008). [NCT00720941]">Motzer 2013a</a>; <a href="./references#CD012796-bbs2-0008" title="HutsonT , NosovD , TomczakP , BondarenkoI , LipatovON , SternbergCN , et al. Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902). Journal of Clinical Oncology2015;33(15 suppl):4557. [DOI: 10.1200/jco.2015.33.15_suppl.4557]MotzerRJ , NosovD , EisenT , BondarenkoI , LesovoyV , LipatovO , et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. Journal of Clinical Oncology2013;31(30):3791-9. [PMID: 24019545]NCT01030783. A study to compare tivozanib (AV-951) to sorafenib in subjects with advanced renal cell carcinoma (TIVO-1) [A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib (AV-951) to sorafenib in subjects with advanced renal cell carcinoma (TIVO-1)]. clinicaltrials.gov/ct2/show/NCT01030783 (first received 11 December 2009). [NCT01030783]">Motzer 2013b</a>; <a href="./references#CD012796-bbs2-0009" title="KnoxJJ , BarriosCH , KimTM , CosgriffT , SrimuninnimitV , PittmanK , et al. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Annals of Oncology2017;28(6):1339-45. [PMID: 28327953]KnoxJJ , BarriosCH , KimTM , CosgriffT , SrimuninnimitV , PittmanKB , et al. Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC). Journal of Clinical Oncology2015;33(15 suppl):4554. [DOI: 10.1200/jco.2015.33.15_suppl.4554]MotzerRJ , BarriosCH , KimTM , FalconS , CosgriffT , HarkerWG , et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2014;32(25):2765-72. [PMID: 25049330]NCT00903175. Efficacy and safety comparison of RAD001 versus sunitinib in the first-line and second-line treatment of patients with metastatic renal cell carcinoma (RECORD-3) [An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as First-line followed by second-line RAD001 in the treatment of patients with metastatic renal cell carcinoma.]. clinicaltrials.gov/ct2/show/NCT00903175 (first received 18 May 2009). [NCT00903175]">Motzer 2014</a>; <a href="./references#CD012796-bbs2-0010" title="MotzerRJ , PenkovK , HaanenJ , RiniB , AlbigesL , CampbellMT , et al. Avelumab plus axitinib versus sunitinib for advanced renal cell carcinoma. New England Journal of Medicine2019;380(12):1103-5. [PMID: 30779531]NCT02684006. A study of avelumab with axitinib versus sunitinib in advanced renal cell cancer (JAVELIN Renal 101) [A phase 3, multinational, randomized, open-label, parallel-arm study of avelumab (MSB0010718C) in combination with axitinib (Inlyta(registered)) versus sunitinib (Sutent(registered)) monotherapy in the first-line treatment of patients with advanced renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT02684006 (first received 17 February 2016). [NCT02684006]">Motzer 2019</a>; <a href="./references#CD012796-bbs2-0013" title="HalabiS , RiniBI , StadlerWM , SmallEJ . Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2010;28(15 suppl):4525. [DOI: 10.1200/jco.2010.28.15_suppl.4525]HarzstarkAL , HalabiS , StadlerWM , et al. Hypertensionis associated with clinical outcome for patients with metastatic renal cell carcinoma treated with interferon and bevacizumab on CALGB 90206. In: Genitourinary Cancers Symposium, ASCO, abstr 351. 2010. NCT00072046. Interferon alfa-2b with or without bevacizumab in treating patients with advanced renal cell carcinoma (Kidney Cancer) [A randomized phase III trial of interferon alfa-2B or interferon alfa-2B plus bevacizumab in patients with advanced renal carcinoma]. clinicaltrials.gov/ct2/show/study/NCT00072046 (first received 6 November 2003). [NCT00072046]RiniBI , HalabiS , RosenbergJ , StadlerWM , VaenaDA , AtkinsJN , et al. Bevacizumab plus interferon-alfa versus interferon-alfa monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206. Journal of Clinical Oncology2009;27(18 suppl):LBA5019. [DOI: 10.1200/jco.2009.27.18_suppl.lba5019 ]RiniBI , HalabiS , RosenbergJE , StadlerWM , VaenaDA , OuSS , et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB90206. Journal of Clinical Oncology2008;26(33):5422-8. [PMID: 18936475]RiniBI , HalabiS , RosenbergJE , et al. CALGB 90206:a phase III trial of bevacizumab plus interferon-alfa versus interferon-alfa monotherapy in metastatic renal cell carcinoma. In: Genitourinary Cancers Symposium, ASCO, abstr 350. 2008. RiniBI , HalabiS , TaylorJ , SmallEJ , SchilskyRL , Cancer and Leukemia Group B . Cancerand Leukemia Group B 90206: a randomized phase III trial of interferon-a or interferon-a plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clinical Cancer Research2004;10(8):2584-6. [PMID: 15102658]">Rini 2008</a>; <a href="./references#CD012796-bbs2-0014" title="NCT00631371. Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (INTORACT). linicaltrials.gov/ct2/show/NCT00631371 (first received 20 May 2019). [NCT00631371]RiniBI , BellmuntJ , ClancyJ , WangK , NiethammerAG , HariharanS , et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. Journal of Clinical Oncology2014;32(8):752-9. [PMID: 24297945]">Rini 2014</a>; <a href="./references#CD012796-bbs2-0015" title="NCT01265901. IMA901 in patients receiving sunitinib for advanced/metastatic renal cell carcinoma [A randomized, controlled phase III study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT01265901 (first received 23 December 2010). [NCT01265901]RiniBI , StenzlA , ZdrojowyR , KoganM , ShkolnikM , OudardS , et al. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncology2016;17(11):1599-611. [PMID: 27720136]">Rini 2016</a>; <a href="./references#CD012796-bbs2-0016" title="NCT02853331. Study to evaluate the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib versus sunitinib monotherapy in participants with renal cell carcinoma (MK-3475-426/KEYNOTE-426) [A phase III randomized, open-label study to evaluate efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib versus sunitinib monotherapy as a first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (KEYNOTE-426)]. clinicaltrials.gov/ct2/show/NCT02853331 (first received 2 August 2016). [NCT02853331]PowlesT , PlimackER , StusV , GafanovRA , HawkinsRE , NosovD . Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study. Journal of Clinical Oncology2019;37(7 suppl):543-543. RiniBI , PlimackER , StusV , GafanovR , HawkinsR , NosovD , et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. New England Journal of Medicine2019;380(12):1116-27. [PMID: 30779529]">Rini 2019a</a>; <a href="./references#CD012796-bbs2-0017" title="AtkinsMB , RiniBI , MotzerRJ , PowlesT , McDermottDF , SuarezC , et al. Patient-reported outcomes from the phase 3 randomized IMmotion151 trial: atezolizumab + bevacizumab vs sunitinib in treatment-naive metastatic renal cell carcinoma. Clinical Cancer Research2020;26(11):2506-2514. EscudierB , MotzerRJ , RiniBI , PowlesT , McDermottDF , SuarezC , et al. Patient-reported outcomes (PROs) in IMmotion151: atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2018;36(15_suppl):4511. [DOI: 10.1200/JCO.2018.36.15_suppl.4511]MotzerRJ , PowlesT , AtkinsMB , EscudierB , McDermottDF , SuarezC , et al. IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2018;36(6 suppl):578. [DOI: 10.1200/JCO.2018.36.6_suppl.578]NCT02420821. A study of atezolizumab in combination with bevacizumab versus sunitinib in participants with untreated advanced renal cell carcinoma (RCC) (IMmotion151) [A phase III, open-label, randomized study of atezolizumab (Anti-PD-L1 Antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT02420821 (first received 20 April 2015). [NCT02420821]RiniBI , PowlesT , AtkinsMB , EscudierB , McDermottDF , SuarezC , et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet2019;393(10189):2404-15. [PMID: 31079938]">Rini 2019b</a>; <a href="./references#CD012796-bbs2-0018" title="CellaD , PickardAS , DuhMS , GuerinA , MishaginaN , AntràsL , et al. Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. European Journal of Cancer2012;48(3):311-23. [PMID: 21689927]HutsonTE , BukowskiRM . A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma. Clinical Genitourinary Cancer2006;4(4):296-8. [PMID: 16729915]HutsonTE , DavisID , MachielsJP , deSouzaPL , HongBF , RotteyS , et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). Journal of Clinical Oncology2007;25(18 suppl):5031. [DOI: 10.1200/jco.2007.25.18_suppl.5031]NCT00334282. Safety and efficacy of GW786034 (pazopanib) In metastatic renal cell carcinoma [A randomised, double-blind, placebo controlled, multi-center phase III study to evaluate the efficacy and safety of pazopanib (GW786034) compared to placebo in patients with locally advanced and/or metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT00334282 (first received 7 June 2006). [NCT00334282]SternbergCN , DavisID , MardiakJ , SzczylikC , LeeE , WagstaffJ , et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of Clinical Oncology2010;28(6):1061-8. [PMID: 20100962]SternbergCN , HawkinsRE , WagstaffJ , SalmanP , MardiakJ , BarriosCH , et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. European Journal of Cancer2013;49(6):1287-96. [PMID: 23321547]SternbergCN , SzczylikC , LeeE , SalmanPV , MardiakJ , DavisID , et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). Journal of Clinical Oncology2009;27(15S):5021. [DOI: 10.1200/jco.2009.27.15s.5021]">Sternberg 2010</a>). The remaining three trials had an unclear risk of bias. </p> </section> <section id="CD012796-sec-0063"> <h5 class="title">Allocation concealment</h5> <p>We judged 14 trials to have a low risk of bias (<a href="./references#CD012796-bbs2-0001" title="EichelbergC , GoebellPJ , VervenneWL , De SantisM , Fischer von WeikersthalL , LerchenmüllerC , et al. Updated overall survival, multivariate, and Q-TWiST analyses of a randomized, sequential, open-label study (SWITCH) to evaluate the efficacy and safety of sorafenib (So)-sunitinib (Su) versus Su-So in the treatment of metastatic renal cell cancer. Annals of Oncology2014;25(suppl 4):iv290. [DOI: 10.1093/annonc/mdu337.28]EichelbergC , VervenneWL , De SantisM , Fischer von WeikersthalL , GoebellPJ , LerchenmüllerC , et al. SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer. European Urology2015;68(5):837-47. [PMID: 25952317]GoebellPJ , VervenneW , De SantisM , Fischer Von WeikersthalL , LerchenmullerCA , ZimmermannU , et al. Subgroup analyses of a randomized sequential open-label study (SWITCH) to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). Journal of Clinical Oncology2014;32(15 suppl):4567. [DOI: 10.1200/jco.2014.32.15_suppl.4567]MichelMS , VervenneW , deSantisM , Fischer von WeikersthalL , GoebellPJ , LerchenmuellerJ , et al. SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). Journal of Clinical Oncology2014;32(4 suppl):393. [DOI: 10.1200/jco.2014.32.4_suppl.393]NCT00732914. Sequential study to treat renal cell carcinoma [A phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by sunitinib versus sunitinib followed by sorafenib in the treatment of first-line advanced / metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00732914 (first received 12 August 2008). [NCT00732914]">Eichelberg 2015</a>; <a href="./references#CD012796-bbs2-0002" title="BajettaE , RavaudA , BracardaS , NégrierS , SzczylikC , BellmuntJ , et al. Efficacy and safety of first-line bevacizumab (BEV) plus interferon-α2a (IFN) in patients (pts) ≥65 years with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2008;26(15 suppl):5095. [DOI: 10.1200/jco.2008.26.15_suppl.5095]BellmuntJ , MelicharB , BracardaS , NegrierSN , RavaudA , LaeufleR , et al. Bevacizumab (BEV) and interferon (IFN) therapy does not increase risk of cardiac events in metastatic renal cell carcinoma(mRCC). European Journal of Cancer Supplements2009;7(2):429. [DOI: 10.1016/S1359-6349(09)71454-5]BracardaS , BellmuntJ , NegrierSN , MelicharB , RavaudA , JethwaS , et al. What is the impact of subsequent antineoplastic therapy on overall survival (OS) following first-line bevacizumab (BEV)/interferonalpha2a (IFN) in metastatic renal cell carcinoma (mRCC)? – Experience from AVOREN. European Journal of Cancer Supplements2009;7(2):431. [DOI: 10.1016/S1359-6349(09)71459-4]BracardaS , KoralewskiP , PluzanskaA , RavaudA , SzczylikC , ChevreauC , et al. Bevacizumab/interferon-alpha2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN). European Journal of Cancer Supplements2007;5(4):281-2. [DOI: 10.1016/S1359-6349(07)71076-5]EscudierB , KoralewskiP , PluzanskaA , RavaudA , BracardaS , SzczylikC , et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma. Journal of Clinical Oncology2007;25(18 suppl):3. [DOI: 10.1200/jco.2007.25.18_suppl.3]EscudierB , PluzanskaA , KoralewskiP , RavaudA , BracardaS , SzczylikC , et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized double-blind phase III trial. Lancet2007;370(9605):2103-11. [PMID: 18156031]EscudierBB , BellmuntJ , NegrierS , BajettaE , MelicharB , BracardaS , et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. Journal of Clinical Oncology2010;28(13):2144-50. [PMID: 20368553]EscudierBJ , BellmuntJ , NegrierS , MelicharB , BracardaS , RavaudA , et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2009;27(15 suppl):5020. [DOI: 10.1200/jco.2009.27.15_suppl.5020]EscudierBJ , NegrierS , ChevreauC , et al. Analysis of prognostic risk categories in the phase III AVOREN trial of first-line bevacizumab plus interferon-α2a in patients with metastatic renal cell carcinoma: French prognostic scoring system. In: Genitourinary Cancers Symposium, ASCO, abst 417. 2010. EscudierBJ , RavaudA , NegrierS , SzczylikC , BellmuntJ , BracardaS , et al. Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis. Journal of Clinical Oncology2008;26(15 suppl):5025. [DOI: 10.1200/jco.2008.26.15_suppl.5025]KarakiewiczP , SunM , SnellerV , EscudierB . Use of a nomogram to quantify overall survival (OS) benefit in patients with metastatic renal cell carcinoma receiving bevacizumab (BEV) with interferon (IFN) versus IFN alone. Journal of Clinical Oncology2010;28(15 suppl):4592. [DOI: 10.1200/jco.2010.28.15_suppl.4592 ]KarakiewiczPI , SunM , SnellerV , et al. Use of a nomogram to quantify progression-free survival benefit in metastatic renal cell carcinoma patients receiving bevacizumab plus interferon or interferon alone. In: Genitourinary Cancers Symposium, ASCO, abstr 392. 2010. MelicharB , KoralewskiP , PluzanskaA , RavaudA , BracardaS , SzczylikC , et al. First-line bevacizumab improves progression-free survival with lower doses of interferon-α2a in the treatment of patients with metastatic renal cell carcinoma (AVOREN). European Journal of Cancer Supplements2007;5(4):304. [DOI: 10.1016/S1359-6349(07)71149-7]MelicharB , KoralewskiP , RavaudA , PluzanskaA , BracardaS , SzczylikC , et al. First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma. Annals of Oncology2008;19(8):1470-6. [PMID: 18408224]NCT00738530. A study of avastin (bevacizumab) added to interferon alfa-2a (roferon) therapy in patients with metastatic renal cell cancer with nephrectomy [A randomised, double-blind study to evaluate the efficacy and safety of avastin plus roferon compared with placebo plus roferon on overall survival and tumor assessment in nephrectomised patients with metastatic clear cell renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00738530 (first received 20 August 2008). [NCT00738530]">Escudier 2010</a>; <a href="./references#CD012796-bbs2-0003" title="CellaD , GrunwaldV , EscudierB , HammersHJ , GeorgeS , NathanP , et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncology2019;20(2):297-310. [PMID: 30658932]EscudierB , TannirN , McDermottDF , FronteraOA , MelicharB , PlimackER , et al. CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups. Annals of Oncology2017;28(suppl 5):621-2. [DOI: 10.1093/annonc/mdx440.029]MotzerRJ , RiniBI , McDermottDF , Aren FronteraO , HammersHJ , CarducciMA , et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncology2019;S1470-2045(19):30413-9. [PMID: 31427204]MotzerRJ , TannirN , McDermottDF , FronteraOA , MelicharB , ChoueiriTK , et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. New England Journal of Medicine2018;378(14):1277-90. [PMID: 29562145]NCT02231749. Nivolumab combined with ipilimumab versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma (CheckMate 214) [A phase 3, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, advanced or metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT02231749 (first received 4 September 2014). [NCT02231749]TannirNM , HammersHJ , AminA , Grimm M-O, RiniBI , MekanS , et al. Characterization of the benefit-risk profile of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced renal cell carcinoma (aRCC; CheckMate 214). Journal of Clinical Oncology2018;28(6 suppl):686. [DOI: 10.1200/JCO.2018.36.6_suppl.686]VyasC , MotzerRJ , TannirNM , McDermottDF , FronteraOA , MelicharB , et al. Nivolumab + ipilimumab (N+I) vs sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (aRCC): results from checkmate 214, including overall survival by subgroups. Journal of Oncology Pharmacy Practice2018;24(5_suppl):17-8. ">Escudier 2017</a>; <a href="./references#CD012796-bbs2-0004" title="AlemaoE , RajagopalanS , YangS , et al. Quality adjusted survival in randomized, controlled trials: application of inverse probability weighting in renal cell cancer. In: Genitourinary Cancers Symposium, ASCO, abstr 399. 2010. ArmstrongAJ , GeorgeDJ , HalabiS . Serum lactate dehydrogenase as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2010;28(15 suppl):4361. [DOI: 10.1200/jco.2010.28.15_suppl.4631]DutcherJP , SzczylikC , TannirN , BenedettoP , RuffP , HsuA , et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon-alpha. Journal of Clinical Oncology2007;25(18 suppl):5033. [DOI: 10.1200/jco.2007.25.18_suppl.5033]DutcherJP , deSouzaP , FiglinR , et al. Effect of temsirolimus versus interferon- on survival of patients with advanced renal cell carcinoma of different histologies. In: Genitourinary Cancers Symposium, ASCO, abstr 384. 2008. DutcherJP , deSouzaP , McDermottD , FiglinRA , BerkenblitA , ThieleA , et al. Effect of temsirolimus versus interferon- on outcome of patients with advanced renal cell carcinoma of different histologies. Medical Oncology2009;26(2):202–9. [PMID: 19229667]HudesG , CarducciM , TomczakP , DutcherJ , FiglinR , KapoorA , et al. A phase 3, randomized, 3-arm study of temsirolimus or interferon alpha or the combination in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma. Journal of Clinical Oncology2006;24(18 suppl):LBA4. [DOI: 10.1200/jco.2006.24.18_suppl.lba4]HudesG , CarducciM , TomczakP , DutcherJ , FiglinR , KapoorA , et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine2007;356(22):2271–81. [PMID: 17538086]LoganT , McDermottD , DutcherJ , et al. Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features. In: Genitourinary Cancers Symposium, ASCO, abstr 281. 2009. NCT00065468. Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma (ARCC). clinicaltrials.gov/ct2/show/results/NCT00065468 (first received July 25 2003). [NCT00065468]PabloM , HudesG , DutcherJ , WhiteC , KrygowskiM , CincottaM , et al. Radiographic findings of drug-induced pneumonitis and clinical correlation inpatients with advanced renal cell carcinoma treated with temsirolimus. European Journal of Cancer Supplements2009;7(2):426-7. [DOI: 10.1016/S1359-6349(09)71446-6]ParasuramanS , HudesG , LevyD , StrahsA , MooreL , De MariniseR , et al. Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon- (IFN) or the combination of IFN+TEMSR. Journal of Clinical Oncology2007;25(18 suppl):5049. [DOI: 10.1200/jco.2007.25.18_suppl.5049]YangS , HudesG , deSouzaP , AlemaoE , StrahsA , PurvisJ . Evaluation of quality of life in patients with advanced renal cell carcinoma treated with temsirolimus vs interferon-alfa: results from a phase III randomized trial. European Journal of Cancer Supplements2009;7(2):433. [DOI: 10.1016/S1359-6349(09)71467-3]ZbrozekAS , HudesG , LevyD , StrahsA , BerkenblitA , DeMarinisR , et al. Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma. Pharmacoeconomics2010;28(7):577–84. [PMID: 20550223]">Hudes 2007</a>; <a href="./references#CD012796-bbs2-0007" title="MotzerRJ , HutsonTE , CellaD , ReevesJ , HawkinsR , GuoJ , et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. New England Journal of Medicine2013;369(8):722-1. [PMID: 23964934]MotzerRJ , HutsonTE , McCannL , DeenK , ChoueiriTK . Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. New England Journal of Medicine2014;370(18):1769-70. [PMID: 24785224]NCT00720941. Pazopanib versus sunitinib in the treatment of locally advanced and/or metastatic renal cell carcinoma (COMPARZ) [Study VEG108844, A study of pazopanib versus sunitinib in the treatment of subjects with locally advanced and/or metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00720941 (first received 23 July 2008). [NCT00720941]">Motzer 2013a</a>; <a href="./references#CD012796-bbs2-0008" title="HutsonT , NosovD , TomczakP , BondarenkoI , LipatovON , SternbergCN , et al. Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902). Journal of Clinical Oncology2015;33(15 suppl):4557. [DOI: 10.1200/jco.2015.33.15_suppl.4557]MotzerRJ , NosovD , EisenT , BondarenkoI , LesovoyV , LipatovO , et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. Journal of Clinical Oncology2013;31(30):3791-9. [PMID: 24019545]NCT01030783. A study to compare tivozanib (AV-951) to sorafenib in subjects with advanced renal cell carcinoma (TIVO-1) [A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib (AV-951) to sorafenib in subjects with advanced renal cell carcinoma (TIVO-1)]. clinicaltrials.gov/ct2/show/NCT01030783 (first received 11 December 2009). [NCT01030783]">Motzer 2013b</a>; <a href="./references#CD012796-bbs2-0009" title="KnoxJJ , BarriosCH , KimTM , CosgriffT , SrimuninnimitV , PittmanK , et al. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Annals of Oncology2017;28(6):1339-45. [PMID: 28327953]KnoxJJ , BarriosCH , KimTM , CosgriffT , SrimuninnimitV , PittmanKB , et al. Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC). Journal of Clinical Oncology2015;33(15 suppl):4554. [DOI: 10.1200/jco.2015.33.15_suppl.4554]MotzerRJ , BarriosCH , KimTM , FalconS , CosgriffT , HarkerWG , et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2014;32(25):2765-72. [PMID: 25049330]NCT00903175. Efficacy and safety comparison of RAD001 versus sunitinib in the first-line and second-line treatment of patients with metastatic renal cell carcinoma (RECORD-3) [An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as First-line followed by second-line RAD001 in the treatment of patients with metastatic renal cell carcinoma.]. clinicaltrials.gov/ct2/show/NCT00903175 (first received 18 May 2009). [NCT00903175]">Motzer 2014</a>; <a href="./references#CD012796-bbs2-0010" title="MotzerRJ , PenkovK , HaanenJ , RiniB , AlbigesL , CampbellMT , et al. Avelumab plus axitinib versus sunitinib for advanced renal cell carcinoma. New England Journal of Medicine2019;380(12):1103-5. [PMID: 30779531]NCT02684006. A study of avelumab with axitinib versus sunitinib in advanced renal cell cancer (JAVELIN Renal 101) [A phase 3, multinational, randomized, open-label, parallel-arm study of avelumab (MSB0010718C) in combination with axitinib (Inlyta(registered)) versus sunitinib (Sutent(registered)) monotherapy in the first-line treatment of patients with advanced renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT02684006 (first received 17 February 2016). [NCT02684006]">Motzer 2019</a>; <a href="./references#CD012796-bbs2-0013" title="HalabiS , RiniBI , StadlerWM , SmallEJ . Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2010;28(15 suppl):4525. [DOI: 10.1200/jco.2010.28.15_suppl.4525]HarzstarkAL , HalabiS , StadlerWM , et al. Hypertensionis associated with clinical outcome for patients with metastatic renal cell carcinoma treated with interferon and bevacizumab on CALGB 90206. In: Genitourinary Cancers Symposium, ASCO, abstr 351. 2010. NCT00072046. Interferon alfa-2b with or without bevacizumab in treating patients with advanced renal cell carcinoma (Kidney Cancer) [A randomized phase III trial of interferon alfa-2B or interferon alfa-2B plus bevacizumab in patients with advanced renal carcinoma]. clinicaltrials.gov/ct2/show/study/NCT00072046 (first received 6 November 2003). [NCT00072046]RiniBI , HalabiS , RosenbergJ , StadlerWM , VaenaDA , AtkinsJN , et al. Bevacizumab plus interferon-alfa versus interferon-alfa monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206. Journal of Clinical Oncology2009;27(18 suppl):LBA5019. [DOI: 10.1200/jco.2009.27.18_suppl.lba5019 ]RiniBI , HalabiS , RosenbergJE , StadlerWM , VaenaDA , OuSS , et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB90206. Journal of Clinical Oncology2008;26(33):5422-8. [PMID: 18936475]RiniBI , HalabiS , RosenbergJE , et al. CALGB 90206:a phase III trial of bevacizumab plus interferon-alfa versus interferon-alfa monotherapy in metastatic renal cell carcinoma. In: Genitourinary Cancers Symposium, ASCO, abstr 350. 2008. RiniBI , HalabiS , TaylorJ , SmallEJ , SchilskyRL , Cancer and Leukemia Group B . Cancerand Leukemia Group B 90206: a randomized phase III trial of interferon-a or interferon-a plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clinical Cancer Research2004;10(8):2584-6. [PMID: 15102658]">Rini 2008</a>; <a href="./references#CD012796-bbs2-0014" title="NCT00631371. Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (INTORACT). linicaltrials.gov/ct2/show/NCT00631371 (first received 20 May 2019). [NCT00631371]RiniBI , BellmuntJ , ClancyJ , WangK , NiethammerAG , HariharanS , et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. Journal of Clinical Oncology2014;32(8):752-9. [PMID: 24297945]">Rini 2014</a>; <a href="./references#CD012796-bbs2-0015" title="NCT01265901. IMA901 in patients receiving sunitinib for advanced/metastatic renal cell carcinoma [A randomized, controlled phase III study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT01265901 (first received 23 December 2010). [NCT01265901]RiniBI , StenzlA , ZdrojowyR , KoganM , ShkolnikM , OudardS , et al. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncology2016;17(11):1599-611. [PMID: 27720136]">Rini 2016</a>; <a href="./references#CD012796-bbs2-0016" title="NCT02853331. Study to evaluate the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib versus sunitinib monotherapy in participants with renal cell carcinoma (MK-3475-426/KEYNOTE-426) [A phase III randomized, open-label study to evaluate efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib versus sunitinib monotherapy as a first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (KEYNOTE-426)]. clinicaltrials.gov/ct2/show/NCT02853331 (first received 2 August 2016). [NCT02853331]PowlesT , PlimackER , StusV , GafanovRA , HawkinsRE , NosovD . Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study. Journal of Clinical Oncology2019;37(7 suppl):543-543. RiniBI , PlimackER , StusV , GafanovR , HawkinsR , NosovD , et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. New England Journal of Medicine2019;380(12):1116-27. [PMID: 30779529]">Rini 2019a</a>; <a href="./references#CD012796-bbs2-0017" title="AtkinsMB , RiniBI , MotzerRJ , PowlesT , McDermottDF , SuarezC , et al. Patient-reported outcomes from the phase 3 randomized IMmotion151 trial: atezolizumab + bevacizumab vs sunitinib in treatment-naive metastatic renal cell carcinoma. Clinical Cancer Research2020;26(11):2506-2514. EscudierB , MotzerRJ , RiniBI , PowlesT , McDermottDF , SuarezC , et al. Patient-reported outcomes (PROs) in IMmotion151: atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2018;36(15_suppl):4511. [DOI: 10.1200/JCO.2018.36.15_suppl.4511]MotzerRJ , PowlesT , AtkinsMB , EscudierB , McDermottDF , SuarezC , et al. IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2018;36(6 suppl):578. [DOI: 10.1200/JCO.2018.36.6_suppl.578]NCT02420821. A study of atezolizumab in combination with bevacizumab versus sunitinib in participants with untreated advanced renal cell carcinoma (RCC) (IMmotion151) [A phase III, open-label, randomized study of atezolizumab (Anti-PD-L1 Antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT02420821 (first received 20 April 2015). [NCT02420821]RiniBI , PowlesT , AtkinsMB , EscudierB , McDermottDF , SuarezC , et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet2019;393(10189):2404-15. [PMID: 31079938]">Rini 2019b</a>; <a href="./references#CD012796-bbs2-0018" title="CellaD , PickardAS , DuhMS , GuerinA , MishaginaN , AntràsL , et al. Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. European Journal of Cancer2012;48(3):311-23. [PMID: 21689927]HutsonTE , BukowskiRM . A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma. Clinical Genitourinary Cancer2006;4(4):296-8. [PMID: 16729915]HutsonTE , DavisID , MachielsJP , deSouzaPL , HongBF , RotteyS , et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). Journal of Clinical Oncology2007;25(18 suppl):5031. [DOI: 10.1200/jco.2007.25.18_suppl.5031]NCT00334282. Safety and efficacy of GW786034 (pazopanib) In metastatic renal cell carcinoma [A randomised, double-blind, placebo controlled, multi-center phase III study to evaluate the efficacy and safety of pazopanib (GW786034) compared to placebo in patients with locally advanced and/or metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT00334282 (first received 7 June 2006). [NCT00334282]SternbergCN , DavisID , MardiakJ , SzczylikC , LeeE , WagstaffJ , et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of Clinical Oncology2010;28(6):1061-8. [PMID: 20100962]SternbergCN , HawkinsRE , WagstaffJ , SalmanP , MardiakJ , BarriosCH , et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. European Journal of Cancer2013;49(6):1287-96. [PMID: 23321547]SternbergCN , SzczylikC , LeeE , SalmanPV , MardiakJ , DavisID , et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). Journal of Clinical Oncology2009;27(15S):5021. [DOI: 10.1200/jco.2009.27.15s.5021]">Sternberg 2010</a>). Three trials had an unclear risk of bias (<a href="./references#CD012796-bbs2-0006" title="CastellanoD , delMuroXG , Pérez-GraciaJL , González-LarribaJL , AbrioMV , RuizMA , et al. Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population. Annals of Oncology2009;20(11):1803-12. [PMID: 19549706]CellaD , CappelleriJC , BushmakinA , CharbonneauC , LiJZ , KimST , et al. Quality of life predicts progression-free survival in patients with renal cell carcinoma treated with sunitinib versus interferon alfa. Journal of Oncology Practice2009;5(2):66-70. [PMID: 20856722]CellaD , LiJZ , CappelariJC , BushmakinA , CharbonneauC , KimST , et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. Journal of Clinical Oncology2008;26(22):3763-9. [PMID: 18669464]CellaD , LiJZ , CappelleriJC , BushmakinA , CharbonneauC , KimST , ChenI , et al. Quality of life (QOL) predicts for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib compared to interferon-alpha (IFN-α). Journal of Clinical Oncology2007;25(18 suppl):6594. [DOI: 10.1200/jco.2007.25.18_suppl.6594]CellaD , MichaelsonMD , BushmakinAG , CappelleriJC , CharbonneauC , KimST , et al. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-a in a phase III trial: final results and geographical analysis. British Journal of Cancer2010;102(4):658-64. [PMID: 20104222]FiginRA , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , NegrierS , et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2008;26(15 suppl):5024. [DOI: 10.1200/jco.2008.26.15_suppl.5024]MotzerRJ , BukowskiRM , FiglinRA , HutsonTE , MichaelsonMD , KimST , et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer2008;113(7):1552-8. [PMID: 18720362]MotzerRJ , FiglinRA , HutsonTE , TomczakP , BukowskiRM , RixeO , et al. Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors. Journal of Clinical Oncology2007;25(18 suppl):5024. [DOI: 10.1200/jco.2007.25.18_suppl.5024]MotzerRJ , FiglinRA , HutsonTE , TomczakP , BukowskiRM , RixeO , et al. Sunitinib versus interferon-alfa as first-line treatment of metastatic renal cell carcinoma: updated results and analysis of prognostic factors. In: www.asco.org/virtual meeting. 2007. MotzerRJ , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , OudardS , et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2009;27(22):3584-90. [PMID: 19487381]MotzerRJ , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , RixeO , et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2006;24(18 suppl):LBA3. [DOI: 10.1200/jco.2006.24.18_suppl.lba3]MotzerRJ , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , RixeO , et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine2007;356(2):115-24. [PMID: 17215529]MotzerRJ , MichaelsonMD , HutsonTE , TomczakP , BukowskiRM , RixeO , et al. Sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors. European Journal of Cancer Supplements2007;5(4):301. [DOI: 10.1016/S1359-6349(07)71140-0]NCT00083889. SU011248 versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma [A phase 3, randomized study of SU011248 versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00083889 (first received 4 June 2004). [NCT00083889]PatilS , FiglinRA , HutsonTE , MichaelsonD , NegrierS , KimST , et al. TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-α). Journal of Clinical Oncology2010;28(15 suppl):4594. [DOI: 10.1200/jco.2010.28.15_suppl.4594]WilkersonJ , SteinWD , KimST , HuangX , MotzerRJ , FojoAT , et al. Validation of kinetic analysis of renal cancer regression and growth following treatment with sunitinib and interferon-alfa: analysis of the pivotal randomized trial. Journal of Clinical Oncology2010;28(15 suppl):4597. [DOI: 10.1200/jco.2010.28.15_suppl.4597]">Motzer 2010</a>; <a href="./references#CD012796-bbs2-0011" title="NCT00719264. Safety and efficacy of bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment in adult patients with kidney cancer [A randomized, open-label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a plus bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney]. clinicaltrials.gov/ct2/show/study/NCT00719264 (first received 21 July 2008). [NCT00719264]RavaudA , BarriosCH , AlekseevB , TayMH , AgarwalaSS , YalcinS , et al. RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. Annals of Oncology2015;26(7):1378-84. [PMID: 25851632]">Ravaud 2015</a>; <a href="./references#CD012796-bbs2-0012" title="NCT01613846. Phase III sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma (SWITCH-II) [Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT01613846 (first received 7 June 2012). [NCT01613846]RetzM , BedkeJ , BögemannM , GrimmMO , ZimmermannU , MüllerL , et al. SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). European Journal of Cancer2019;107:37-45. [PMID: 30529901]RetzM , BedkeJ, HerrmannE , GrimmM , ZimmermannU , MüllerL , et al. Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib sorafenib in the treatment of metastatic renal cell carcinoma(SWITCH-II). Annals of Oncology2017;28(suppl 5):295. [DOI: 10.1093/annonc/mdx371]">Retz 2019</a>); and we judged one trial to have a high risk of bias (<a href="./references#CD012796-bbs2-0005" title="AtkinsMB , McDermottDF , PowlesT , MotzerRJ , RiniBI , FongL , et al. IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). Journal of Clinical Oncology2017;35(15 suppl):4505. [DOI: 10.1200/JCO.2017.35.15_suppl.4505]McDermottDF , AtkinsMB , MotzerRJ , RiniBI , EscudierBJ , FongL , et al. A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). Journal of Clinical Oncology2017;35(6 suppl):431. [DOI: 10.1200/JCO.2017.35.6_suppl.431]McDermottDF , HuseniMA , AtkinsMB , MotzerRJ , RiniBI , EscudierB , et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine2018;24(6):749-57. [PMID: 29867230]NCT01984242. A study of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) as monotherapy or in combination with bevacizumab (avastin®) compared to sunitinib (Sutent®) in participants with untreated advanced renal cell carcinoma (IMmotion150) [A phase II, randomized study of atezolizumab (anti-PD-L1 antibody) administered as monotherapy or in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT01984242 (first received 14 November 2013). [NCT01984242]PalSK , McDermottDF , AtkinsMB , EscudierB , RiniBI , MotzerRJ , et al. Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. BJU Int2020;126:73-82. [DOI: 10.1111/bju.15058]PowlesT, McDermottDF , RiniB , MotzerRJ , AtkinsMB , FongL , et al. IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC). Annals of Oncology2017;28(suppl 5):624. [DOI: 10.1093/annonc/mdx440.033]">McDermott 2018</a>). </p> </section> </section> <section id="CD012796-sec-0064"> <h4 class="title">Blinding</h4> <section id="CD012796-sec-0065"> <h5 class="title">Blinding of participants and personnel</h5> <p>For objective outcomes we judged all studies to have a low risk of bias. For subjective outcomes we rated only two trials as low risk of bias (<a href="./references#CD012796-bbs2-0002" title="BajettaE , RavaudA , BracardaS , NégrierS , SzczylikC , BellmuntJ , et al. Efficacy and safety of first-line bevacizumab (BEV) plus interferon-α2a (IFN) in patients (pts) ≥65 years with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2008;26(15 suppl):5095. [DOI: 10.1200/jco.2008.26.15_suppl.5095]BellmuntJ , MelicharB , BracardaS , NegrierSN , RavaudA , LaeufleR , et al. Bevacizumab (BEV) and interferon (IFN) therapy does not increase risk of cardiac events in metastatic renal cell carcinoma(mRCC). European Journal of Cancer Supplements2009;7(2):429. [DOI: 10.1016/S1359-6349(09)71454-5]BracardaS , BellmuntJ , NegrierSN , MelicharB , RavaudA , JethwaS , et al. What is the impact of subsequent antineoplastic therapy on overall survival (OS) following first-line bevacizumab (BEV)/interferonalpha2a (IFN) in metastatic renal cell carcinoma (mRCC)? – Experience from AVOREN. European Journal of Cancer Supplements2009;7(2):431. [DOI: 10.1016/S1359-6349(09)71459-4]BracardaS , KoralewskiP , PluzanskaA , RavaudA , SzczylikC , ChevreauC , et al. Bevacizumab/interferon-alpha2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN). European Journal of Cancer Supplements2007;5(4):281-2. [DOI: 10.1016/S1359-6349(07)71076-5]EscudierB , KoralewskiP , PluzanskaA , RavaudA , BracardaS , SzczylikC , et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma. Journal of Clinical Oncology2007;25(18 suppl):3. [DOI: 10.1200/jco.2007.25.18_suppl.3]EscudierB , PluzanskaA , KoralewskiP , RavaudA , BracardaS , SzczylikC , et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized double-blind phase III trial. Lancet2007;370(9605):2103-11. [PMID: 18156031]EscudierBB , BellmuntJ , NegrierS , BajettaE , MelicharB , BracardaS , et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. Journal of Clinical Oncology2010;28(13):2144-50. [PMID: 20368553]EscudierBJ , BellmuntJ , NegrierS , MelicharB , BracardaS , RavaudA , et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2009;27(15 suppl):5020. [DOI: 10.1200/jco.2009.27.15_suppl.5020]EscudierBJ , NegrierS , ChevreauC , et al. Analysis of prognostic risk categories in the phase III AVOREN trial of first-line bevacizumab plus interferon-α2a in patients with metastatic renal cell carcinoma: French prognostic scoring system. In: Genitourinary Cancers Symposium, ASCO, abst 417. 2010. EscudierBJ , RavaudA , NegrierS , SzczylikC , BellmuntJ , BracardaS , et al. Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis. Journal of Clinical Oncology2008;26(15 suppl):5025. [DOI: 10.1200/jco.2008.26.15_suppl.5025]KarakiewiczP , SunM , SnellerV , EscudierB . Use of a nomogram to quantify overall survival (OS) benefit in patients with metastatic renal cell carcinoma receiving bevacizumab (BEV) with interferon (IFN) versus IFN alone. Journal of Clinical Oncology2010;28(15 suppl):4592. [DOI: 10.1200/jco.2010.28.15_suppl.4592 ]KarakiewiczPI , SunM , SnellerV , et al. Use of a nomogram to quantify progression-free survival benefit in metastatic renal cell carcinoma patients receiving bevacizumab plus interferon or interferon alone. In: Genitourinary Cancers Symposium, ASCO, abstr 392. 2010. MelicharB , KoralewskiP , PluzanskaA , RavaudA , BracardaS , SzczylikC , et al. First-line bevacizumab improves progression-free survival with lower doses of interferon-α2a in the treatment of patients with metastatic renal cell carcinoma (AVOREN). European Journal of Cancer Supplements2007;5(4):304. [DOI: 10.1016/S1359-6349(07)71149-7]MelicharB , KoralewskiP , RavaudA , PluzanskaA , BracardaS , SzczylikC , et al. First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma. Annals of Oncology2008;19(8):1470-6. [PMID: 18408224]NCT00738530. A study of avastin (bevacizumab) added to interferon alfa-2a (roferon) therapy in patients with metastatic renal cell cancer with nephrectomy [A randomised, double-blind study to evaluate the efficacy and safety of avastin plus roferon compared with placebo plus roferon on overall survival and tumor assessment in nephrectomised patients with metastatic clear cell renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00738530 (first received 20 August 2008). [NCT00738530]">Escudier 2010</a>; <a href="./references#CD012796-bbs2-0018" title="CellaD , PickardAS , DuhMS , GuerinA , MishaginaN , AntràsL , et al. Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. European Journal of Cancer2012;48(3):311-23. [PMID: 21689927]HutsonTE , BukowskiRM . A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma. Clinical Genitourinary Cancer2006;4(4):296-8. [PMID: 16729915]HutsonTE , DavisID , MachielsJP , deSouzaPL , HongBF , RotteyS , et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). Journal of Clinical Oncology2007;25(18 suppl):5031. [DOI: 10.1200/jco.2007.25.18_suppl.5031]NCT00334282. Safety and efficacy of GW786034 (pazopanib) In metastatic renal cell carcinoma [A randomised, double-blind, placebo controlled, multi-center phase III study to evaluate the efficacy and safety of pazopanib (GW786034) compared to placebo in patients with locally advanced and/or metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT00334282 (first received 7 June 2006). [NCT00334282]SternbergCN , DavisID , MardiakJ , SzczylikC , LeeE , WagstaffJ , et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of Clinical Oncology2010;28(6):1061-8. [PMID: 20100962]SternbergCN , HawkinsRE , WagstaffJ , SalmanP , MardiakJ , BarriosCH , et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. European Journal of Cancer2013;49(6):1287-96. [PMID: 23321547]SternbergCN , SzczylikC , LeeE , SalmanPV , MardiakJ , DavisID , et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). Journal of Clinical Oncology2009;27(15S):5021. [DOI: 10.1200/jco.2009.27.15s.5021]">Sternberg 2010</a>); and one we rated unclear risk of bias (<a href="./references#CD012796-bbs2-0011" title="NCT00719264. Safety and efficacy of bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment in adult patients with kidney cancer [A randomized, open-label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a plus bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney]. clinicaltrials.gov/ct2/show/study/NCT00719264 (first received 21 July 2008). [NCT00719264]RavaudA , BarriosCH , AlekseevB , TayMH , AgarwalaSS , YalcinS , et al. RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. Annals of Oncology2015;26(7):1378-84. [PMID: 25851632]">Ravaud 2015</a>). The remaining trials had a high risk of bias. </p> </section> <section id="CD012796-sec-0066"> <h5 class="title">Blinding of outcome assessment</h5> <p>We rated all trials at low risk of bias for assessment of objective outcomes. Ten trials had a high risk of bias (<a href="./references#CD012796-bbs2-0001" title="EichelbergC , GoebellPJ , VervenneWL , De SantisM , Fischer von WeikersthalL , LerchenmüllerC , et al. Updated overall survival, multivariate, and Q-TWiST analyses of a randomized, sequential, open-label study (SWITCH) to evaluate the efficacy and safety of sorafenib (So)-sunitinib (Su) versus Su-So in the treatment of metastatic renal cell cancer. Annals of Oncology2014;25(suppl 4):iv290. [DOI: 10.1093/annonc/mdu337.28]EichelbergC , VervenneWL , De SantisM , Fischer von WeikersthalL , GoebellPJ , LerchenmüllerC , et al. SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer. European Urology2015;68(5):837-47. [PMID: 25952317]GoebellPJ , VervenneW , De SantisM , Fischer Von WeikersthalL , LerchenmullerCA , ZimmermannU , et al. Subgroup analyses of a randomized sequential open-label study (SWITCH) to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). Journal of Clinical Oncology2014;32(15 suppl):4567. [DOI: 10.1200/jco.2014.32.15_suppl.4567]MichelMS , VervenneW , deSantisM , Fischer von WeikersthalL , GoebellPJ , LerchenmuellerJ , et al. SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). Journal of Clinical Oncology2014;32(4 suppl):393. [DOI: 10.1200/jco.2014.32.4_suppl.393]NCT00732914. Sequential study to treat renal cell carcinoma [A phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by sunitinib versus sunitinib followed by sorafenib in the treatment of first-line advanced / metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00732914 (first received 12 August 2008). [NCT00732914]">Eichelberg 2015</a>; <a href="./references#CD012796-bbs2-0003" title="CellaD , GrunwaldV , EscudierB , HammersHJ , GeorgeS , NathanP , et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncology2019;20(2):297-310. [PMID: 30658932]EscudierB , TannirN , McDermottDF , FronteraOA , MelicharB , PlimackER , et al. CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups. Annals of Oncology2017;28(suppl 5):621-2. [DOI: 10.1093/annonc/mdx440.029]MotzerRJ , RiniBI , McDermottDF , Aren FronteraO , HammersHJ , CarducciMA , et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncology2019;S1470-2045(19):30413-9. [PMID: 31427204]MotzerRJ , TannirN , McDermottDF , FronteraOA , MelicharB , ChoueiriTK , et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. New England Journal of Medicine2018;378(14):1277-90. [PMID: 29562145]NCT02231749. Nivolumab combined with ipilimumab versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma (CheckMate 214) [A phase 3, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, advanced or metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT02231749 (first received 4 September 2014). [NCT02231749]TannirNM , HammersHJ , AminA , Grimm M-O, RiniBI , MekanS , et al. Characterization of the benefit-risk profile of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced renal cell carcinoma (aRCC; CheckMate 214). Journal of Clinical Oncology2018;28(6 suppl):686. [DOI: 10.1200/JCO.2018.36.6_suppl.686]VyasC , MotzerRJ , TannirNM , McDermottDF , FronteraOA , MelicharB , et al. Nivolumab + ipilimumab (N+I) vs sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (aRCC): results from checkmate 214, including overall survival by subgroups. Journal of Oncology Pharmacy Practice2018;24(5_suppl):17-8. ">Escudier 2017</a>; <a href="./references#CD012796-bbs2-0004" title="AlemaoE , RajagopalanS , YangS , et al. Quality adjusted survival in randomized, controlled trials: application of inverse probability weighting in renal cell cancer. In: Genitourinary Cancers Symposium, ASCO, abstr 399. 2010. ArmstrongAJ , GeorgeDJ , HalabiS . Serum lactate dehydrogenase as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2010;28(15 suppl):4361. [DOI: 10.1200/jco.2010.28.15_suppl.4631]DutcherJP , SzczylikC , TannirN , BenedettoP , RuffP , HsuA , et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon-alpha. Journal of Clinical Oncology2007;25(18 suppl):5033. [DOI: 10.1200/jco.2007.25.18_suppl.5033]DutcherJP , deSouzaP , FiglinR , et al. Effect of temsirolimus versus interferon- on survival of patients with advanced renal cell carcinoma of different histologies. In: Genitourinary Cancers Symposium, ASCO, abstr 384. 2008. DutcherJP , deSouzaP , McDermottD , FiglinRA , BerkenblitA , ThieleA , et al. Effect of temsirolimus versus interferon- on outcome of patients with advanced renal cell carcinoma of different histologies. Medical Oncology2009;26(2):202–9. [PMID: 19229667]HudesG , CarducciM , TomczakP , DutcherJ , FiglinR , KapoorA , et al. A phase 3, randomized, 3-arm study of temsirolimus or interferon alpha or the combination in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma. Journal of Clinical Oncology2006;24(18 suppl):LBA4. [DOI: 10.1200/jco.2006.24.18_suppl.lba4]HudesG , CarducciM , TomczakP , DutcherJ , FiglinR , KapoorA , et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine2007;356(22):2271–81. [PMID: 17538086]LoganT , McDermottD , DutcherJ , et al. Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features. In: Genitourinary Cancers Symposium, ASCO, abstr 281. 2009. NCT00065468. Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma (ARCC). clinicaltrials.gov/ct2/show/results/NCT00065468 (first received July 25 2003). [NCT00065468]PabloM , HudesG , DutcherJ , WhiteC , KrygowskiM , CincottaM , et al. Radiographic findings of drug-induced pneumonitis and clinical correlation inpatients with advanced renal cell carcinoma treated with temsirolimus. European Journal of Cancer Supplements2009;7(2):426-7. [DOI: 10.1016/S1359-6349(09)71446-6]ParasuramanS , HudesG , LevyD , StrahsA , MooreL , De MariniseR , et al. Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon- (IFN) or the combination of IFN+TEMSR. Journal of Clinical Oncology2007;25(18 suppl):5049. [DOI: 10.1200/jco.2007.25.18_suppl.5049]YangS , HudesG , deSouzaP , AlemaoE , StrahsA , PurvisJ . Evaluation of quality of life in patients with advanced renal cell carcinoma treated with temsirolimus vs interferon-alfa: results from a phase III randomized trial. European Journal of Cancer Supplements2009;7(2):433. [DOI: 10.1016/S1359-6349(09)71467-3]ZbrozekAS , HudesG , LevyD , StrahsA , BerkenblitA , DeMarinisR , et al. Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma. Pharmacoeconomics2010;28(7):577–84. [PMID: 20550223]">Hudes 2007</a>; <a href="./references#CD012796-bbs2-0005" title="AtkinsMB , McDermottDF , PowlesT , MotzerRJ , RiniBI , FongL , et al. IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). Journal of Clinical Oncology2017;35(15 suppl):4505. [DOI: 10.1200/JCO.2017.35.15_suppl.4505]McDermottDF , AtkinsMB , MotzerRJ , RiniBI , EscudierBJ , FongL , et al. A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). Journal of Clinical Oncology2017;35(6 suppl):431. [DOI: 10.1200/JCO.2017.35.6_suppl.431]McDermottDF , HuseniMA , AtkinsMB , MotzerRJ , RiniBI , EscudierB , et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine2018;24(6):749-57. [PMID: 29867230]NCT01984242. A study of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) as monotherapy or in combination with bevacizumab (avastin®) compared to sunitinib (Sutent®) in participants with untreated advanced renal cell carcinoma (IMmotion150) [A phase II, randomized study of atezolizumab (anti-PD-L1 antibody) administered as monotherapy or in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT01984242 (first received 14 November 2013). [NCT01984242]PalSK , McDermottDF , AtkinsMB , EscudierB , RiniBI , MotzerRJ , et al. Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. BJU Int2020;126:73-82. [DOI: 10.1111/bju.15058]PowlesT, McDermottDF , RiniB , MotzerRJ , AtkinsMB , FongL , et al. IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC). Annals of Oncology2017;28(suppl 5):624. [DOI: 10.1093/annonc/mdx440.033]">McDermott 2018</a>; <a href="./references#CD012796-bbs2-0007" title="MotzerRJ , HutsonTE , CellaD , ReevesJ , HawkinsR , GuoJ , et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. New England Journal of Medicine2013;369(8):722-1. [PMID: 23964934]MotzerRJ , HutsonTE , McCannL , DeenK , ChoueiriTK . Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. New England Journal of Medicine2014;370(18):1769-70. [PMID: 24785224]NCT00720941. Pazopanib versus sunitinib in the treatment of locally advanced and/or metastatic renal cell carcinoma (COMPARZ) [Study VEG108844, A study of pazopanib versus sunitinib in the treatment of subjects with locally advanced and/or metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00720941 (first received 23 July 2008). [NCT00720941]">Motzer 2013a</a>; <a href="./references#CD012796-bbs2-0008" title="HutsonT , NosovD , TomczakP , BondarenkoI , LipatovON , SternbergCN , et al. Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902). Journal of Clinical Oncology2015;33(15 suppl):4557. [DOI: 10.1200/jco.2015.33.15_suppl.4557]MotzerRJ , NosovD , EisenT , BondarenkoI , LesovoyV , LipatovO , et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. Journal of Clinical Oncology2013;31(30):3791-9. [PMID: 24019545]NCT01030783. A study to compare tivozanib (AV-951) to sorafenib in subjects with advanced renal cell carcinoma (TIVO-1) [A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib (AV-951) to sorafenib in subjects with advanced renal cell carcinoma (TIVO-1)]. clinicaltrials.gov/ct2/show/NCT01030783 (first received 11 December 2009). [NCT01030783]">Motzer 2013b</a>; <a href="./references#CD012796-bbs2-0009" title="KnoxJJ , BarriosCH , KimTM , CosgriffT , SrimuninnimitV , PittmanK , et al. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Annals of Oncology2017;28(6):1339-45. [PMID: 28327953]KnoxJJ , BarriosCH , KimTM , CosgriffT , SrimuninnimitV , PittmanKB , et al. Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC). Journal of Clinical Oncology2015;33(15 suppl):4554. [DOI: 10.1200/jco.2015.33.15_suppl.4554]MotzerRJ , BarriosCH , KimTM , FalconS , CosgriffT , HarkerWG , et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2014;32(25):2765-72. [PMID: 25049330]NCT00903175. Efficacy and safety comparison of RAD001 versus sunitinib in the first-line and second-line treatment of patients with metastatic renal cell carcinoma (RECORD-3) [An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as First-line followed by second-line RAD001 in the treatment of patients with metastatic renal cell carcinoma.]. clinicaltrials.gov/ct2/show/NCT00903175 (first received 18 May 2009). [NCT00903175]">Motzer 2014</a>; <a href="./references#CD012796-bbs2-0011" title="NCT00719264. Safety and efficacy of bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment in adult patients with kidney cancer [A randomized, open-label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a plus bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney]. clinicaltrials.gov/ct2/show/study/NCT00719264 (first received 21 July 2008). [NCT00719264]RavaudA , BarriosCH , AlekseevB , TayMH , AgarwalaSS , YalcinS , et al. RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. Annals of Oncology2015;26(7):1378-84. [PMID: 25851632]">Ravaud 2015</a>; <a href="./references#CD012796-bbs2-0013" title="HalabiS , RiniBI , StadlerWM , SmallEJ . Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2010;28(15 suppl):4525. [DOI: 10.1200/jco.2010.28.15_suppl.4525]HarzstarkAL , HalabiS , StadlerWM , et al. Hypertensionis associated with clinical outcome for patients with metastatic renal cell carcinoma treated with interferon and bevacizumab on CALGB 90206. In: Genitourinary Cancers Symposium, ASCO, abstr 351. 2010. NCT00072046. Interferon alfa-2b with or without bevacizumab in treating patients with advanced renal cell carcinoma (Kidney Cancer) [A randomized phase III trial of interferon alfa-2B or interferon alfa-2B plus bevacizumab in patients with advanced renal carcinoma]. clinicaltrials.gov/ct2/show/study/NCT00072046 (first received 6 November 2003). [NCT00072046]RiniBI , HalabiS , RosenbergJ , StadlerWM , VaenaDA , AtkinsJN , et al. Bevacizumab plus interferon-alfa versus interferon-alfa monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206. Journal of Clinical Oncology2009;27(18 suppl):LBA5019. [DOI: 10.1200/jco.2009.27.18_suppl.lba5019 ]RiniBI , HalabiS , RosenbergJE , StadlerWM , VaenaDA , OuSS , et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB90206. Journal of Clinical Oncology2008;26(33):5422-8. [PMID: 18936475]RiniBI , HalabiS , RosenbergJE , et al. CALGB 90206:a phase III trial of bevacizumab plus interferon-alfa versus interferon-alfa monotherapy in metastatic renal cell carcinoma. In: Genitourinary Cancers Symposium, ASCO, abstr 350. 2008. RiniBI , HalabiS , TaylorJ , SmallEJ , SchilskyRL , Cancer and Leukemia Group B . Cancerand Leukemia Group B 90206: a randomized phase III trial of interferon-a or interferon-a plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clinical Cancer Research2004;10(8):2584-6. [PMID: 15102658]">Rini 2008</a>; <a href="./references#CD012796-bbs2-0017" title="AtkinsMB , RiniBI , MotzerRJ , PowlesT , McDermottDF , SuarezC , et al. Patient-reported outcomes from the phase 3 randomized IMmotion151 trial: atezolizumab + bevacizumab vs sunitinib in treatment-naive metastatic renal cell carcinoma. Clinical Cancer Research2020;26(11):2506-2514. EscudierB , MotzerRJ , RiniBI , PowlesT , McDermottDF , SuarezC , et al. Patient-reported outcomes (PROs) in IMmotion151: atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2018;36(15_suppl):4511. [DOI: 10.1200/JCO.2018.36.15_suppl.4511]MotzerRJ , PowlesT , AtkinsMB , EscudierB , McDermottDF , SuarezC , et al. IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2018;36(6 suppl):578. [DOI: 10.1200/JCO.2018.36.6_suppl.578]NCT02420821. A study of atezolizumab in combination with bevacizumab versus sunitinib in participants with untreated advanced renal cell carcinoma (RCC) (IMmotion151) [A phase III, open-label, randomized study of atezolizumab (Anti-PD-L1 Antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT02420821 (first received 20 April 2015). [NCT02420821]RiniBI , PowlesT , AtkinsMB , EscudierB , McDermottDF , SuarezC , et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet2019;393(10189):2404-15. [PMID: 31079938]">Rini 2019b</a>); one we rated unclear risk of bias (<a href="./references#CD012796-bbs2-0012" title="NCT01613846. Phase III sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma (SWITCH-II) [Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT01613846 (first received 7 June 2012). [NCT01613846]RetzM , BedkeJ , BögemannM , GrimmMO , ZimmermannU , MüllerL , et al. SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). European Journal of Cancer2019;107:37-45. [PMID: 30529901]RetzM , BedkeJ, HerrmannE , GrimmM , ZimmermannU , MüllerL , et al. Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib sorafenib in the treatment of metastatic renal cell carcinoma(SWITCH-II). Annals of Oncology2017;28(suppl 5):295. [DOI: 10.1093/annonc/mdx371]">Retz 2019</a>); and seven had a low risk of bias for subjective outcomes. </p> </section> </section> <section id="CD012796-sec-0067"> <h4 class="title">Incomplete outcome data</h4> <p>All studies had a low risk of bias for OS and PFS. One trial we judged to have a high risk of bias for tumour response data (<a href="./references#CD012796-bbs2-0004" title="AlemaoE , RajagopalanS , YangS , et al. Quality adjusted survival in randomized, controlled trials: application of inverse probability weighting in renal cell cancer. In: Genitourinary Cancers Symposium, ASCO, abstr 399. 2010. ArmstrongAJ , GeorgeDJ , HalabiS . Serum lactate dehydrogenase as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2010;28(15 suppl):4361. [DOI: 10.1200/jco.2010.28.15_suppl.4631]DutcherJP , SzczylikC , TannirN , BenedettoP , RuffP , HsuA , et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon-alpha. Journal of Clinical Oncology2007;25(18 suppl):5033. [DOI: 10.1200/jco.2007.25.18_suppl.5033]DutcherJP , deSouzaP , FiglinR , et al. Effect of temsirolimus versus interferon- on survival of patients with advanced renal cell carcinoma of different histologies. In: Genitourinary Cancers Symposium, ASCO, abstr 384. 2008. DutcherJP , deSouzaP , McDermottD , FiglinRA , BerkenblitA , ThieleA , et al. Effect of temsirolimus versus interferon- on outcome of patients with advanced renal cell carcinoma of different histologies. Medical Oncology2009;26(2):202–9. [PMID: 19229667]HudesG , CarducciM , TomczakP , DutcherJ , FiglinR , KapoorA , et al. A phase 3, randomized, 3-arm study of temsirolimus or interferon alpha or the combination in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma. Journal of Clinical Oncology2006;24(18 suppl):LBA4. [DOI: 10.1200/jco.2006.24.18_suppl.lba4]HudesG , CarducciM , TomczakP , DutcherJ , FiglinR , KapoorA , et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine2007;356(22):2271–81. [PMID: 17538086]LoganT , McDermottD , DutcherJ , et al. Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features. In: Genitourinary Cancers Symposium, ASCO, abstr 281. 2009. NCT00065468. Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma (ARCC). clinicaltrials.gov/ct2/show/results/NCT00065468 (first received July 25 2003). [NCT00065468]PabloM , HudesG , DutcherJ , WhiteC , KrygowskiM , CincottaM , et al. Radiographic findings of drug-induced pneumonitis and clinical correlation inpatients with advanced renal cell carcinoma treated with temsirolimus. European Journal of Cancer Supplements2009;7(2):426-7. [DOI: 10.1016/S1359-6349(09)71446-6]ParasuramanS , HudesG , LevyD , StrahsA , MooreL , De MariniseR , et al. Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon- (IFN) or the combination of IFN+TEMSR. Journal of Clinical Oncology2007;25(18 suppl):5049. [DOI: 10.1200/jco.2007.25.18_suppl.5049]YangS , HudesG , deSouzaP , AlemaoE , StrahsA , PurvisJ . Evaluation of quality of life in patients with advanced renal cell carcinoma treated with temsirolimus vs interferon-alfa: results from a phase III randomized trial. European Journal of Cancer Supplements2009;7(2):433. [DOI: 10.1016/S1359-6349(09)71467-3]ZbrozekAS , HudesG , LevyD , StrahsA , BerkenblitA , DeMarinisR , et al. Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma. Pharmacoeconomics2010;28(7):577–84. [PMID: 20550223]">Hudes 2007</a>); the remaining trials we judged as low risk of bias. For QoL, we rated four trials as unclear risk of bias (<a href="./references#CD012796-bbs2-0003" title="CellaD , GrunwaldV , EscudierB , HammersHJ , GeorgeS , NathanP , et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncology2019;20(2):297-310. [PMID: 30658932]EscudierB , TannirN , McDermottDF , FronteraOA , MelicharB , PlimackER , et al. CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups. Annals of Oncology2017;28(suppl 5):621-2. [DOI: 10.1093/annonc/mdx440.029]MotzerRJ , RiniBI , McDermottDF , Aren FronteraO , HammersHJ , CarducciMA , et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncology2019;S1470-2045(19):30413-9. [PMID: 31427204]MotzerRJ , TannirN , McDermottDF , FronteraOA , MelicharB , ChoueiriTK , et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. New England Journal of Medicine2018;378(14):1277-90. [PMID: 29562145]NCT02231749. Nivolumab combined with ipilimumab versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma (CheckMate 214) [A phase 3, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, advanced or metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT02231749 (first received 4 September 2014). [NCT02231749]TannirNM , HammersHJ , AminA , Grimm M-O, RiniBI , MekanS , et al. Characterization of the benefit-risk profile of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced renal cell carcinoma (aRCC; CheckMate 214). Journal of Clinical Oncology2018;28(6 suppl):686. [DOI: 10.1200/JCO.2018.36.6_suppl.686]VyasC , MotzerRJ , TannirNM , McDermottDF , FronteraOA , MelicharB , et al. Nivolumab + ipilimumab (N+I) vs sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (aRCC): results from checkmate 214, including overall survival by subgroups. Journal of Oncology Pharmacy Practice2018;24(5_suppl):17-8. ">Escudier 2017</a>; <a href="./references#CD012796-bbs2-0006" title="CastellanoD , delMuroXG , Pérez-GraciaJL , González-LarribaJL , AbrioMV , RuizMA , et al. Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population. Annals of Oncology2009;20(11):1803-12. [PMID: 19549706]CellaD , CappelleriJC , BushmakinA , CharbonneauC , LiJZ , KimST , et al. Quality of life predicts progression-free survival in patients with renal cell carcinoma treated with sunitinib versus interferon alfa. Journal of Oncology Practice2009;5(2):66-70. [PMID: 20856722]CellaD , LiJZ , CappelariJC , BushmakinA , CharbonneauC , KimST , et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. Journal of Clinical Oncology2008;26(22):3763-9. [PMID: 18669464]CellaD , LiJZ , CappelleriJC , BushmakinA , CharbonneauC , KimST , ChenI , et al. Quality of life (QOL) predicts for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib compared to interferon-alpha (IFN-α). Journal of Clinical Oncology2007;25(18 suppl):6594. [DOI: 10.1200/jco.2007.25.18_suppl.6594]CellaD , MichaelsonMD , BushmakinAG , CappelleriJC , CharbonneauC , KimST , et al. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-a in a phase III trial: final results and geographical analysis. British Journal of Cancer2010;102(4):658-64. [PMID: 20104222]FiginRA , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , NegrierS , et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2008;26(15 suppl):5024. [DOI: 10.1200/jco.2008.26.15_suppl.5024]MotzerRJ , BukowskiRM , FiglinRA , HutsonTE , MichaelsonMD , KimST , et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer2008;113(7):1552-8. [PMID: 18720362]MotzerRJ , FiglinRA , HutsonTE , TomczakP , BukowskiRM , RixeO , et al. Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors. Journal of Clinical Oncology2007;25(18 suppl):5024. [DOI: 10.1200/jco.2007.25.18_suppl.5024]MotzerRJ , FiglinRA , HutsonTE , TomczakP , BukowskiRM , RixeO , et al. Sunitinib versus interferon-alfa as first-line treatment of metastatic renal cell carcinoma: updated results and analysis of prognostic factors. In: www.asco.org/virtual meeting. 2007. MotzerRJ , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , OudardS , et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2009;27(22):3584-90. [PMID: 19487381]MotzerRJ , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , RixeO , et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2006;24(18 suppl):LBA3. [DOI: 10.1200/jco.2006.24.18_suppl.lba3]MotzerRJ , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , RixeO , et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine2007;356(2):115-24. [PMID: 17215529]MotzerRJ , MichaelsonMD , HutsonTE , TomczakP , BukowskiRM , RixeO , et al. Sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors. European Journal of Cancer Supplements2007;5(4):301. [DOI: 10.1016/S1359-6349(07)71140-0]NCT00083889. SU011248 versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma [A phase 3, randomized study of SU011248 versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00083889 (first received 4 June 2004). [NCT00083889]PatilS , FiglinRA , HutsonTE , MichaelsonD , NegrierS , KimST , et al. TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-α). Journal of Clinical Oncology2010;28(15 suppl):4594. [DOI: 10.1200/jco.2010.28.15_suppl.4594]WilkersonJ , SteinWD , KimST , HuangX , MotzerRJ , FojoAT , et al. Validation of kinetic analysis of renal cancer regression and growth following treatment with sunitinib and interferon-alfa: analysis of the pivotal randomized trial. Journal of Clinical Oncology2010;28(15 suppl):4597. [DOI: 10.1200/jco.2010.28.15_suppl.4597]">Motzer 2010</a>; <a href="./references#CD012796-bbs2-0011" title="NCT00719264. Safety and efficacy of bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment in adult patients with kidney cancer [A randomized, open-label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a plus bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney]. clinicaltrials.gov/ct2/show/study/NCT00719264 (first received 21 July 2008). [NCT00719264]RavaudA , BarriosCH , AlekseevB , TayMH , AgarwalaSS , YalcinS , et al. RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. Annals of Oncology2015;26(7):1378-84. [PMID: 25851632]">Ravaud 2015</a>; <a href="./references#CD012796-bbs2-0017" title="AtkinsMB , RiniBI , MotzerRJ , PowlesT , McDermottDF , SuarezC , et al. Patient-reported outcomes from the phase 3 randomized IMmotion151 trial: atezolizumab + bevacizumab vs sunitinib in treatment-naive metastatic renal cell carcinoma. Clinical Cancer Research2020;26(11):2506-2514. EscudierB , MotzerRJ , RiniBI , PowlesT , McDermottDF , SuarezC , et al. Patient-reported outcomes (PROs) in IMmotion151: atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2018;36(15_suppl):4511. [DOI: 10.1200/JCO.2018.36.15_suppl.4511]MotzerRJ , PowlesT , AtkinsMB , EscudierB , McDermottDF , SuarezC , et al. IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2018;36(6 suppl):578. [DOI: 10.1200/JCO.2018.36.6_suppl.578]NCT02420821. A study of atezolizumab in combination with bevacizumab versus sunitinib in participants with untreated advanced renal cell carcinoma (RCC) (IMmotion151) [A phase III, open-label, randomized study of atezolizumab (Anti-PD-L1 Antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT02420821 (first received 20 April 2015). [NCT02420821]RiniBI , PowlesT , AtkinsMB , EscudierB , McDermottDF , SuarezC , et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet2019;393(10189):2404-15. [PMID: 31079938]">Rini 2019b</a>); three trials at high risk of bias (<a href="./references#CD012796-bbs2-0004" title="AlemaoE , RajagopalanS , YangS , et al. Quality adjusted survival in randomized, controlled trials: application of inverse probability weighting in renal cell cancer. In: Genitourinary Cancers Symposium, ASCO, abstr 399. 2010. ArmstrongAJ , GeorgeDJ , HalabiS . Serum lactate dehydrogenase as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2010;28(15 suppl):4361. [DOI: 10.1200/jco.2010.28.15_suppl.4631]DutcherJP , SzczylikC , TannirN , BenedettoP , RuffP , HsuA , et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon-alpha. Journal of Clinical Oncology2007;25(18 suppl):5033. [DOI: 10.1200/jco.2007.25.18_suppl.5033]DutcherJP , deSouzaP , FiglinR , et al. Effect of temsirolimus versus interferon- on survival of patients with advanced renal cell carcinoma of different histologies. In: Genitourinary Cancers Symposium, ASCO, abstr 384. 2008. DutcherJP , deSouzaP , McDermottD , FiglinRA , BerkenblitA , ThieleA , et al. Effect of temsirolimus versus interferon- on outcome of patients with advanced renal cell carcinoma of different histologies. Medical Oncology2009;26(2):202–9. [PMID: 19229667]HudesG , CarducciM , TomczakP , DutcherJ , FiglinR , KapoorA , et al. A phase 3, randomized, 3-arm study of temsirolimus or interferon alpha or the combination in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma. Journal of Clinical Oncology2006;24(18 suppl):LBA4. [DOI: 10.1200/jco.2006.24.18_suppl.lba4]HudesG , CarducciM , TomczakP , DutcherJ , FiglinR , KapoorA , et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine2007;356(22):2271–81. [PMID: 17538086]LoganT , McDermottD , DutcherJ , et al. Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features. In: Genitourinary Cancers Symposium, ASCO, abstr 281. 2009. NCT00065468. Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma (ARCC). clinicaltrials.gov/ct2/show/results/NCT00065468 (first received July 25 2003). [NCT00065468]PabloM , HudesG , DutcherJ , WhiteC , KrygowskiM , CincottaM , et al. Radiographic findings of drug-induced pneumonitis and clinical correlation inpatients with advanced renal cell carcinoma treated with temsirolimus. European Journal of Cancer Supplements2009;7(2):426-7. [DOI: 10.1016/S1359-6349(09)71446-6]ParasuramanS , HudesG , LevyD , StrahsA , MooreL , De MariniseR , et al. Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon- (IFN) or the combination of IFN+TEMSR. Journal of Clinical Oncology2007;25(18 suppl):5049. [DOI: 10.1200/jco.2007.25.18_suppl.5049]YangS , HudesG , deSouzaP , AlemaoE , StrahsA , PurvisJ . Evaluation of quality of life in patients with advanced renal cell carcinoma treated with temsirolimus vs interferon-alfa: results from a phase III randomized trial. European Journal of Cancer Supplements2009;7(2):433. [DOI: 10.1016/S1359-6349(09)71467-3]ZbrozekAS , HudesG , LevyD , StrahsA , BerkenblitA , DeMarinisR , et al. Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma. Pharmacoeconomics2010;28(7):577–84. [PMID: 20550223]">Hudes 2007</a>; <a href="./references#CD012796-bbs2-0007" title="MotzerRJ , HutsonTE , CellaD , ReevesJ , HawkinsR , GuoJ , et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. New England Journal of Medicine2013;369(8):722-1. [PMID: 23964934]MotzerRJ , HutsonTE , McCannL , DeenK , ChoueiriTK . Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. New England Journal of Medicine2014;370(18):1769-70. [PMID: 24785224]NCT00720941. Pazopanib versus sunitinib in the treatment of locally advanced and/or metastatic renal cell carcinoma (COMPARZ) [Study VEG108844, A study of pazopanib versus sunitinib in the treatment of subjects with locally advanced and/or metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00720941 (first received 23 July 2008). [NCT00720941]">Motzer 2013a</a>; <a href="./references#CD012796-bbs2-0012" title="NCT01613846. Phase III sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma (SWITCH-II) [Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT01613846 (first received 7 June 2012). [NCT01613846]RetzM , BedkeJ , BögemannM , GrimmMO , ZimmermannU , MüllerL , et al. SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). European Journal of Cancer2019;107:37-45. [PMID: 30529901]RetzM , BedkeJ, HerrmannE , GrimmM , ZimmermannU , MüllerL , et al. Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib sorafenib in the treatment of metastatic renal cell carcinoma(SWITCH-II). Annals of Oncology2017;28(suppl 5):295. [DOI: 10.1093/annonc/mdx371]">Retz 2019</a>); five trials we judged at low risk of bias (.<a href="./references#CD012796-bbs2-0005" title="AtkinsMB , McDermottDF , PowlesT , MotzerRJ , RiniBI , FongL , et al. IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). Journal of Clinical Oncology2017;35(15 suppl):4505. [DOI: 10.1200/JCO.2017.35.15_suppl.4505]McDermottDF , AtkinsMB , MotzerRJ , RiniBI , EscudierBJ , FongL , et al. A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). Journal of Clinical Oncology2017;35(6 suppl):431. [DOI: 10.1200/JCO.2017.35.6_suppl.431]McDermottDF , HuseniMA , AtkinsMB , MotzerRJ , RiniBI , EscudierB , et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine2018;24(6):749-57. [PMID: 29867230]NCT01984242. A study of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) as monotherapy or in combination with bevacizumab (avastin®) compared to sunitinib (Sutent®) in participants with untreated advanced renal cell carcinoma (IMmotion150) [A phase II, randomized study of atezolizumab (anti-PD-L1 antibody) administered as monotherapy or in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT01984242 (first received 14 November 2013). [NCT01984242]PalSK , McDermottDF , AtkinsMB , EscudierB , RiniBI , MotzerRJ , et al. Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. BJU Int2020;126:73-82. [DOI: 10.1111/bju.15058]PowlesT, McDermottDF , RiniB , MotzerRJ , AtkinsMB , FongL , et al. IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC). Annals of Oncology2017;28(suppl 5):624. [DOI: 10.1093/annonc/mdx440.033]">McDermott 2018</a>; <a href="./references#CD012796-bbs2-0008" title="HutsonT , NosovD , TomczakP , BondarenkoI , LipatovON , SternbergCN , et al. Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902). Journal of Clinical Oncology2015;33(15 suppl):4557. [DOI: 10.1200/jco.2015.33.15_suppl.4557]MotzerRJ , NosovD , EisenT , BondarenkoI , LesovoyV , LipatovO , et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. Journal of Clinical Oncology2013;31(30):3791-9. [PMID: 24019545]NCT01030783. A study to compare tivozanib (AV-951) to sorafenib in subjects with advanced renal cell carcinoma (TIVO-1) [A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib (AV-951) to sorafenib in subjects with advanced renal cell carcinoma (TIVO-1)]. clinicaltrials.gov/ct2/show/NCT01030783 (first received 11 December 2009). [NCT01030783]">Motzer 2013b</a>; <a href="./references#CD012796-bbs2-0009" title="KnoxJJ , BarriosCH , KimTM , CosgriffT , SrimuninnimitV , PittmanK , et al. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Annals of Oncology2017;28(6):1339-45. [PMID: 28327953]KnoxJJ , BarriosCH , KimTM , CosgriffT , SrimuninnimitV , PittmanKB , et al. Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC). Journal of Clinical Oncology2015;33(15 suppl):4554. [DOI: 10.1200/jco.2015.33.15_suppl.4554]MotzerRJ , BarriosCH , KimTM , FalconS , CosgriffT , HarkerWG , et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2014;32(25):2765-72. [PMID: 25049330]NCT00903175. Efficacy and safety comparison of RAD001 versus sunitinib in the first-line and second-line treatment of patients with metastatic renal cell carcinoma (RECORD-3) [An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as First-line followed by second-line RAD001 in the treatment of patients with metastatic renal cell carcinoma.]. clinicaltrials.gov/ct2/show/NCT00903175 (first received 18 May 2009). [NCT00903175]">Motzer 2014</a>; <a href="./references#CD012796-bbs2-0014" title="NCT00631371. Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (INTORACT). linicaltrials.gov/ct2/show/NCT00631371 (first received 20 May 2019). [NCT00631371]RiniBI , BellmuntJ , ClancyJ , WangK , NiethammerAG , HariharanS , et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. Journal of Clinical Oncology2014;32(8):752-9. [PMID: 24297945]">Rini 2014</a>; <a href="./references#CD012796-bbs2-0018" title="CellaD , PickardAS , DuhMS , GuerinA , MishaginaN , AntràsL , et al. Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. European Journal of Cancer2012;48(3):311-23. [PMID: 21689927]HutsonTE , BukowskiRM . A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma. Clinical Genitourinary Cancer2006;4(4):296-8. [PMID: 16729915]HutsonTE , DavisID , MachielsJP , deSouzaPL , HongBF , RotteyS , et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). Journal of Clinical Oncology2007;25(18 suppl):5031. [DOI: 10.1200/jco.2007.25.18_suppl.5031]NCT00334282. Safety and efficacy of GW786034 (pazopanib) In metastatic renal cell carcinoma [A randomised, double-blind, placebo controlled, multi-center phase III study to evaluate the efficacy and safety of pazopanib (GW786034) compared to placebo in patients with locally advanced and/or metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT00334282 (first received 7 June 2006). [NCT00334282]SternbergCN , DavisID , MardiakJ , SzczylikC , LeeE , WagstaffJ , et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of Clinical Oncology2010;28(6):1061-8. [PMID: 20100962]SternbergCN , HawkinsRE , WagstaffJ , SalmanP , MardiakJ , BarriosCH , et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. European Journal of Cancer2013;49(6):1287-96. [PMID: 23321547]SternbergCN , SzczylikC , LeeE , SalmanPV , MardiakJ , DavisID , et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). Journal of Clinical Oncology2009;27(15S):5021. [DOI: 10.1200/jco.2009.27.15s.5021]">Sternberg 2010</a>); and the remaining trials did not assess the QoL. </p> </section> <section id="CD012796-sec-0068"> <h4 class="title">Selective reporting</h4> <p>Two studies had an unclear risk of bias (<a href="./references#CD012796-bbs2-0010" title="MotzerRJ , PenkovK , HaanenJ , RiniB , AlbigesL , CampbellMT , et al. Avelumab plus axitinib versus sunitinib for advanced renal cell carcinoma. New England Journal of Medicine2019;380(12):1103-5. [PMID: 30779531]NCT02684006. A study of avelumab with axitinib versus sunitinib in advanced renal cell cancer (JAVELIN Renal 101) [A phase 3, multinational, randomized, open-label, parallel-arm study of avelumab (MSB0010718C) in combination with axitinib (Inlyta(registered)) versus sunitinib (Sutent(registered)) monotherapy in the first-line treatment of patients with advanced renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT02684006 (first received 17 February 2016). [NCT02684006]">Motzer 2019</a>; <a href="./references#CD012796-bbs2-0012" title="NCT01613846. Phase III sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma (SWITCH-II) [Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT01613846 (first received 7 June 2012). [NCT01613846]RetzM , BedkeJ , BögemannM , GrimmMO , ZimmermannU , MüllerL , et al. SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). European Journal of Cancer2019;107:37-45. [PMID: 30529901]RetzM , BedkeJ, HerrmannE , GrimmM , ZimmermannU , MüllerL , et al. Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib sorafenib in the treatment of metastatic renal cell carcinoma(SWITCH-II). Annals of Oncology2017;28(suppl 5):295. [DOI: 10.1093/annonc/mdx371]">Retz 2019</a>); the remaining 16 we judged at low risk because both the outcomes reported and the analytic approach in the published report matched those of the predefined protocol. </p> </section> <section id="CD012796-sec-0069"> <h4 class="title">Other potential sources of bias</h4> <p>We found eight trials to have a low risk of bias (<a href="./references#CD012796-bbs2-0003" title="CellaD , GrunwaldV , EscudierB , HammersHJ , GeorgeS , NathanP , et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncology2019;20(2):297-310. [PMID: 30658932]EscudierB , TannirN , McDermottDF , FronteraOA , MelicharB , PlimackER , et al. CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups. Annals of Oncology2017;28(suppl 5):621-2. [DOI: 10.1093/annonc/mdx440.029]MotzerRJ , RiniBI , McDermottDF , Aren FronteraO , HammersHJ , CarducciMA , et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncology2019;S1470-2045(19):30413-9. [PMID: 31427204]MotzerRJ , TannirN , McDermottDF , FronteraOA , MelicharB , ChoueiriTK , et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. New England Journal of Medicine2018;378(14):1277-90. [PMID: 29562145]NCT02231749. Nivolumab combined with ipilimumab versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma (CheckMate 214) [A phase 3, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, advanced or metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT02231749 (first received 4 September 2014). [NCT02231749]TannirNM , HammersHJ , AminA , Grimm M-O, RiniBI , MekanS , et al. Characterization of the benefit-risk profile of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced renal cell carcinoma (aRCC; CheckMate 214). Journal of Clinical Oncology2018;28(6 suppl):686. [DOI: 10.1200/JCO.2018.36.6_suppl.686]VyasC , MotzerRJ , TannirNM , McDermottDF , FronteraOA , MelicharB , et al. Nivolumab + ipilimumab (N+I) vs sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (aRCC): results from checkmate 214, including overall survival by subgroups. Journal of Oncology Pharmacy Practice2018;24(5_suppl):17-8. ">Escudier 2017</a>; <a href="./references#CD012796-bbs2-0004" title="AlemaoE , RajagopalanS , YangS , et al. Quality adjusted survival in randomized, controlled trials: application of inverse probability weighting in renal cell cancer. In: Genitourinary Cancers Symposium, ASCO, abstr 399. 2010. ArmstrongAJ , GeorgeDJ , HalabiS . Serum lactate dehydrogenase as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2010;28(15 suppl):4361. [DOI: 10.1200/jco.2010.28.15_suppl.4631]DutcherJP , SzczylikC , TannirN , BenedettoP , RuffP , HsuA , et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon-alpha. Journal of Clinical Oncology2007;25(18 suppl):5033. [DOI: 10.1200/jco.2007.25.18_suppl.5033]DutcherJP , deSouzaP , FiglinR , et al. Effect of temsirolimus versus interferon- on survival of patients with advanced renal cell carcinoma of different histologies. In: Genitourinary Cancers Symposium, ASCO, abstr 384. 2008. DutcherJP , deSouzaP , McDermottD , FiglinRA , BerkenblitA , ThieleA , et al. Effect of temsirolimus versus interferon- on outcome of patients with advanced renal cell carcinoma of different histologies. Medical Oncology2009;26(2):202–9. [PMID: 19229667]HudesG , CarducciM , TomczakP , DutcherJ , FiglinR , KapoorA , et al. A phase 3, randomized, 3-arm study of temsirolimus or interferon alpha or the combination in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma. Journal of Clinical Oncology2006;24(18 suppl):LBA4. [DOI: 10.1200/jco.2006.24.18_suppl.lba4]HudesG , CarducciM , TomczakP , DutcherJ , FiglinR , KapoorA , et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine2007;356(22):2271–81. [PMID: 17538086]LoganT , McDermottD , DutcherJ , et al. Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features. In: Genitourinary Cancers Symposium, ASCO, abstr 281. 2009. NCT00065468. Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma (ARCC). clinicaltrials.gov/ct2/show/results/NCT00065468 (first received July 25 2003). [NCT00065468]PabloM , HudesG , DutcherJ , WhiteC , KrygowskiM , CincottaM , et al. Radiographic findings of drug-induced pneumonitis and clinical correlation inpatients with advanced renal cell carcinoma treated with temsirolimus. European Journal of Cancer Supplements2009;7(2):426-7. [DOI: 10.1016/S1359-6349(09)71446-6]ParasuramanS , HudesG , LevyD , StrahsA , MooreL , De MariniseR , et al. Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon- (IFN) or the combination of IFN+TEMSR. Journal of Clinical Oncology2007;25(18 suppl):5049. [DOI: 10.1200/jco.2007.25.18_suppl.5049]YangS , HudesG , deSouzaP , AlemaoE , StrahsA , PurvisJ . Evaluation of quality of life in patients with advanced renal cell carcinoma treated with temsirolimus vs interferon-alfa: results from a phase III randomized trial. European Journal of Cancer Supplements2009;7(2):433. [DOI: 10.1016/S1359-6349(09)71467-3]ZbrozekAS , HudesG , LevyD , StrahsA , BerkenblitA , DeMarinisR , et al. Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma. Pharmacoeconomics2010;28(7):577–84. [PMID: 20550223]">Hudes 2007</a>; <a href="./references#CD012796-bbs2-0010" title="MotzerRJ , PenkovK , HaanenJ , RiniB , AlbigesL , CampbellMT , et al. Avelumab plus axitinib versus sunitinib for advanced renal cell carcinoma. New England Journal of Medicine2019;380(12):1103-5. [PMID: 30779531]NCT02684006. A study of avelumab with axitinib versus sunitinib in advanced renal cell cancer (JAVELIN Renal 101) [A phase 3, multinational, randomized, open-label, parallel-arm study of avelumab (MSB0010718C) in combination with axitinib (Inlyta(registered)) versus sunitinib (Sutent(registered)) monotherapy in the first-line treatment of patients with advanced renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT02684006 (first received 17 February 2016). [NCT02684006]">Motzer 2019</a>; <a href="./references#CD012796-bbs2-0012" title="NCT01613846. Phase III sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma (SWITCH-II) [Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT01613846 (first received 7 June 2012). [NCT01613846]RetzM , BedkeJ , BögemannM , GrimmMO , ZimmermannU , MüllerL , et al. SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). European Journal of Cancer2019;107:37-45. [PMID: 30529901]RetzM , BedkeJ, HerrmannE , GrimmM , ZimmermannU , MüllerL , et al. Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib sorafenib in the treatment of metastatic renal cell carcinoma(SWITCH-II). Annals of Oncology2017;28(suppl 5):295. [DOI: 10.1093/annonc/mdx371]">Retz 2019</a>; <a href="./references#CD012796-bbs2-0013" title="HalabiS , RiniBI , StadlerWM , SmallEJ . Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2010;28(15 suppl):4525. [DOI: 10.1200/jco.2010.28.15_suppl.4525]HarzstarkAL , HalabiS , StadlerWM , et al. Hypertensionis associated with clinical outcome for patients with metastatic renal cell carcinoma treated with interferon and bevacizumab on CALGB 90206. In: Genitourinary Cancers Symposium, ASCO, abstr 351. 2010. NCT00072046. Interferon alfa-2b with or without bevacizumab in treating patients with advanced renal cell carcinoma (Kidney Cancer) [A randomized phase III trial of interferon alfa-2B or interferon alfa-2B plus bevacizumab in patients with advanced renal carcinoma]. clinicaltrials.gov/ct2/show/study/NCT00072046 (first received 6 November 2003). [NCT00072046]RiniBI , HalabiS , RosenbergJ , StadlerWM , VaenaDA , AtkinsJN , et al. Bevacizumab plus interferon-alfa versus interferon-alfa monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206. Journal of Clinical Oncology2009;27(18 suppl):LBA5019. [DOI: 10.1200/jco.2009.27.18_suppl.lba5019 ]RiniBI , HalabiS , RosenbergJE , StadlerWM , VaenaDA , OuSS , et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB90206. Journal of Clinical Oncology2008;26(33):5422-8. [PMID: 18936475]RiniBI , HalabiS , RosenbergJE , et al. CALGB 90206:a phase III trial of bevacizumab plus interferon-alfa versus interferon-alfa monotherapy in metastatic renal cell carcinoma. In: Genitourinary Cancers Symposium, ASCO, abstr 350. 2008. RiniBI , HalabiS , TaylorJ , SmallEJ , SchilskyRL , Cancer and Leukemia Group B . Cancerand Leukemia Group B 90206: a randomized phase III trial of interferon-a or interferon-a plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clinical Cancer Research2004;10(8):2584-6. [PMID: 15102658]">Rini 2008</a>; <a href="./references#CD012796-bbs2-0016" title="NCT02853331. Study to evaluate the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib versus sunitinib monotherapy in participants with renal cell carcinoma (MK-3475-426/KEYNOTE-426) [A phase III randomized, open-label study to evaluate efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib versus sunitinib monotherapy as a first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (KEYNOTE-426)]. clinicaltrials.gov/ct2/show/NCT02853331 (first received 2 August 2016). [NCT02853331]PowlesT , PlimackER , StusV , GafanovRA , HawkinsRE , NosovD . Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study. Journal of Clinical Oncology2019;37(7 suppl):543-543. RiniBI , PlimackER , StusV , GafanovR , HawkinsR , NosovD , et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. New England Journal of Medicine2019;380(12):1116-27. [PMID: 30779529]">Rini 2019a</a>; <a href="./references#CD012796-bbs2-0017" title="AtkinsMB , RiniBI , MotzerRJ , PowlesT , McDermottDF , SuarezC , et al. Patient-reported outcomes from the phase 3 randomized IMmotion151 trial: atezolizumab + bevacizumab vs sunitinib in treatment-naive metastatic renal cell carcinoma. Clinical Cancer Research2020;26(11):2506-2514. EscudierB , MotzerRJ , RiniBI , PowlesT , McDermottDF , SuarezC , et al. Patient-reported outcomes (PROs) in IMmotion151: atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2018;36(15_suppl):4511. [DOI: 10.1200/JCO.2018.36.15_suppl.4511]MotzerRJ , PowlesT , AtkinsMB , EscudierB , McDermottDF , SuarezC , et al. IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2018;36(6 suppl):578. [DOI: 10.1200/JCO.2018.36.6_suppl.578]NCT02420821. A study of atezolizumab in combination with bevacizumab versus sunitinib in participants with untreated advanced renal cell carcinoma (RCC) (IMmotion151) [A phase III, open-label, randomized study of atezolizumab (Anti-PD-L1 Antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT02420821 (first received 20 April 2015). [NCT02420821]RiniBI , PowlesT , AtkinsMB , EscudierB , McDermottDF , SuarezC , et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet2019;393(10189):2404-15. [PMID: 31079938]">Rini 2019b</a>; <a href="./references#CD012796-bbs2-0018" title="CellaD , PickardAS , DuhMS , GuerinA , MishaginaN , AntràsL , et al. Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. European Journal of Cancer2012;48(3):311-23. [PMID: 21689927]HutsonTE , BukowskiRM . A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma. Clinical Genitourinary Cancer2006;4(4):296-8. [PMID: 16729915]HutsonTE , DavisID , MachielsJP , deSouzaPL , HongBF , RotteyS , et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). Journal of Clinical Oncology2007;25(18 suppl):5031. [DOI: 10.1200/jco.2007.25.18_suppl.5031]NCT00334282. Safety and efficacy of GW786034 (pazopanib) In metastatic renal cell carcinoma [A randomised, double-blind, placebo controlled, multi-center phase III study to evaluate the efficacy and safety of pazopanib (GW786034) compared to placebo in patients with locally advanced and/or metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT00334282 (first received 7 June 2006). [NCT00334282]SternbergCN , DavisID , MardiakJ , SzczylikC , LeeE , WagstaffJ , et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of Clinical Oncology2010;28(6):1061-8. [PMID: 20100962]SternbergCN , HawkinsRE , WagstaffJ , SalmanP , MardiakJ , BarriosCH , et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. European Journal of Cancer2013;49(6):1287-96. [PMID: 23321547]SternbergCN , SzczylikC , LeeE , SalmanPV , MardiakJ , DavisID , et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). Journal of Clinical Oncology2009;27(15S):5021. [DOI: 10.1200/jco.2009.27.15s.5021]">Sternberg 2010</a>); six trials we rated unclear risk of bias (<a href="./references#CD012796-bbs2-0001" title="EichelbergC , GoebellPJ , VervenneWL , De SantisM , Fischer von WeikersthalL , LerchenmüllerC , et al. Updated overall survival, multivariate, and Q-TWiST analyses of a randomized, sequential, open-label study (SWITCH) to evaluate the efficacy and safety of sorafenib (So)-sunitinib (Su) versus Su-So in the treatment of metastatic renal cell cancer. Annals of Oncology2014;25(suppl 4):iv290. [DOI: 10.1093/annonc/mdu337.28]EichelbergC , VervenneWL , De SantisM , Fischer von WeikersthalL , GoebellPJ , LerchenmüllerC , et al. SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer. European Urology2015;68(5):837-47. [PMID: 25952317]GoebellPJ , VervenneW , De SantisM , Fischer Von WeikersthalL , LerchenmullerCA , ZimmermannU , et al. Subgroup analyses of a randomized sequential open-label study (SWITCH) to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). Journal of Clinical Oncology2014;32(15 suppl):4567. [DOI: 10.1200/jco.2014.32.15_suppl.4567]MichelMS , VervenneW , deSantisM , Fischer von WeikersthalL , GoebellPJ , LerchenmuellerJ , et al. SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). Journal of Clinical Oncology2014;32(4 suppl):393. [DOI: 10.1200/jco.2014.32.4_suppl.393]NCT00732914. Sequential study to treat renal cell carcinoma [A phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by sunitinib versus sunitinib followed by sorafenib in the treatment of first-line advanced / metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00732914 (first received 12 August 2008). [NCT00732914]">Eichelberg 2015</a>; <a href="./references#CD012796-bbs2-0002" title="BajettaE , RavaudA , BracardaS , NégrierS , SzczylikC , BellmuntJ , et al. Efficacy and safety of first-line bevacizumab (BEV) plus interferon-α2a (IFN) in patients (pts) ≥65 years with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2008;26(15 suppl):5095. [DOI: 10.1200/jco.2008.26.15_suppl.5095]BellmuntJ , MelicharB , BracardaS , NegrierSN , RavaudA , LaeufleR , et al. Bevacizumab (BEV) and interferon (IFN) therapy does not increase risk of cardiac events in metastatic renal cell carcinoma(mRCC). European Journal of Cancer Supplements2009;7(2):429. [DOI: 10.1016/S1359-6349(09)71454-5]BracardaS , BellmuntJ , NegrierSN , MelicharB , RavaudA , JethwaS , et al. What is the impact of subsequent antineoplastic therapy on overall survival (OS) following first-line bevacizumab (BEV)/interferonalpha2a (IFN) in metastatic renal cell carcinoma (mRCC)? – Experience from AVOREN. European Journal of Cancer Supplements2009;7(2):431. [DOI: 10.1016/S1359-6349(09)71459-4]BracardaS , KoralewskiP , PluzanskaA , RavaudA , SzczylikC , ChevreauC , et al. Bevacizumab/interferon-alpha2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN). European Journal of Cancer Supplements2007;5(4):281-2. [DOI: 10.1016/S1359-6349(07)71076-5]EscudierB , KoralewskiP , PluzanskaA , RavaudA , BracardaS , SzczylikC , et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma. Journal of Clinical Oncology2007;25(18 suppl):3. [DOI: 10.1200/jco.2007.25.18_suppl.3]EscudierB , PluzanskaA , KoralewskiP , RavaudA , BracardaS , SzczylikC , et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized double-blind phase III trial. Lancet2007;370(9605):2103-11. [PMID: 18156031]EscudierBB , BellmuntJ , NegrierS , BajettaE , MelicharB , BracardaS , et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. Journal of Clinical Oncology2010;28(13):2144-50. [PMID: 20368553]EscudierBJ , BellmuntJ , NegrierS , MelicharB , BracardaS , RavaudA , et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2009;27(15 suppl):5020. [DOI: 10.1200/jco.2009.27.15_suppl.5020]EscudierBJ , NegrierS , ChevreauC , et al. Analysis of prognostic risk categories in the phase III AVOREN trial of first-line bevacizumab plus interferon-α2a in patients with metastatic renal cell carcinoma: French prognostic scoring system. In: Genitourinary Cancers Symposium, ASCO, abst 417. 2010. EscudierBJ , RavaudA , NegrierS , SzczylikC , BellmuntJ , BracardaS , et al. Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis. Journal of Clinical Oncology2008;26(15 suppl):5025. [DOI: 10.1200/jco.2008.26.15_suppl.5025]KarakiewiczP , SunM , SnellerV , EscudierB . Use of a nomogram to quantify overall survival (OS) benefit in patients with metastatic renal cell carcinoma receiving bevacizumab (BEV) with interferon (IFN) versus IFN alone. Journal of Clinical Oncology2010;28(15 suppl):4592. [DOI: 10.1200/jco.2010.28.15_suppl.4592 ]KarakiewiczPI , SunM , SnellerV , et al. Use of a nomogram to quantify progression-free survival benefit in metastatic renal cell carcinoma patients receiving bevacizumab plus interferon or interferon alone. In: Genitourinary Cancers Symposium, ASCO, abstr 392. 2010. MelicharB , KoralewskiP , PluzanskaA , RavaudA , BracardaS , SzczylikC , et al. First-line bevacizumab improves progression-free survival with lower doses of interferon-α2a in the treatment of patients with metastatic renal cell carcinoma (AVOREN). European Journal of Cancer Supplements2007;5(4):304. [DOI: 10.1016/S1359-6349(07)71149-7]MelicharB , KoralewskiP , RavaudA , PluzanskaA , BracardaS , SzczylikC , et al. First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma. Annals of Oncology2008;19(8):1470-6. [PMID: 18408224]NCT00738530. A study of avastin (bevacizumab) added to interferon alfa-2a (roferon) therapy in patients with metastatic renal cell cancer with nephrectomy [A randomised, double-blind study to evaluate the efficacy and safety of avastin plus roferon compared with placebo plus roferon on overall survival and tumor assessment in nephrectomised patients with metastatic clear cell renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00738530 (first received 20 August 2008). [NCT00738530]">Escudier 2010</a>; <a href="./references#CD012796-bbs2-0005" title="AtkinsMB , McDermottDF , PowlesT , MotzerRJ , RiniBI , FongL , et al. IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). Journal of Clinical Oncology2017;35(15 suppl):4505. [DOI: 10.1200/JCO.2017.35.15_suppl.4505]McDermottDF , AtkinsMB , MotzerRJ , RiniBI , EscudierBJ , FongL , et al. A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). Journal of Clinical Oncology2017;35(6 suppl):431. [DOI: 10.1200/JCO.2017.35.6_suppl.431]McDermottDF , HuseniMA , AtkinsMB , MotzerRJ , RiniBI , EscudierB , et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine2018;24(6):749-57. [PMID: 29867230]NCT01984242. A study of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) as monotherapy or in combination with bevacizumab (avastin®) compared to sunitinib (Sutent®) in participants with untreated advanced renal cell carcinoma (IMmotion150) [A phase II, randomized study of atezolizumab (anti-PD-L1 antibody) administered as monotherapy or in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT01984242 (first received 14 November 2013). [NCT01984242]PalSK , McDermottDF , AtkinsMB , EscudierB , RiniBI , MotzerRJ , et al. Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. BJU Int2020;126:73-82. [DOI: 10.1111/bju.15058]PowlesT, McDermottDF , RiniB , MotzerRJ , AtkinsMB , FongL , et al. IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC). Annals of Oncology2017;28(suppl 5):624. [DOI: 10.1093/annonc/mdx440.033]">McDermott 2018</a>; <a href="./references#CD012796-bbs2-0007" title="MotzerRJ , HutsonTE , CellaD , ReevesJ , HawkinsR , GuoJ , et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. New England Journal of Medicine2013;369(8):722-1. [PMID: 23964934]MotzerRJ , HutsonTE , McCannL , DeenK , ChoueiriTK . Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. New England Journal of Medicine2014;370(18):1769-70. [PMID: 24785224]NCT00720941. Pazopanib versus sunitinib in the treatment of locally advanced and/or metastatic renal cell carcinoma (COMPARZ) [Study VEG108844, A study of pazopanib versus sunitinib in the treatment of subjects with locally advanced and/or metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00720941 (first received 23 July 2008). [NCT00720941]">Motzer 2013a</a>; <a href="./references#CD012796-bbs2-0011" title="NCT00719264. Safety and efficacy of bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment in adult patients with kidney cancer [A randomized, open-label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a plus bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney]. clinicaltrials.gov/ct2/show/study/NCT00719264 (first received 21 July 2008). [NCT00719264]RavaudA , BarriosCH , AlekseevB , TayMH , AgarwalaSS , YalcinS , et al. RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. Annals of Oncology2015;26(7):1378-84. [PMID: 25851632]">Ravaud 2015</a>; <a href="./references#CD012796-bbs2-0014" title="NCT00631371. Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (INTORACT). linicaltrials.gov/ct2/show/NCT00631371 (first received 20 May 2019). [NCT00631371]RiniBI , BellmuntJ , ClancyJ , WangK , NiethammerAG , HariharanS , et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. Journal of Clinical Oncology2014;32(8):752-9. [PMID: 24297945]">Rini 2014</a>); and four studies had a high risk of bias (<a href="./references#CD012796-bbs2-0006" title="CastellanoD , delMuroXG , Pérez-GraciaJL , González-LarribaJL , AbrioMV , RuizMA , et al. Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population. Annals of Oncology2009;20(11):1803-12. [PMID: 19549706]CellaD , CappelleriJC , BushmakinA , CharbonneauC , LiJZ , KimST , et al. Quality of life predicts progression-free survival in patients with renal cell carcinoma treated with sunitinib versus interferon alfa. Journal of Oncology Practice2009;5(2):66-70. [PMID: 20856722]CellaD , LiJZ , CappelariJC , BushmakinA , CharbonneauC , KimST , et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. Journal of Clinical Oncology2008;26(22):3763-9. [PMID: 18669464]CellaD , LiJZ , CappelleriJC , BushmakinA , CharbonneauC , KimST , ChenI , et al. Quality of life (QOL) predicts for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib compared to interferon-alpha (IFN-α). Journal of Clinical Oncology2007;25(18 suppl):6594. [DOI: 10.1200/jco.2007.25.18_suppl.6594]CellaD , MichaelsonMD , BushmakinAG , CappelleriJC , CharbonneauC , KimST , et al. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-a in a phase III trial: final results and geographical analysis. British Journal of Cancer2010;102(4):658-64. [PMID: 20104222]FiginRA , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , NegrierS , et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2008;26(15 suppl):5024. [DOI: 10.1200/jco.2008.26.15_suppl.5024]MotzerRJ , BukowskiRM , FiglinRA , HutsonTE , MichaelsonMD , KimST , et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer2008;113(7):1552-8. [PMID: 18720362]MotzerRJ , FiglinRA , HutsonTE , TomczakP , BukowskiRM , RixeO , et al. Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors. Journal of Clinical Oncology2007;25(18 suppl):5024. [DOI: 10.1200/jco.2007.25.18_suppl.5024]MotzerRJ , FiglinRA , HutsonTE , TomczakP , BukowskiRM , RixeO , et al. Sunitinib versus interferon-alfa as first-line treatment of metastatic renal cell carcinoma: updated results and analysis of prognostic factors. In: www.asco.org/virtual meeting. 2007. MotzerRJ , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , OudardS , et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2009;27(22):3584-90. [PMID: 19487381]MotzerRJ , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , RixeO , et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2006;24(18 suppl):LBA3. [DOI: 10.1200/jco.2006.24.18_suppl.lba3]MotzerRJ , HutsonTE , TomczakP , MichaelsonMD , BukowskiRM , RixeO , et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine2007;356(2):115-24. [PMID: 17215529]MotzerRJ , MichaelsonMD , HutsonTE , TomczakP , BukowskiRM , RixeO , et al. Sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors. European Journal of Cancer Supplements2007;5(4):301. [DOI: 10.1016/S1359-6349(07)71140-0]NCT00083889. SU011248 versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma [A phase 3, randomized study of SU011248 versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00083889 (first received 4 June 2004). [NCT00083889]PatilS , FiglinRA , HutsonTE , MichaelsonD , NegrierS , KimST , et al. TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-α). Journal of Clinical Oncology2010;28(15 suppl):4594. [DOI: 10.1200/jco.2010.28.15_suppl.4594]WilkersonJ , SteinWD , KimST , HuangX , MotzerRJ , FojoAT , et al. Validation of kinetic analysis of renal cancer regression and growth following treatment with sunitinib and interferon-alfa: analysis of the pivotal randomized trial. Journal of Clinical Oncology2010;28(15 suppl):4597. [DOI: 10.1200/jco.2010.28.15_suppl.4597]">Motzer 2010</a>; <a href="./references#CD012796-bbs2-0008" title="HutsonT , NosovD , TomczakP , BondarenkoI , LipatovON , SternbergCN , et al. Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902). Journal of Clinical Oncology2015;33(15 suppl):4557. [DOI: 10.1200/jco.2015.33.15_suppl.4557]MotzerRJ , NosovD , EisenT , BondarenkoI , LesovoyV , LipatovO , et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. Journal of Clinical Oncology2013;31(30):3791-9. [PMID: 24019545]NCT01030783. A study to compare tivozanib (AV-951) to sorafenib in subjects with advanced renal cell carcinoma (TIVO-1) [A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib (AV-951) to sorafenib in subjects with advanced renal cell carcinoma (TIVO-1)]. clinicaltrials.gov/ct2/show/NCT01030783 (first received 11 December 2009). [NCT01030783]">Motzer 2013b</a>; <a href="./references#CD012796-bbs2-0009" title="KnoxJJ , BarriosCH , KimTM , CosgriffT , SrimuninnimitV , PittmanK , et al. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Annals of Oncology2017;28(6):1339-45. [PMID: 28327953]KnoxJJ , BarriosCH , KimTM , CosgriffT , SrimuninnimitV , PittmanKB , et al. Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC). Journal of Clinical Oncology2015;33(15 suppl):4554. [DOI: 10.1200/jco.2015.33.15_suppl.4554]MotzerRJ , BarriosCH , KimTM , FalconS , CosgriffT , HarkerWG , et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology2014;32(25):2765-72. [PMID: 25049330]NCT00903175. Efficacy and safety comparison of RAD001 versus sunitinib in the first-line and second-line treatment of patients with metastatic renal cell carcinoma (RECORD-3) [An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as First-line followed by second-line RAD001 in the treatment of patients with metastatic renal cell carcinoma.]. clinicaltrials.gov/ct2/show/NCT00903175 (first received 18 May 2009). [NCT00903175]">Motzer 2014</a>; <a href="./references#CD012796-bbs2-0015" title="NCT01265901. IMA901 in patients receiving sunitinib for advanced/metastatic renal cell carcinoma [A randomized, controlled phase III study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT01265901 (first received 23 December 2010). [NCT01265901]RiniBI , StenzlA , ZdrojowyR , KoganM , ShkolnikM , OudardS , et al. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncology2016;17(11):1599-611. [PMID: 27720136]">Rini 2016</a>) </p> </section> </section> <section id="CD012796-sec-0070"> <h3 class="title" id="CD012796-sec-0070">Effects of interventions</h3> <p>See: <a href="./full#CD012796-tbl-0001"><b>Summary of findings 1</b> Sorafenib compared to sunitinib (targeted agent versus targeted agent)</a>; <a href="./full#CD012796-tbl-0002"><b>Summary of findings 2</b> Pazopanib compared to sunitinib (targeted agent versus targeted agent)</a>; <a href="./full#CD012796-tbl-0003"><b>Summary of findings 3</b> Tivozanib compared to sorafenib (targeted agent versus targeted agent)</a>; <a href="./full#CD012796-tbl-0004"><b>Summary of findings 4</b> Sorafenib compared to pazopanib (targeted agent versus targeted agent)</a>; <a href="./full#CD012796-tbl-0005"><b>Summary of findings 5</b> Sunitinib compared to everolimus (targeted agent versus targeted agent)</a>; <a href="./full#CD012796-tbl-0006"><b>Summary of findings 6</b> Sunitinib compared to avelumab + axitinib (targeted agent versus immunotherapy + targeted agent)</a>; <a href="./full#CD012796-tbl-0007"><b>Summary of findings 7</b> Sunitinib compared to pembrolizumab + axitinib (targeted agent versus immunotherapy + targeted agent)</a>; <a href="./full#CD012796-tbl-0008"><b>Summary of findings 8</b> Sunitinib compared to atezolizumab + bevacizumab (targeted agent versus immunotherapy + targeted agent)</a>; <a href="./full#CD012796-tbl-0009"><b>Summary of findings 9</b> Sunitinib compared to IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted agent)</a>; <a href="./full#CD012796-tbl-0010"><b>Summary of findings 10</b> Sunitinib compared to interferon‐α (IFN‐α) (targeted agent versus classic immunotherapy)</a>; <a href="./full#CD012796-tbl-0011"><b>Summary of findings 11</b> Temsirolimus compared to IFN‐α (targeted agent versus classic immunotherapy)</a>; <a href="./full#CD012796-tbl-0012"><b>Summary of findings 12</b> Sunitinib compared to atezolizumab (targeted therapy versus immunotherapy)</a>; <a href="./full#CD012796-tbl-0013"><b>Summary of findings 13</b> Bevacizumab + IFN compared to IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)</a>; <a href="./full#CD012796-tbl-0014"><b>Summary of findings 14</b> Temsirolimus + IFN‐α compared to IFN‐α (targeted agent + classic immunotherapy versus classic immunotherapy)</a>; <a href="./full#CD012796-tbl-0015"><b>Summary of findings 15</b> Temsirolimus + bevacizumab compared to bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)</a>; <a href="./full#CD012796-tbl-0016"><b>Summary of findings 16</b> Everolimus + bevacizumab compared to IFN α‐2a + bevacizumab (targeted agent + targeted agent versus targeted agent + classic immunotherapy)</a>; <a href="./full#CD012796-tbl-0017"><b>Summary of findings 17</b> Sunitinib compared to nivolumab + ipilimumab (targeted agent versus combinations of immunotherapy)</a>; <a href="./full#CD012796-tbl-0018"><b>Summary of findings 18</b> Pazopanib compared to placebo (targeted agent versus placebo)</a> </p> <p>We performed two meta‐analyses using studies which had the same population and the same comparison (<a href="./references#CD012796-bbs2-0002" title="BajettaE , RavaudA , BracardaS , NégrierS , SzczylikC , BellmuntJ , et al. Efficacy and safety of first-line bevacizumab (BEV) plus interferon-α2a (IFN) in patients (pts) ≥65 years with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2008;26(15 suppl):5095. [DOI: 10.1200/jco.2008.26.15_suppl.5095]BellmuntJ , MelicharB , BracardaS , NegrierSN , RavaudA , LaeufleR , et al. Bevacizumab (BEV) and interferon (IFN) therapy does not increase risk of cardiac events in metastatic renal cell carcinoma(mRCC). European Journal of Cancer Supplements2009;7(2):429. [DOI: 10.1016/S1359-6349(09)71454-5]BracardaS , BellmuntJ , NegrierSN , MelicharB , RavaudA , JethwaS , et al. What is the impact of subsequent antineoplastic therapy on overall survival (OS) following first-line bevacizumab (BEV)/interferonalpha2a (IFN) in metastatic renal cell carcinoma (mRCC)? – Experience from AVOREN. European Journal of Cancer Supplements2009;7(2):431. [DOI: 10.1016/S1359-6349(09)71459-4]BracardaS , KoralewskiP , PluzanskaA , RavaudA , SzczylikC , ChevreauC , et al. Bevacizumab/interferon-alpha2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN). European Journal of Cancer Supplements2007;5(4):281-2. [DOI: 10.1016/S1359-6349(07)71076-5]EscudierB , KoralewskiP , PluzanskaA , RavaudA , BracardaS , SzczylikC , et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma. Journal of Clinical Oncology2007;25(18 suppl):3. [DOI: 10.1200/jco.2007.25.18_suppl.3]EscudierB , PluzanskaA , KoralewskiP , RavaudA , BracardaS , SzczylikC , et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized double-blind phase III trial. Lancet2007;370(9605):2103-11. [PMID: 18156031]EscudierBB , BellmuntJ , NegrierS , BajettaE , MelicharB , BracardaS , et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. Journal of Clinical Oncology2010;28(13):2144-50. [PMID: 20368553]EscudierBJ , BellmuntJ , NegrierS , MelicharB , BracardaS , RavaudA , et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2009;27(15 suppl):5020. [DOI: 10.1200/jco.2009.27.15_suppl.5020]EscudierBJ , NegrierS , ChevreauC , et al. Analysis of prognostic risk categories in the phase III AVOREN trial of first-line bevacizumab plus interferon-α2a in patients with metastatic renal cell carcinoma: French prognostic scoring system. In: Genitourinary Cancers Symposium, ASCO, abst 417. 2010. EscudierBJ , RavaudA , NegrierS , SzczylikC , BellmuntJ , BracardaS , et al. Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis. Journal of Clinical Oncology2008;26(15 suppl):5025. [DOI: 10.1200/jco.2008.26.15_suppl.5025]KarakiewiczP , SunM , SnellerV , EscudierB . Use of a nomogram to quantify overall survival (OS) benefit in patients with metastatic renal cell carcinoma receiving bevacizumab (BEV) with interferon (IFN) versus IFN alone. Journal of Clinical Oncology2010;28(15 suppl):4592. [DOI: 10.1200/jco.2010.28.15_suppl.4592 ]KarakiewiczPI , SunM , SnellerV , et al. Use of a nomogram to quantify progression-free survival benefit in metastatic renal cell carcinoma patients receiving bevacizumab plus interferon or interferon alone. In: Genitourinary Cancers Symposium, ASCO, abstr 392. 2010. MelicharB , KoralewskiP , PluzanskaA , RavaudA , BracardaS , SzczylikC , et al. First-line bevacizumab improves progression-free survival with lower doses of interferon-α2a in the treatment of patients with metastatic renal cell carcinoma (AVOREN). European Journal of Cancer Supplements2007;5(4):304. [DOI: 10.1016/S1359-6349(07)71149-7]MelicharB , KoralewskiP , RavaudA , PluzanskaA , BracardaS , SzczylikC , et al. First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma. Annals of Oncology2008;19(8):1470-6. [PMID: 18408224]NCT00738530. A study of avastin (bevacizumab) added to interferon alfa-2a (roferon) therapy in patients with metastatic renal cell cancer with nephrectomy [A randomised, double-blind study to evaluate the efficacy and safety of avastin plus roferon compared with placebo plus roferon on overall survival and tumor assessment in nephrectomised patients with metastatic clear cell renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT00738530 (first received 20 August 2008). [NCT00738530]">Escudier 2010</a>; <a href="./references#CD012796-bbs2-0005" title="AtkinsMB , McDermottDF , PowlesT , MotzerRJ , RiniBI , FongL , et al. IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). Journal of Clinical Oncology2017;35(15 suppl):4505. [DOI: 10.1200/JCO.2017.35.15_suppl.4505]McDermottDF , AtkinsMB , MotzerRJ , RiniBI , EscudierBJ , FongL , et al. A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). Journal of Clinical Oncology2017;35(6 suppl):431. [DOI: 10.1200/JCO.2017.35.6_suppl.431]McDermottDF , HuseniMA , AtkinsMB , MotzerRJ , RiniBI , EscudierB , et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine2018;24(6):749-57. [PMID: 29867230]NCT01984242. A study of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) as monotherapy or in combination with bevacizumab (avastin®) compared to sunitinib (Sutent®) in participants with untreated advanced renal cell carcinoma (IMmotion150) [A phase II, randomized study of atezolizumab (anti-PD-L1 antibody) administered as monotherapy or in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT01984242 (first received 14 November 2013). [NCT01984242]PalSK , McDermottDF , AtkinsMB , EscudierB , RiniBI , MotzerRJ , et al. Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. BJU Int2020;126:73-82. [DOI: 10.1111/bju.15058]PowlesT, McDermottDF , RiniB , MotzerRJ , AtkinsMB , FongL , et al. IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC). Annals of Oncology2017;28(suppl 5):624. [DOI: 10.1093/annonc/mdx440.033]">McDermott 2018</a>; <a href="./references#CD012796-bbs2-0013" title="HalabiS , RiniBI , StadlerWM , SmallEJ . Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2010;28(15 suppl):4525. [DOI: 10.1200/jco.2010.28.15_suppl.4525]HarzstarkAL , HalabiS , StadlerWM , et al. Hypertensionis associated with clinical outcome for patients with metastatic renal cell carcinoma treated with interferon and bevacizumab on CALGB 90206. In: Genitourinary Cancers Symposium, ASCO, abstr 351. 2010. NCT00072046. Interferon alfa-2b with or without bevacizumab in treating patients with advanced renal cell carcinoma (Kidney Cancer) [A randomized phase III trial of interferon alfa-2B or interferon alfa-2B plus bevacizumab in patients with advanced renal carcinoma]. clinicaltrials.gov/ct2/show/study/NCT00072046 (first received 6 November 2003). [NCT00072046]RiniBI , HalabiS , RosenbergJ , StadlerWM , VaenaDA , AtkinsJN , et al. Bevacizumab plus interferon-alfa versus interferon-alfa monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206. Journal of Clinical Oncology2009;27(18 suppl):LBA5019. [DOI: 10.1200/jco.2009.27.18_suppl.lba5019 ]RiniBI , HalabiS , RosenbergJE , StadlerWM , VaenaDA , OuSS , et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB90206. Journal of Clinical Oncology2008;26(33):5422-8. [PMID: 18936475]RiniBI , HalabiS , RosenbergJE , et al. CALGB 90206:a phase III trial of bevacizumab plus interferon-alfa versus interferon-alfa monotherapy in metastatic renal cell carcinoma. In: Genitourinary Cancers Symposium, ASCO, abstr 350. 2008. RiniBI , HalabiS , TaylorJ , SmallEJ , SchilskyRL , Cancer and Leukemia Group B . Cancerand Leukemia Group B 90206: a randomized phase III trial of interferon-a or interferon-a plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clinical Cancer Research2004;10(8):2584-6. [PMID: 15102658]">Rini 2008</a>; <a href="./references#CD012796-bbs2-0017" title="AtkinsMB , RiniBI , MotzerRJ , PowlesT , McDermottDF , SuarezC , et al. Patient-reported outcomes from the phase 3 randomized IMmotion151 trial: atezolizumab + bevacizumab vs sunitinib in treatment-naive metastatic renal cell carcinoma. Clinical Cancer Research2020;26(11):2506-2514. EscudierB , MotzerRJ , RiniBI , PowlesT , McDermottDF , SuarezC , et al. Patient-reported outcomes (PROs) in IMmotion151: atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2018;36(15_suppl):4511. [DOI: 10.1200/JCO.2018.36.15_suppl.4511]MotzerRJ , PowlesT , AtkinsMB , EscudierB , McDermottDF , SuarezC , et al. IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2018;36(6 suppl):578. [DOI: 10.1200/JCO.2018.36.6_suppl.578]NCT02420821. A study of atezolizumab in combination with bevacizumab versus sunitinib in participants with untreated advanced renal cell carcinoma (RCC) (IMmotion151) [A phase III, open-label, randomized study of atezolizumab (Anti-PD-L1 Antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT02420821 (first received 20 April 2015). [NCT02420821]RiniBI , PowlesT , AtkinsMB , EscudierB , McDermottDF , SuarezC , et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet2019;393(10189):2404-15. [PMID: 31079938]">Rini 2019b</a>). The remaining trials had considerable clinical heterogeneity and we judged them inappropriate for pooling of data and meta‐analysis. </p> <section id="CD012796-sec-0071"> <h4 class="title">1. Sorafenib versus sunitinib</h4> <p>Please refer to <a href="./full#CD012796-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD012796-sec-0072"> <h5 class="title">Primary outcomes</h5> <section id="CD012796-sec-0073"> <h6 class="title">Progression‐free survival (PFS)</h6> <p>Sorafenib may reduce PFS when compared to sunitinib (HR 1.19, 95% CI 0.92 to 1.53; 1 study, 365 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0004" title="">Analysis 1.1</a>) although the CI also includes the possibility of no effect. Based on a control event risk of 340 per 1000 in this trial at 10 months, this corresponds to 63 fewer participants experiencing PFS (95% CI 148 fewer to 31 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance, detection and other bias) and imprecision, given that the CI was also compatible with little to no increase in PFS. </p> </section> <section id="CD012796-sec-0074"> <h6 class="title">Overall survival (OS)</h6> <p>We are very uncertain how sorafenib compares to sunitinib for OS (HR 0.99, 95% CI 0.74 to 1.33; 1 study, 365 participants; very low‐certainty evidence; <a href="./references#CD012796-fig-0005" title="">Analysis 1.2</a>). We rated the certainty of evidence as very low due to study limitations (other bias, downgraded one level) and imprecision (downgraded two levels), given that the CI was compatible with both an appreciable reduction in OS as well as an appreciable increase in OS. </p> </section> <section id="CD012796-sec-0075"> <h6 class="title">Serious adverse events (SAEs, assessed with: CTCAE v3.0)</h6> <p>We are very uncertain how sorafenib compares to sunitinib with regard to SAEs (RR 0.99, 95% CI 0.85 to 1.14; 1 study, 353 participants; very low certainty evidence; <a href="./references#CD012796-fig-0006" title="">Analysis 1.3</a>). We rated the certainty of evidence as very low due to study limitations (performance, detection and other bias, downgraded one level) and imprecision (downgraded two levels), given that the CI was compatible with both an appreciable reduction in SAEs as well as an appreciable increase in SAEs. </p> </section> </section> <section id="CD012796-sec-0076"> <h5 class="title">Secondary outcomes</h5> <section id="CD012796-sec-0077"> <h6 class="title">Quality of life (QoL)</h6> <p>We found no studies that reported this outcome.</p> </section> <section id="CD012796-sec-0078"> <h6 class="title">Response rate (assessed with: RECIST version not reported)</h6> <p>Sorafenib may result in little to no difference in response rate as compared to sunitinib (RR 1.07, 95% CI 0.78 to 1.47; 1 study, 353 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0007" title="">Analysis 1.4</a>). Based on the control event risk of 290 per 1000 in this trial, this corresponds to 20 more response (95% CI 64 fewer to 136 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance, detection and other bias) and imprecision, given that the CI was also compatible with an appreciable increase in the response rate. </p> </section> <section id="CD012796-sec-0079"> <h6 class="title">Minor adverse events (AEs, assessed with: CTCAE v3.0)</h6> <p>Sorafenib may result in little to no difference in minor AEs as compared to sunitinib (RR 1.13, 95% CI 0.77 to 1.65; 1 study, 353 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0008" title="">Analysis 1.5</a>). Based on the control event risk of 216 per 1000 in this trial, this corresponds to 28 more minor AEs (95% CI 50 fewer to 140 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance, detection and other bias) and imprecision, given that the CI was also compatible with an appreciable increase in minor AEs. </p> </section> </section> <section id="CD012796-sec-0080"> <h5 class="title">Subgroup analysis</h5> <p>We were unable to perform any of the predefined subgroup analyses.</p> </section> <section id="CD012796-sec-0081"> <h5 class="title">Sensitivity analysis</h5> <p>We were unable to perform a sensitivity analysis because there was only one study.</p> </section> </section> <section id="CD012796-sec-0082"> <h4 class="title">2. Pazopanib versus sunitinib</h4> <p>Please refer to <a href="./full#CD012796-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD012796-sec-0083"> <h5 class="title">Primary outcomes</h5> <section id="CD012796-sec-0084"> <h6 class="title">PFS</h6> <p>Pazopanib may result in little to no difference in PFS as compared to sunitinib (HR 1.05, 95% CI 0.90 to 1.23; 1 study, 1110 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0009" title="">Analysis 2.1</a>). Based on the control event risk of 420 per 1000 in this trial at 12 months, this corresponds to 18 fewer participants experiencing PFS (95% CI 76 fewer to 38 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance, detection and other bias) and imprecision, given that the CI was also compatible with an appreciable reduction in PFS. </p> </section> <section id="CD012796-sec-0085"> <h6 class="title">OS</h6> <p>Pazopanib may result in little to no difference in OS compared to sunitinib (HR 0.92, 95% CI 0.80 to 1.06; 1 study, 1110 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0010" title="">Analysis 2.2</a>). Based on the control event risk of 550 per 1000 in this trial at 12 months, this corresponds to 27 more participants experiencing OS (95% CI 19 fewer to 70 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (other bias) and imprecision, given that the CI was also compatible with an appreciable increase in OS. </p> </section> <section id="CD012796-sec-0086"> <h6 class="title">SAEs (assessed with: CTCAE v3.0)</h6> <p>Pazopanib may result in little to no difference in SAEs as compared to sunitinib (RR 1.01, 95% CI 0.94 to 1.09; 1 study, 1102 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0011" title="">Analysis 2.3</a>). Based on the control event risk of 734 per 1000 in this trial, this corresponds to seven more participants experiencing SAEs (95% CI 44 fewer to 66 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance, detection and other bias) and imprecision, given that the CI was also compatible with an appreciable increase in SAEs.  </p> </section> </section> <section id="CD012796-sec-0087"> <h5 class="title">Secondary outcomes</h5> <section id="CD012796-sec-0088"> <h6 class="title">QoL</h6> <p>Pazopanib may increase QoL as compared to sunitinib (MD 3.60, 95% CI 1.76 to 5.44; 1 study, 467 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0012" title="">Analysis 2.4</a>) assessed with FACIT‐F (scale 0 to 52; higher scores indicating less fatigue; MCID: 3 points). We rated the certainty of evidence as low due to study limitations (performance, detection, attrition and other bias), and imprecision, given that the CI was also compatible with no increase in QoL. </p> </section> <section id="CD012796-sec-0089"> <h6 class="title">Response rate (assessed by RECIST v1.0)</h6> <p>Pazopanib may result in little to no difference in response rate as compared to sunitinib (RR 1.24, 95% CI 1.02 to 1.50; 1 study, 1110 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0013" title="">Analysis 2.5</a>). Based on the control event risk of 248 per 1000 in this trial, this corresponds to 59 more response (95% CI 5 more to 124 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance, detection and other bias) and imprecision, given that the CI was also compatible with an appreciable increase in the response rate. </p> </section> <section id="CD012796-sec-0090"> <h6 class="title">Minor AEs (assessed with: CTCAE v3.0)</h6> <p>Pazopanib probably results in little to no difference in minor AEs as compared to sunitinib (RR 1.00, 95% CI 0.81 to 1.23; 1 study, 1102 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0014" title="">Analysis 2.6</a>). Based on the control event risk of 237 per 1000 in this trial, this corresponds to no fewer minor AEs (95% CI 45 fewer to 55 more) per 1000 participants. We rated the certainty of evidence as moderate due to study limitations (performance, detection and other bias). </p> </section> </section> <section id="CD012796-sec-0091"> <h5 class="title">Subgroup analyses</h5> <p>We were unable to perform any of the predefined subgroup analyses.</p> </section> <section id="CD012796-sec-0092"> <h5 class="title">Sensitivity analyses</h5> <p>We were unable to perform a sensitivity analysis because there was only one study.</p> </section> </section> <section id="CD012796-sec-0093"> <h4 class="title">3. Tivozanib versus sorafenib </h4> <p>Please refer to <a href="./full#CD012796-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD012796-sec-0094"> <h5 class="title">Primary outcomes</h5> <section id="CD012796-sec-0095"> <h6 class="title">PFS</h6> <p>Tivozanib may extend PFS as compared to sorafenib (HR 0.79, 95% CI 0.64 to 0.99; 1 study, 517 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0015" title="">Analysis 3.1</a>). Based on the control event risk of 360 per 1000 in this trial at 12 months, this corresponds to 86 more participants experiencing PFS (95% CI 4 more to 160 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance, detection and other bias) and imprecision, given that the CI was also compatible with a little to no increase in PFS. </p> </section> <section id="CD012796-sec-0096"> <h6 class="title">OS</h6> <p>Tivozanib may reduce OS as compared to sorafenib (HR 1.25, 95% CI 0.95 to 1.64; 1 study, 517 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0016" title="">Analysis 3.2</a>) although the CI also includes the possibility of no effect. Based on the control event risk of 620 per 1000 in this trial at 24 months, this would result in 70 fewer OSs (95% CI 163 fewer to 15 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (other bias) and imprecision, given that the CI was also compatible with little to no increase in OS. </p> </section> <section id="CD012796-sec-0097"> <h6 class="title">SAEs (assessed with: CTCAE v3.0)</h6> <p>Tivozanib may reduce SAEs as compared to sorafenib (RR 0.85, 95% CI 0.74 to 0.97; 1 study, 516 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0017" title="">Analysis 3.3</a>). Based on the control event risk of 689 per 1000 in this trial, this corresponds to 103 fewer SAEs (95% CI 179 fewer to 21 fewer) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance, detection and other bias) and imprecision, given that the CI was also compatible with little to no reduction in SAEs. </p> </section> </section> <section id="CD012796-sec-0098"> <h5 class="title">Secondary outcomes</h5> <section id="CD012796-sec-0099"> <h6 class="title">QoL</h6> <p>Tivozanib may result in little to no difference in QoL (assessed with EQ‐5D; scale: −0.59 to 1; higher values reflect better QoL; MCID 0.06) as compared to sorafenib (MD 0.01, 95% CI −0.05 to 0.07; 1 study, 506 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0018" title="">Analysis 3.4</a>). We rated the certainty of evidence as low due to study limitations (performance, detection and other bias), and imprecision, given that the CI was also compatible with an increase in QoL. </p> </section> <section id="CD012796-sec-0100"> <h6 class="title">Response rate (assessed by RECIST v1.0)</h6> <p>Tivozanib may increase the response rate as compared to sorafenib (RR 1.42, 95% CI 1.07 to 1.88; 1 study, 517 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0019" title="">Analysis 3.5</a>). Based on the control event risk of 233 per 1000 in this trial, this corresponds to 98 more responses (16 more to 205 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance, detection and other bias) and imprecision, given that the CI was also compatible with little to no increase in the response rate. </p> </section> <section id="CD012796-sec-0101"> <h6 class="title">Minor AEs (assessed with: CTCAE v3.0)</h6> <p>Tivozanib may result in little to no difference in minor AEs as compared to sorafenib (RR 1.16, 95% CI 0.89 to 1.51; 1 study, 516 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0020" title="">Analysis 3.6</a>). Based on the control event risk of 280 per 1000 in this trial, this corresponds to 45 more minor AEs (95% CI 31 fewer to 143 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance, detection and other bias) and imprecision, given that the CI was also compatible with an appreciable increase in minor AEs. </p> </section> </section> <section id="CD012796-sec-0102"> <h5 class="title">Subgroup analyses</h5> <p>We were unable to perform any of the predefined subgroup analyses.</p> </section> <section id="CD012796-sec-0103"> <h5 class="title">Sensitivity analyses</h5> <p>We were unable to perform a sensitivity analyses because there was only one study.</p> </section> </section> <section id="CD012796-sec-0104"> <h4 class="title">4. Sorafenib versus pazopanib </h4> <p>Please refer to <a href="./full#CD012796-tbl-0004">summary of findings Table 4</a>. </p> <section id="CD012796-sec-0105"> <h5 class="title">Primary outcomes</h5> <section id="CD012796-sec-0106"> <h6 class="title">PFS</h6> <p>Sorafenib probably reduces PFS as compared to pazopanib (HR 1.92, 95% CI 1.74 to 2.11; 1 study, 377 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0021" title="">Analysis 4.1</a>). Based on the control event risk of 380 per 1000 in this trial at 12 months, this corresponds to 224 fewer participants experiencing PFS (95% CI 250 fewer to 194 fewer) per 1000 participants. We rated the certainty of evidence as moderate due to study limitations (selection, performance, detection, and reporting bias). </p> </section> <section id="CD012796-sec-0107"> <h6 class="title">OS</h6> <p>Sorafenib may reduce OS as compared to pazopanib (HR 1.22, 95% CI 0.91 to 1.64; 1 study, 377 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0022" title="">Analysis 4.2</a>) although the CI also includes the possibility of no effect. Based on the control event risk of 520 per 1000 in this trial at 24 months, this would result in 70 fewer OSs (95% CI 178 fewer to 32 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (selection and reporting bias) and imprecision, given that the CI was also compatible with little to no reduction in OS. </p> </section> <section id="CD012796-sec-0108"> <h6 class="title">SAEs (assessed with: CTCAE v4.03)</h6> <p>We are very uncertain how sorafenib compares to pazopanib (RR 0.92, 95% CI 0.78 to 1.09; 1 study, 366 participants; very low certainty evidence; <a href="./references#CD012796-fig-0023" title="">Analysis 4.3</a>) with regard to SAEs. We rated the certainty of evidence as very low due to study limitations (selection, performance, detection, and reporting bias, downgrade one level) and imprecision (downgrade two levels), given that the CI was compatible with both an appreciable reduction in SAEs as well as an appreciable increase in SAEs. </p> </section> </section> <section id="CD012796-sec-0109"> <h5 class="title">Secondary outcomes</h5> <section id="CD012796-sec-0110"> <h6 class="title">QoL</h6> <p>Sorafenib may increase QoL slightly (assessed with FACIT‐F; scale 0 to 52; higher scores indicating less fatigue; MCID: 3 points) as compared to pazopanib (MD 3.10, 95% CI −1.82 to 8.02; 1 study, 267 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0024" title="">Analysis 4.4</a>). We rated the certainty of evidence as low due to study limitations (selection, performance, detection, attrition and reporting bias) and imprecision, given that the CI was also compatible with no increase in QoL. </p> </section> <section id="CD012796-sec-0111"> <h6 class="title">Response rate (assessed with RECIST v1.1)</h6> <p>Sorafenib may reduce the response rate as compared to pazopanib (RR 0.62, 95% CI 0.47 to 0.81; 1 study, 377 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0025" title="">Analysis 4.5</a>). Based on the control event risk of 463 per 1000 in this trial, this corresponds to 176 fewer response (95% CI 245 fewer to 88 fewer) per 1000 participants. We rated the certainty of evidence as low due to study limitations (selection, performance, detection, and reporting bias) and imprecision, given that the CI was also compatible with no reduction in the response rate. </p> </section> <section id="CD012796-sec-0112"> <h6 class="title">Minor AEs (assessed with: CTCAE v4.03)</h6> <p>Sorafenib may result in little to no difference in minor AEs (assessed with: CTCAE v4.03) as compared to pazopanib (RR 1.15, 95% CI 0.87 to 1.52; 1 study, 366 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0026" title="">Analysis 4.6</a>). Based on the control event risk of 328 per 1000 in this trial, this corresponds to 49 more minor AEs (95% CI 43 fewer to 170 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (selection, performance, detection, and reporting bias) and imprecision, given that the CI was also compatible with an appreciable increase in minor AEs. </p> </section> </section> <section id="CD012796-sec-0113"> <h5 class="title">Subgroup analyses</h5> <p>We were unable to perform any of the predefined subgroup analyses.</p> </section> <section id="CD012796-sec-0114"> <h5 class="title">Sensitivity analyses</h5> <p>We were unable to perform a sensitivity analysis because there was only one study.</p> </section> </section> <section id="CD012796-sec-0115"> <h4 class="title">5. Sunitinib versus everolimus </h4> <p>Please refer to <a href="./full#CD012796-tbl-0005">summary of findings Table 5</a>. </p> <section id="CD012796-sec-0116"> <h5 class="title">Primary outcomes</h5> <section id="CD012796-sec-0117"> <h6 class="title">PFS</h6> <p>Sunitinib probably increases PFS as compared to everolimus (HR 0.71, 95% CI 0.59 to 0.87; 1 study, 471 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0027" title="">Analysis 5.1</a>). Based on the control event risk of 300 per 1000 in this trial at 12 months, this corresponds to 125 participants experiencing PFS (95% CI 51 more to 191 more) per 1000 participants. We rated the certainty of evidence as moderate due to study limitations (performance, detection and other bias). </p> </section> <section id="CD012796-sec-0118"> <h6 class="title">OS</h6> <p>Sunitinib may result in little to no difference in OS as compared to everolimus (HR 0.90, 95% CI 0.72 to 1.11; 1 study, 471 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0028" title="">Analysis 5.2</a>). Based on the control event risk of 470 per 1000 in this trial at 24 months, this would result in 37 more OSs (95% CI 37 fewer to 111 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (other bias) and imprecision, given that the CI was also compatible with an appreciable increase in OS. </p> </section> <section id="CD012796-sec-0119"> <h6 class="title">SAEs (assessed with: CTCAE v3.0)</h6> <p>Sunitinib probably increases SAEs as compared to everolimus (RR 1.34, 95% CI 1.14 to 1.59; 1 study, 469 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0029" title="">Analysis 5.3</a>). Based on the control event risk of 471 per 1000 in this trial, this corresponds to 160 more SAEs (95% CI 66 more to 278 more) per 1000 participants. We rated the certainty of evidence as moderate due to study limitations (performance, detection and other bias).  </p> </section> </section> <section id="CD012796-sec-0120"> <h5 class="title">Secondary outcomes</h5> <section id="CD012796-sec-0121"> <h6 class="title">QoL</h6> <p>Sunitinib may result in little to no difference in QoL (assessed with EORTC QLQ‐C30; scale: 0 to 100; high score represent better functioning, MCID: 10 points) as compared to everolimus (MD −5.00, 95% CI −10.40 to 0.40; 1 study, 288 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0030" title="">Analysis 5.4</a>). We rated the certainty of evidence as low due to study limitations (performance, detection and other bias) and imprecision, given that the CI was also compatible with a decrease in QoL. </p> </section> <section id="CD012796-sec-0122"> <h6 class="title">Response rate (assessed with RECIST v1.0)</h6> <p>Sunitinib may increase response rate as compared to everolimus (RR 3.33, 95% CI 2.06 to 5.39; 1 study, 471 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0031" title="">Analysis 5.5</a>). Based on the control event risk of 80 per 1000 in this trial, this corresponds to 186 more responses (95% CI 85 more to 350 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance, detection and other bias) and imprecision, given that the CI was also compatible with little to no increase in response rate. </p> </section> <section id="CD012796-sec-0123"> <h6 class="title">Minor AEs (assessed with: CTCAE v3.0)</h6> <p>Sunitinib probably results in little to no difference in minor AEs as compared to everolimus (RR 1.02, 95% CI 0.99 to 1.04; 1 study, 469 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0032" title="">Analysis 5.6</a>). Based on the control event risk of 971 per 1000 in this trial, this corresponds to 19 more minor AEs (95% CI 10 fewer to 39 more) per 1000 participants. We rated the certainty of evidence as moderate due to study limitations (performance, detection and other bias). </p> </section> </section> <section id="CD012796-sec-0124"> <h5 class="title">Subgroup analyses</h5> <p>We were unable to perform any of the predefined subgroup analyses.</p> </section> <section id="CD012796-sec-0125"> <h5 class="title">Sensitivity analyses</h5> <p>We were unable to perform a sensitivity analysis because there was only one study.</p> </section> </section> <section id="CD012796-sec-0126"> <h4 class="title">6. Sunitinib versus avelumab + axitinib </h4> <p>Please refer to <a href="./full#CD012796-tbl-0006">summary of findings Table 6</a>. </p> <section id="CD012796-sec-0127"> <h5 class="title">Primary outcomes</h5> <section id="CD012796-sec-0128"> <h6 class="title">PFS</h6> <p>Sunitinib probably reduces PFS as compared to avelumab plus axitinib (HR 1.45, 95% CI 1.17 to 1.80; 1 study, 886 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0033" title="">Analysis 6.1</a>). Based on the control event risk of 550 per 1000 in this trial at 12 months, this corresponds to 130 fewer participants experiencing PFS (95% CI 209 fewer to 53 fewer) per 1000 participants. We rated the certainty of evidence as moderate due to study limitations (performance bias and reporting bias). </p> </section> <section id="CD012796-sec-0129"> <h6 class="title">OS</h6> <p>Sunitinib may result in little to no difference in OS as compared to avelumab plus axitinib (HR 1.28, 95% CI 0.92 to 1.79; 1 study, 886 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0034" title="">Analysis 6.2</a>). Based on the control event risk of 890 per 1000 in this trial at 12 months, this would result in 29 fewer OSs (95% CI 78 fewer to 8 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (reporting bias) and imprecision given that the CI was also compatible with an appreciable reduction in OS. </p> </section> <section id="CD012796-sec-0130"> <h6 class="title">SAEs (assessed with: CTCAE v4.03)</h6> <p>Sunitinib may result in little to no difference in SAEs as compared to avelumab plus axitinib (RR 1.01, 95% CI 0.93 to 1.10; 1 study, 873 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0035" title="">Analysis 6.3</a>). Based on the control event risk of 705 per 1000 in this trial, this corresponds to 7 more SAEs (95% CI 49 fewer to 71 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance bias and reporting bias) and imprecision given that the CI was also compatible with an increase in SAEs. </p> </section> </section> <section id="CD012796-sec-0131"> <h5 class="title">Secondary outcomes</h5> <section id="CD012796-sec-0132"> <h6 class="title">QoL</h6> <p>We found no studies that reported this outcome.</p> </section> <section id="CD012796-sec-0133"> <h6 class="title">Response rate (assessed with: RECIST v1.1)</h6> <p>Sunitinib probably reduces the response rate as compared to avelumab plus axitinib (RR 0.50, 95% CI 0.42 to 0.60; 1 study, 886 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0036" title="">Analysis 6.4</a>). Based on the control event risk of 514 per 1000 in this trial, this corresponds to 257 fewer responses (95% CI 298 fewer to 205 fewer) per 1000 participants. We rated the certainty of evidence as moderate due to study limitations (performance bias and reporting bias). </p> </section> <section id="CD012796-sec-0134"> <h6 class="title">Minor AEs (assessed with CTCAE v4.03)</h6> <p>Sunitinib probably results in little to no difference in minor AEs as compared to avelumab plus axitinib (RR 0.97, 95% CI 0.78 to 1.19; 1 study, 873 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0037" title="">Analysis 6.5</a>). Based on the control event risk of 290 per 1000 in this trial, this corresponds to nine fewer minor AEs (95% CI 64 fewer to 55 more) per 1000 participants. We rated the certainty of evidence as moderate due to study limitations (performance bias and reporting bias) </p> </section> </section> <section id="CD012796-sec-0135"> <h5 class="title">Subgroup analyses</h5> <p>We were unable to perform any of the predefined subgroup analyses.</p> </section> <section id="CD012796-sec-0136"> <h5 class="title">Sensitivity analyses</h5> <p>We were unable to perform a sensitivity analysis because there was only one study.</p> </section> </section> <section id="CD012796-sec-0137"> <h4 class="title">7. Sunitinib versus pembrolizumab + axitinib </h4> <p>Please refer to <a href="./full#CD012796-tbl-0007">summary of findings Table 7</a>. </p> <section id="CD012796-sec-0138"> <h5 class="title">Primary outcomes</h5> <section id="CD012796-sec-0139"> <h6 class="title">PFS</h6> <p>Sunitinib probably reduces PFS as compared to pembrolizumab plus axitinib (HR 1.45, 95% CI 1.19 to 1.76; 1 study, 861 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0038" title="">Analysis 7.1</a>). Based on the control event risk of 590 per 1000 in this trial at 12 months, this corresponds to 125 fewer participants experiencing PFS (95% CI 195 fewer to 56 fewer) per 1000 participants. We rated the certainty of evidence as moderate due to study limitations (performance bias). </p> </section> <section id="CD012796-sec-0140"> <h6 class="title">OS</h6> <p>Sunitinib probably reduces OS as compared to pembrolizumab plus axitinib (HR 1.90, 95% CI 1.36 to 2.65; 1 study, 861 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0039" title="">Analysis 7.2</a>). Based on the control event risk of 880 per 1000 in this trial at 12 months, this would result in 96 fewer OSs (95% CI 167 fewer to 40 fewer) per 1000 participants. We rated the certainty of evidence as moderate due to imprecision, given that the CI was also compatible with little to no reduction in OS. </p> </section> <section id="CD012796-sec-0141"> <h6 class="title">SAEs (assessed with CTCAE v4.0)</h6> <p>Sunitinib may reduce SAEs as compared to pembrolizumab plus axitinib (RR 0.90, 95% CI 0.81 to 1.02; 1 study, 854 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0040" title="">Analysis 7.3</a>) although the CI also includes the possibility of no effect. Based on the control event risk of 604 per 1000 in this trial, this corresponds to 60 fewer SAEs (95% CI 115 fewer to 12 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance bias) and imprecision, given that the CI was also compatible with little to no increase in SAEs. </p> </section> </section> <section id="CD012796-sec-0142"> <h5 class="title">Secondary outcomes</h5> <section id="CD012796-sec-0143"> <h6 class="title">QoL</h6> <p>We found no studies that reported this outcome.</p> </section> <section id="CD012796-sec-0144"> <h6 class="title">Response rate (assessed with: RECIST v1.1)</h6> <p>Sunitinib probably reduces the response rate as compared to pembrolizumab plus axitinib (RR 0.60, 95% CI 0.52 to 0.70; 1 study, 861 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0041" title="">Analysis 7.4</a>). Based on the control event risk of 593 per 1000 in this trial, this corresponds to 237 fewer response (95% CI 284 fewer to 178 fewer) per 1000 participants. We rated the certainty of evidence as moderate due to study limitations (performance bias) </p> </section> <section id="CD012796-sec-0145"> <h6 class="title">Minor AEs (assessed with CTCAE v4.0)</h6> <p>Sunitinib may result in little to no difference in minor AEs as compared to pembrolizumab plus axitinib (RR 1.19, 95% CI 0.99 to 1.42; 1 study, 854 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0042" title="">Analysis 7.5</a>). Based on the control event risk of 333 per 1000 in this trial, this corresponds to 63 more minor AEs (95% CI 3 fewer to 140 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance bias) and imprecision, given that the CI was also compatible with an increase in minor AEs. </p> </section> </section> <section id="CD012796-sec-0146"> <h5 class="title">Subgroup analyses</h5> <p>We were unable to perform any of the predefined subgroup analyses.</p> </section> <section id="CD012796-sec-0147"> <h5 class="title">Sensitivity analyses</h5> <p>We were unable to perform a sensitivity analysis because there was only one study.</p> </section> </section> <section id="CD012796-sec-0148"> <h4 class="title">8. Sunitinib versus atezolizumab + bevacizumab</h4> <p>Please refer to <a href="./full#CD012796-tbl-0008">summary of findings Table 8</a>. </p> <section id="CD012796-sec-0149"> <h5 class="title">Primary outcomes</h5> <section id="CD012796-sec-0150"> <h6 class="title">PFS</h6> <p>Sunitinib may reduce PFS as compared to atezolizumab plus bevacizumab (HR 1.18, 95% CI 1.02 to 1.36; 2 studies, 1117 participants; I² = 0%; low‐certainty evidence; <a href="./references#CD012796-fig-0043" title="">Analysis 8.1</a>). Based on the control event risk of 480 per 1000 in this trial at 12 months, this corresponds to 59 fewer PFSs (95% CI 111 fewer to 7 fewer) per 1000 participants. We rated the certainty of evidence as low due to study limitations (high and unclear risk of one or more domains) and imprecision, given that the CI was also compatible with no reduction in PFS. </p> </section> <section id="CD012796-sec-0151"> <h6 class="title">OS</h6> <p>We are very uncertain how sunitinib compares to atezolizumab plus bevacizumab for OS (HR 0.99, 95% CI 0.73 to 1.33; 2 studies, 1117 participants; I² = 37%; very low certainty evidence; <a href="./references#CD012796-fig-0044" title="">Analysis 8.2</a>). We rated the certainty of evidence as very low due to study limitations (high and unclear risk of one or more domains, downgrade one level) and imprecision (downgrade two levels), given that the CI was compatible with an appreciable reduction in the OS as well as an appreciable increase in OS. </p> </section> <section id="CD012796-sec-0152"> <h6 class="title">SAEs (assessed with: CTCAE v4.0)</h6> <p>We are very uncertain how sunitinib compares to atezolizumab plus bevacizumab for SAEs as compared to atezolizumab + bevacizumab (RR 1.22, 95% CI 1.00 to 1.49; 2 studies, 1098 participants; I² = 64%; very low certainty evidence; <a href="./references#CD012796-fig-0045" title="">Analysis 8.3</a>). We rated the certainty of evidence as very low due to study limitations (high and unclear risk of one or more domains), inconsistency (unexplained differences between study results) and imprecision, given that the CI was compatible with no increase in SAEs as well as an appreciable increase in SAEs. </p> </section> </section> <section id="CD012796-sec-0153"> <h5 class="title">Secondary outcomes</h5> <section id="CD012796-sec-0154"> <h6 class="title">QoL</h6> <p>Sunitinib may decrease QoL (assessed with MD Anderson Symptom Inventory Interference Score (MDASI); scale 0 to 10; higher scores indicate worse QoL; MCID 1.0) as compared to atezolizumab plus bevacizumab (MD 1.00, 95% CI 0.68 to 1.32; 2 studies, 691 participants; I² = 0%; low‐certainty evidence; <a href="./references#CD012796-fig-0046" title="">Analysis 8.4</a>). We rated the certainty of evidence as low due to study limitations (high and unclear risk of one or more domains) and imprecision, given that the CI was compatible with possibly no decrease in QoL. </p> </section> <section id="CD012796-sec-0155"> <h6 class="title">Response rate (assessed with: RECIST v1.1)</h6> <p>Sunitinib probably results in little to no difference in response rate as compared to atezolizumab plus bevacizumab (RR 0.91, 95% CI 0.77 to 1.07; 2 studies, 1117 participants; I² = 0%; moderate‐certainty evidence; <a href="./references#CD012796-fig-0047" title="">Analysis 8.5</a>). Based on the control event risk of 357 per 1000 in this trial, this corresponds to 32 fewer responses (95% CI 82 fewer to 25 more) per 1000 participants. We rated the certainty of evidence as moderate due to study limitations (high and unclear risk of one or more domains). </p> </section> <section id="CD012796-sec-0156"> <h6 class="title">Minor AEs (assessed with CTCAE v4.0)</h6> <p>Sunitinib may result in little to no difference in minor AEs as compared to atezolizumab plus bevacizumab (RR 0.85, 95% CI 0.74 to 0.97; 2 studies, 1098 participants; I² = 0%; low‐certainty evidence; <a href="./references#CD012796-fig-0048" title="">Analysis 8.6</a>). Based on the control event risk of 467 per 1000 in this trial, this corresponds to 70 fewer minor AEs (95% CI 112 fewer to 14 fewer) per 1000 participants. We rated the certainty of evidence as low due to study limitations (high and unclear risk of one or more domains) and imprecision, given that the CI was also compatible with an appreciable reduction in minor AEs. </p> </section> </section> <section id="CD012796-sec-0157"> <h5 class="title">Subgroup analysis</h5> <p>We were unable to perform any of the predefined subgroup analyses.</p> </section> <section id="CD012796-sec-0158"> <h5 class="title">Sensitivity analysis</h5> <p>We rated all of the included studies as high or unclear risk of bias and were unable to perform a sensitivity analysis. </p> </section> </section> <section id="CD012796-sec-0159"> <h4 class="title">9. Sunitinib versus IMA901 + sunitinib </h4> <p>Please refer to <a href="./full#CD012796-tbl-0009">summary of findings Table 9</a>. </p> <section id="CD012796-sec-0160"> <h5 class="title">Primary outcomes</h5> <section id="CD012796-sec-0161"> <h6 class="title">PFS</h6> <p>We are very uncertain about the effect of sunitinib on PFS as compared to IMA901 plus sunitinib (HR 0.95, 95% CI 0.70 to 1.30; 1 study, 339 participants; very low certainty evidence; <a href="./references#CD012796-fig-0049" title="">Analysis 9.1</a>). We rated the certainty of evidence as very low due to study limitations (performance and other bias, downgrade one level) and imprecision (downgrade two levels), given that the CI was compatible with an appreciable reduction in PFS as well as an appreciable increase in PFS. </p> </section> <section id="CD012796-sec-0162"> <h6 class="title">OS</h6> <p>Sunitinib may result in little to no difference in OS as compared to IMA901 plus sunitinib (HR 0.75, 95% CI 0.54 to 1.04; 1 study, 339 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0050" title="">Analysis 9.2</a>). Based on the control event risk of 800 per 1000 in this trial at 12 months, this would result in 46 more OSs (95% CI 7 fewer to 86 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (other bias) and imprecision, given that the CI was also compatible with an increase in OS. </p> </section> <section id="CD012796-sec-0163"> <h6 class="title">SAEs (assessed with CTCAE v4.0)</h6> <p>Sunitinib may reduce SAEs as compared to IMA901 plus sunitinib (RR 0.74, 95% CI 0.59 to 0.95; 1 study, 334 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0051" title="">Analysis 9.3</a>). Based on the control event risk of 550 per 1000 in this trial, this corresponds to 143 fewer SAEs (95% CI 225 fewer to 27 fewer) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance and other bias) and imprecision, given that the CI was also compatible with a small to no reduction in SAEs. </p> </section> </section> <section id="CD012796-sec-0164"> <h5 class="title">Secondary outcomes</h5> <section id="CD012796-sec-0165"> <h6 class="title">QoL</h6> <p>We found no studies that reported this outcome.</p> </section> <section id="CD012796-sec-0166"> <h6 class="title">Response rate (assessed with: RECIST v1.1)</h6> <p>Sunitinib may result in little to no difference in response rate as compared to IMA901 plus sunitinib (RR 0.87, 95% CI 0.64 to 1.19; 1 study, 339 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0052" title="">Analysis 9.4</a>). Based on the control event risk of 358 per 1000 in this trial, this corresponds to 47 fewer response (95% CI 129 fewer to 68 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance and other bias) and imprecision, given that the CI was also compatible with an appreciable reduction in response rate. </p> </section> <section id="CD012796-sec-0167"> <h6 class="title">Minor AEs (assessed with CTCAE v4.0)</h6> <p>Sunitinib may result in little to no difference in minor AEs as compared to IMA901 plus sunitinib (RR 1.29, 95% CI 0.96 to 1.72; 1 study, 334 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0053" title="">Analysis 9.5</a>). Based on the control event risk of 312 per 1000 in this trial, this corresponds to 90 more minor AEs (95% CI 12 fewer to 225 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance and other bias) and imprecision, given that the CI was also compatible with an appreciable increase in minor AEs. </p> </section> </section> <section id="CD012796-sec-0168"> <h5 class="title">Subgroup analysis</h5> <p>We were unable to perform any of the predefined subgroup analyses.</p> </section> <section id="CD012796-sec-0169"> <h5 class="title">Sensitivity analysis</h5> <p>We were unable to perform a sensitivity analysis because there was only one study.</p> </section> </section> <section id="CD012796-sec-0170"> <h4 class="title">10. Sunitinib versus interferon‐α (IFN‐α) (targeted agent versus classic immunotherapy)</h4> <p>Please refer to <a href="./full#CD012796-tbl-0010">summary of findings Table 10</a>. </p> <section id="CD012796-sec-0171"> <h5 class="title">Primary outcomes</h5> <section id="CD012796-sec-0172"> <h6 class="title">PFS</h6> <p>Sunitinib probably increases PFS as compared to IFN‐α (HR 0.54, 95% CI 0.45 to 0.64; 1 study, 750 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0054" title="">Analysis 10.1</a>). Based on the control event risk of 400 per 1000 in this trial at six months, this corresponds to 210 more PFSs (95% CI 156 more to 262 more) per 1000 participants. We rated the certainty of evidence as moderate due to study limitations (selection, performance and other bias). </p> </section> <section id="CD012796-sec-0173"> <h6 class="title">OS</h6> <p>Sunitinib may increase OS as compared to IFN‐α (HR 0.82, 95% CI 0.67 to 1.00; 1 study, 750 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0055" title="">Analysis 10.2</a>) although the CI also includes the possibility of no effect. Based on the control event risk of 480 per 1000 in this trial at 24 months, this would result in 68 more OSs (95% CI 0 fewer to 132 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (selection and other bias) and imprecision, given that the CI was also compatible with no increase in OS. </p> </section> <section id="CD012796-sec-0174"> <h6 class="title">SAEs (assessed with CTCAE v3.0)</h6> <p>Sunitinib probably increases SAEs as compared to IFN‐α (RR 1.75, 95% CI 1.43 to 2.16; 1 study, 735 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0056" title="">Analysis 10.3</a>). Based on the control event risk of 258 per 1000 in this trial, this corresponds to 194 more SAEs (95% CI 111 more to 300 more) per 1000 participants. We rated the certainty of evidence as moderate due to study limitations (selection, performance and other bias). </p> </section> </section> <section id="CD012796-sec-0175"> <h5 class="title">Secondary outcomes</h5> <section id="CD012796-sec-0176"> <h6 class="title">QoL</h6> <p>Sunitinib probably results in little to no difference in QoL (assessed with EQ‐5D; scale: −0.59 to 1.00 with higher scores indicating better QoL; MCID 0.06) as compared to IFN‐α (MD −0.01, 95% CI −0.05 to 0.03; 1 study, 544 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0057" title="">Analysis 10.4</a>). We rated the certainty of evidence as moderate due to study limitations (selection, performance and other bias). </p> </section> <section id="CD012796-sec-0177"> <h6 class="title">Response rate (assessed with RECIST v1.0)</h6> <p>Sunitinib probably increases response rate as compared to IFN‐α (RR 3.83, 95% CI 2.86 to 5.12; 1 study, 750 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0058" title="">Analysis 10.5</a>). Based on the control event risk of 123 per 1000 in this trial, this corresponds to 347 more response (95% CI 228 more to 505 more) per 1000 participants. We rated the certainty of evidence as moderate due to study limitations (selection, performance and other bias). </p> </section> <section id="CD012796-sec-0178"> <h6 class="title">Minor AEs (assessed with CTCAE v3.0)</h6> <p>Sunitinib probably results in little to no difference in minor AEs as compared to IFN‐α (RR 1.03, 95% CI 1.00 to 1.05; 1 study, 735 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0059" title="">Analysis 10.6</a>). Based on the control event risk of 956 per 1000 in this trial, this corresponds to 29 more minor AEs (95% CI 0 fewer to 48 more) per 1000 participants. We rated the certainty of evidence as moderate due to study limitations (selection, performance and other bias). </p> </section> </section> <section id="CD012796-sec-0179"> <h5 class="title">Subgroup analysis</h5> <p>We were unable to perform any of the predefined subgroup analyses.</p> </section> <section id="CD012796-sec-0180"> <h5 class="title">Sensitivity analysis</h5> <p>We were unable to perform a sensitivity analysis because there was only one study.</p> </section> </section> <section id="CD012796-sec-0181"> <h4 class="title">11. Temsirolimus versus IFN‐α (targeted agent versus classic immunotherapy)</h4> <p>Please refer to <a href="./full#CD012796-tbl-0011">summary of findings Table 11</a>. </p> <section id="CD012796-sec-0182"> <h5 class="title">Primary outcomes</h5> <section id="CD012796-sec-0183"> <h6 class="title">PFS</h6> <p>Temsirolimus may increase PFS as compared to IFN‐α (HR 0.74, 95% CI 0.60 to 0.91; 1 study, 416 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0060" title="">Analysis 11.1</a>). Based on the control event risk of 100 per 1000 in this trial at 12 months, this corresponds to 82 more PFSs (95% CI 23 more to 151 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance and detection bias) and imprecision, given that the CI was also compatible with a small or no increase in PFS. </p> </section> <section id="CD012796-sec-0184"> <h6 class="title">OS</h6> <p>Temsirolimus probably increases OS as compared to IFN‐α (HR 0.78, 95% CI 0.63 to 0.97; 1 study, 416 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0061" title="">Analysis 11.2</a>). Based on the control event risk of 300 per 1000 in this trial at 12 months, this would result in 91 more OSs (95% CI 11 more to 168 more) per 1000 participants. We rated the certainty of evidence as moderate due to imprecision, given that the CI was also compatible with a small or no increase in OS. </p> </section> <section id="CD012796-sec-0185"> <h6 class="title">SAEs (assessed with CTCAE version not reported)</h6> <p>Temsirolimus may reduce SAEs as compared to IFN‐α (RR 0.86, 95% CI 0.76 to 0.97; 1 study, 408 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0062" title="">Analysis 11.3</a>). Based on the control event risk of 780 per 1000 in this trial, this corresponds to 109 fewer SAEs (95% CI 187 fewer to 23 fewer) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance and detection bias) and imprecision, given that the CI was also compatible with a small or no reduction in SAEs. </p> </section> </section> <section id="CD012796-sec-0186"> <h5 class="title">Secondary outcomes</h5> <section id="CD012796-sec-0187"> <h6 class="title">QoL</h6> <p>Temsirolimus may result in little to no difference in QoL (assessed with EQ‐5D; scale −0.59 to 1.0 with higher values indicating better QoL; MCID: 0.06) as compared to IFN‐α (MD 0.03, 95% CI −0.01 to 0.07; 1 study, 401 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0063" title="">Analysis 11.4</a>). We rated the certainty of evidence as low due to study limitations (performance, detection and attrition bias), and imprecision, given that the CI was also compatible with an increase in QoL. </p> </section> <section id="CD012796-sec-0188"> <h6 class="title">Response rate (assessed with RECIST version not reported)</h6> <p>Temsirolimus may result in little to no difference in response rate as compared to IFN‐α (RR 1.78, 95% CI 0.84 to 3.77; 1 study, 416 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0064" title="">Analysis 11.5</a>). Based on the control event risk of 48 per 1000 in this trial, this corresponds to 38 more response (95% CI 8 fewer to 134 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance, detection and attrition bias), and imprecision, given that the CI is also compatible with an appreciable increase in response rate. </p> </section> <section id="CD012796-sec-0189"> <h6 class="title">Minor AEs (assessed with CTCAE version not reported)</h6> <p>Temsirolimus probably results in little to no difference in minor AEs as compared to IFN‐α (RR 1.02, 95% CI 1.00 to 1.04; 1 study, 408 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0065" title="">Analysis 11.6</a>). Based on the control event risk of 985 per 1000 in this trial, this corresponds to 20 more minor AEs (95% CI 0 fewer to 39 more) per 1000 participants. We rated the certainty of evidence as moderate due to study limitations (performance and detection bias). </p> </section> </section> <section id="CD012796-sec-0190"> <h5 class="title">Subgroup analysis</h5> <p>We were unable to perform any of the predefined subgroup analyses.</p> </section> <section id="CD012796-sec-0191"> <h5 class="title">Sensitivity analysis</h5> <p>We were unable to perform a sensitivity analysis because there was only one study.</p> </section> </section> <section id="CD012796-sec-0192"> <h4 class="title">12. Sunitinib versus atezolizumab (targeted therapy versus immunotherapy)</h4> <p>Please refer to <a href="./full#CD012796-tbl-0012">summary of findings Table 12</a>. </p> <section id="CD012796-sec-0193"> <h5 class="title">Primary outcomes</h5> <section id="CD012796-sec-0194"> <h6 class="title">PFS</h6> <p>We are very uncertain how sunitinib affects PFS as compared to atezolizumab (HR 0.84, 95% CI 0.58 to 1.22; 1 study, 204 participants; very low certainty evidence; <a href="./references#CD012796-fig-0066" title="">Analysis 12.1</a>). We rated the certainty of evidence as very low due to study limitations (selection, performance, detection and other bias, downgrade one level) and imprecision (downgrade two levels), given that the CI was compatible with both an appreciable reduction and increase in PFS. </p> </section> <section id="CD012796-sec-0195"> <h6 class="title">OS</h6> <p>We are very uncertain how sunitinib affects OS as compared to atezolizumab (HR 0.94, 95% CI 0.58 to 1.54; 1 study, 204 participants; very low certainty evidence; <a href="./references#CD012796-fig-0067" title="">Analysis 12.2</a>). We rated the certainty of evidence as very low due to study limitations (selection and other bias, downgrade one level) and imprecision (downgrade two levels), given that the CI was compatible with both an appreciable reduction and increase in OS. </p> </section> <section id="CD012796-sec-0196"> <h6 class="title">SAEs (assessed with: CTCAE v4.0)</h6> <p>Sunitinib probably increases SAEs as compared to atezolizumab (RR 1.73, 95% CI 1.32 to 2.27; 1 study, 203 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0068" title="">Analysis 12.3</a>). Based on the control event risk of 398 per 1000 in this trial, this corresponds to 291 more SAEs (95% CI 127 more to 506 more) per 1000 participants. We rated the certainty of evidence as moderate due to study limitations (selection, performance, detection and other bias). </p> </section> </section> <section id="CD012796-sec-0197"> <h5 class="title">Secondary outcomes</h5> <section id="CD012796-sec-0198"> <h6 class="title">QoL</h6> <p>Sunitinib may decrease QoL slightly (assessed with MD Anderson Symptom Inventory Interference Score (MDASI); scale 0 to 10; higher scores indicate worse QoL; MCID 1.0) as compared to atezolizumab (MD 1.46, 95% CI 0.80 to 2.12; 1 study, 157 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0069" title="">Analysis 12.4</a>). We rated the certainty of evidence as low due to study limitations (selection, performance, detection, attrition and other bias) and imprecision, given that the CI was also compatible with no decrease in QoL. </p> </section> <section id="CD012796-sec-0199"> <h6 class="title">Response rate (assessed with: RECIST v1.1)</h6> <p>Sunitinib may result in little to no difference in response rate as compared to atezolizumab (RR 1.14, 95% CI 0.72 to 1.79; 1 study, 204 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0070" title="">Analysis 12.5</a>). Based on the control event risk of 252 per 1000 in this trial, this corresponds to 35 more response (95% CI 71 fewer to 199 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (selection, performance, detection and other bias) and imprecision, given that the CI was also compatible with an appreciable increase in response rate. </p> </section> <section id="CD012796-sec-0200"> <h6 class="title">Minor AEs (assessed with: CTCAE v4.0)</h6> <p>Sunitinib probably reduces minor AEs as compared to atezolizumab (RR 0.50, 95% CI 0.35 to 0.71; 1 study, 203 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0071" title="">Analysis 12.6</a>). Based on the control event risk of 563 per 1000 in this trial, this corresponds to 282 fewer minor AEs (95% CI 366 fewer to 163 fewer) per 1000 participants. We rated the certainty of evidence as moderate due to study limitations (selection, performance, detection and other bias). </p> </section> </section> <section id="CD012796-sec-0201"> <h5 class="title">Subgroup analysis</h5> <p>We were unable to perform any of the predefined subgroup analyses.</p> </section> <section id="CD012796-sec-0202"> <h5 class="title">Sensitivity analysis</h5> <p>We were unable to perform a sensitivity analysis because there was only one study.</p> </section> </section> <section id="CD012796-sec-0203"> <h4 class="title">13. Bevacizumab + IFN versus IFN (+ placebo)</h4> <p>Please refer to <a href="./full#CD012796-tbl-0013">summary of findings Table 13</a>. </p> <section id="CD012796-sec-0204"> <h5 class="title">Primary outcomes</h5> <section id="CD012796-sec-0205"> <h6 class="title">PFS</h6> <p>Bevacizumab plus IFN probably increases PFS as compared to IFN (+ placebo) (HR 0.68, 95% CI 0.60 to 0.77; 2 studies, 1381 participants; I² = 14%; moderate‐certainty evidence; <a href="./references#CD012796-fig-0072" title="">Analysis 13.1</a>). Based on the control event risk of 200 per 1000 in this trial at 12 months, this corresponds to 135 more PFSs (95% CI 90 more to 181 more) per 1000 participants. We rated the certainty of evidence as moderate due to study limitations (high and unclear risk of one or more domains). </p> </section> <section id="CD012796-sec-0206"> <h6 class="title">OS</h6> <p>Bevacizumab + IFN may result in little to no difference in OS as compared to IFN (+ placebo) (HR 0.88, 95% CI 0.79 to 0.99; 2 studies, 1381 participants; I² = 0%; low‐certainty evidence; <a href="./references#CD012796-fig-0073" title="">Analysis 13.2</a>). Based on the control event risk of 500 per 1000 in this trial at 24 months, this would result in 43 more OSs (95% CI 3 more to 78 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (high and unclear risk of one or more domains) and imprecision, given that the CI was also compatible with an increase in OS. </p> </section> <section id="CD012796-sec-0207"> <h6 class="title">SAEs (assessed with: CTCAE v3.0)</h6> <p>Bevacizumab plus IFN probably increases SAEs as compared to IFN (+ placebo) (RR 1.31, 95% CI 1.20 to 1.42; 2 studies, 1356 participants; I² = 0%; moderate‐certainty evidence; <a href="./references#CD012796-fig-0074" title="">Analysis 13.3</a>). Based on the control event risk of 536 per 1000 in this trial, this corresponds to 166 more SAEs (95% CI 107 more to 225 more) per 1000 participants. We rated the certainty of evidence as moderate due to study limitations (high and unclear risk of one or more domains). </p> </section> </section> <section id="CD012796-sec-0208"> <h5 class="title">Secondary outcomes</h5> <section id="CD012796-sec-0209"> <h6 class="title">QoL</h6> <p>We found no studies that reported this outcome.</p> </section> <section id="CD012796-sec-0210"> <h6 class="title">Response rate (assessed with: RECIST v1.0)</h6> <p>Bevacizumab plus IFN may increase response rate as compared to IFN (+ placebo) (RR 2.45, 95% CI 1.74 to 3.45; 1 study, 595 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0075" title="">Analysis 13.4</a>). Based on the control event risk of 128 per 1000 in this trial, this corresponds to 186 more response (95% CI 95 more to 314 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (unclear risk of other bias) and imprecision, given that the CI was also compatible with a small or no increase response rate. </p> </section> <section id="CD012796-sec-0211"> <h6 class="title">Minor AEs (assessed with: CTCAE v3.0)</h6> <p>Bevacizumab plus IFN may reduce minor AEs (grade 1 or 2) as compared to IFN (+ placebo) (RR 0.75, 95% CI 0.63 to 0.90; 1 study, 641 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0076" title="">Analysis 13.5</a>). Based on the control event risk of 493 per 1000 in this trial, this corresponds to 123 fewer minor AEs (95% CI 183 fewer to 49 fewer) per 1000 participants. We rated the certainty of evidence as low due to study limitations (unclear risk of other bias) and imprecision, given that the CI was also compatible with a small or no reduction in minor AEs.  </p> </section> </section> <section id="CD012796-sec-0212"> <h5 class="title">Subgroup analysis</h5> <p>We were unable to perform any of the predefined subgroup analyses.</p> </section> <section id="CD012796-sec-0213"> <h5 class="title">Sensitivity analysis</h5> <p>We rated all of the included studies as high or unclear risk of bias and were unable to perform a sensitivity analysis. </p> </section> </section> <section id="CD012796-sec-0214"> <h4 class="title">14. Temsirolimus + IFN‐α versus IFN‐α</h4> <p>Please refer to <a href="./full#CD012796-tbl-0014">summary of findings Table 14</a>. </p> <section id="CD012796-sec-0215"> <h5 class="title">Primary outcomes</h5> <section id="CD012796-sec-0216"> <h6 class="title">PFS</h6> <p>Temsirolimus plus IFN‐α may increase PFS as compared to IFN‐α (HR 0.76, 95% CI 0.62 to 0.93; 1 study, 417 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0077" title="">Analysis 14.1</a>). Based on the control event risk of 100 per 1000 in this trial at 12 months, this corresponds to 74 more PFSs (95% CI 17 more to 140 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance and detection bias) and imprecision, given that the CI was also compatible with little to no increase in PFS. </p> </section> <section id="CD012796-sec-0217"> <h6 class="title">OS</h6> <p>Temsirolimus plus IFN‐α may result in little to no difference in OS as compared to IFN‐α (HR 0.93, 95% CI 0.75 to 1.15; 1 study, 417 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0078" title="">Analysis 14.2</a>). Based on the control event risk of 300 per 1000 in this trial at 12 months, this would result in 26 more OSs (95% CI 50 fewer to 105 more) per 1000 participants. We rated the certainty of evidence as low due to imprecision (downgrade two levels), given that the CI was also compatible with both an appreciable reduction or increase in OS. </p> </section> <section id="CD012796-sec-0218"> <h6 class="title">SAEs (assessed with: CTCAE version not reported)</h6> <p>Temsirolimus plus IFN‐α may increase SAEs as compared to IFN‐α (RR 1.12, 95% CI 1.02 to 1.22; 1 study, 408 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0079" title="">Analysis 14.3</a>). Based on the control event risk of 780 per 1000 in this trial, this corresponds to 94 more SAEs (95% CI 16 more to 172 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance and detection bias) and imprecision, given that the CI was also compatible with little to no increase in SAEs. </p> </section> </section> <section id="CD012796-sec-0219"> <h5 class="title">Secondary outcomes</h5> <section id="CD012796-sec-0220"> <h6 class="title">QoL</h6> <p>Temsirolimus plus IFN‐α may result in little to no difference in QoL (assessed with EQ‐5D; scale −0.59 to 1.0 with higher scores indicating better QoL; MCID 0.06) as compared to IFN‐α (MD 0.03, 95% CI −0.01 to 0.07; 1 study, 394 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0080" title="">Analysis 14.4</a>). We rated the certainty of evidence as low due to study limitations (performance, detection and attrition bias), and imprecision, given that the CI was also compatible with an increase in QoL. </p> </section> <section id="CD012796-sec-0221"> <h6 class="title">Response rate (assessed with: RECIST version not reported)</h6> <p>Temsirolimus plus IFN‐α may result in little to no difference in response rate as compared to IFN‐α (RR 1.68, 95% CI 0.79 to 3.57; 1 study, 417 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0081" title="">Analysis 14.5</a>). Based on the control event risk of 48 per 1000 in this trial, this corresponds to 33 more response (95% CI 10 fewer to 124 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance, detection and attrition bias), and imprecision, given that the CI was also compatible with an appreciable increase in response rate. </p> </section> <section id="CD012796-sec-0222"> <h6 class="title">Minor AEs (assessed with: CTCAE version not reported)</h6> <p>Temsirolimus plus IFN‐α probably results in little to no difference in minor AEs (grade 1 or 2) as compared to IFN‐α (RR 1.00, 95% CI 0.98 to 1.02; 1 study, 408 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0082" title="">Analysis 14.6</a>). Based on the control event risk of 985 per 1000 in this trial, this corresponds to zero fewer minor AEs (95% CI 20 fewer to 20 more) per 1000 participants. We rated the certainty of evidence as moderate due to study limitations (performance and detection bias). </p> </section> </section> <section id="CD012796-sec-0223"> <h5 class="title">Subgroup analysis</h5> <p>We were unable to perform any of the predefined subgroup analyses.</p> </section> <section id="CD012796-sec-0224"> <h5 class="title">Sensitivity analysis</h5> <p>We were unable to perform a sensitivity analysis because there was only one study.</p> </section> </section> <section id="CD012796-sec-0225"> <h4 class="title">15. Temsirolimus + bevacizumab versus bevacizumab + IFN‐α </h4> <p>Please refer to <a href="./full#CD012796-tbl-0015">summary of findings Table 15</a>. </p> <section id="CD012796-sec-0226"> <h5 class="title">Primary outcomes</h5> <section id="CD012796-sec-0227"> <h6 class="title">PFS</h6> <p>Temsirolimus plus bevacizumab may result in little to no difference in PFS as compared to bevacizumab plus IFN‐α (HR 1.10, 95% CI 0.90 to 1.34; 1 study, 791 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0083" title="">Analysis 15.1</a>). Based on the control event risk of 420 per 1000 in this trial at 12 months, this corresponds to 35 fewer PFSs (95% CI 107 fewer to 38 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance bias) and imprecision, given that the CI was also compatible with an appreciable reduction in PFS. </p> </section> <section id="CD012796-sec-0228"> <h6 class="title">OS</h6> <p>Temsirolimus plus bevacizumab probably results in little to no difference in OS as compared to bevacizumab plus IFN‐α (HR 1.08, 95% CI 0.90 to 1.30; 1 study, 791 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0084" title="">Analysis 15.2</a>). Based on the control event risk of 550 per 1000 in this trial at 24 months, this would result in 26 fewer OSs (95% CI 90 fewer to 34 more) per 1000 participants. We rated the certainty of evidence as moderate due to imprecision, given that the CI was also compatible with a reduction in OS. </p> </section> <section id="CD012796-sec-0229"> <h6 class="title">SAEs (assessed with: CTCAE v3.0)</h6> <p>Temsirolimus plus bevacizumab may result in little to no difference in SAEs (grade 3 or 4) as compared to bevacizumab plus IFN‐α (RR 1.05, 95% CI 0.98 to 1.13; 1 study, 784 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0085" title="">Analysis 15.3</a>). Based on the control event risk of 760 per 1000 in this trial, this corresponds to 38 more SAEs (95% CI 15 fewer to 99 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance bias) and imprecision, given that the CI was also compatible with an appreciable increase in SAEs. </p> </section> </section> <section id="CD012796-sec-0230"> <h5 class="title">Secondary outcomes</h5> <section id="CD012796-sec-0231"> <h6 class="title">QoL</h6> <p><a href="./references#CD012796-bbs2-0014" title="NCT00631371. Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (INTORACT). linicaltrials.gov/ct2/show/NCT00631371 (first received 20 May 2019). [NCT00631371]RiniBI , BellmuntJ , ClancyJ , WangK , NiethammerAG , HariharanS , et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. Journal of Clinical Oncology2014;32(8):752-9. [PMID: 24297945]">Rini 2014</a> reported QoL measured by Functional Assessment of Cancer Therapy–Kidney Symptom Index (FKSI)–15, which contains 15 questions representing concerns specific to patients with advanced kidney cancer and FKSI‐Disease Related Symptoms (FKSI‐DRS) subscale. We could not obtain a mean and standard deviation in each arm, however, and therefore we were unable to estimate this outcome. </p> </section> <section id="CD012796-sec-0232"> <h6 class="title">Response rate (assessed with: RECIST version not reported)</h6> <p>Temsirolimus plus bevacizumab probably results in little to no difference in response rate as compared to bevacizumab plus IFN‐α (RR 0.99, 95% CI 0.79 to 1.24; 1 study, 791 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0086" title="">Analysis 15.4</a>). Based on the control event risk of 274 per 1000 in this trial, this corresponds to 3 fewer response (95% CI 57 fewer to 66 more) per 1000 participants. We rated the certainty of evidence as moderate due to study limitations (performance bias). </p> </section> <section id="CD012796-sec-0233"> <h6 class="title">Minor AEs (assessed with: CTCAE v3.0)</h6> <p>Temsirolimus plus bevacizumab probably results in little to no difference in minor AEs as compared to bevacizumab plus IFN‐α (RR 1.01, 95% CI 0.98 to 1.03; 1 study, 784 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0087" title="">Analysis 15.5</a>). Based on the control event risk of 967 per 1000 in this trial, this corresponds to 10 more minor AEs (95% CI 19 fewer to 29 more) per 1000 participants. We rated the certainty of evidence as moderate due to study limitations (performance bias). </p> </section> </section> <section id="CD012796-sec-0234"> <h5 class="title">Subgroup analysis</h5> <p>We were unable to perform any of the predefined subgroup analyses.</p> </section> <section id="CD012796-sec-0235"> <h5 class="title">Sensitivity analysis</h5> <p>We were unable to perform a sensitivity analysis because there was only one study.</p> </section> </section> <section id="CD012796-sec-0236"> <h4 class="title">16. Everolimus + bevacizumab versus IFN α‐2a + bevacizumab</h4> <p>Please refer to <a href="./full#CD012796-tbl-0016">summary of findings Table 16</a>. </p> <section id="CD012796-sec-0237"> <h5 class="title">Primary outcomes</h5> <section id="CD012796-sec-0238"> <h6 class="title">PFS</h6> <p>We are very uncertain how everolimus plus bevacizumab affects PFS as compared to IFN α‐2a plus bevacizumab (HR 0.91, 95% CI 0.69 to 1.20; 1 study, 365 participants; very low certainty evidence; <a href="./references#CD012796-fig-0088" title="">Analysis 16.1</a>). We rated the certainty of evidence as very low due to study limitations (selection, performance, detection and other bias, downgrade one level) and imprecision (downgrade two levels), given that the CI was compatible with both an appreciable reduction and increase in PFS.  </p> </section> <section id="CD012796-sec-0239"> <h6 class="title">OS</h6> <p>We are very uncertain how everolimus plus bevacizumab affects OS as compared to IFN α‐2a plus bevacizumab (HR 1.01, 95% CI 0.75 to 1.36; 1 study, 365 participants; very low certainty evidence; <a href="./references#CD012796-fig-0089" title="">Analysis 16.2</a>). We rated the certainty of evidence as very low due to study limitations (selection and other bias, downgrade one level) and imprecision (downgrade two levels), given that the CI was compatible with both an appreciable reduction and increase in OS. </p> </section> <section id="CD012796-sec-0240"> <h6 class="title">SAEs (assessed with: CTCAE v3.0)</h6> <p>Everolimus plus bevacizumab may result in little to no difference in SAEs as compared to IFN α‐2a plus bevacizumab (RR 1.06, 95% CI 0.95 to 1.18; 1 study, 361 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0090" title="">Analysis 16.3</a>). Based on the control event risk of 762 per 1000 in this trial, this corresponds to 46 more SAEs (95% CI 38 fewer to 137 more) per 1000 participants. We rated the certainty of evidence as low due to study limitations (selection, performance, detection and other bias) and imprecision, given that the CI was also compatible with an appreciable increase in SAEs. </p> </section> </section> <section id="CD012796-sec-0241"> <h5 class="title">Secondary outcomes</h5> <section id="CD012796-sec-0242"> <h6 class="title">QoL</h6> <p><a href="./references#CD012796-bbs2-0011" title="NCT00719264. Safety and efficacy of bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment in adult patients with kidney cancer [A randomized, open-label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a plus bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney]. clinicaltrials.gov/ct2/show/study/NCT00719264 (first received 21 July 2008). [NCT00719264]RavaudA , BarriosCH , AlekseevB , TayMH , AgarwalaSS , YalcinS , et al. RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. Annals of Oncology2015;26(7):1378-84. [PMID: 25851632]">Ravaud 2015</a> reported time to deterioration of global health status measured by the European Organisation for the Research and Treatment of Cancer (EORTC)‐Core Quality of Life Questionnaire (QLQ‐C30) (<a href="http://clinicaltrials.gov/ct2/show/results/NCT00719264" target="_blank">NCT00719264</a>). We could not obtain a mean and standard deviation in each arm, however, and therefore we were unable to estimate this outcome. </p> </section> <section id="CD012796-sec-0243"> <h6 class="title">Response rate (assessed with: RECIST v1.0)</h6> <p>Everolimus plus bevacizumab probably results in little to no difference in response rate as compared to IFN α‐2a plus bevacizumab (RR 0.97, 95% CI 0.69 to 1.35; 1 study, 365 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0091" title="">Analysis 16.4</a>). Based on the control event risk of 279 per 1000 in this trial, this corresponds to 8 fewer response (95% CI 86 fewer to 98 more) per 1000 participants. We rated the certainty of evidence as moderate due to study limitations (selection, performance, detection and other bias). </p> </section> <section id="CD012796-sec-0244"> <h6 class="title">Minor AEs (assessed with CTCAE v3.0)</h6> <p>Everolimus plus bevacizumab probably results in little to no difference in minor AEs as compared to IFN α‐2a plus bevacizumab (RR 0.63, 95% CI 0.34 to 1.16; 1 study, 361 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0092" title="">Analysis 16.5</a>). Based on the control event risk of 133 per 1000 in this trial, this corresponds to 49 fewer minor AEs (95% CI 88 fewer to 21 more) per 1000 participants. We rated the certainty of evidence as moderate due to study limitations (selection, performance, detection and other bias). </p> </section> </section> <section id="CD012796-sec-0245"> <h5 class="title">Subgroup analysis</h5> <p>We were unable to perform any of the predefined subgroup analyses.</p> </section> <section id="CD012796-sec-0246"> <h5 class="title">Sensitivity analysis</h5> <p>We were unable to perform a sensitivity analysis because there was only one study.</p> </section> </section> <section id="CD012796-sec-0247"> <h4 class="title">17. Sunitinib versus nivolumab + ipilimumab (Targeted agent versus combinations of immunotherapy) </h4> <p>Please refer to <a href="./full#CD012796-tbl-0017">summary of findings Table 17</a>. </p> <section id="CD012796-sec-0248"> <h5 class="title">Primary outcomes</h5> <section id="CD012796-sec-0249"> <h6 class="title">PFS</h6> <p>Sunitinib may reduce PFS as compared to nivolumab plus ipilimumab (HR 1.30, 95% CI 1.11 to 1.52; 1 study, 847 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0093" title="">Analysis 17.1</a>). Based on the control event risk of 280 per 1000 in this trial at 30 months, this corresponds to 89 fewer PFSs (95% CI 136 fewer to 37 fewer) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance and detection bias) and imprecision, given that the CI was also compatible with no reduction in PFS. </p> </section> <section id="CD012796-sec-0250"> <h6 class="title">OS</h6> <p>Sunitinib reduces OS as compared to nivolumab plus ipilimumab (HR 1.52, 95% CI 1.23 to 1.89; 1 study, 847 participants; high‐certainty evidence; <a href="./references#CD012796-fig-0094" title="">Analysis 17.2</a>). Based on the control event risk 600 per 1000 in this trial at 30 months, this would result in 140 fewer OSs (95% CI 219 fewer to 67 fewer) per 1000 participants. We rated the certainty of evidence as high. </p> </section> <section id="CD012796-sec-0251"> <h6 class="title">SAEs (assessed with: CTCAE v4.0)</h6> <p>Sunitinib probably increases SAEs (grade 3 or 4) as compared to nivolumab plus ipilimumab (RR 1.37, 95% CI 1.22 to 1.53; 1 study, 1082 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0095" title="">Analysis 17.3</a>). Based on the control event risk of 457 per 1000 in this trial, this corresponds to 169 more SAEs (95% CI 101 more to 242 more) per 1000 participants. We rated the certainty of evidence as moderate due to study limitations (performance and detection bias). </p> </section> </section> <section id="CD012796-sec-0252"> <h5 class="title">Secondary outcomes</h5> <section id="CD012796-sec-0253"> <h6 class="title">QoL</h6> <p>Sunitinib probably reduces QoL (assessed with FKSI‐19; scale 0 to 76 with higher scores indicating better QoL; MCID: 2) as compared to nivolumab plus ipilimumab (MD −4.10, 95% CI −5.75 to −2.45; 1 study, 460 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0096" title="">Analysis 17.4</a>). We rated the certainty of evidence as moderate due to study limitations (performance, detection and attrition bias). </p> </section> <section id="CD012796-sec-0254"> <h6 class="title">Response rate (assessed with: RECIST v1.1)</h6> <p>Sunitinib may reduce response rate as compared to nivolumab plus ipilimumab (RR 0.70, 95% CI 0.58 to 0.84; 1 study, 847 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0097" title="">Analysis 17.5</a>). Based on the control event risk of 419 per 1000 in this trial, this corresponds to 126 fewer response (95% CI 176 fewer to 67 fewer) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance and detection bias) and imprecision, given that the CI was also compatible with little to no reduction in response rate. </p> </section> <section id="CD012796-sec-0255"> <h6 class="title">Minor AEs (assessed with CTCAE v4.0)</h6> <p>Sunitinib may reduce minor AEs as compared to nivolumab plus ipilimumab (RR 0.74, 95% CI 0.64 to 0.86; 1 study, 1082 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0098" title="">Analysis 17.6</a>). Based on the control event risk of 459 per 1000 in this trial, this corresponds to 119 fewer minor AEs (95% CI 165 fewer to 64 fewer) per 1000 participants. We rated the certainty of evidence as low due to study limitations (performance and detection bias) and imprecision, given that the CI was compatible with little to no reduction in minor AEs. </p> </section> </section> <section id="CD012796-sec-0256"> <h5 class="title">Subgroup analysis</h5> <p>We were unable to perform any of the predefined subgroup analyses.</p> </section> <section id="CD012796-sec-0257"> <h5 class="title">Sensitivity analysis</h5> <p>We were unable to perform a sensitivity analysis because there was only one study.</p> </section> </section> <section id="CD012796-sec-0258"> <h4 class="title">18. Pazopanib versus placebo (targeted agent versus placebo)</h4> <p>Please refer to <a href="./full#CD012796-tbl-0018">summary of findings Table 18</a>. </p> <section id="CD012796-sec-0259"> <h5 class="title">Primary outcomes</h5> <section id="CD012796-sec-0260"> <h6 class="title">PFS</h6> <p>Pazopanib increases PFS as compared to placebo (HR 0.46, 95% CI 0.34 to 0.62; 1 study, 435 participants; high‐certainty evidence; <a href="./references#CD012796-fig-0099" title="">Analysis 18.1</a>). Based on the control event risk of 180 per 1000 in this trial at 12 months, this corresponds to 274 more PFSs (95% CI 165 more to 378 more) per 1000 participants. </p> </section> <section id="CD012796-sec-0261"> <h6 class="title">OS</h6> <p>Pazopanib may result in little to no difference in OS as compared to placebo (HR 0.91, 95% CI 0.72 to 1.16; 1 study, 435 participants; low‐certainty evidence; <a href="./references#CD012796-fig-0100" title="">Analysis 18.2</a>). Based on the control event risk of 480 per 1000 in this trial at 24 months, this would result in 33 more OSs (95% CI 53 fewer to 110 more) per 1000 participants. We rated the certainty of evidence as low due to imprecision (downgrade two levels), given that the CI was both compatible with an appreciable reduction and increase in OS.  </p> </section> <section id="CD012796-sec-0262"> <h6 class="title">SAEs (assessed with CTCAE v3.0)</h6> <p>Pazopanib increases SAEs as compared to placebo (RR 2.00, 95% CI 1.40 to 2.85; 1 study, 435 participants; high‐certainty evidence; <a href="./references#CD012796-fig-0101" title="">Analysis 18.3</a>). Based on the control event risk in this trial of 200 per 1000, this corresponds to 200 more SAEs (95% CI 80 more to 370 more) per 1000 participants. </p> </section> </section> <section id="CD012796-sec-0263"> <h5 class="title">Secondary outcomes</h5> <section id="CD012796-sec-0264"> <h6 class="title">QoL</h6> <p>Pazopanib results in little to no difference in QoL (assessed with EORTC QLQ‐C30; scale 0 to 100 with higher values reflecting better QoL; MCID 10) as compared to placebo (MD −3.10, 95% CI −7.76 to 1.56; 1 study, 300 participants; high‐certainty evidence; <a href="./references#CD012796-fig-0102" title="">Analysis 18.4</a>). </p> </section> <section id="CD012796-sec-0265"> <h6 class="title">Response rate (assessed with: RECIST v1.0)</h6> <p>Pazopanib probably increases response rate as compared to placebo (RR 8.80, 95% CI 3.65 to 21.19; 1 study, 435 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0103" title="">Analysis 18.5</a>). Based on the control event risk of 34 per 1000 in this trial, this corresponds to 269 more response (95% CI 91 more to 696 more) per 1000 participants. We rated the certainty of evidence as moderate due to imprecision, given that the CI was also compatible with little to no increase in response rate. </p> </section> <section id="CD012796-sec-0266"> <h6 class="title">Minor AEs (assessed with CTCAE v3.0)</h6> <p>Pazopanib probably increases minor AEs as compared to placebo (RR 1.31, 95% CI 1.13 to 1.52; 1 study, 435 participants; moderate‐certainty evidence; <a href="./references#CD012796-fig-0104" title="">Analysis 18.6</a>). Based on the control event risk of 600 per 1000 in this trial, this corresponds to 186 more minor AEs (95% CI 78 more to 312 more) per 1000 participants. We rated the certainty of evidence as moderate due to imprecision, given that the CI was also compatible with little to no increase in minor AEs.  </p> </section> </section> <section id="CD012796-sec-0267"> <h5 class="title">Subgroup analysis</h5> <p>We were unable to perform any of the predefined subgroup analyses.</p> </section> <section id="CD012796-sec-0268"> <h5 class="title">Sensitivity analysis</h5> <p>We were unable to perform a sensitivity analysis because there was only one study.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012796-sec-0269" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012796-sec-0269"></div> <p>For this review, we considered targeted therapies as the index intervention. This group of drugs included VEGFR‐TKIs (e.g. sunitinib, sorafenib, pazopanib, tivozanib and axitinib), VEGF‐inhibitors (e.g. bevacizumab) and mTOR inhibitors (e.g. everolimus or temsirolimus). Comparators included placebo, alternative targeted therapy (i.e. targeted therapy vs targeted therapy), cytokines (i.e. classic non‐targeted immunotherapy, e.g. interferon‐alpha), immune checkpoint inhibitors, or combinations of different classes of drugs. Immune checkpoint inhibitors included programmed death 1 inhibitors (PD‐1), programmed death ligand 1 inhibitors (PD‐L1) and cytotoxic T‐lymphocyte associated antigen 4 (CTLA‐4) inhibitors (e.g. avelumab, pembrolizumab, atezolizumab, nivolumab and ipilimumab). </p> <section id="CD012796-sec-0270"> <h3 class="title" id="CD012796-sec-0270">Summary of main results</h3> <p>One trial compared targeted agent (pazopanib) against placebo (<a href="./full#CD012796-tbl-0018">summary of findings Table 18</a>). There was high quality evidence showing pazopanib was significantly superior to placebo in terms of PFS, but inferior in terms of incidence of SAEs. There was low certainty evidence showing no difference between the groups in terms of OS. </p> <p>For the intra‐group comparison of single‐agent targeted therapy against each other, we found some differences between them (<a href="./full#CD012796-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD012796-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD012796-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD012796-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD012796-tbl-0005">summary of findings Table 5</a>). Pazopanib and tivozanib were both superior to sorafenib in terms of PFS but there were some differences in terms of OS; the certainty of evidence was moderate for pazopanib for PFS and low for OS but low for tivozanib for both PFS and OS. Sunitinib was superior to everolimus for PFS although there was no difference for OS, with moderate to low certainty of evidence for both outcomes. Sorafenib was inferior to sunitinib for PFS but there was no difference for OS (low and very low certainty evidence, respectively), nor between pazopanib versus sunitinib for PFS and OS (low certainty evidence for both). For AE, there was very low to low‐certainty evidence that there were no statistically significant differences between the drugs, except for sunitinib versus everolimus; sunitinib appeared to have a higher incidence of SAEs compared with everolimus (moderate‐certainty evidence). </p> <p>Next, for the comparison of targeted therapy versus cytokines (i.e. classic non‐targeted immunotherapy, <a href="./full#CD012796-tbl-0010">summary of findings Table 10</a>; <a href="./full#CD012796-tbl-0011">summary of findings Table 11</a>; <a href="./full#CD012796-tbl-0013">summary of findings Table 13</a>; <a href="./full#CD012796-tbl-0014">summary of findings Table 14</a>; <a href="./full#CD012796-tbl-0015">summary of findings Table 15</a>; <a href="./full#CD012796-tbl-0016">summary of findings Table 16</a>), there was low‐ to moderate‐certainty evidence showing that single‐agent targeted therapy was superior to single‐agent interferon‐alpha for PFS and OS (for sunitinib and temsirolimus). Regarding the incidence of SAEs, temsirolimus was better than interferon‐alpha (low‐certainty evidence), but sunitinib was worse than interferon‐alpha (moderate‐certainty evidence). The results for the comparison between combination of targeted therapies with each other or with interferon‐alpha versus single‐agent interferon‐alpha suggest combinations of targeted therapy involving either bevacizumab or temsirolimus with interferon‐alpha are superior to single‐agent interferon‐alpha for PFS (low‐ to moderate‐certainty evidence) but there was no difference in OS (low‐certainty evidence); however the targeted therapy combinations had a significantly higher incidence of SAEs (low‐ to moderate‐certainty evidence). The comparison of combinations of targeted therapy (temsirolimus and bevacizumab, and everolimus and bevacizumab) versus combination of bevacizumab and interferon‐alpha did not show any differences in PFS, OS nor SAEs (very low to moderate‐certainty evidence). </p> <p>For the comparison of targeted therapy versus combination of tumour vaccine (IMA901) with sunitinib, (<a href="./full#CD012796-tbl-0009">summary of findings Table 9</a>), there was low‐certainty evidence that single‐agent sunitinib had significantly better OS and better SAEs profile compared with combination of IMA901 plus sunitinib. </p> <p>For the comparison of single‐agent targeted therapy (all based on sunitinib) versus immune checkpoint inhibitor, the results can be summarised into three sub‐sections: (1) sunitinib versus single‐agent immune checkpoint inhibitor (atezolizumab, <a href="./full#CD012796-tbl-0012">summary of findings Table 12</a>); (2) sunitinib versus combination of targeted drug with immune checkpoint inhibitor (axitinib + avelumab; axitinib + pembrolizumab; and bevacizumab + atezolizumab; <a href="./full#CD012796-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD012796-tbl-0007">summary of findings Table 7</a>; <a href="./full#CD012796-tbl-0008">summary of findings Table 8</a>); and (3) sunitinib versus combination of immune checkpoint inhibitors (nivolumab + ipilimumab, <a href="./full#CD012796-tbl-0017">summary of findings Table 17</a>). For the comparison of sunitinib versus atezolizumab, there were no significant differences between them for PFS and OS (very low certainty evidence); however, sunitinib had worse incidence of SAEs (moderate certainty evidence). For the comparison of sunitinib versus combination of targeted therapy with immune checkpoint inhibitor, sunitinib appeared to have worse PFS than two of the combinations (moderate‐certainty evidence) and worse OS (moderate‐certainty evidence) than one combination of targeted drug and immune checkpoint inhibitor; Sunitinib may have no difference or less SAEs compared to combinations (low‐certainty evidence). Finally, for the comparison of sunitinib versus combination of immune checkpoint inhibitors (nivolumab + ipilimumab), sunitinib had worse PFS (low‐certainty evidence), worse OS (high‐certainty evidence) and worse incidence of SAEs (moderate‐certainty evidence) compared with the combination of nivolumab and ipilimumab. Sunitinib was also associated with worse QoL (moderate‐certainty evidence) and worse response rate (low‐certainty evidence). </p> <p>In summary, when comparing targeted therapy (i.e. sunitinib) against immune checkpoint inhibitor either singly or in combination, there was high‐ to moderate‐quality evidence (from two trials) demonstrating sunitinib was inferior to a combination of targeted therapy with immune checkpoint inhibitor (i.e. axitinib + pembrolizumab), and a combination of immune checkpoint inhibitors (i.e. nivolumab + ipilimumab), in terms of OS. The result for PFS was also worse for sunitinib compared with the other combinations involving immune checkpoint inhibitors, with low‐ to moderate‐certainty evidence across all studies. There was also moderate‐quality evidence from two studies that sunitinib had worse incidence of SAEs compared with immune checkpoint inhibitors (involving atezolizumab as single agent, and nivolumab + ipilimumab combination). Although sunitinib was the comparator in all of those trials, a meta‐analysis was only possible for the two studies which used the combination of atezolizumab and bevacizumab. This was due to considerable clinical heterogeneity across the trials namely in the use of eligibility criteria, primary endpoints (e.g. results reported only for the intention‐to‐treat the population or those with PD‐L1 expression on tumour cells or tumour‐infiltrating lymphocytes), inconsistent use validated risk scores such as the Memorial Sloan Kettering Cancer Center (MSKCC) or International Metastatic RCC Database Consortium (IMDC) risks models, and experimental drugs used. </p> </section> <section id="CD012796-sec-0271"> <h3 class="title" id="CD012796-sec-0271">Overall completeness and applicability of evidence</h3> <p>We identified studies to include in this review by independent searches. Results were comparable and we resolved disagreements by discussion within the author group. We also identified trials through hand searching of conference proceedings and tried to acquire additional data whenever they were needed by contacting authors. </p> <p>Participants were comparable amongst the identified studies, which all had a multicentre design. All except two trials (<a href="./references#CD012796-bbs2-0008" title="HutsonT , NosovD , TomczakP , BondarenkoI , LipatovON , SternbergCN , et al. Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902). Journal of Clinical Oncology2015;33(15 suppl):4557. [DOI: 10.1200/jco.2015.33.15_suppl.4557]MotzerRJ , NosovD , EisenT , BondarenkoI , LesovoyV , LipatovO , et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. Journal of Clinical Oncology2013;31(30):3791-9. [PMID: 24019545]NCT01030783. A study to compare tivozanib (AV-951) to sorafenib in subjects with advanced renal cell carcinoma (TIVO-1) [A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib (AV-951) to sorafenib in subjects with advanced renal cell carcinoma (TIVO-1)]. clinicaltrials.gov/ct2/show/NCT01030783 (first received 11 December 2009). [NCT01030783]">Motzer 2013b</a> and <a href="./references#CD012796-bbs2-0018" title="CellaD , PickardAS , DuhMS , GuerinA , MishaginaN , AntràsL , et al. Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. European Journal of Cancer2012;48(3):311-23. [PMID: 21689927]HutsonTE , BukowskiRM . A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma. Clinical Genitourinary Cancer2006;4(4):296-8. [PMID: 16729915]HutsonTE , DavisID , MachielsJP , deSouzaPL , HongBF , RotteyS , et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). Journal of Clinical Oncology2007;25(18 suppl):5031. [DOI: 10.1200/jco.2007.25.18_suppl.5031]NCT00334282. Safety and efficacy of GW786034 (pazopanib) In metastatic renal cell carcinoma [A randomised, double-blind, placebo controlled, multi-center phase III study to evaluate the efficacy and safety of pazopanib (GW786034) compared to placebo in patients with locally advanced and/or metastatic renal cell carcinoma]. clinicaltrials.gov/ct2/show/study/NCT00334282 (first received 7 June 2006). [NCT00334282]SternbergCN , DavisID , MardiakJ , SzczylikC , LeeE , WagstaffJ , et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of Clinical Oncology2010;28(6):1061-8. [PMID: 20100962]SternbergCN , HawkinsRE , WagstaffJ , SalmanP , MardiakJ , BarriosCH , et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. European Journal of Cancer2013;49(6):1287-96. [PMID: 23321547]SternbergCN , SzczylikC , LeeE , SalmanPV , MardiakJ , DavisID , et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). Journal of Clinical Oncology2009;27(15S):5021. [DOI: 10.1200/jco.2009.27.15s.5021]">Sternberg 2010</a>) had a homogeneous population which had not received previous treatment. A phase 3 study was the favoured trial design which was used in 15 trials. Another three used a phase 2 design. All included studies investigated our primary and secondary outcomes except for QoL data, which was not available in seven trials. </p> <p>We imposed strict criteria for study inclusion for methodological reasons which excluded studies with less than 100 participants per arm. This meant excluding the CABOSUN trial comparing cabozantinib versus sunitinib, an initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk (n = 157 in total) (<a href="./references#CD012796-bbs2-0025" title="ChoueiriTK , HalabiS , SanfordBL , HahnO , MichaelsonMD , WalshMK , et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The Alliance A031203 CABOSUN Trial. Journal of Clinical Oncology2017;35(6):591-7. [PMID: 28199818]">Choueiri 2017</a>). Guidelines panels of ESMO and EAU consider cabozantinib an alternative for IMDC intermediate‐ and poor‐risk patients only who cannot receive immune checkpoint inhibitor combination therapies but on the same par as sunitinib and pazopanib, which have been tested in randomised controlled phase 3 trials in this setting (<a href="./references#CD012796-bbs2-0081" title="LjungbergB , AlbigesL , BensalahK , BexA , GilesRH , HoraM , et al. EAU Guidelines on Renal Cell Carcinoma. Edn. presented at the EAU Annual Congress Amsterdam. EAU Guidelines Office, 2020. 978-94-92671-07-3.">EAU Guidelines 2020</a>; <a href="./references#CD012796-bbs2-0083" title="EscudierB , PortaC , SchmidingerM , Rioux-LeclerqN , BexA , KhooV , et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology2019;30(5):706-20. [PMID: 30788497]">ESMO Clinical Practice Guidelines 2019</a>). This decision was taken because CABOSUN was a randomised phase 2 trial in which cabozantinib had a PFS but no OS benefit compared to sunitinib. This was considered not enough evidence to argue that cabozantinib is qualitatively superior to sunitinib. </p> </section> <section id="CD012796-sec-0272"> <h3 class="title" id="CD012796-sec-0272">Quality of the evidence</h3> <p>We used GRADE to rate the quality of evidence and created 18 'Summary of findings' tables for the different comparisons. We rated most of the comparisons at a low to moderate level of evidence. The main reasons for downgrading were study limitations, especially those due to lack of blinding with the risk of performance and detection bias. Imprecision was another important factor for lowering the certainty of evidence in efficacy outcomes. </p> </section> <section id="CD012796-sec-0273"> <h3 class="title" id="CD012796-sec-0273">Potential biases in the review process</h3> <p>Two reviewers screened all search results independently. There were no language restrictions but all identified studies were published in the English language. We did not receive additional data after contacting authors except for one study, which could be a source of bias. </p> <p>After publication of our protocol we amended our inclusion criteria. We chose to limit the number of participants to a minimum of 100 per study arm to ensure our evidence synthesis was based on more robust data by reducing the risk of small‐study bias. We also chose to only include participants who were naïve to systemic therapy. This decision was mainly driven by the large number of studies assessing patients with metastatic renal cell carcinoma in the second‐line treatment setting or beyond. Including these trials would have distracted us from the main focus of our review which was on the first‐line treatment setting, and the burden of work would have become unfeasibly high. </p> <p>For the interpretation of clinically important effect sizes, we used absolute effect estimates that were informed by the input of expert clinicians on our team; unless there were published thresholds (as was the case for quality of life instruments) we used 5% for the most patient‐important primary outcomes of PFS and OS and 10% for the secondary outcomes of response rates and minor AEs. We recognise that different thresholds might lead to different interpretations and have therefore made all our judgments as transparent as possible.  </p> </section> <section id="CD012796-sec-0274"> <h3 class="title" id="CD012796-sec-0274">Agreements and disagreements with other studies or reviews</h3> <p>A systematic review with a broader approach on systemic treatment for metastatic renal cell carcinoma was published in 2018 (<a href="./references#CD012796-bbs2-0101" title="LalaniAA , McGregorBA , AlbigesL , ChoueiriTK , MotzerR , PowlesT , et al. Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: Current paradigms, use of immunotherapy, and future directions. European Urology2018;75(1):100-10. [PMID: 30327274]">Lalani 2018</a>). In total 26 trials were identified for first and later line treatments. All studies of that review that met our inclusion criteria were also identified and included in our review. The authors expected combinations therapies to become the new promising standard of care in treatment‐naïve renal cell carcinoma. </p> <p>Another systematic review, also published in 2018, was focusing on first line systemic therapy for metastatic renal cell carcinoma (<a href="./references#CD012796-bbs2-0120" title="WallisCJD , KlaassenZ , BhindiB , YeXY , ChandrasekarT , FarrellAM , et al. First-line systemic therapy for metastatic renal cell carcinoma: A systematic review and network meta-analysis. European Urology2018;74(3):309-321. [PMID: 29656851]">Wallis 2018</a>). Of the 37 identified trials for a qualitative synthesis 13 were eligible for a quantitative synthesis. All trials that meet our inclusion criteria were part of our review. Cabozantinib was judged as being highly likely to provide the greatest PFS benefit, while the combination of nivolumab plus ipilimumab was most likely to provide the greatest OS benefit. The later combination was rated likely to have the most beneficial tolerance profile. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012796-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012796-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Categories: green point (+) = low risk of bias; yellow point (?) = unclear risk of bias; red point (‐) = high risk of bias." data-id="CD012796-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Categories: green point (+) = low risk of bias; yellow point (?) = unclear risk of bias; red point (‐) = high risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012796-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Sorafenib versus Sunitinib, Outcome 1: Progression‐free survival" data-id="CD012796-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Sorafenib versus Sunitinib, Outcome 1: Progression‐free survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Sorafenib versus Sunitinib, Outcome 2: Overall survival" data-id="CD012796-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Sorafenib versus Sunitinib, Outcome 2: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Sorafenib versus Sunitinib, Outcome 3: Serious adverse events (Grade 3 or 4)" data-id="CD012796-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Sorafenib versus Sunitinib, Outcome 3: Serious adverse events (Grade 3 or 4) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Sorafenib versus Sunitinib, Outcome 4: Response rate" data-id="CD012796-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Sorafenib versus Sunitinib, Outcome 4: Response rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Sorafenib versus Sunitinib, Outcome 5: Minor adverse events (Grade 1 or 2)" data-id="CD012796-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Sorafenib versus Sunitinib, Outcome 5: Minor adverse events (Grade 1 or 2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Pazopanib versus Sunitinib, Outcome 1: Progression‐free survival" data-id="CD012796-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Pazopanib versus Sunitinib, Outcome 1: Progression‐free survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Pazopanib versus Sunitinib, Outcome 2: Overall survival" data-id="CD012796-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Pazopanib versus Sunitinib, Outcome 2: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Pazopanib versus Sunitinib, Outcome 3: Serious adverse events (Grade 3 or 4)" data-id="CD012796-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Pazopanib versus Sunitinib, Outcome 3: Serious adverse events (Grade 3 or 4) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Pazopanib versus Sunitinib, Outcome 4: Health‐related quality of life" data-id="CD012796-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Pazopanib versus Sunitinib, Outcome 4: Health‐related quality of life</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Pazopanib versus Sunitinib, Outcome 5: Response rate" data-id="CD012796-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Pazopanib versus Sunitinib, Outcome 5: Response rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Pazopanib versus Sunitinib, Outcome 6: Minor adverse events (Grade 1 or 2)" data-id="CD012796-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Pazopanib versus Sunitinib, Outcome 6: Minor adverse events (Grade 1 or 2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Tivozanib versus Sorafenib, Outcome 1: Progression‐free survival" data-id="CD012796-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Tivozanib versus Sorafenib, Outcome 1: Progression‐free survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Tivozanib versus Sorafenib, Outcome 2: Overall survival" data-id="CD012796-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Tivozanib versus Sorafenib, Outcome 2: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Tivozanib versus Sorafenib, Outcome 3: Serious adverse events (Grade 3 or 4)" data-id="CD012796-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Tivozanib versus Sorafenib, Outcome 3: Serious adverse events (Grade 3 or 4) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Tivozanib versus Sorafenib, Outcome 4: Health‐related quality of life" data-id="CD012796-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Tivozanib versus Sorafenib, Outcome 4: Health‐related quality of life</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Tivozanib versus Sorafenib, Outcome 5: Response rate" data-id="CD012796-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Tivozanib versus Sorafenib, Outcome 5: Response rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Tivozanib versus Sorafenib, Outcome 6: Minor adverse events (Grade 1 or 2)" data-id="CD012796-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Tivozanib versus Sorafenib, Outcome 6: Minor adverse events (Grade 1 or 2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sorafenib versus Pazopanib, Outcome 1: Progression‐free survival" data-id="CD012796-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Sorafenib versus Pazopanib, Outcome 1: Progression‐free survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sorafenib versus Pazopanib, Outcome 2: Overall survival" data-id="CD012796-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Sorafenib versus Pazopanib, Outcome 2: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sorafenib versus Pazopanib, Outcome 3: Serious adverse events (Grade 3 or 4)" data-id="CD012796-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Sorafenib versus Pazopanib, Outcome 3: Serious adverse events (Grade 3 or 4) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sorafenib versus Pazopanib, Outcome 4: Health‐related quality of life" data-id="CD012796-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Sorafenib versus Pazopanib, Outcome 4: Health‐related quality of life</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sorafenib versus Pazopanib, Outcome 5: Response rate" data-id="CD012796-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Sorafenib versus Pazopanib, Outcome 5: Response rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sorafenib versus Pazopanib, Outcome 6: Minor adverse events (Grade 1 or 2)" data-id="CD012796-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Sorafenib versus Pazopanib, Outcome 6: Minor adverse events (Grade 1 or 2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sunitinib versus Everolimus, Outcome 1: Progression‐free survival" data-id="CD012796-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Sunitinib versus Everolimus, Outcome 1: Progression‐free survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sunitinib versus Everolimus, Outcome 2: Overall survival" data-id="CD012796-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Sunitinib versus Everolimus, Outcome 2: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sunitinib versus Everolimus, Outcome 3: Serious adverse events (Grade 3 or 4)" data-id="CD012796-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Sunitinib versus Everolimus, Outcome 3: Serious adverse events (Grade 3 or 4) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sunitinib versus Everolimus, Outcome 4: Health‐related quality of life" data-id="CD012796-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Sunitinib versus Everolimus, Outcome 4: Health‐related quality of life</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sunitinib versus Everolimus, Outcome 5: Response rate" data-id="CD012796-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Sunitinib versus Everolimus, Outcome 5: Response rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sunitinib versus Everolimus, Outcome 6: Minor adverse events (Grade 1 or 2)" data-id="CD012796-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Sunitinib versus Everolimus, Outcome 6: Minor adverse events (Grade 1 or 2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Sunitinib versus Avelumab + Axitinib, Outcome 1: Progression‐free survival" data-id="CD012796-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Sunitinib versus Avelumab + Axitinib, Outcome 1: Progression‐free survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Sunitinib versus Avelumab + Axitinib, Outcome 2: Overall survival" data-id="CD012796-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Sunitinib versus Avelumab + Axitinib, Outcome 2: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Sunitinib versus Avelumab + Axitinib, Outcome 3: Serious adverse events (Grade 3 or 4)" data-id="CD012796-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Sunitinib versus Avelumab + Axitinib, Outcome 3: Serious adverse events (Grade 3 or 4) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Sunitinib versus Avelumab + Axitinib, Outcome 4: Response rate" data-id="CD012796-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Sunitinib versus Avelumab + Axitinib, Outcome 4: Response rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Sunitinib versus Avelumab + Axitinib, Outcome 5: Minor adverse events (Grade 1 or 2)" data-id="CD012796-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Sunitinib versus Avelumab + Axitinib, Outcome 5: Minor adverse events (Grade 1 or 2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Sunitinib versus Pembrolizumab + Axitinib, Outcome 1: Progression‐free survival" data-id="CD012796-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Sunitinib versus Pembrolizumab + Axitinib, Outcome 1: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Sunitinib versus Pembrolizumab + Axitinib, Outcome 2: Overall survival" data-id="CD012796-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Sunitinib versus Pembrolizumab + Axitinib, Outcome 2: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Sunitinib versus Pembrolizumab + Axitinib, Outcome 3: Serious adverse events (Grade 3 or 4)" data-id="CD012796-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Sunitinib versus Pembrolizumab + Axitinib, Outcome 3: Serious adverse events (Grade 3 or 4) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Sunitinib versus Pembrolizumab + Axitinib, Outcome 4: Response rate" data-id="CD012796-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Sunitinib versus Pembrolizumab + Axitinib, Outcome 4: Response rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Sunitinib versus Pembrolizumab + Axitinib, Outcome 5: Minor adverse events (Grade 1 or 2)" data-id="CD012796-fig-0042" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: Sunitinib versus Pembrolizumab + Axitinib, Outcome 5: Minor adverse events (Grade 1 or 2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Sunitinib versus Atezolizumab + Bevacizumab, Outcome 1: Progression‐free survival" data-id="CD012796-fig-0043" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Sunitinib versus Atezolizumab + Bevacizumab, Outcome 1: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Sunitinib versus Atezolizumab + Bevacizumab, Outcome 2: Overall survival" data-id="CD012796-fig-0044" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Sunitinib versus Atezolizumab + Bevacizumab, Outcome 2: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Sunitinib versus Atezolizumab + Bevacizumab, Outcome 3: Serious adverse events (Grade 3 or 4)" data-id="CD012796-fig-0045" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Sunitinib versus Atezolizumab + Bevacizumab, Outcome 3: Serious adverse events (Grade 3 or 4) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-008.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Sunitinib versus Atezolizumab + Bevacizumab, Outcome 4: Health‐related quality of life" data-id="CD012796-fig-0046" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-008.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-008.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8: Sunitinib versus Atezolizumab + Bevacizumab, Outcome 4: Health‐related quality of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-008.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-008.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Sunitinib versus Atezolizumab + Bevacizumab, Outcome 5: Response rate" data-id="CD012796-fig-0047" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-008.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-008.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8: Sunitinib versus Atezolizumab + Bevacizumab, Outcome 5: Response rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-008.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-008.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Sunitinib versus Atezolizumab + Bevacizumab, Outcome 6: Minor adverse events (Grade 1 or 2)" data-id="CD012796-fig-0048" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-008.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-008.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8: Sunitinib versus Atezolizumab + Bevacizumab, Outcome 6: Minor adverse events (Grade 1 or 2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-008.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Sunitinib versus IMA901 + Sunitinib, Outcome 1: Progression‐free survival" data-id="CD012796-fig-0049" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Sunitinib versus IMA901 + Sunitinib, Outcome 1: Progression‐free survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Sunitinib versus IMA901 + Sunitinib, Outcome 2: Overall survival" data-id="CD012796-fig-0050" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Sunitinib versus IMA901 + Sunitinib, Outcome 2: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Sunitinib versus IMA901 + Sunitinib, Outcome 3: Serious adverse events (Grade 3 or 4)" data-id="CD012796-fig-0051" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Sunitinib versus IMA901 + Sunitinib, Outcome 3: Serious adverse events (Grade 3 or 4) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-009.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Sunitinib versus IMA901 + Sunitinib, Outcome 4: Response rate" data-id="CD012796-fig-0052" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-009.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-009.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9: Sunitinib versus IMA901 + Sunitinib, Outcome 4: Response rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-009.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-009.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Sunitinib versus IMA901 + Sunitinib, Outcome 5: Minor adverse events (Grade 1 or 2)" data-id="CD012796-fig-0053" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-009.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-009.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9: Sunitinib versus IMA901 + Sunitinib, Outcome 5: Minor adverse events (Grade 1 or 2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-009.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Sunitinib versus Interferon‐α (IFN‐α), Outcome 1: Progression‐free survival" data-id="CD012796-fig-0054" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Sunitinib versus Interferon‐α (IFN‐α), Outcome 1: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Sunitinib versus Interferon‐α (IFN‐α), Outcome 2: Overall survival" data-id="CD012796-fig-0055" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Sunitinib versus Interferon‐α (IFN‐α), Outcome 2: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Sunitinib versus Interferon‐α (IFN‐α), Outcome 3: Serious adverse events (Grade 3 or 4)" data-id="CD012796-fig-0056" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: Sunitinib versus Interferon‐α (IFN‐α), Outcome 3: Serious adverse events (Grade 3 or 4) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-010.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Sunitinib versus Interferon‐α (IFN‐α), Outcome 4: Health‐related quality of life" data-id="CD012796-fig-0057" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-010.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-010.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10: Sunitinib versus Interferon‐α (IFN‐α), Outcome 4: Health‐related quality of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-010.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-010.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Sunitinib versus Interferon‐α (IFN‐α), Outcome 5: Response rate" data-id="CD012796-fig-0058" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-010.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-010.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10: Sunitinib versus Interferon‐α (IFN‐α), Outcome 5: Response rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-010.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-010.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Sunitinib versus Interferon‐α (IFN‐α), Outcome 6: Minor adverse events (Grade 1 or 2)" data-id="CD012796-fig-0059" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-010.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-010.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.6</div> <div class="figure-caption"> <p>Comparison 10: Sunitinib versus Interferon‐α (IFN‐α), Outcome 6: Minor adverse events (Grade 1 or 2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-010.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Temsirolimus versus IFN‐α, Outcome 1: Progression‐free survival" data-id="CD012796-fig-0060" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Temsirolimus versus IFN‐α, Outcome 1: Progression‐free survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Temsirolimus versus IFN‐α, Outcome 2: Overall survival" data-id="CD012796-fig-0061" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: Temsirolimus versus IFN‐α, Outcome 2: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-011.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Temsirolimus versus IFN‐α, Outcome 3: Serious adverse events (Grade 3 or 4)" data-id="CD012796-fig-0062" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-011.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-011.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11: Temsirolimus versus IFN‐α, Outcome 3: Serious adverse events (Grade 3 or 4) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-011.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-011.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Temsirolimus versus IFN‐α, Outcome 4: Health‐related quality of life" data-id="CD012796-fig-0063" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-011.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-011.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11: Temsirolimus versus IFN‐α, Outcome 4: Health‐related quality of life</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-011.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-011.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Temsirolimus versus IFN‐α, Outcome 5: Response rate" data-id="CD012796-fig-0064" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-011.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-011.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.5</div> <div class="figure-caption"> <p>Comparison 11: Temsirolimus versus IFN‐α, Outcome 5: Response rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-011.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-011.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Temsirolimus versus IFN‐α, Outcome 6: Minor adverse events (Grade 1 or 2)" data-id="CD012796-fig-0065" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-011.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-011.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.6</div> <div class="figure-caption"> <p>Comparison 11: Temsirolimus versus IFN‐α, Outcome 6: Minor adverse events (Grade 1 or 2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-011.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Sunitinib versus Atezolizumab, Outcome 1: Progression‐free survival" data-id="CD012796-fig-0066" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: Sunitinib versus Atezolizumab, Outcome 1: Progression‐free survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Sunitinib versus Atezolizumab, Outcome 2: Overall survival" data-id="CD012796-fig-0067" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: Sunitinib versus Atezolizumab, Outcome 2: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-012.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Sunitinib versus Atezolizumab, Outcome 3: Serious adverse events (Grade 3 or 4)" data-id="CD012796-fig-0068" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-012.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-012.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12: Sunitinib versus Atezolizumab, Outcome 3: Serious adverse events (Grade 3 or 4) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-012.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-012.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Sunitinib versus Atezolizumab, Outcome 4: Health‐related quality of life" data-id="CD012796-fig-0069" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-012.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-012.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12: Sunitinib versus Atezolizumab, Outcome 4: Health‐related quality of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-012.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-012.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Sunitinib versus Atezolizumab, Outcome 5: Response rate" data-id="CD012796-fig-0070" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-012.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-012.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.5</div> <div class="figure-caption"> <p>Comparison 12: Sunitinib versus Atezolizumab, Outcome 5: Response rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-012.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-012.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Sunitinib versus Atezolizumab, Outcome 6: Minor adverse events (Grade 1 or 2)" data-id="CD012796-fig-0071" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-012.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-012.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.6</div> <div class="figure-caption"> <p>Comparison 12: Sunitinib versus Atezolizumab, Outcome 6: Minor adverse events (Grade 1 or 2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-012.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Bevacizumab + IFN versus IFN (+ placebo), Outcome 1: Progression‐free survival" data-id="CD012796-fig-0072" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: Bevacizumab + IFN versus IFN (+ placebo), Outcome 1: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-013.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Bevacizumab + IFN versus IFN (+ placebo), Outcome 2: Overall survival" data-id="CD012796-fig-0073" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-013.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-013.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13: Bevacizumab + IFN versus IFN (+ placebo), Outcome 2: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-013.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-013.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Bevacizumab + IFN versus IFN (+ placebo), Outcome 3: Serious adverse events (Grade 3 or 4)" data-id="CD012796-fig-0074" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-013.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-013.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13: Bevacizumab + IFN versus IFN (+ placebo), Outcome 3: Serious adverse events (Grade 3 or 4) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-013.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-013.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Bevacizumab + IFN versus IFN (+ placebo), Outcome 4: Response rate" data-id="CD012796-fig-0075" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-013.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-013.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13: Bevacizumab + IFN versus IFN (+ placebo), Outcome 4: Response rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-013.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-013.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Bevacizumab + IFN versus IFN (+ placebo), Outcome 5: Minor adverse events (Grade 1 or 2)" data-id="CD012796-fig-0076" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-013.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-013.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.5</div> <div class="figure-caption"> <p>Comparison 13: Bevacizumab + IFN versus IFN (+ placebo), Outcome 5: Minor adverse events (Grade 1 or 2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-013.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-014.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Temsirolimus + IFN‐α versus IFN‐α, Outcome 1: Progression‐free survival" data-id="CD012796-fig-0077" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-014.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-014.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14: Temsirolimus + IFN‐α versus IFN‐α, Outcome 1: Progression‐free survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-014.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-014.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Temsirolimus + IFN‐α versus IFN‐α, Outcome 2: Overall survival" data-id="CD012796-fig-0078" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-014.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-014.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14: Temsirolimus + IFN‐α versus IFN‐α, Outcome 2: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-014.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-014.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Temsirolimus + IFN‐α versus IFN‐α, Outcome 3: Serious adverse events (Grade 3 or 4)" data-id="CD012796-fig-0079" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-014.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-014.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14: Temsirolimus + IFN‐α versus IFN‐α, Outcome 3: Serious adverse events (Grade 3 or 4) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-014.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-014.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Temsirolimus + IFN‐α versus IFN‐α, Outcome 4: Health‐related quality of life" data-id="CD012796-fig-0080" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-014.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-014.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.4</div> <div class="figure-caption"> <p>Comparison 14: Temsirolimus + IFN‐α versus IFN‐α, Outcome 4: Health‐related quality of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-014.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-014.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Temsirolimus + IFN‐α versus IFN‐α, Outcome 5: Response rate" data-id="CD012796-fig-0081" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-014.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-014.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.5</div> <div class="figure-caption"> <p>Comparison 14: Temsirolimus + IFN‐α versus IFN‐α, Outcome 5: Response rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-014.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-014.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Temsirolimus + IFN‐α versus IFN‐α, Outcome 6: Minor adverse events (Grade 1 or 2)" data-id="CD012796-fig-0082" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-014.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-014.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.6</div> <div class="figure-caption"> <p>Comparison 14: Temsirolimus + IFN‐α versus IFN‐α, Outcome 6: Minor adverse events (Grade 1 or 2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-014.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-015.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Temsirolimus + Bevacizumab versus Bevacizumab + IFN‐α, Outcome 1: Progression‐free survival" data-id="CD012796-fig-0083" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-015.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-015.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15: Temsirolimus + Bevacizumab versus Bevacizumab + IFN‐α, Outcome 1: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-015.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-015.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Temsirolimus + Bevacizumab versus Bevacizumab + IFN‐α, Outcome 2: Overall survival" data-id="CD012796-fig-0084" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-015.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-015.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15: Temsirolimus + Bevacizumab versus Bevacizumab + IFN‐α, Outcome 2: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-015.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-015.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Temsirolimus + Bevacizumab versus Bevacizumab + IFN‐α, Outcome 3: Serious adverse events (Grade 3 or 4)" data-id="CD012796-fig-0085" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-015.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-015.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.3</div> <div class="figure-caption"> <p>Comparison 15: Temsirolimus + Bevacizumab versus Bevacizumab + IFN‐α, Outcome 3: Serious adverse events (Grade 3 or 4) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-015.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-015.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Temsirolimus + Bevacizumab versus Bevacizumab + IFN‐α, Outcome 4: Response rate" data-id="CD012796-fig-0086" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-015.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-015.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.4</div> <div class="figure-caption"> <p>Comparison 15: Temsirolimus + Bevacizumab versus Bevacizumab + IFN‐α, Outcome 4: Response rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-015.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-015.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Temsirolimus + Bevacizumab versus Bevacizumab + IFN‐α, Outcome 5: Minor adverse events (Grade 1 or 2)" data-id="CD012796-fig-0087" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-015.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-015.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.5</div> <div class="figure-caption"> <p>Comparison 15: Temsirolimus + Bevacizumab versus Bevacizumab + IFN‐α, Outcome 5: Minor adverse events (Grade 1 or 2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-015.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-016.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Everolimus + Bevacizumab versus IFN α‐2a + Bevacizumab, Outcome 1: Progression‐free survival" data-id="CD012796-fig-0088" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-016.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-016.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16: Everolimus + Bevacizumab versus IFN α‐2a + Bevacizumab, Outcome 1: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-016.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-016.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Everolimus + Bevacizumab versus IFN α‐2a + Bevacizumab, Outcome 2: Overall survival" data-id="CD012796-fig-0089" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-016.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-016.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.2</div> <div class="figure-caption"> <p>Comparison 16: Everolimus + Bevacizumab versus IFN α‐2a + Bevacizumab, Outcome 2: Overall survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-016.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-016.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Everolimus + Bevacizumab versus IFN α‐2a + Bevacizumab, Outcome 3: Serious adverse events (Grade 3 or 4)" data-id="CD012796-fig-0090" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-016.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-016.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.3</div> <div class="figure-caption"> <p>Comparison 16: Everolimus + Bevacizumab versus IFN α‐2a + Bevacizumab, Outcome 3: Serious adverse events (Grade 3 or 4) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-016.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-016.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Everolimus + Bevacizumab versus IFN α‐2a + Bevacizumab, Outcome 4: Response rate" data-id="CD012796-fig-0091" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-016.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-016.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.4</div> <div class="figure-caption"> <p>Comparison 16: Everolimus + Bevacizumab versus IFN α‐2a + Bevacizumab, Outcome 4: Response rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-016.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-016.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Everolimus + Bevacizumab versus IFN α‐2a + Bevacizumab, Outcome 5: Minor adverse events (Grade 1 or 2)" data-id="CD012796-fig-0092" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-016.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-016.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.5</div> <div class="figure-caption"> <p>Comparison 16: Everolimus + Bevacizumab versus IFN α‐2a + Bevacizumab, Outcome 5: Minor adverse events (Grade 1 or 2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-016.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-017.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Sunitinib versus Nivolumab + Ipilimumab, Outcome 1: Progression‐free survival" data-id="CD012796-fig-0093" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-017.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-017.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17: Sunitinib versus Nivolumab + Ipilimumab, Outcome 1: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-017.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-017.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Sunitinib versus Nivolumab + Ipilimumab, Outcome 2: Overall survival" data-id="CD012796-fig-0094" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-017.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-017.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.2</div> <div class="figure-caption"> <p>Comparison 17: Sunitinib versus Nivolumab + Ipilimumab, Outcome 2: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-017.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-017.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Sunitinib versus Nivolumab + Ipilimumab, Outcome 3: Serious adverse events (Grade 3 or 4)" data-id="CD012796-fig-0095" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-017.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-017.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.3</div> <div class="figure-caption"> <p>Comparison 17: Sunitinib versus Nivolumab + Ipilimumab, Outcome 3: Serious adverse events (Grade 3 or 4) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-017.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-017.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Sunitinib versus Nivolumab + Ipilimumab, Outcome 4: Health‐related quality of life" data-id="CD012796-fig-0096" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-017.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-017.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.4</div> <div class="figure-caption"> <p>Comparison 17: Sunitinib versus Nivolumab + Ipilimumab, Outcome 4: Health‐related quality of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-017.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-017.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Sunitinib versus Nivolumab + Ipilimumab, Outcome 5: Response rate" data-id="CD012796-fig-0097" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-017.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-017.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.5</div> <div class="figure-caption"> <p>Comparison 17: Sunitinib versus Nivolumab + Ipilimumab, Outcome 5: Response rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-017.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-017.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Sunitinib versus Nivolumab + Ipilimumab, Outcome 6: Minor adverse events (Grade 1 or 2)" data-id="CD012796-fig-0098" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-017.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-017.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.6</div> <div class="figure-caption"> <p>Comparison 17: Sunitinib versus Nivolumab + Ipilimumab, Outcome 6: Minor adverse events (Grade 1 or 2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-017.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-018.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Pazopanib versus Placebo, Outcome 1: Progression‐free survival" data-id="CD012796-fig-0099" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-018.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-018.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18: Pazopanib versus Placebo, Outcome 1: Progression‐free survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-018.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-018.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Pazopanib versus Placebo, Outcome 2: Overall survival" data-id="CD012796-fig-0100" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-018.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-018.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.2</div> <div class="figure-caption"> <p>Comparison 18: Pazopanib versus Placebo, Outcome 2: Overall survival</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-018.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-018.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Pazopanib versus Placebo, Outcome 3: Serious adverse events (Grade 3 or 4)" data-id="CD012796-fig-0101" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-018.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-018.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.3</div> <div class="figure-caption"> <p>Comparison 18: Pazopanib versus Placebo, Outcome 3: Serious adverse events (Grade 3 or 4) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-018.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-018.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Pazopanib versus Placebo, Outcome 4: Health‐related quality of life" data-id="CD012796-fig-0102" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-018.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-018.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.4</div> <div class="figure-caption"> <p>Comparison 18: Pazopanib versus Placebo, Outcome 4: Health‐related quality of life</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-018.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-018.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Pazopanib versus Placebo, Outcome 5: Response rate" data-id="CD012796-fig-0103" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-018.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-018.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.5</div> <div class="figure-caption"> <p>Comparison 18: Pazopanib versus Placebo, Outcome 5: Response rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-018.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012796-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/urn:x-wiley:14651858:media:CD012796:CD012796-CMP-018.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Pazopanib versus Placebo, Outcome 6: Minor adverse events (Grade 1 or 2)" data-id="CD012796-fig-0104" src="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-018.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_t/tCD012796-CMP-018.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.6</div> <div class="figure-caption"> <p>Comparison 18: Pazopanib versus Placebo, Outcome 6: Minor adverse events (Grade 1 or 2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/media/CDSR/CD012796/image_n/nCD012796-CMP-018.06.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012796-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Sorafenib compared to sunitinib (targeted agent versus targeted agent)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (any cell type)<br/><b>Setting:</b> Germany and the Netherlands/muticentre/likely outpatient<br/><b>Intervention:</b> Sorafenib<br/><b>Comparison:</b> Sunitinib </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Sunitinib</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Sorafenib</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> <p>(absolute effect size estimates based on survival rate at 10 months)<br/>follow‐up: mean 10.3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>365<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.19<br/>(0.92 to 1.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>340 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 fewer per 1000<br/>(148 fewer to 31 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 24 months)<br/>follow‐up: mean 10.3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>365<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.99<br/>(0.74 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>550 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 more per 1000<br/>(98 fewer to 92 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v3.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>353<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.99<br/>(0.85 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>670 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 fewer per 1000<br/>(101 fewer to 94 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><sup>5</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for study limitations; high risk of performance and detection bias and unclear risk of other bias </p> <p><sup>2</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (included harm and no harm) </p> <p><sup>3</sup> Downgraded by 1 level for study limitations; unclear risk of other bias </p> <p><sup>4</sup> Downgraded by 2 levels for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference: wide confidence interval (included both benefit and harm) </p> <p><sup>5</sup> Health‐related quality of life: no available data </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Sorafenib compared to sunitinib (targeted agent versus targeted agent)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012796-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Pazopanib compared to sunitinib (targeted agent versus targeted agent)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (clear cell type)<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Pazopanib<br/><b>Comparison:</b> Sunitinib </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Sunitinib</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Pazopanib</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> <p>(absolute effect size estimates based on survival rate at 12 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1110<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.05<br/>(0.90 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>420 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 fewer per 1000<br/>(76 fewer to 38 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 24 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1110<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.92<br/>(0.80 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>550 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 more per 1000<br/>(19 fewer to 70 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v3.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1102<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(0.94 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>734 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 more per 1000<br/>(44 fewer to 66 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> (mean change value)<br/>assessed with: FACIT‐F (higher scores indicating less fatigue)<br/>Scale from: 0 to 52 </p> <p>follow‐up: after 4 cycle</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>467<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>5 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life (mean change value) was ‐6.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.6 higher<br/>(1.76 higher to 5.44 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>FACIT‐F:</b> Functional Assessment of Chronic Illness Therapy–Fatigue scale; <b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for study limitations; high risk of performance and detection bias and unclear risk of other bias </p> <p><sup>2</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (included harm and no harm) </p> <p><sup>3</sup> Downgraded by 1 level for study limitations; unclear risk of other bias </p> <p><sup>4</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (included no benefit and benefit) </p> <p><sup>5</sup> Downgraded by 1 level for study limitations; high risk of performance, detection and attrition bias and unclear risk of other bias </p> <p><sup>6</sup> Downgraded by 1 level for imprecision; confidence interval crossed the assumed threshold of a clinically important difference (3 points, included benefit and little benefit) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Pazopanib compared to sunitinib (targeted agent versus targeted agent)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012796-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Tivozanib compared to sorafenib (targeted agent versus targeted agent)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (clear cell type)<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Tivozanib<br/><b>Comparison:</b> Sorafenib </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Sorafenib</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Tivozanib</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> <p>(absolute effect size estimates based on survival rate at 12 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>517<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.79<br/>(0.64 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>360 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86 more per 1000<br/>(4 more to 160 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 24 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>517<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.25<br/>(0.95 to 1.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>620 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 fewer per 1000<br/>(163 fewer to 15 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v3.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>516<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.85<br/>(0.74 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>689 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103 fewer per 1000<br/>(179 fewer to 21 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><br/>assessed with: EQ‐5D Health State Index<br/>Scale from: ‐0.59 (worst health state) to 1 (best health state)<br/>follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>506<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life was ‐0.06</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.01 higher<br/>(0.05 lower to 0.07 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>EQ‐5D:</b> EuroQol‐5D; <b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for imprecision; confidence interval crossed the assumed threshold of a clinically important difference (included benefit and little benefit) </p> <p><sup>2</sup> Downgraded by 1 level for study limitations; high risk of performance, detection and other bias </p> <p><sup>3</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (included harm and no harm) </p> <p><sup>4</sup> Downgraded by 1 level for study limitations; high risk of other bias </p> <p><sup>5</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (0.06 points, included benefit and no benefit) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Tivozanib compared to sorafenib (targeted agent versus targeted agent)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012796-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Sorafenib compared to pazopanib (targeted agent versus targeted agent)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (any cell type)<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Sorafenib<br/><b>Comparison:</b> Pazopanib </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Pazopanib</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Sorafenib</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> <p>(absolute effect size estimates based on survival rate at 12 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>377<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.92<br/>(1.74 to 2.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>380 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>224 fewer per 1000<br/>(250 fewer to 194 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 24 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>377<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.22<br/>(0.91 to 1.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>520 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 fewer per 1000<br/>(178 fewer to 32 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v4.03 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>366<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.92<br/>(0.78 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>639 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 fewer per 1000<br/>(141 fewer to 58 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><br/>(mean change value)<br/>assessed with: FACIT‐F (higher scores indicating less fatigue)<br/>Scale from: 0 to 52 </p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>267<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>5 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life was ‐9.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.1 higher<br/>(1.82 lower to 8.02 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>FACIT‐F:</b> Functional Assessment of Chronic Illness Therapy–Fatigue scale; <b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for study limitations; unclear risk of selection, detection, and reporting bias and high risk of performance bias </p> <p><sup>2</sup> Downgraded by 1 level for study limitations; unclear risk of selection, and reporting bias </p> <p><sup>3</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (included harm and no harm) </p> <p><sup>4</sup> Downgraded by 2 levels for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference: wide confidence interval (included both benefit and harm) </p> <p><sup>5</sup> Downgraded by 1 level for study limitations; unclear risk of selection, detection, and reporting bias and high risk of performance and attrition bias </p> <p><sup>6</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (3 points, included benefit and no benefit) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Sorafenib compared to pazopanib (targeted agent versus targeted agent)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012796-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Sunitinib compared to everolimus (targeted agent versus targeted agent)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (any cell type)<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Sunitinib<br/><b>Comparison:</b> Everolimus </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Everolimus</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Sunitinib</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> <p>(absolute effect size estimates based on survival rate at 12 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>471<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.71<br/>(0.59 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125 more per 1000<br/>(51 more to 191 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 24 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>471<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.90<br/>(0.72 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>470 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 more per 1000<br/>(37 fewer to 111 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v3.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>469<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.34<br/>(1.14 to 1.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>471 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160 more per 1000<br/>(66 more to 278 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><br/>assessed with: EORTC QLQ‐C30 (Global health status scale: high score represent better functioning)<br/>Scale from: 0 to 100<br/>follow‐up: 16 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>288<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life was 65.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 5 lower<br/>(10.4 lower to 0.4 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>EORTC QLQ‐C30:</b> European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; <b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for study limitations; high risk of performance, detection and other bias </p> <p><sup>2</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (included benefit and no benefit) </p> <p><sup>3</sup> Downgraded by 1 level for study limitations; high risk of other bias </p> <p><sup>4</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (10 points, included harm and no harm) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Sunitinib compared to everolimus (targeted agent versus targeted agent)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012796-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Sunitinib compared to avelumab + axitinib (targeted agent versus immunotherapy + targeted agent)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (clear cell type)<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Sunitinib<br/><b>Comparison:</b> Avelumab + Axitinib </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Avelumab + Axitinib</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Sunitinib</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b><br/>(absolute effect size estimates based on survival rate at 12 months) </p> <p>follow‐up: median 10.8 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>886<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.45<br/>(1.17 to 1.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>550 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130 fewer per 1000<br/>(209 fewer to 53 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 12 months)<br/>follow‐up: median 12.0 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>886<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.28<br/>(0.92 to 1.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>890 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 fewer per 1000<br/>(78 fewer to 8 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v4.03 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>873<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(0.93 to 1.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>705 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 more per 1000<br/>(49 fewer to 71 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><sup>4</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for study limitations: high risk of performance bias and unclear risk of reporting bias </p> <p><sup>2</sup> Downgraded by 1 level for imprecision: confidence interval crossed the assumed threshold of a clinically important difference (included no benefit and harm) </p> <p><sup>3</sup> Downgraded by 1 level for study limitations: unclear risk of reporting bias </p> <p><sup>4</sup> Health‐related quality of life: no available data </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Sunitinib compared to avelumab + axitinib (targeted agent versus immunotherapy + targeted agent)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012796-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Sunitinib compared to pembrolizumab + axitinib (targeted agent versus immunotherapy + targeted agent)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (clear cell type)<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Sunitinib<br/><b>Comparison:</b> Pembrolizumab + Axitinib </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Pembrolizumab + Axitinib</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Sunitinib</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b><br/>(absolute effect size estimates based on survival rate at 12 months) </p> <p>follow‐up: median 12.8 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>861<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.45<br/>(1.19 to 1.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>590 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125 fewer per 1000<br/>(195 fewer to 56 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 12 months)<br/>follow‐up: median 12.8 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>861<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.90<br/>(1.36 to 2.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>880 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 fewer per 1000<br/>(167 fewer to 40 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v4.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>854<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/>(0.81 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>604 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 fewer per 1000<br/>(115 fewer to 12 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><sup>4</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for study limitations; high risk of performance bias </p> <p><sup>2</sup> Downgraded by 1 level for imprecision; confidence interval crossed the assumed threshold of a clinically important difference (included harm and little harm) </p> <p><sup>3</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (included benefit and no benefit) </p> <p><sup>4</sup> Health‐related quality of life: no available data </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Sunitinib compared to pembrolizumab + axitinib (targeted agent versus immunotherapy + targeted agent)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012796-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Sunitinib compared to atezolizumab + bevacizumab (targeted agent versus immunotherapy + targeted agent)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (clear cell type)<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Sunitinib<br/><b>Comparison:</b> Atezolizumab + Bevacizumab </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Atezolizumab + Bevacizumab</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Sunitinib</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b><br/>(absolute effect size estimates based on survival rate at 12 months) </p> <p>follow‐up: range 15 months to 20.7 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1117<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.18<br/>(1.02 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>480 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 fewer per 1000<br/>(111 fewer to 7 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b><br/>(absolute effect size estimates based on survival rate at 24 months) </p> <p>follow‐up: range 20.7 months to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1117<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.99<br/>(0.73 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>630 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 more per 1000<br/>(89 fewer to 84 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v4.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1098<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2 4 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.22<br/>(1.00 to 1.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>446 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 more per 1000<br/>(0 fewer to 218 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><br/>assessed with: MDASI (high score indicates worse QoL)<br/>Scale from: 0 to 10<br/>follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>691<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life ranged from 0.56 to 1.57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1 higher<br/>(0.68 higher to 1.32 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>HR:</b> Hazard ratio; <b>MDASI:</b> MD Anderson Symptom Inventory; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for imprecision; confidence interval crossed the assumed threshold of a clinically important difference (included harm and little harm) </p> <p><sup>2</sup> Downgraded by 1 level for study limitations; high and unclear risk of 1 or more domains. </p> <p><sup>3</sup> Downgraded by 2 levels for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference: wide confidence interval (included both benefit and harm) </p> <p><sup>4</sup> Downgraded by 1 level for inconsistency; moderate to substantial heterogeneity: unexplained differences between study results </p> <p><sup>5</sup> Downgraded by 1 level for imprecision; confidence interval reached the line of no difference and crossed the assumed threshold of a clinically important difference (included harm and no harm) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Sunitinib compared to atezolizumab + bevacizumab (targeted agent versus immunotherapy + targeted agent)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012796-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Sunitinib compared to IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted agent)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (clear cell type)<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Sunitinib<br/><b>Comparison:</b> IMA901 + Sunitinib </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with IMA901 + Sunitinib</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Sunitinib</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> <p>(absolute effect size estimates based on survival rate at 12 months)<br/>follow‐up: median 33.27 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>339<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.95<br/>(0.70 to 1.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>590 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 more per 1000<br/>(86 fewer to 101 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 12 months)<br/>follow‐up: median 33.27 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>339<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.75<br/>(0.54 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>800 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 more per 1000<br/>(7 fewer to 86 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse</b> events (Grade 3 or 4)<br/>assessed with: CTCAE v4.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>334<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.74<br/>(0.59 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>550 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143 fewer per 1000<br/>(225 fewer to 27 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><sup>6</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 2 levels for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference: wide confidence interval (included both benefit and harm) </p> <p><sup>2</sup> Downgraded by 1 level for study limitations; high risk of performance and other bias </p> <p><sup>3</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (included benefit and no benefit) </p> <p><sup>4</sup> Downgraded by 1 level for study limitations: high risk of other bias </p> <p><sup>5</sup> Downgraded by 1 level for imprecision; confidence interval crossed the assumed threshold of a clinically important difference (included benefit and little benefit) </p> <p><sup>6</sup> Health‐related quality of life: no available data </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Sunitinib compared to IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted agent)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012796-tbl-0010"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Sunitinib compared to interferon‐α (IFN‐α) (targeted agent versus classic immunotherapy)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (clear cell type)<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Sunitinib<br/><b>Comparison:</b> Interferon‐α (IFN‐α) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Interferon‐α (IFN‐α)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Sunitinib</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> <p>(absolute effect size estimates based on survival rate at 6 months)<br/>follow‐up: median 31 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>750<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.54<br/>(0.45 to 0.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210 more per 1000<br/>(156 more to 262 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 24 months)<br/>follow‐up: median 31 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>750<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.82<br/>(0.67 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>480 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 more per 1000<br/>(0 fewer to 132 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed as: CTCAE v3.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>735<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.75<br/>(1.43 to 2.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>258 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194 more per 1000<br/>(111 more to 300 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><br/>assessed with: EQ‐5D Health State Index<br/>Scale from: ‐0.59 (worst health state) to 1 (best health state) </p> <p>follow‐up: after 2 cycle</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>544<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life was 0.74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.01 lower<br/>(0.05 lower to 0.03 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval;<b>EQ‐5D:</b> EuroQol‐5D; <b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for study limitations; unclear risk of selection bias and high risk of performance and other bias </p> <p><sup>2</sup> Downgraded by 1 level for study limitations; unclear risk of selection bias and high risk of other bias </p> <p><sup>3</sup> Downgraded by 1 level for imprecision; confidence interval reached the line of no difference and crossed the assumed threshold of a clinically important difference (included benefit and no benefit) </p> <p><sup>4</sup> Downgraded by 1 level for study limitations; unclear risk of selection and attrition bias and high risk of performance and other bias </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Sunitinib compared to interferon‐α (IFN‐α) (targeted agent versus classic immunotherapy)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012796-tbl-0011"> <div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Temsirolimus compared to IFN‐α (targeted agent versus classic immunotherapy)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (any cell type [80% clear cell])<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Temsirolimus<br/><b>Comparison:</b> IFN‐α </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with IFN‐α</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Temsirolimus</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> (absolute effect size estimates based on survival rate at 12 months) </p> <p>follow‐up: up to 80 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>416<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.74<br/>(0.60 to 0.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82 more per 1000<br/>(23 more to 151 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival survival (</b>absolute effect size estimates based on survival rate at 12 months ) </p> <p>follow‐up: up to 80 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>416<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.78<br/>(0.63 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 more per 1000<br/>(11 more to 168 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE version: not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>408<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/>(0.76 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>780 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109 fewer per 1000<br/>(187 fewer to 23 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> <br/>assessed with: EQ‐5D Health State Index<br/>Scale from: ‐0.59 (worst health state) to 1 (best health state) </p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>401<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life was 0.66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.03 higher<br/>(0.01 lower to 0.07 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>EQ‐5D:</b> EuroQol‐5D; <b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for imprecision; confidence interval crossed the assumed threshold of a clinically important difference (included benefit and no benefit) </p> <p><sup>2</sup> Downgraded by 1 level for study limitations; high risk of performance and detection bias </p> <p><sup>3</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (included benefit and no benefit) </p> <p><sup>4</sup> Downgraded by 1 level for study limitations; high risk of performance, detection and attrition bias </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Temsirolimus compared to IFN‐α (targeted agent versus classic immunotherapy)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012796-tbl-0012"> <div class="table-heading"><span class="table-label">Summary of findings 12.</span> <span class="table-title">Sunitinib compared to atezolizumab (targeted therapy versus immunotherapy)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (clear cell type)<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Sunitinib<br/><b>Comparison:</b> Atezolizumab </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Atezolizumab</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Sunitinib</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> <p>(absolute effect size estimates based on survival rate at 12 months)<br/>follow‐up: median 20.7 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>204<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.84<br/>(0.58 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>420 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 more per 1000<br/>(73 fewer to 185 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 24 months)<br/>follow‐up: median 20.7 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>204<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.94<br/>(0.58 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>630 per 1000 <sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 more per 1000<br/>(139 fewer to 135 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v4.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>203<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.73<br/>(1.32 to 2.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>398 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>291 more per 1000<br/>(127 more to 506 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><br/>assessed with: MDASI (high score indicates worse QoL)<br/>Scale from: 0 to 10<br/>follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>157<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>4 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life was 1.04</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 1.46 higher<br/>(0.8 higher to 2.12 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>HR:</b> Hazard ratio; <b>MDASI:</b> MD Anderson Symptom Inventory; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 2 levels for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference: wide confidence interval (included both benefit and harm) </p> <p><sup>2</sup> Downgraded by 1 level for study limitations; high risk of selection, performance and detection bias and unclear risk of other bias </p> <p><sup>3</sup> Downgraded by 1 level for study limitations; high risk of selection and unclear risk of other bias </p> <p><sup>4</sup> Downgraded by 1 level for imprecision; confidence interval crossed the assumed threshold of a clinically important difference (1 point, included harm and little harm) </p> <p><sup>5</sup> Downgraded by 1 level for study limitations; high risk of selection, performance and detection bias and unclear risk of other bias </p> <p><sup>6</sup> Baseline risk for overall survival in the atezolizumab group was assumed to be 63% (moderate risk) at 24 months as reported in <a href="./references#CD012796-bbs2-0017" title="AtkinsMB , RiniBI , MotzerRJ , PowlesT , McDermottDF , SuarezC , et al. Patient-reported outcomes from the phase 3 randomized IMmotion151 trial: atezolizumab + bevacizumab vs sunitinib in treatment-naive metastatic renal cell carcinoma. Clinical Cancer Research2020;26(11):2506-2514. EscudierB , MotzerRJ , RiniBI , PowlesT , McDermottDF , SuarezC , et al. Patient-reported outcomes (PROs) in IMmotion151: atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2018;36(15_suppl):4511. [DOI: 10.1200/JCO.2018.36.15_suppl.4511]MotzerRJ , PowlesT , AtkinsMB , EscudierB , McDermottDF , SuarezC , et al. IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology2018;36(6 suppl):578. [DOI: 10.1200/JCO.2018.36.6_suppl.578]NCT02420821. A study of atezolizumab in combination with bevacizumab versus sunitinib in participants with untreated advanced renal cell carcinoma (RCC) (IMmotion151) [A phase III, open-label, randomized study of atezolizumab (Anti-PD-L1 Antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma]. clinicaltrials.gov/ct2/show/NCT02420821 (first received 20 April 2015). [NCT02420821]RiniBI , PowlesT , AtkinsMB , EscudierB , McDermottDF , SuarezC , et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet2019;393(10189):2404-15. [PMID: 31079938]">Rini 2019b</a> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 12.</span> <span class="table-title">Sunitinib compared to atezolizumab (targeted therapy versus immunotherapy)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012796-tbl-0013"> <div class="table-heading"><span class="table-label">Summary of findings 13.</span> <span class="table-title">Bevacizumab + IFN compared to IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (clear cell type)<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Bevacizumab + IFN<br/><b>Comparison:</b> IFN (+ placebo) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with IFN (+ placebo)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Bevacizumab + IFN</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> <p>(absolute effect size estimates based on survival rate at 12 months)</p> <p>follow‐up: intervention: 13.3 months</p> <p>comparator: 12.8 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1381<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.68<br/>(0.60 to 0.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135 more per 1000<br/>(90 more to 181 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 24 months)</p> <p>follow‐up: intervention: 23 months</p> <p>comparator: 21 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1381<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.88<br/>(0.79 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 more per 1000<br/>(3 more to 78 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v3.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1356<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.31<br/>(1.20 to 1.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>536 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166 more per 1000<br/>(107 more to 225 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><sup>3</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for study limitations; high and unclear risk of 1 or more domains </p> <p><sup>2</sup> Downgraded by 1 level for imprecision; confidence interval crossed the assumed threshold of a clinically important difference (included benefit and little benefit) </p> <p><sup>3</sup> Health‐related quality of life: no available data </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 13.</span> <span class="table-title">Bevacizumab + IFN compared to IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012796-tbl-0014"> <div class="table-heading"><span class="table-label">Summary of findings 14.</span> <span class="table-title">Temsirolimus + IFN‐α compared to IFN‐α (targeted agent + classic immunotherapy versus classic immunotherapy)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (any cell type [80% clear cell])<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Temsirolimus + IFN‐α<br/><b>Comparison:</b> IFN‐α </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with IFN‐α</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Temsirolimus + IFN‐α</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> (absolute effect size estimates based on survival rate at 12 months) follow‐up: up to 80 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>417<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.76<br/>(0.62 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74 more per 1000<br/>(17 more to 140 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 12 months) follow‐up: up to 80 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>417<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.93<br/>(0.75 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 more per 1000<br/>(50 fewer to 105 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE version: not reported </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>408<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.12<br/>(1.02 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>780 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94 more per 1000<br/>(16 more to 172 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> <br/>assessed with: EQ‐5D Health State Index<br/>Scale from: ‐0.59 (worst health state) to 1 (best health state) </p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>394<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>5 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life was 0.66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.03 higher<br/>(0.01 lower to 0.07 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>EQ‐5D:</b> EuroQol‐5D; <b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for imprecision; confidence interval crossed the assumed threshold of a clinically important difference (included benefit and no benefit) </p> <p><sup>2</sup> Downgraded by 1 level for study limitations; high risk of performance and detection bias </p> <p><sup>3</sup> Downgraded by 2 levels for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference: wide confidence interval (included both benefit and harm) </p> <p><sup>4</sup> Downgraded by 1 level for imprecision; confidence interval crossed the assumed threshold of a clinically important difference (included harm and no harm) </p> <p><sup>5</sup> Downgraded by 1 level for study limitations; high risk of performance, detection and attrition bias </p> <p><sup>6</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (included benefit and no benefit) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 14.</span> <span class="table-title">Temsirolimus + IFN‐α compared to IFN‐α (targeted agent + classic immunotherapy versus classic immunotherapy)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012796-tbl-0015"> <div class="table-heading"><span class="table-label">Summary of findings 15.</span> <span class="table-title">Temsirolimus + bevacizumab compared to bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (any cell type [80% clear cell])<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Temsirolimus + Bevacizumab<br/><b>Comparison:</b> Bevacizumab + IFN‐α </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Bevacizumab + IFN‐α</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Temsirolimus + Bevacizumab</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> <p>(absolute effect size estimates based on survival rate at 12 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>791<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.10<br/>(0.90 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>420 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 fewer per 1000<br/>(107 fewer to 38 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 24 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>791<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.08<br/>(0.90 to 1.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>550 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 fewer per 1000<br/>(90 fewer to 34 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v3.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>784<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05<br/>(0.98 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>760 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 more per 1000<br/>(15 fewer to 99 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><sup>3</sup> </p> <p>assessed with: FKSI–15</p> <p>Scale from: 0 to 60</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>no available data</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>FKSI:</b> Functional Assessment of Cancer Therapy–Kidney Symptom Index; <b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (included harm and no harm) </p> <p><sup>2</sup> Downgraded by 1 level for study limitations; high risk of performance bias (we are not concerned with unclear risk of other bias) </p> <p><sup>3</sup> Health‐related quality of life: no available data </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 15.</span> <span class="table-title">Temsirolimus + bevacizumab compared to bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012796-tbl-0016"> <div class="table-heading"><span class="table-label">Summary of findings 16.</span> <span class="table-title">Everolimus + bevacizumab compared to IFN α‐2a + bevacizumab (targeted agent + targeted agent versus targeted agent + classic immunotherapy)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (any cell type)<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Everolimus + Bevacizumab<br/><b>Comparison:</b> IFN α‐2a + Bevacizumab </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with IFN α‐2a + Bevacizumab</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Everolimus + Bevacizumab</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> <p>(absolute effect size estimates based on survival rate at 18 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>365<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.91<br/>(0.69 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 more per 1000<br/>(61 fewer to 134 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 24 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>365<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.01<br/>(0.75 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>533 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 fewer per 1000<br/>(108 fewer to 91 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v3.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>361<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.06<br/>(0.95 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>762 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 more per 1000<br/>(38 fewer to 137 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><sup>5</sup><br/>assessed with: EORTC QLQ‐C30 (Global health status scale: high score represent better functioning)<br/>Scale from: 0 to 100 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>no available data</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>EORTC QLQ‐C30:</b> European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; <b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for study limitations; unclear risk of selection, performance and other bias and high risk of detection bias </p> <p><sup>2</sup> Downgraded by 2 levels for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference: wide confidence interval (included both benefit and harm) </p> <p><sup>3</sup> Downgraded by 1 level for study limitations; unclear risk of selection and other bias </p> <p><sup>4</sup> Downgraded by 1 level for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (included harm and no harm) </p> <p><sup>5</sup> Health‐related quality of life: no available data </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 16.</span> <span class="table-title">Everolimus + bevacizumab compared to IFN α‐2a + bevacizumab (targeted agent + targeted agent versus targeted agent + classic immunotherapy)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012796-tbl-0017"> <div class="table-heading"><span class="table-label">Summary of findings 17.</span> <span class="table-title">Sunitinib compared to nivolumab + ipilimumab (targeted agent versus combinations of immunotherapy)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Sunitinib<br/><b>Comparison:</b> Nivolumab + Ipilimumab </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Nivolumab + Ipilimumab</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Sunitinib</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> <p>(absolute effect size estimates based on survival rate at 30 months)<br/>follow‐up: median 32.4 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>847<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.30<br/>(1.11 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>280 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89 fewer per 1000<br/>(136 fewer to 37 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 30 months)<br/>follow‐up: median 32.4 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>847<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.52<br/>(1.23 to 1.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140 fewer per 1000<br/>(219 fewer to 67 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v4.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1082<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.37<br/>(1.22 to 1.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>457 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169 more per 1000<br/>(101 more to 242 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><br/>assessed with: FKSI‐19 (higher scores indicating fewer symptoms) </p> <p>Scale from: 0 to 76<br/>follow‐up: 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>460<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life was 2.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 4.1 lower<br/>(5.75 lower to 2.45 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>FKSI:</b> Functional Assessment of Cancer Therapy–Kidney Symptom Index<b>HR:</b> Hazard ratio; <b>IMDC:</b> International Metastatic Renal Cell Carcinoma Database Consortium; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 level for imprecision; confidence interval crossed the assumed threshold of a clinically important difference (included harm and no harm) </p> <p><sup>2</sup> Downgraded by 1 level for study limitations; high risk of performance and detection bias </p> <p><sup>3</sup> Downgraded by 1 level for study limitations; high risk of performance and detection bias and unclear risk of attrition bias </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 17.</span> <span class="table-title">Sunitinib compared to nivolumab + ipilimumab (targeted agent versus combinations of immunotherapy)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012796-tbl-0018"> <div class="table-heading"><span class="table-label">Summary of findings 18.</span> <span class="table-title">Pazopanib compared to placebo (targeted agent versus placebo)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type)<br/><b>Setting:</b> Multinational muticentre/likely outpatient<br/><b>Intervention:</b> Pazopanib<br/><b>Comparison:</b> Placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Placebo</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with Pazopanib</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Progression‐free survival</b> </p> <p>(absolute effect size estimates based on survival rate at 12 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>435<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.46<br/>(0.34 to 0.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>274 more per 1000<br/>(165 more to 378 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Overall survival</b> </p> <p>(absolute effect size estimates based on survival rate at 24 months)</p> <p>follow‐up: not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>435<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.91<br/>(0.72 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>480 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 more per 1000<br/>(53 fewer to 110 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events (Grade 3 or 4)</b><br/>assessed with: CTCAE v3.0 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>435<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.00<br/>(1.40 to 2.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 more per 1000<br/>(80 more to 370 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b><br/>assessed with: EORTC QLQ‐C30 (Global health status scale: high score represent better functioning but negative change from baseline represents a worsening condition)<br/>Scale from: 0 to 100<br/>follow‐up: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life was ‐0.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 3.1 lower<br/>(7.76 lower to 1.56 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>CTCAE:</b> Common Terminology Criteria for Adverse Events;<b>EORTC QLQ‐C30:</b> European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; <b>HR:</b> Hazard ratio; <b>RCT</b> : Randomized controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 2 levels for imprecision; confidence interval crossed the line of no difference and the assumed threshold of a clinically important difference (included both benefit and harm) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 18.</span> <span class="table-title">Pazopanib compared to placebo (targeted agent versus placebo)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012796-tbl-0019"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Individual targeted agents to be searched</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Axitinib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bevacizumab</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dovitinib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Erlotinib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Everolimus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lapatinib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pazopanib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sorafenib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Temsirolimus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tivozanib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other agents identified during search</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Individual targeted agents to be searched</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012796-tbl-0020"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Participants disposition</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention(s)/ Comparator(s)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Randomised (N)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Received treatment (N)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Discontinued treatment (N)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Efficacy analysis (N)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Safety analysis (N)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Eichelberg 2015</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Soreafenib/ Sunitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>177</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib/ Sorafenib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>176</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Escudier 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bevacizumab + IFN‐a2a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>325</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>337</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IFN‐a2a + Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>304</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Escudier 2017 <sup>1</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>535</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nivolumab + Ipilimumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>547</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Hudes 2007</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Temsirolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>208</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Temsirolimus + Interferon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>208</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interferon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>McDermott 2017</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atezolizumab + Bevacizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atezolizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Motzer 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IFN‐a2a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>360</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Motzer 2013a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pazopanib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>557</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>554</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>557</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>554</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>548</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Motzer 2013b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tivozanib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>259</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sorafenib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>257</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Motzer 2014</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib/ Everolimus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>231</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Everolimus/ Sunitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>238</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Motzer 2019</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>439</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Avelumab + Axitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>434</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Ravaud 2015</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Everolimus + Bevacizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>180</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interferon + Bevacizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>181</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Retz 2019</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sorafenib/ Pazopanib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pazopanib/ Sorafenib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>183</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Rini 2008</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bevacizumab + IFN‐a2b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>366</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IFN‐a2b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>349</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Rini 2014</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Temsirolimus + Bevacizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>393</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Temsirolimus + Interferon</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>391</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Rini 2016</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>132</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IMA901 + Sunitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>202</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Rini 2019a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>425</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pembrolizumab + Axitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>429</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Rini 2019b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>446</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>446</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atezolizumab + Bevacizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>451</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Sternberg 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pazopanib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>290</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11590</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11590</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11437</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Included overall population; but in the data and analyses section and summary of findings table, we used IMDC intermediate and poor risk patients for efficacy analysis. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Participants disposition</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012796-tbl-0021"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Baseline characteristics</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Phase of study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Accrual</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Blinding</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>RCC subtype</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Prior therapy</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparator</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Eichelberg 2015</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Feb 2009 to Dec 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>any, 87% clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Soreafenib/Sunitinib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib/Sorafenib</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Escudier 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Jun 2004 to Oct 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>double‐blind study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bevacizumab + IFN‐a2a</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IFN‐a2a + Placebo</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Escudier 2017</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Oct 2014 to Feb 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nivolumab + Ipilimumab</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>Hudes 2007</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Jul 2003 to Apr 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>any, 80% clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Temsirolimus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Temsirolimus + Interferon</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inferferon</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign=""> <p><b>McDermott 2017</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Jan 2014 to Mar 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atezolizumab + Bevacizumab</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atezolizumab</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Motzer 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Aug 2004 to Oct 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>radiologic assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IFN‐a2a</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Motzer 2013a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Aug 2008 to Sep 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pazopanib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Motzer 2013b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Feb 2010 to Aug 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tivozanib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sorafenib</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Motzer 2014</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Sep 2009 to Jun 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>any, 85% clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib/ Everolimus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Everolimus/ Sunitinib</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Motzer 2019</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Mar 2016 to Dec 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Avelumab + Axitinib</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Ravaud 2015</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>any 96% clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Everolimus + Bevacizumab</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interferon + Bevacizumab</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Retz 2019</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Jun 2012 to Nov 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>any, 87% clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sorafenib/ Pazopanib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pazopanib/ Sorafenib</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Rini 2008</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Oct 2003 to Jul 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bevacizumab + IFN‐a2b</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IFN‐a2b</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Rini 2014</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Apr 2008 to Oct 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>any, 80% clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Temsirolimus + Bevacizumab</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bevacizumab + Inferferon</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Rini 2016</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Dec 2010 to Dec 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IMA901 + Sunitinib</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Rini 2019a</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Oct 2016 to Jan 2018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pembrolizumab + Axitinib</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Rini 2019b</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>May 2015 to Oct 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>open label study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sunitinib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atezolizumab + Bevacizumab</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Sternberg 2010</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Apr 2006 to Apr 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>double‐blind study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>clear cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>54% naive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pazopanib</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>‐ denotes not reported</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>IFN: interferon; RCC: renal cell carcinoma</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Baseline characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/full#CD012796-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012796-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Sorafenib versus Sunitinib</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Serious adverse events (Grade 3 or 4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Minor adverse events (Grade 1 or 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Sorafenib versus Sunitinib</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012796-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Pazopanib versus Sunitinib</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Serious adverse events (Grade 3 or 4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Health‐related quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Minor adverse events (Grade 1 or 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Pazopanib versus Sunitinib</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012796-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Tivozanib versus Sorafenib</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Serious adverse events (Grade 3 or 4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Health‐related quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Minor adverse events (Grade 1 or 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Tivozanib versus Sorafenib</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012796-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Sorafenib versus Pazopanib</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Serious adverse events (Grade 3 or 4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Health‐related quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Minor adverse events (Grade 1 or 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Sorafenib versus Pazopanib</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012796-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Sunitinib versus Everolimus</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Serious adverse events (Grade 3 or 4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Health‐related quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Minor adverse events (Grade 1 or 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Sunitinib versus Everolimus</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012796-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Sunitinib versus Avelumab + Axitinib</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Serious adverse events (Grade 3 or 4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Minor adverse events (Grade 1 or 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Sunitinib versus Avelumab + Axitinib</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012796-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Sunitinib versus Pembrolizumab + Axitinib</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Serious adverse events (Grade 3 or 4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 Minor adverse events (Grade 1 or 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Sunitinib versus Pembrolizumab + Axitinib</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012796-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Sunitinib versus Atezolizumab + Bevacizumab</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [1.02, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.73, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Serious adverse events (Grade 3 or 4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1098</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [1.00, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.4 Health‐related quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>691</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.68, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.5 Response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.77, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.6 Minor adverse events (Grade 1 or 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1098</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.74, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Sunitinib versus Atezolizumab + Bevacizumab</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012796-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Sunitinib versus IMA901 + Sunitinib</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Serious adverse events (Grade 3 or 4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.4 Response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.5 Minor adverse events (Grade 1 or 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Sunitinib versus IMA901 + Sunitinib</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012796-tbl-0031"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Sunitinib versus Interferon‐α (IFN‐α)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Serious adverse events (Grade 3 or 4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.4 Health‐related quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.5 Response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.6 Minor adverse events (Grade 1 or 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Sunitinib versus Interferon‐α (IFN‐α)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012796-tbl-0032"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Temsirolimus versus IFN‐α</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.3 Serious adverse events (Grade 3 or 4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.4 Health‐related quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.5 Response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.6 Minor adverse events (Grade 1 or 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Temsirolimus versus IFN‐α</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-tbl-0032">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012796-tbl-0033"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Sunitinib versus Atezolizumab</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.3 Serious adverse events (Grade 3 or 4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.4 Health‐related quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.5 Response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.6 Minor adverse events (Grade 1 or 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Sunitinib versus Atezolizumab</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-tbl-0033">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012796-tbl-0034"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Bevacizumab + IFN versus IFN (+ placebo)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.60, 0.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.79, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.3 Serious adverse events (Grade 3 or 4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [1.20, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.4 Response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.5 Minor adverse events (Grade 1 or 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Bevacizumab + IFN versus IFN (+ placebo)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-tbl-0034">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012796-tbl-0035"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Temsirolimus + IFN‐α versus IFN‐α</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.1 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.3 Serious adverse events (Grade 3 or 4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.4 Health‐related quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.5 Response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.6 Minor adverse events (Grade 1 or 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Temsirolimus + IFN‐α versus IFN‐α</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-tbl-0035">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012796-tbl-0036"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Temsirolimus + Bevacizumab versus Bevacizumab + IFN‐α</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.1 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.3 Serious adverse events (Grade 3 or 4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.4 Response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.5 Minor adverse events (Grade 1 or 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Temsirolimus + Bevacizumab versus Bevacizumab + IFN‐α</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-tbl-0036">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012796-tbl-0037"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Everolimus + Bevacizumab versus IFN α‐2a + Bevacizumab</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.1 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.3 Serious adverse events (Grade 3 or 4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.4 Response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.5 Minor adverse events (Grade 1 or 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Everolimus + Bevacizumab versus IFN α‐2a + Bevacizumab</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-tbl-0037">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012796-tbl-0038"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Sunitinib versus Nivolumab + Ipilimumab</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.1 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.3 Serious adverse events (Grade 3 or 4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.4 Health‐related quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.5 Response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.6 Minor adverse events (Grade 1 or 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Sunitinib versus Nivolumab + Ipilimumab</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-tbl-0038">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012796-tbl-0039"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Pazopanib versus Placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.1 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.3 Serious adverse events (Grade 3 or 4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.4 Health‐related quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.5 Response rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.6 Minor adverse events (Grade 1 or 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Pazopanib versus Placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012796.pub2/references#CD012796-tbl-0039">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012796.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012796-note-0023">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012796-note-0033">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012796-note-0031">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012796-note-0032">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012796-note-0030">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD012796-note-0029">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD012796-note-0026">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD012796-note-0028">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD012796-note-0027">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012796-note-0024">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012796-note-0025">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012796\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012796\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012796\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012796\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012796\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012796\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012796\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012796\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012796\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012796\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012796\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012796\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012796\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012796\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012796\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012796\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012796\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012796\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=f00EizoA&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012796.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012796.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012796.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012796.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012796.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727809625"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012796.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727809628"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012796.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eb5118ecd9368',t:'MTc0MDcyNzgxMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 